0000919956-15-000014.txt : 20150507 0000919956-15-000014.hdr.sgml : 20150507 20150507160445 ACCESSION NUMBER: 0000919956-15-000014 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 12 CONFORMED PERIOD OF REPORT: 20150331 FILED AS OF DATE: 20150507 DATE AS OF CHANGE: 20150507 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Diversicare Healthcare Services, Inc. CENTRAL INDEX KEY: 0000919956 STANDARD INDUSTRIAL CLASSIFICATION: SERVICES-SKILLED NURSING CARE FACILITIES [8051] IRS NUMBER: 621559667 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 001-12996 FILM NUMBER: 15841689 BUSINESS ADDRESS: STREET 1: 1621 GALLERIA BLVD. CITY: BRENTWOOD STATE: TN ZIP: 37027 BUSINESS PHONE: 6157717575 MAIL ADDRESS: STREET 1: 1621 GALLERIA BLVD. CITY: BRENTWOOD STATE: TN ZIP: 37027 FORMER COMPANY: FORMER CONFORMED NAME: ADVOCAT INC DATE OF NAME CHANGE: 19940309 10-Q 1 dvcr-20150331x10q.htm 10-Q DVCR-2015.03.31-10Q


 
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
________________________________ 
FORM 10-Q
________________________________ 
CHECK ONE:
ý
QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the Quarterly Period Ended: March 31, 2015
OR
¨
TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the transition period from              to             .

Commission file No.: 1-12996
________________________________ 
Diversicare Healthcare Services, Inc.
(exact name of registrant as specified in its charter)
 ________________________________
Delaware
 
62-1559667
(State or other jurisdiction of
incorporation or organization)
 
(IRS Employer
Identification No.)
1621 Galleria Boulevard, Brentwood, TN 37027
(Address of principal executive offices) (Zip Code)
(615) 771-7575
(Registrant’s telephone number, including area code)
Indicate by check mark whether the registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.    Yes  ý    No  ¨
Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files).    Yes  ý    No  ¨
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer or a smaller reporting company. See the definitions of “large accelerated filer,” “accelerated filer” and a “smaller reporting company” in Rule 12b-2 of the Exchange Act. (Check one):
Large accelerated filer
 
¨
Accelerated filer
 
¨
 
 
 
 
Non-accelerated filer
 
¨
Smaller reporting Company
 
ý
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).    Yes  ¨    No  ý
6,233,738
(Outstanding shares of the issuer’s common stock as of April 30, 2015)
 




Part I. FINANCIAL INFORMATION
ITEM 1 – FINANCIAL STATEMENTS
DIVERSICARE HEALTHCARE SERVICES, INC. AND SUBSIDIARIES
INTERIM CONSOLIDATED BALANCE SHEETS
(in thousands)
 
 
March 31,
2015
 
December 31,
2014
 
(Unaudited)
 
 
CURRENT ASSETS:
 
 
 
Cash and cash equivalents
$
3,604

 
$
3,818

Receivables, less allowance for doubtful accounts of $6,533 and $6,044, respectively
43,480

 
41,272

Other receivables
443

 
862

Prepaid expenses and other current assets
2,702

 
2,339

Income tax refundable
694

 
559

Current assets of discontinued operations
37

 
73

Deferred income taxes
6,962

 
7,016

Total current assets
57,922

 
55,939

PROPERTY AND EQUIPMENT, at cost
107,279

 
98,869

Less accumulated depreciation and amortization
(56,793
)
 
(55,014
)
Discontinued operations, net

 

Property and equipment, net
50,486

 
43,855

OTHER ASSETS:
 
 
 
Deferred income taxes
13,090

 
12,885

Deferred financing and other costs, net
1,686

 
1,692

Investment in unconsolidated affiliate
571

 
463

Other noncurrent assets
4,442

 
6,411

Acquired leasehold interest, net
7,748

 
7,844

Total other assets
27,537

 
29,295

 
$
135,945

 
$
129,089

The accompanying notes are an integral part of these interim consolidated financial statements.

2



DIVERSICARE HEALTHCARE SERVICES, INC. AND SUBSIDIARIES
INTERIM CONSOLIDATED BALANCE SHEETS
(in thousands, except share and per share amounts)
(continued)
 
 
March 31,
2015
 
December 31,
2014
 
(Unaudited)
 
 
CURRENT LIABILITIES:
 
 
 
Current portion of long-term debt and capitalized lease obligations
$
8,302

 
$
5,705

Trade accounts payable
8,928

 
8,121

Current liabilities of discontinued operations
317

 
482

Accrued expenses:
 
 
 
Payroll and employee benefits
15,293

 
14,642

Self-insurance reserves, current portion
12,077

 
11,833

Other current liabilities
4,932

 
6,359

Total current liabilities
49,849

 
47,142

NONCURRENT LIABILITIES:
 
 
 
Long-term debt and capitalized lease obligations, less current portion
47,428

 
42,559

Self-insurance reserves, noncurrent portion
14,430

 
14,268

Other noncurrent liabilities
12,942

 
13,366

Total noncurrent liabilities
74,800

 
70,193

COMMITMENTS AND CONTINGENCIES

 

SERIES C REDEEMABLE PREFERRED STOCK
 
 
 
$.10 par value, 5,000 shares authorized, none issued and outstanding

 

SHAREHOLDERS’ EQUITY:
 
 
 
Series A preferred stock, authorized 200,000 shares, $.10 par value, none issued and outstanding

 

Common stock, authorized 20,000,000 shares, $.01 par value, 6,466,000 and 6,388,000 shares issued, and 6,234,000 and 6,156,000 shares outstanding, respectively
65

 
64

Treasury stock at cost, 232,000 shares of common stock
(2,500
)
 
(2,500
)
Paid-in capital
20,174

 
19,970

Accumulated deficit
(5,890
)
 
(5,285
)
Accumulated other comprehensive loss
(553
)
 
(495
)
Total shareholders’ equity
11,296


11,754

 
$
135,945

 
$
129,089

The accompanying notes are an integral part of these interim consolidated financial statements.

3



DIVERSICARE HEALTHCARE SERVICES, INC. AND SUBSIDIARIES
INTERIM CONSOLIDATED STATEMENTS OF OPERATIONS
(in thousands, except per share amounts, unaudited)
 
Three Months Ended
March 31,
 
2015
 
2014
PATIENT REVENUES, net
$
95,225

 
$
77,799

EXPENSES:
 
 
 
Operating
77,145

 
62,824

Lease and rent expense
7,145

 
5,967

Professional liability
2,155

 
2,061

General and administrative
6,051

 
5,114

Depreciation and amortization
1,879

 
1,735

Total expenses
94,375

 
77,701

OPERATING INCOME
850

 
98

OTHER EXPENSE:
 
 
 
Equity in net income (loss) of unconsolidated affiliate
108

 
(3
)
Interest expense, net
(950
)
 
(892
)
Total other expense
(842
)
 
(895
)
INCOME (LOSS) FROM CONTINUING OPERATIONS BEFORE INCOME TAXES
8

 
(797
)
BENEFIT (PROVISION) FOR INCOME TAXES
(3
)
 
364

INCOME (LOSS) FROM CONTINUING OPERATIONS
5

 
(433
)
INCOME (LOSS) FROM DISCONTINUED OPERATIONS:
 
 
 
Operating loss, net of tax benefit of $168 and $767, respectively
(263
)
 
(612
)
Loss from discontinued operations
(263
)
 
(612
)
NET LOSS
(258
)
 
(1,045
)
Less: (income) loss attributable to noncontrolling interests

 
25

NET LOSS ATTRIBUTABLE TO DIVERSICARE HEALTHCARE SERVICES, INC.
(258
)
 
(1,020
)
PREFERRED STOCK DIVIDENDS

 
(86
)
NET LOSS FOR DIVERSICARE HEALTHCARE SERVICES, INC. COMMON SHAREHOLDERS
$
(258
)
 
$
(1,106
)
NET INCOME (LOSS) PER COMMON SHARE FOR DIVERSICARE HEALTHCARE SERVICES, INC. SHAREHOLDERS:
 
 
 
Per common share – basic and diluted
 
 
 
Continuing operations
$

 
$
(0.08
)
Discontinued operations
(0.04
)
 
(0.11
)
 
$
(0.04
)
 
$
(0.19
)
COMMON STOCK DIVIDENDS DECLARED PER SHARE OF COMMON STOCK
$
0.055

 
$
0.055

WEIGHTED AVERAGE COMMON SHARES OUTSTANDING:
 
 
 
Basic and diluted
6,045

 
5,975

                              
The accompanying notes are an integral part of these interim consolidated financial statements.

4



DIVERSICARE HEALTHCARE SERVICES, INC. AND SUBSIDIARIES
INTERIM CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS)
(in thousands and unaudited)
 
 
Three Months Ended
March 31,
 
2015
 
2014
NET LOSS
$
(258
)
 
$
(1,045
)
OTHER COMPREHENSIVE INCOME:
 
 
 
Change in fair value of cash flow hedge, net of tax
178

 
140

Less: reclassification adjustment for amounts recognized in net income
(120
)
 
(119
)
Total other comprehensive income
58

 
21

COMPREHENSIVE LOSS
(200
)
 
(1,024
)
Less: comprehensive income attributable to noncontrolling interest

 
25

COMPREHENSIVE LOSS ATTRIBUTABLE TO DIVERSICARE HEALTHCARE SERVICES, INC.
$
(200
)
 
$
(999
)

The accompanying notes are an integral part of these interim consolidated financial statements.

5



DIVERSICARE HEALTHCARE SERVICES, INC. AND SUBSIDIARIES
INTERIM CONSOLIDATED STATEMENTS OF CASH FLOWS
(in thousands and unaudited)
 
 
Three Months Ended March 31,
 
2015
 
2014
CASH FLOWS FROM OPERATING ACTIVITIES:
 
 
 
Net loss
$
(258
)
 
$
(1,045
)
Discontinued operations
(263
)
 
(612
)
Income (Loss) from continuing operations
5

 
(433
)
Adjustments to reconcile income (loss) from continuing operations to net cash provided by (used in) operating activities:
 
 
 
Depreciation and amortization
1,879

 
1,735

Provision for doubtful accounts
1,503

 
1,361

Deferred income tax benefit
(116
)
 
(660
)
Provision for self-insured professional liability, net of cash payments
930

 
711

Stock-based compensation
155

 
141

Equity in net (income) losses of unconsolidated affiliate, net of investment
(108
)
 
3

Non-cash interest accretion

 
(26
)
Other
(311
)
 
(160
)
Changes in assets and liabilities affecting operating activities:
 
 
 
Receivables, net
(3,436
)
 
(7,445
)
Prepaid expenses and other assets
(875
)
 
(254
)
Trade accounts payable and accrued expenses
716

 
100

Net cash provided by (used in) continuing operations
342

 
(4,927
)
Discontinued operations
(1,579
)
 
360

Net cash used in operating activities
(1,237
)
 
(4,567
)
CASH FLOWS FROM INVESTING ACTIVITIES:
 
 
 
Purchases of property and equipment
(1,411
)
 
(702
)
Acquisition of property and equipment through business combination
(7,000
)
 

Change in restricted cash
2,490

 
36

Deposits and other deferred balances
(9
)
 

Net cash used in continuing operations
(5,930
)
 
(666
)
Discontinued operations

 
54

Net cash used in investing activities
(5,930
)
 
(612
)
CASH FLOWS FROM FINANCING ACTIVITIES:
 
 
 
Repayment of debt obligations
(1,301
)
 
(422
)
Proceeds from issuance of debt
8,767

 
5,050

Financing costs
(104
)
 
(83
)
Issuance and redemption of employee equity awards
79

 
82

Payment of common stock dividends
(335
)
 
(331
)
Payment of preferred stock dividends

 
(86
)
Distributions to noncontrolling interest

 
(1,410
)
Payment for preferred stock restructuring
(153
)
 
(148
)
Net cash provided by financing activities
6,953

 
2,652

Discontinued operations

 
2,498

Net cash provided by financing activities
$
6,953

 
$
5,150


6



DIVERSICARE HEALTHCARE SERVICES, INC. AND SUBSIDIARIES
INTERIM CONSOLIDATED STATEMENTS OF CASH FLOWS
(in thousands and unaudited)
(continued)
 
 
Three Months Ended March 31,
 
2015
 
2014
NET DECREASE IN CASH AND CASH EQUIVALENTS
$
(214
)
 
$
(29
)
CASH AND CASH EQUIVALENTS, beginning of period
3,818

 
3,781

CASH AND CASH EQUIVALENTS, end of period
$
3,604

 
$
3,752

SUPPLEMENTAL INFORMATION:
 
 
 
Cash payments of interest, net of amounts capitalized
$
857

 
$
739

Cash payments of income taxes
$
84

 
$
2

The accompanying notes are an integral part of these interim consolidated financial statements.

7



DIVERSICARE HEALTHCARE SERVICES, INC. AND SUBSIDIARIES
NOTES TO INTERIM CONSOLIDATED FINANCIAL STATEMENTS
MARCH 31, 2015 AND 2014

1.
BUSINESS
Diversicare Healthcare Services, Inc. (together with its subsidiaries, “Diversicare Healthcare Services” or the “Company”) provides long-term care services to nursing center patients in nine states, primarily in the Southeast, Midwest, and Southwest. The Company’s centers provide a range of health care services to their patients and residents that include nursing, personal care, and social services. Additionally, the Company’s nursing centers also offer a variety of comprehensive rehabilitation services, as well as nutritional support services. The Company's continuing operations include centers in Alabama, Florida, Indiana, Kansas, Kentucky, Missouri, Ohio, Tennessee, and Texas.
As of March 31, 2015, the Company’s continuing operations consist of 54 nursing centers with 6,004 licensed nursing beds. The Company owns 14 and leases 40 of its nursing centers. Our nursing centers range in size from 50 to 320 licensed nursing beds. The licensed nursing bed count does not include 496 licensed assisted living beds.

2.
CONSOLIDATION AND BASIS OF PRESENTATION OF FINANCIAL STATEMENTS
The interim consolidated financial statements include the operations and accounts of Diversicare Healthcare Services and its subsidiaries, all wholly-owned. All significant intercompany accounts and transactions have been eliminated in consolidation. The investment in an unconsolidated affiliate (a 50 percent-owned joint venture partnership) is accounted for using the equity method and is described in Note 8.
The interim consolidated financial statements for the three month periods ended March 31, 2015 and 2014, included herein have been prepared by the Company, without audit, pursuant to the rules and regulations of the Securities and Exchange Commission. Certain information and footnote disclosures normally included in financial statements prepared in accordance with accounting principles generally accepted in the United States of America have been condensed or omitted pursuant to such rules and regulations. In the opinion of management of the Company, the accompanying interim consolidated financial statements reflect all normal, recurring adjustments necessary to present fairly the Company’s financial position at March 31, 2015, and the results of operations for the three month periods ended March 31, 2015 and 2014, and cash flows for the three month periods ended March 31, 2015 and 2014. The Company’s balance sheet information at December 31, 2014, was derived from its audited consolidated financial statements as of December 31, 2014.
The results of operations for the periods ended March 31, 2015 and 2014 are not necessarily indicative of the operating results that may be expected for a full year. These interim consolidated financial statements should be read in connection with the audited consolidated financial statements and notes thereto included in the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2014.

3.
RECENT ACCOUNTING GUIDANCE
In April 2014, the FASB issued ASU 2014-08, Presentation of Financial Statements (Topic 205) and Property, Plant, and Equipment (Topic 360): Reporting Discontinued Operations and Disclosures of Disposals of Components of an Entity changing the criteria for reporting discontinued operations. The ASU states that only those disposed components (or components held-for-sale) representing a strategic shift that have a significant effect on operations and financial results will be reported in discontinued operations. The ASU also required expanded disclosures about discontinued operations in the financial statement notes. The ASU is effective for disposals (or classifications as held-for-sale) that occur within annual periods beginning on or after December 15, 2014 and interim periods within those annual periods. Early application is permitted, but only for those disposals that have not been reported in financial statements previously issued or available for issuance. We chose to early adopt this ASU and applied the new criteria in determining the accounting treatment for the nursing centers exited during 2014. The adoption of this guidance did not have a material impact on the Company's consolidated financial statements.
In May 2014, the FASB issued ASU No. 2014-09, Revenue from Contracts with Customers (Topic 606), which requires an entity to recognize the amount of revenue to which it expects to be entitled for the transfer of promised goods or services to customers. The ASU will replace most existing revenue recognition guidance in U.S. GAAP when it becomes effective. The new standard is effective for the Company on January 1, 2017. Early application is not permitted. The standard permits the use of either the retrospective or cumulative effect transition method. The Company is evaluating the effect that ASU 2014-09 will have on its consolidated financial statements and related disclosures. The Company has not yet selected a transition method nor has it determined the effect of the standard on its ongoing financial reporting.



8




4.
LONG-TERM DEBT AND INTEREST RATE SWAP
The Company has agreements with a syndicate of banks for a mortgage term loan ("Original Mortgage Loan") and the Company’s revolving credit agreement ("Original Revolver"). On May 1, 2013, the Company executed an Amended and Restated Credit Agreement (the "Credit Agreement") which modified the terms of the Original Mortgage Loan and the Original Revolver Agreements dated February 28, 2011. The Credit Agreement increases the Company's borrowing capacity to $65,000,000 allocated between a $45,000,000 Mortgage Loan ("Amended Mortgage Loan") and a $20,000,000 Revolver ("Amended Revolver"). Loan acquisition costs associated with the Amended Mortgage Loan and the Amended Revolver were capitalized in the amount of $1,341,000 and are being amortized over the five-year term of the agreements.
Under the terms of the amended agreements, the syndicate of banks provided the Amended Mortgage Loan with an original balance of $45,000,000 with a five-year maturity through April 30, 2018, and a $27,500,000 Amended Revolver through April 30, 2018. The Amended Mortgage Loan has a term of five years, with principal and interest payable monthly based on a 25-year amortization. Interest is based on LIBOR plus 4.5%. A portion of the Amended Mortgage Loan is effectively fixed at 6.87% pursuant to an interest rate swap with a notional amount of $21,594,000. As of March 31, 2015, the interest rate related to the Amended Mortgage Loan was 4.70%. The Amended Mortgage Loan is secured by thirteen owned nursing centers, related equipment and a lien on the accounts receivable of these centers. The Amended Mortgage Loan and the Amended Revolver are cross-collateralized. The Company’s Amended Revolver has an interest rate of LIBOR plus 4.5% and is secured by accounts receivable and is subject to limits on the maximum amount of loans that can be outstanding under the revolver based on borrowing base restrictions.
Effective March 31, 2014, the Company entered into the Second Amendment to the Amended and Restated Revolver ("Second Amendment"). The Second Amendment temporarily increased the Amended Revolver capacity from the $20,000,000 in the original Amended Revolver to $27,500,000 through September 30, 2014, as a result of the increase in receivables related to new facilities that continue to progress through the change in ownership process. Effective July 1, 2014, the Company entered into the Third Amendment to the Amended and Restated Revolver ("Third Amendment"). The Third Amendment makes the previously temporary increase to the Amended Revolver capacity from the $20,000,000 in the original Amended Revolver to $27,500,000, a permanent change to the borrowing capacity as a result of the increase in receivables related to new facilities that continue to progress through the change in ownership process.
As of March 31, 2015, the Company had $7,000,000 borrowings outstanding under the revolving credit facility compared to $4,500,000 outstanding as of December 31, 2014. The outstanding borrowings on the revolver primarily reflect the Company's approach to accumulated Medicaid and Medicare receivables at recently acquired facilities as these facilities proceed through the change in ownership process with CMS. Annual fees for letters of credit issued under this Revolver are 3.00% of the amount outstanding. The Company has eleven letters of credit with a total value of $8,106,000 outstanding as of March 31, 2015. Considering the balance of eligible accounts receivable, the letters of credit, the amounts outstanding under the revolving credit facility and the maximum loan amount of $27,500,000, the balance available for borrowing under the revolving credit center is $11,540,000 at March 31, 2015.
The Company’s debt agreements contain various financial covenants, the most restrictive of which relate to minimum cash deposits, cash flow and debt service coverage ratios. The Company is in compliance with all such covenants at March 31, 2015.
Interest Rate Swap Transaction
As part of the debt agreements entered into in March 2011, the Company entered into an interest rate swap agreement with a member of the bank syndicate as the counterparty. The Company designated its interest rate swap as a cash flow hedge and the earnings component of the hedge, net of taxes, is reflected as a component of other comprehensive income. In conjunction with the amendment to the credit facility, the Company retained the previously agreed upon interest rate swap terms, and redesignated the interest rate swap as a cash flow hedge. The interest rate swap agreement requires the Company to make fixed rate payments to the bank calculated on the applicable notional amount of $21,594,000 at an annual fixed rate of 6.87% while the bank is obligated to make payments to the Company based on LIBOR on the same notional amounts.
The Company assesses the effectiveness of its interest rate swap on a quarterly basis, and at March 31, 2015, the Company determined that the interest rate swap was effective. The interest rate swap valuation model indicated a net liability of $891,000 at March 31, 2015. The fair value of the interest rate swap is included in “other noncurrent liabilities” on the Company’s interim consolidated balance sheet. The balance of accumulated other comprehensive loss at March 31, 2015 is $553,000 and reflects the liability related to the interest rate swap, net of the income tax benefit of $338,000. As the Company’s interest rate swap is not traded on a market exchange, the fair value is determined using a valuation based on a discounted cash flow analysis. This analysis reflects the contractual terms of the interest rate swap agreement and uses observable market-based inputs, including estimated future LIBOR interest rates. The interest rate swap valuation is classified in Level 2 of the fair value hierarchy, in accordance with the FASB guidance set forth in ASC 820, Fair Value Measurement.

9



Glasgow Term Loan
On February 1, 2015, in conjunction with the acquisition of Diversicare of Glasgow, a 94-bed skilled nursing facility in Glasgow, Kentucky, the Company entered into a $5,000,000 Term Loan and Security Agreement (the "Glasgow term loan") with The PrivateBank in order to finance the purchase of the assets. The Glasgow term loan is an interest-only loan that has an 18-month maturity dated August 1, 2016, and a variable interest rate based on LIBOR, with a minimum base rate of 4.75%. See Note 9 for further information regarding the acquisition of the Glasgow facility.

5.
INSURANCE MATTERS
Professional Liability and Other Liability Insurance
The Company has professional liability insurance coverage for its nursing centers that, based on historical claims experience, is likely to be substantially less than the claims that are expected to be incurred. Effective July 1, 2013, the Company established a wholly-owned, consolidated offshore limited purpose insurance subsidiary, SHC Risk Carriers, Inc. (“SHC”) which has issued a policy insuring claims made against all of the Company's nursing centers in Florida and Tennessee, as well as the Company’s formerly operated Arkansas and West Virginia facilities. Several of the Company’s nursing centers in Alabama, Kentucky, Ohio, and Texas are also covered under this policy. The SHC policy provides coverage limits of either $500,000 or $1,000,000 per medical incident with a sublimit per center of $1,000,000 and total annual aggregate policy limits of $5,000,000. The remaining nursing centers are covered by one of seven claims made professional liability insurance policies purchased from entities unaffiliated with the Company. These policies provide coverage limits of $1,000,000 per claim and have sublimits of $3,000,000 per center, with varying aggregate policy limits. 
Reserve for Estimated Self-Insured Professional Liability Claims
Because the Company’s actual liability for existing and anticipated professional liability and general liability claims will likely exceed the Company’s limited insurance coverage, the Company has recorded total liabilities for reported and estimated future claims of $24,906,000 as of March 31, 2015. This accrual includes estimates of liability for incurred but not reported claims, estimates of liability for reported but unresolved claims, actual liabilities related to settlements, including settlements to be paid over time, and estimates of legal costs related to these claims. All losses are projected on an undiscounted basis and are presented without regard to any potential insurance recoveries. Amounts are added to the accrual for estimates of anticipated liability for claims incurred during each period, and amounts are deducted from the accrual for settlements paid on existing claims during each period.
The Company evaluates the adequacy of this liability on a quarterly basis. Semi-annually, the Company retains a third-party actuarial firm to assist in the evaluation of the current portion of this reserve. Merlinos & Associates, Inc. (“Merlinos”) assisted management in the preparation of an estimate of the appropriate accrual for the current claims period and for incurred, but not reported general and professional liability claims based on data furnished as of November 30, 2014.  The Company used this estimate from Merlinos in the preparation of its estimate of liability for incurred, but unreported professional liability claims as of as of March 31, 2015.
On a quarterly basis, the Company obtains reports of asserted claims and lawsuits incurred. These reports, which are provided by the Company’s insurers and a third-party claims administrator, contain information relevant to the actual expense already incurred with each claim as well as the third-party administrator’s estimate of the anticipated total cost of the claim. This information is reviewed by the Company quarterly and provided to the actuary semi-annually. Based on the Company’s evaluation of the actual claim information obtained, the semi-annual estimates received from the third-party actuary, the amounts paid and committed for settlements of claims and on estimates regarding the number and cost of additional claims anticipated in the future, the reserve estimate for a particular period may be revised upward or downward on a quarterly basis. Any increase in the accrual decreases results of operations in the period and any reduction in the accrual increases results of operations during the period.
As of March 31, 2015, the Company is engaged in 45 professional liability lawsuits. Four lawsuits are currently scheduled for trial or arbitration during the next twelve months, and it is expected that additional cases will be set for trial or hearing. The Company’s cash expenditures for self-insured professional liability costs from continuing operations were $840,000 and $1,088,000 for the three months ended March 31, 2015 and 2014, respectively.
Although the Company adjusts its accrual for professional and general liability claims on a quarterly basis and retains a third-party actuarial firm semi-annually to assist management in estimating the appropriate accrual, professional and general liability claims are inherently uncertain, and the liability associated with anticipated claims is very difficult to estimate. Professional liability cases have a long cycle from the date of an incident to the date a case is resolved, and final determination of the Company’s actual liability for claims incurred in any given period is a process that takes years. As a result, the Company’s actual liabilities may vary significantly from the accrual, and the amount of the accrual has and may continue to fluctuate by a material amount in any given period. Each change in the amount of this accrual will directly affect the Company’s reported earnings and financial position for the period in which the change in accrual is made.

10



Other Insurance
With respect to workers’ compensation insurance, substantially all of the Company’s employees became covered under either an indemnity insurance plan or state-sponsored programs in May 1997. The Company is completely self-insured for workers’ compensation exposures prior to May 1997. The Company has been and remains a non-subscriber to the Texas workers’ compensation system and is, therefore, completely self-insured for employee injuries with respect to its Texas operations. From June 30, 2003 until June 30, 2007, the Company’s workers’ compensation insurance programs provided coverage for claims incurred with premium adjustments depending on incurred losses. For the period from July 1, 2008 through March 31, 2015, the Company is covered by a prefunded deductible policy. Under this policy, the Company is self-insured for the first $500,000 per claim, subject to an aggregate maximum of $3,000,000. The Company funds a loss fund account with the insurer to pay for claims below the deductible. The Company accounts for premium expense under this policy based on its estimate of the level of claims subject to the policy deductibles expected to be incurred. The liability for workers’ compensation claims is $449,000 at March 31, 2015. The Company has a non-current receivable for workers’ compensation policies covering previous years of $1,501,000 as of March 31, 2015. The non-current receivable is a function of payments paid to the Company’s insurance carrier in excess of the estimated level of claims expected to be incurred.
As of March 31, 2015, the Company is self-insured for health insurance benefits for certain employees and dependents for amounts up to $175,000 per individual annually. The Company provides reserves for the settlement of outstanding self-insured health claims at amounts believed to be adequate. The liability for reported claims and estimates for incurred but unreported claims is $1,152,000 at March 31, 2015. The differences between actual settlements and reserves are included in expense in the period finalized.
The Company follows current accounting guidance set forth in FASB ASU 2010-24, “Presentation of Insurance Claims and Related Insurance Recoveries,” that clarifies that a health care entity should not net insurance recoveries against a related claim, and that the amount of the claim liability should be determined without consideration of insurance recoveries. Accordingly, the Company has recorded assets and equal liabilities of $85,000 at March 31, 2015 and $246,000 at December 31, 2014, respectively.

6.
STOCK-BASED COMPENSATION

Overview of Plans
In December 2005, the Compensation Committee of the Board of Directors adopted the 2005 Long-Term Incentive Plan (“2005 Plan”). The 2005 Plan allows the Company to issue stock options and other share and cash based awards. Under the 2005 Plan, 700,000 shares of the Company's common stock have been reserved for issuance upon exercise of equity awards granted thereunder. All grants under this plan expire 10 years from the date the grants were authorized by the Board of Directors.
In June 2008, the Company adopted the Advocat Inc. 2008 Stock Purchase Plan for Key Personnel (“Stock Purchase Plan”). The Stock Purchase Plan provides for the granting of rights to purchase shares of the Company's common stock to directors and officers and 150,000 shares of the Company's common stock has been reserved for issuance under the Stock Purchase Plan. The Stock Purchase Plan allows participants to elect to utilize a specified portion of base salary, annual cash bonus, or director compensation to purchase restricted shares or restricted share units (“RSU's”) at 85% of the quoted market price of a share of the Company's common stock on the date of purchase. The restriction period under the Stock Purchase Plan is generally two years from the date of purchase and during which the shares will have the rights to receive dividends, however, the restricted share certificates will not be delivered to the shareholder and the shares cannot be sold, assigned or disposed of during the restriction period. No grants can be made under the Stock Purchase Plan after April 25, 2018.
In April 2010, the Compensation Committee of the Board of Directors adopted the 2010 Long-Term Incentive Plan (“2010 Plan”), followed by approval by the Company's shareholders in June 2010. The 2010 Plan allows the Company to issue stock appreciation rights, stock options and other share and cash based awards. Under the 2010 Plan, 380,000 shares of the Company's common stock have been reserved for issuance upon exercise of equity awards granted.

Equity Grants and Valuations
During 2015 and 2014, the Compensation Committee of the Board of Directors approved grants totaling approximately 74,000 and 68,000 shares of restricted common stock to certain employees and members of the Board of Directors, respectively. The fair value of restricted shares are determined as the quoted market price of the underlying common shares at the date of the grant. The restricted shares typically vest 33% on the first, second and third anniversaries of the grant date. Unvested shares may not be sold or transferred. During the vesting period, dividends accrue on the restricted shares, but are paid in additional shares of common stock upon vesting, subject to the vesting provisions of the underlying restricted shares. The restricted shares are entitled to the same voting rights as other common shares. Upon vesting, all restrictions are removed.

11



Summarized activity of the equity compensation plans is presented below:
 
 
 
Weighted
 
Options/
 
Average
 
SOSARs
 
Exercise Price
Outstanding, December 31, 2014
271,000

 
$
6.67

Granted

 

Exercised
(9,000
)
 
8.19

Expired or cancelled

 

Outstanding, March 31, 2015
262,000

 
$
6.62

 
 
 
 
Exercisable, March 31, 2015
249,000

 
$
6.66


 
 
 
Weighted
 
 
 
Average
 
Restricted
 
Grant Date
 
Shares
 
Fair Value
Outstanding, December 31, 2014
130,000

 
$
5.45

Granted
74,000

 
12.31

Dividend Equivalents
1,000

 
13.85

Vested
(57,000
)
 
5.44

Cancelled

 

Outstanding March 31, 2015
148,000

 
$
8.93


Summarized activity of the Restricted Share Units for the Stock Purchase Plan is as follows:
 
 
 
Weighted
 
 
 
Average
 
Restricted
 
Grant Date
 
Share Units
 
Fair Value
Outstanding, December 31, 2014
46,000

 
$
5.35

Granted
36,000

 
12.31

Dividend Equivalents
1,000

 
13.85

Vested
(22,000
)
 
5.09

Cancelled

 

Outstanding March 31, 2015
61,000

 
$
9.57



Prior to 2014, the Compensation Committee of the Board of Directors also approved grants of Stock Only Stock Appreciation Rights (“SOSARs”) and Stock Options at the market price of the Company's common stock on the grant date. The SOSARs and Options vest 33% on the first, second and third anniversaries of the grant date, and expire 10 years from the grant date. The SOSARs and Options were valued and recorded in the same manner, and will be settled with issuance of new stock for the difference between the market price on the date of exercise and the exercise price. The Company estimated the total recognized and unrecognized compensation related to SOSARs and stock options using the Black-Scholes-Merton equity grant valuation model.

In computing the fair value estimates using the Black-Scholes-Merton valuation model, the Company took into consideration the exercise price of the equity grants and the market price of the Company's stock on the date of grant. The Company used an expected volatility that equals the historical volatility over the most recent period equal to the expected life of the equity grants. The risk free interest rate is based on the U.S. treasury yield curve in effect at the time of grant. The Company used the expected dividend yield at the date of grant, reflecting the level of annual cash dividends currently being paid on its common stock.


12



While no SOSARs or Options were granted during 2015 and 2014, previously granted SOSARs and Options remain outstanding as of March 31, 2015. The following table summarizes information regarding stock options and SOSAR grants outstanding as of March 31, 2015:
 
 
Weighted
 
 
 
 
 
 
 
 
 
 
Average
 
 
 
Intrinsic
 
 
 
Intrinsic
Range of
 
Exercise
 
Grants
 
Value-Grants
 
Grants
 
Value-Grants
Exercise Prices
 
Prices
 
Outstanding
 
Outstanding
 
Exercisable
 
Exercisable
$10.40 to $11.59
 
$
11.10

 
52,000

 
$
144,000

 
52,000

 
$
144,000

$2.37 to $6.21
 
$
5.50

 
210,000

 
$
1,751,000

 
197,000

 
$
1,644,000

 
 
 
 
262,000

 
 
 
249,000

 
 
Stock-based compensation expense is non-cash and is included as a component of general and administrative expense or operating expense based upon the classification of cash compensation paid to the related employees. The Company recorded total stock-based compensation expense of $155,000 and $141,000 in the three month periods ended March 31, 2015 and 2014, respectively.

7.
EARNINGS (LOSS) PER COMMON SHARE
Information with respect to basic and diluted net loss per common share is presented below in thousands, except per share:
 
 
Three Months Ended
March 31,
 
 
 
 
 
2015
 
2014
 
Numerator: Loss amounts attributable to Diversicare Healthcare Services, Inc. common shareholders:
 
 
 
 
Income (loss) from continuing operations
$
5

 
$
(433
)
 
Less: income attributable to noncontrolling interests

 
25

 
Income (loss) from continuing operations attributable to Diversicare Healthcare Services, Inc.
5

 
(408
)
 
Preferred stock dividends

 
(86
)
 
Income (loss) from continuing operations attributable to Diversicare Healthcare Services, Inc. common shareholders
5

 
(494
)
 
Loss from discontinued operations, net of income taxes
(263
)
 
(612
)
 
Net loss attributable to Diversicare Healthcare Services, Inc. common shareholders
$
(258
)
 
$
(1,106
)
 
 

13



 
Three Months Ended
March 31,
 
 
2015
 
2014
 
Net loss per common share:
 
 
 
 
Per common share – basic
 
 
 
 
Loss from continuing operations
$

 
$
(0.08
)
 
Income from discontinued operations
 
 
 
 
Operating income (loss), net of taxes
(0.04
)
 
(0.11
)
 
Gain on disposal, net of taxes

 

 
Discontinued operations, net of taxes
(0.04
)
 
(0.11
)
 
Net loss per common share – basic
$
(0.04
)
 
$
(0.19
)
 
Per common share – diluted
 
 
 
 
Loss from continuing operations
$

 
$
(0.08
)
 
Income from discontinued operations
 
 
 
 
Operating income, net of taxes
(0.04
)
 
(0.11
)
 
Gain on disposal, net of taxes

 

 
Discontinued operations, net of taxes
(0.04
)
 
(0.11
)
 
Net loss per common share - diluted
$
(0.04
)
 
$
(0.19
)
 
Denominator: Weighted Average Common Shares Outstanding:
 
 
 
 
Basic
6,045

 
5,975

 
Diluted
6,045

 
5,975

 
The effects of 52,000 and 288,000 SOSARs and options outstanding were excluded from the computation of diluted earnings per common share in 2015 and 2014, respectively, because these securities would have been anti-dilutive due to the net loss. The weighted average common shares for basic and diluted earnings for common shares were the same due to the year-to-date loss in 2015 and 2014.

8. EQUITY METHOD INVESTMENT
The investment in unconsolidated affiliate reflected on the interim consolidated balance sheet relates to a pharmacy joint venture partnership in which the Company owns 50%. The joint venture was initially funded by the Company and its partner and began operations during 2012. This investment in unconsolidated affiliate is accounted for using the equity method as the Company exerts significant influence, but does not control or otherwise consolidate the entity. The investment in unconsolidated affiliate balance at March 31, 2015, was $571,000 as compared to $463,000 at December 31, 2014. Additionally, the Company's share of the net profits and losses of the unconsolidated affiliate are reported in equity in net earnings or losses of unconsolidated affiliate in our statement of operations. The Company's equity in the net income of unconsolidated affiliate for the period ended March 31, 2015, was $108,000 as compared to a net loss of $3,000 for the period ended March 31, 2014.

9.
BUSINESS DEVELOPMENT
Acquisitions
On February 1, 2015, the Company entered into an Asset Purchase Agreement (the “Purchase Agreement”) with Barren County Health Care Center, Inc. to acquire certain land, improvements, furniture, fixtures and equipment, personal property and intangible property, together comprising a 94-bed skilled nursing center in Glasgow, Kentucky, for an aggregate purchase price of $7,000,000 partially financed through a $5,000,000 mortgage loan with The PrivateBank with the balance paid in cash consideration.

As a result of the consummation of the Agreement, the Company allocated the purchase price of $7,000,000 between the assets associated with the transaction based on the fair value of the acquired net assets. The allocation of the purchase price was

14



determined with the assistance of HealthTrust LLC, a third-party real estate valuation firm. The allocation for the net assets acquired is as follows:

 
February 1, 2015
Purchase Price
$
7,000,000

 
 
Land
672,000

Buildings
5,778,000

Furniture, Fixtures, and Equipment
550,000

 
$
7,000,000


Lease Agreements
During the the first quarter of 2015 and the year ended December 31, 2014, the Company has completed several transactions to assume the operations of additional nursing centers through the assumption of long-term operating leases. The transactions during these periods are as follows:
On February 1, 2015, the Company assumed operations at Diversicare of Hutchinson, an 85-bed skilled nursing center in Hutchinson, Kansas. The facility has an initial lease term of 10 years and includes an option to purchase at a fixed price of $4,250,000, exercisable after the first year of the lease. The center was already operating and treating patients on the transition date. There was no purchase price paid to enter into the lease agreement for this skilled nursing center.
On October 1, 2014, the Company assumed operations at Diversicare of Greenville, a 62-bed skilled nursing facility in Greenville, Kentucky. This facility has an initial lease terms of 14 years. The center was already operating and treating patients on the transition date. There was no purchase price paid to enter into the lease agreement for this skilled nursing center.
On August 1, 2014, the Company assumed operations of two centers in Ohio. The centers included in this transaction are a 142-bed skilled nursing facility and a 42-bed assisted living center. The lease provides for an initial lease term of 10 years. The centers were already operating and treating patients on the transition date. There was no purchase price paid to enter into the lease agreement for these skilled nursing centers.
On July 1, 2014, the Company completed a transaction to enter the state of Missouri through the assumption of operations of three facilities totaling 339 skilled nursing beds. The lease provides for an initial 15-year lease term with a 5-year renewal option. The centers were already operating and treating patients on the transition date. There was no purchase price paid to enter into the lease agreement for these skilled nursing centers.
On June 1, 2014, the Company assumed operations at Diversicare of Nicholasville, an existing 73-bed facility in Nicholasville, Kentucky. The lease provides for an initial 15-year lease term with a 5-year renewal option. The center was already operating and treating patients on the transition date. There was no purchase price paid to enter into the lease agreement for this skilled nursing center.
On March 1, 2014, the Company assumed operations at Diversicare of Big Springs, an existing 135-bed facility in Huntsville, Alabama. The nursing center is owned by an unrelated third-party and the lease provides for an initial 10-year lease term with two additional 5-year renewal options. The additional skilled nursing center increases the Company's footprint in Alabama to seven centers, and the third center in the Huntsville market. The center was already operating and treating patients on the transition date. There was no purchase price paid to enter into the lease agreement for this skilled nursing center.


10.
DISCONTINUED OPERATIONS
West Virginia Disposition
Effective April 3, 2014, the Company entered into an asset purchase agreement with Rose Terrace Acq., LLC (“Purchaser”) to sell its skilled nursing facility in Culloden, West Virginia. The original asset purchase agreement was subject to a number of conditions including an amendment to the Consolidated Amended and Restated Master Lease ("Master Lease") with Omega to terminate the lease only with respect to two other skilled nursing facilities in West Virginia, state licensure and regulatory approval.

15



Effective July 1, 2014, the Company completed the transaction with Rose Terrace Acq., LLC to sell Rose Terrace, a 90-bed skilled nursing facility in Culloden, West Virginia for a sales price of $16,500,000. The Company also entered into the Fifteenth Amendment to the Master Lease with Omega to terminate the lease only with respect to two other skilled nursing facilities in West Virginia, and concurrently entered into an operations transfer agreement with American Health Care Management, LLC, an affiliate of the purchaser with respect to two other skilled nursing facilities located in Danville and Ivydale, West Virginia. The amendment effectively reduced the annual rent payments due under the Master Lease by $1,900,000. Upon completion of the transaction, Diversicare no longer operates any skilled nursing centers in the state of West Virginia. In conjunction with the closing of the sale, the Company paid the balance of the $8,000,000 mortgage loan outstanding on the Rose Terrace facility.
The transaction resulted in a gain on the disposition of Rose Terrace which, along with the results of operations for these nursing facilities, is presented within Discontinued Operations on the Consolidated Statements of Operations. The pretax gain on the transaction was $7,522,000. The tax expense associated with the gain was $2,793,000 for which the Company plans to apply net operating loss carryforwards from our deferred tax assets to substantially offset and minimize the cash outlay for this transaction.
These centers contributed revenues of $0 and $5,564,000 and net income (loss) of $(90,000) and $221,000 during the periods ended March 31, 2015 and 2014, respectively.  The net income or loss for the nursing centers included in discontinued operations does not reflect any allocation of corporate general and administrative expense or any allocation of corporate interest expense. The Company considered these additional costs along with the centers' future prospects based upon operating history when determining the contribution of the skilled nursing centers to its operations.
Other Discontinued Operations
In addition to the ongoing impact of the West Virginia discontinued operations, the Company also experienced ongoing expense during the quarter as it relates to the exit from our Arkansas operations which occurred in September 2013. The activity within Arkansas primarily relates to the progress as it relates to outstanding professional liability claims and finalizing the collection and/or write-off of remaining accounts receivable. These centers contributed net loss of $(173,000) and $(610,000) during the periods ended March 31, 2015 and 2014, respectively. 


16




ITEM 2 – MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS
Overview
Diversicare Healthcare Services, Inc. (together with its subsidiaries, “Diversicare Healthcare Services” or the “Company”) provides long-term care services to nursing center patients in nine states, primarily in the Southeast, Midwest, and Southwest. The Company’s centers provide a range of health care services to their patients and residents that include nursing, personal care, and social services. Additionally, the Company’s nursing centers also offer a variety of comprehensive rehabilitation services, as well as nutritional support services. The Company's continuing operations include centers in Alabama, Florida, Indiana, Kansas, Kentucky, Missouri, Ohio, Tennessee, and Texas.
As of March 31, 2015, the Company’s continuing operations consist of 54 nursing centers with 6,004 licensed nursing beds. The Company owns 14 and leases 40 of its nursing centers. Our nursing centers range in size from 50 to 320 licensed nursing beds. The licensed nursing bed count does not include 496 licensed assisted living and residential beds.
Discontinued Operations
Effective July 1, 2014, the Company completed the transaction with Rose Terrace Acq., LLC to sell Rose Terrace, a 90-bed skilled nursing facility in Culloden, West Virginia for a sales price of $16,500,000. The Company also entered into the Fifteenth Amendment to Consolidated Amended and Restated Master Lease with Omega to terminate the lease only with respect to two other skilled nursing facilities in West Virginia, and concurrently entered into an operations transfer agreement with American Health Care Management, LLC, an affiliate of the purchaser with respect to two other skilled nursing facilities located in Danville and Ivydale, West Virginia. The amendment effectively reduced the annual rent payments due under the Master Lease by $1,900,000. Upon completion of the transaction, Diversicare no longer operates any skilled nursing centers in the state of West Virginia. In conjunction with the closing of the sale, the Company paid the balance of the $8,000,000 mortgage loan outstanding on the Rose Terrace facility.
Strategic Operating Initiatives
During the third quarter of 2010, we identified several key strategic objectives to increase shareholder value through improved operations and business development. These strategic operating initiatives included: improving skilled mix in our nursing centers, improving our average Medicare rate, implementing Electronic Medical Records (“EMR”) to improve Medicaid capture, accelerating center renovations and completing strategic acquisitions. We have experienced success in these initiatives and expect to continue to build on these improvements. We describe each of these below as well as provide metrics for our most recent quarter versus the third quarter of 2010, the quarter before we embarked on our strategic operating initiatives.
Improving skilled mix and average Medicare rate:
Our strategic operating initiatives of improving our skilled mix and our average Medicare rate by accurately capturing the delivery of care required investing in nursing and clinical care to treat more acute patients along with nursing center based sales representatives to attract these patients. These initiatives developed referral and Managed Care relationships that have attracted and are expected to continue to attract patients whose stay in the centers is covered by Medicare and Managed Care. A comparison of our most recent quarter versus the third quarter of 2010, the quarter before we embarked on our strategic operating initiatives, reflects our success with these strategic operating initiatives: 
 
Three Months Ended
 
March 31, 2015
 
September 30,
2010
As a percent of total census:
 
 
 
Medicare census
13.6
%
 
12.3
%
Managed Care census
4.0
%
 
1.3
%
Total skilled mix census
17.6
%
 
13.6
%
As a percent of total revenues:
 
 
 
Medicare revenues
31.0
%
 
29.3
%
Managed Care revenues
7.2
%
 
2.8
%
Total skilled mix revenues
38.2
%
 
32.1
%
Medicare average rate per day:
$
453.84

 
$
394.23


17



The initiatives have developed positive results in growing our skilled patient population, increasing the Managed Care census to 4.0% of total census in the first quarter of 2015, as compared to 1.3% in the third quarter of 2010, and total skilled mix census to 17.6% from 13.6%over the same period.
Implementing Electronic Medical Records to improve Medicaid capture:
As another part of our strategic operating initiative, we implemented EMR to improve documentation of the delivery of care. We completed the implementation of EMR in all our nursing centers in December 2011, on time and under budget. A comparison of our most recent quarter versus the third quarter of 2010 reflects the increase in our average Medicaid rate per day:
 
Three Months Ended
 
March 31, 2015
 
September 30,
2010
Medicaid average rate per day:
$
164.39

 
$
147.93


Completing strategic acquisitions:
Our strategic operating initiatives include a renewed focus on completing strategic acquisitions. We continue to pursue and investigate opportunities to acquire, lease or develop new centers, focusing primarily on opportunities within our existing areas of operation. We expect to announce additional development projects in the near future. We have added six skilled nursing centers in Kentucky, five in Ohio, one in Indiana, one in Alabama, and six in Kansas since the inception of our strategic plan.
As part of our strategic efforts, we have also performed thorough analysis on our existing centers in order to determine whether continuing operations within certain markets or regions was in line with the short-term and long-term strategy of the business. As a result, we disposed of an owned building in Arkansas in 2012, and reached an agreement to terminate our lease for eleven other facilities in Arkansas in 2013. In addition in 2014, the Company disposed of an owned building and two leased facilities in West Virginia. As a result of these transactions, we no longer operate within the states of Arkansas or West Virginia.
Basis of Financial Statements
Our patient revenues consist of the fees charged for the care of patients in the nursing centers we own and lease. Our operating expenses include the costs, other than lease, professional liability, depreciation and amortization expenses, incurred in the operation of the nursing centers we own and lease. Our general and administrative expenses consist of the costs of the corporate office and regional support functions. Our interest, depreciation and amortization expenses include all such expenses across the range of our operations.

Critical Accounting Policies and Judgments
A “critical accounting policy” is one which is both important to the understanding of our financial condition and results of operations and requires management’s most difficult, subjective or complex judgments often involving estimates of the effect of matters that are inherently uncertain. Actual results could differ from those estimates and cause our reported net income or loss to vary significantly from period to period. Our critical accounting policies are more fully described in our 2014 Annual Report on Form 10-K.
Revenue Sources
We classify our revenues from patients and residents into four major categories: Medicaid, Medicare, Managed Care, and Private Pay and other. Medicaid revenues are composed of the traditional Medicaid program established to provide benefits to those in need of financial assistance in the securing of medical services. Medicare revenues include revenues received under both Part A and Part B of the Medicare program. Managed Care revenues include payments for patients who are insured by a third-party entity, typically called a Health Maintenance Organization, often referred to as an HMO plan, or are Medicare beneficiaries who assign their Medicare benefits to a Managed Care replacement plan often referred to as Medicare replacement products. The Private Pay and other revenues are composed primarily of individuals or parties who directly pay for their services. Included in the Private Pay and other are patients who are hospice beneficiaries as well as the recipients of Veterans Administration benefits. Veterans Administration payments are made pursuant to renewable contracts negotiated with these payors.
The following table sets forth net patient and resident revenues related to our continuing operations by payor source for the periods presented (dollar amounts in thousands):

18



 
 
Three Months Ended
March 31,
 
2015
 
2014
Medicaid
$
44,759

 
47.0
%
 
$
38,309

 
49.2
%
Medicare
29,515

 
31.0

 
22,347

 
28.7

Managed Care
6,850

 
7.2

 
5,430

 
7.0

Private Pay and other
14,101

 
14.8

 
11,713

 
15.1

Total
$
95,225

 
100.0
%
 
$
77,799

 
100.0
%
The following table sets forth average daily skilled nursing census by payor source for our continuing operations for the periods presented: 
 
Three Months Ended
March 31,
 
2015
2014
Medicaid
3,040

 
66.4
%
 
2,709

 
68.0
%
Medicare
623

 
13.6

 
500

 
12.5

Managed Care
182

 
4.0

 
150

 
3.8

Private Pay and other
735

 
16.0

 
627

 
15.7

Total
4,580

 
100.0
%
 
3,986

 
100.0
%
Consistent with the nursing home industry in general, changes in the mix of a facility’s patient population among Medicaid, Medicare, Managed Care, and Private Pay and other can significantly affect the profitability of the facility’s operations.

Health Care Industry
The health care industry is subject to numerous laws and regulations of federal, state and local governments. These laws and regulations include, but are not necessarily limited to, matters such as licensure, accreditation, government health care program participation requirements, reimbursement for patient services, quality of resident care and Medicare and Medicaid fraud and abuse. Over the last several years, government activity has increased with respect to investigations and allegations concerning possible violations by health care providers of fraud and abuse laws and regulations as well as laws and regulations governing quality of care issues in the skilled nursing profession in general. Violations of these laws and regulations could result in exclusion from government health care programs together with the imposition of significant fines and penalties, as well as significant repayments for patient services previously billed. Compliance with such laws and regulations is subject to ongoing government review and interpretation, as well as regulatory actions in which government agencies seek to impose fines and penalties. From time to time, the Company, like other in the healthcare industry, may be involved in regulatory actions of this type.
In March 2010, significant legislation concerning health care and health insurance was passed, including the “Patient Protection and Affordable Care Act,” (“Affordable Care Act”) along with the “Health Care and Education Reconciliation Act of 2010” (“Reconciliation Act”) collectively defined as the “Legislation.” The impact of this Legislation remains uncertain to a large degree due to various implementation, timing, cost and regulatory requirements imposed by the Legislation. While much remains uncertain, we expect this Legislation to impact our Company, our employees and our patients and residents in a variety of ways. This Legislation significantly changes the future responsibility of employers with respect to providing health care coverage to employees in the United States. Two of the main provisions of the Legislation became effective in 2014 whereby most individuals are required to either have health insurance or pay a fine and employers with 50 or more employees either have to provide minimum essential coverage or will be subject to additional taxes. On July 2, 2013, the United States Treasury Department announced that it will delay the employer reporting mandate, which was to be effective for 2014, until 2015 to allow additional time for process improvement and system integration. We have not estimated the financial impact of the Legislation and the costs associated with complying with the increased levels of health insurance we will be required to provide our employees and their dependents in future years. We expect the Legislation will result in increased operating expenses.
We also expect for this Legislation to continue to impact our Medicaid and Medicare reimbursement as well, though the exact timing and level of that impact is currently unknown. For example, the Legislation expands the role of home-based and community services, which may place downward pressure on our ability to maintain our population of Medicaid residents. Additional provisions under the Legislation for skilled nursing facilities participating in Medicaid and/or Medicare, including but not limited to, new transparency, reporting, and certification requirements, will likely lead to an increase in the Company's administrative and other costs.

19



On June 28, 2012, the United States Supreme Court upheld many key provisions of the Affordable Care Act. Since this decision, the Affordable Care Act and the implementation thereof still continue to receive challenges and scrutiny from Congress, state attorneys general and legislators, private individuals, and organizations. The potential future impact of these efforts create additional uncertainty about the ultimate impact of the Affordable Care Act on the Company and the long-term care industry.
The provisions of the Affordable Care Act discussed above are only examples of federal health reform provisions that we believe may have a material impact on the long-term care industry and on our business. We anticipate that many of the changes and reforms resulting from the Legislation, as well as other similar health care reforms, may be subject to further clarification and modification through promulgation of regulations, executive orders, and judicial review and could have a material adverse impact on our business, financial condition, and results of operations.
Medicare and Medicaid Reimbursement
A significant portion of our revenues are derived from government-sponsored health insurance programs. Our nursing centers derive revenues under Medicaid, Medicare, Managed Care, Private Pay and other third party sources. We employ third-party specialists in reimbursement and also use these services to monitor regulatory developments and other changes to applicable coverage criteria to comply with reporting requirements and to ensure that proper payments are made to our operated nursing centers. It is generally recognized that all government-funded programs have been and will continue to be under cost containment pressures, but the extent to which these pressures will affect our future reimbursement is unknown.
Medicare
Effective October 1, 2011, Medicare rates were reduced by a nationwide average of 11.1%, the net effect of a reduction to restore overall payments to their intended levels on a prospective basis and the application of a 2.7% market basket increase and a negative 1.0% productivity adjustment required by the Affordable Care Act. The final Centers for Medicare and Medicaid Services (“CMS”) rule also adjusts the method by which group therapy is counted for reimbursement purposes and, for patients receiving therapy, changes the timing of reassessment for purposes of determining patient RUG categories. These October 2011 Medicare reimbursement changes decreased our Medicare revenue and our Medicare rate per patient day. The new regulations also resulted in an increase in costs to provide therapy services to our patients.
The Budget Control Act of 2011 (“BCA”), enacted on August 2, 2011, increased the United States debt ceiling and linked the debt ceiling increase to corresponding deficit reductions through 2021. The BCA also established a 12 member joint committee of Congress known as the Joint Select Committee on Deficit Reduction (“Super Committee”). The Super Committee’s objective was to create proposed legislation to reduce the United States federal budget deficit by $1.5 trillion for fiscal years 2012 through 2021. Part of the BCA required this legislation to be enacted by December 23, 2011, or approximately $1.2 trillion in spending reductions would automatically begin through sequestration on January 1, 2013, split between domestic and defense spending. As no legislation was passed that would achieve the targeted savings outlined in the BCA, payments to Medicare providers have been reduced by 2% from planned levels effective April 1, 2013. In April 2015, congressional committees began deliberations on proposed legislation that would extend sequestration and increase the amount cut by $700 million. If the bill were to become law, it would result in a net effect of increasing the sequester in 2024 beyond the 2% in the BCA.
In July 2014, CMS issued Medicare payment rates, effective October 1, 2014, that increased reimbursement to skilled nursing centers by approximately 1.6% compared to the fiscal year ending September 30, 2014. The increase is the net effect of a 2.5% inflation increase as measured by the SNF market basket, offset by a 0.5% market basket update factor. The wage index budget neutrality factor resulted in an additional 0.4% downward adjustment in rates for the Company's facilities. This adjustment is further offset by the ongoing sequestration from the BCA as mentioned above. The 2% sequestration is not applied to the payment rate, but rather it is applied to Medicare claims after determining coinsurance, any applicable deductibles, and any applicable Medicare secondary payment adjustments.
Therapy Services. There are annual Medicare Part B reimbursement limits on therapy services that can be provided to an individual. The limits impose a $1,940 per patient annual ceiling on physical and speech therapy services, and a separate $1,940 per patient annual ceiling on occupational therapy services. CMS established an exception process to permit therapy services in certain situations and we provide services that are reimbursed under the exceptions process. The exceptions process has been extended several times, most recently in April 2015 by the Medicare Access and CHIP Reauthorization Act, which extended this exception process through December 31, 2017. This allows Part B providers to continue delivering therapy services above the current $1,940 threshold for therapy services, provided the services were medically necessary. In addition, the legislation replaced the mandatory medical manual review of therapy claims exceeding the cap with a review process

20



targeting providers with high denial rates and outlier billing patterns, new providers and certain medical conditions within group practices.
Related to the exceptions process discussed above, for services provided with dates of service, providers are required to submit a request for an exception for therapy services above the threshold of $3,700 which will then be manually medically reviewed, consistent with the treatment of these services historically. Similar to the therapy cap exceptions process, the threshold process will have a $3,700 per patient threshold on physical and speech therapy services, and a separate $3,700 per patient threshold on occupational therapy services. The exception reviews were conducted by Medicare Administrative Contractors during this period.
On November 2, 2010, CMS released a final proposed rule as part of the Medicare Physician Fee Schedule (“MPFS”) that was effective January 1, 2011. The policy impacts the reimbursement we receive for Medicare Part B therapy services in our facilities. The policy provides that Medicare Part B pay the full rate for the therapy unit of service that has the highest Practice Expense ("PE") component for each patient on each day they receive multiple therapy treatments. Reimbursement for the second and subsequent therapy units for each patient each day they receive multiple therapy treatments is reimbursed at a rate equal to 75% of the applicable PE component through March 31, 2013. Effective April 1, 2013, the rate at which these services are reimbursed was reduced to 50% of the applicable PE component.
Medicare Part B therapy services in our centers are determined according to MPFS. Annually since 1997, the MPFS has been subject to a Sustainable Growth Rate Adjustment (“SGR”) intended to keep spending growth in line with allowable spending. Each year since the SGR was enacted, this adjustment produced a scheduled negative update to payment for physicians, therapists and other healthcare providers paid under the MPFS. In April 2015, as part of the Medicare Access and CHIP Reauthorization Act, Congress passed and the President signed into law the "permanent SGR fix" or "doc fix." Under this legislation, the Medicare formula for establishing physician payment rates was permanently replaced. Since 2003, Congress had passed 17 temporary patches that resulted in estimated Medicare Part B payment reductions to skilled nursing facilities of more than $27 billion. The permanent fix is expected to remove a substantial annual risk of future payment reductions.
The Medicare Access and CHIP Reauthorization Act also extended several other elements of the Middle Class Tax Relief and Job Creation Act of 2012, including the reduction of bad debt treated as an allowable cost. Prior to this act, Medicare reimbursed providers for beneficiaries’ unpaid coinsurance and deductible amounts after reasonable collection efforts at a rate between 70 and 100 percent of beneficiary bad debt. This provision reduced bad debt reimbursement exposure for all providers to 65 percent. In addition to the provisions above, the legislation sets for that for fiscal year 2018 (October 1, 2017 through September 30, 2018), all Medicare Part B providers will receive inflationary market basket increases no greater than 1%. This provision is expected to reduce Medicare payments to all post-acute providers by approximately $15.4 billion over the 2018-2025 period.
Medicaid
Several states in which we operate face budget shortfalls, which could result in reductions in Medicaid funding for nursing centers. The federal government made an effort to address the financial challenges state Medicaid programs are facing by increasing the amount of Medicaid funding available to states. Pressures on state budgets are expected to continue in the future and are expected to result in Medicaid rate reductions.
We receive the majority of our annual Medicaid rate increases during the third quarter of each year. The rate changes received in the third quarter of 2014 and the third quarter of 2013, along with increased Medicaid acuity in our acuity based states, was the primary contributor to our 4.2% increase in average rate per day for Medicaid patients in 2015 compared to 2014. Based on the rate changes received during the third quarter of 2014, we expect a favorable impact to our rate per day for Medicaid patients as we move into 2015 due to modest rate increases in many of the states within which we operate.
Effective February 1, 2015, the Company began participating in the Upper Payment Limit ("UPL") supplemental payment program in the state of Indiana that provides supplemental Medicaid payments for skilled nursing facilities that are licensed to non-state government entities such as county hospital districts. One skilled nursing facility previously operated by the Company entered into a transaction with one such hospital providing for the transfer of the license from the Company to the hospital district, and providing further for the Company's operating subsidiaries to retain the management of the facility on behalf of the hospital district, which is participating in the UPL program. The affected operating subsidiary therefore retains operations of its skill nursing facility and the agreement between the hospital district and the Company is terminable by either party to fully restore the prior license status.
We are unable to predict what, if any, reform proposals or reimbursement limitations will be implemented in the future, or the effect such changes would have on our operations. For the three months ended March 31, 2015, we derived 31.0% and 47.0% of our total patient revenues related to continuing operations from the Medicare and Medicaid programs, respectively. Any

21



health care reforms that significantly limit rates of reimbursement under these programs could, therefore, have a material adverse effect on our profitability.
We will attempt to increase revenues from non-governmental sources to the extent capital is available to do so. However, private payors, including Managed Care payors, are increasingly demanding that providers accept discounted fees or assume all or a portion of the financial risk for the delivery of health care services. Such measures may include capitated payments, which can result in significant losses to health care providers if patients require expensive treatment not adequately covered by the capitated rate.
Licensure and Other Health Care Laws
All of our nursing centers must be licensed by the state in which they are located in order to accept patients, regardless of payor source. In most states, nursing centers are subject to certificate of need laws, which require us to obtain government approval for the construction of new nursing centers or the addition of new licensed beds to existing centers. Our nursing centers must comply with detailed statutory and regulatory requirements on an ongoing basis in order to qualify for licensure, as well as for certification as a provider eligible to receive payments from the Medicare and Medicaid programs. Generally, the requirements for licensure and Medicare/Medicaid certification are similar and relate to quality and adequacy of personnel, quality of medical care, record keeping, dietary services, patient rights, and the physical condition of the center and the adequacy of the equipment used therein. Each center is subject to periodic inspections, known as “surveys” by health care regulators, to determine compliance with all applicable licensure and certification standards. Such requirements are both subjective and subject to change. If the survey concludes that there are deficiencies in compliance, the center is subject to various sanctions, including, but not limited to, monetary fines and penalties, suspension of new admissions, non-payment for new admissions and loss of licensure or certification. Generally, however, once a center receives written notice of any compliance deficiencies, it may submit a written plan of correction and is given a reasonable opportunity to correct the deficiencies. There can be no assurance that, in the future, we will be able to maintain such licenses and certifications for our facilities or that we will not be required to expend significant sums in order to comply with regulatory requirements.

Contractual Obligations and Commercial Commitments
We have certain contractual obligations of continuing operations as of March 31, 2015, summarized by the period in which payment is due, as follows (dollar amounts in thousands):
Contractual Obligations
Total
 
Less than
1  year
 
1 to 3
Years
 
3 to 5
Years
 
After
5 Years
Long-term debt obligations (1)
$
64,925

 
$
11,444

 
$
13,349

 
$
40,132

 
$

Settlement obligations (2)
6,554

 
6,554

 

 

 

Elimination of Preferred Stock Conversion feature (3)
2,404

 
687

 
1,374

 
343

 

Operating leases (4)
592,161

 
31,565

 
64,170

 
66,855

 
429,571

Required capital expenditures under operating leases (5)
4,325

 
235

 
471

 
471

 
3,148

Total
$
670,369

 
$
50,485

 
$
79,364

 
$
107,801

 
$
432,719

 
(1)
Long-term debt obligations include scheduled future payments of principal and interest of long-term debt and amounts outstanding on our capital lease obligations.
(2)
Settlement obligations relate to professional liability cases that are expected to be paid within the next twelve months. The professional liabilities are included in our current portion of self-insurance reserves.
(3)
Payments to Omega Health Investors ("Omega"), from which we lease 23 nursing centers, for the elimination of the preferred stock conversion feature in connection with restructuring the preferred stock and master lease agreements. Monthly payments of approximately $57,000 will be made through the end of the initial lease period that ends in September 2018.
(4)
Represents lease payments under our operating lease agreements. Assumes all renewal periods are enacted.
(5)
Includes annual expenditure requirements under operating leases.
We have employment agreements with certain members of management that provide for the payment to these members of amounts up to two times their annual salary in the event of a termination without cause, a constructive discharge (as defined therein), or upon a change of control of the Company (as defined therein). The maximum contingent liability under these agreements is approximately $1,767,000 as of March 31, 2015. The terms of such agreements are for one year and automatically renew for one year if not terminated by us or the employee. In addition, upon the occurrence of any triggering

22



event, those certain members of management may elect to require that we purchase equity awards granted to them for a purchase price equal to the difference in the fair market value of our common stock at the date of termination versus the stated equity award exercise price. Based on the closing price of our common stock on March 31, 2015, the potential contingent liability for the repurchase of the equity grants is $806,000.

Results of Operations
The results of operations presented have been reclassified to present the effects of certain divestitures discussed in the overview to "Management's Discussion and Analysis of Financial Condition and Results of Operations."
The following tables present the unaudited interim statements of operations and related data for the three month periods ended March 31, 2015 and 2014:
 
(in thousands)
Three Months Ended
March 31,
 
2015
 
2014
 
Change
 
%
PATIENT REVENUES, net
$
95,225

 
$
77,799

 
$
17,426

 
22.4
 %
EXPENSES:
 
 
 
 
 
 
 
Operating
77,145

 
62,824

 
14,321

 
22.8
 %
Lease and rent expense
7,145

 
5,967

 
1,178

 
19.7
 %
Professional liability
2,155

 
2,061

 
94

 
4.6
 %
General and administrative
6,051

 
5,114

 
937

 
18.3
 %
Depreciation and amortization
1,879

 
1,735

 
144

 
8.3
 %
Total expenses
94,375

 
77,701

 
16,674

 
21.5
 %
OPERATING INCOME
850

 
98

 
752

 
767.3
 %
OTHER INCOME (EXPENSE):
 
 
 
 
 
 
 
Equity in net income (loss) of unconsolidated affiliate
108

 
(3
)
 
111

 
3,700.0
 %
Interest expense, net
(950
)
 
(892
)
 
(58
)
 
(6.5
)%
 
(842
)
 
(895
)
 
53

 
5.9
 %
INCOME (LOSS) FROM CONTINUING OPERATIONS BEFORE INCOME TAXES
8

 
(797
)
 
805

 
101.0
 %
BENEFIT (PROVISION) FOR INCOME TAXES
(3
)
 
364

 
(367
)
 
(100.8
)%
INCOME (LOSS) FROM CONTINUING OPERATIONS
$
5

 
$
(433
)
 
$
438

 
101.2
 %
 

23



Percentage of Net Revenues
Three Months Ended
March 31,
 
2015
 
2014
PATIENT REVENUES, net
100.0
%
 
100.0
 %
EXPENSES:
 
 
 
Operating
81.0

 
80.8

Lease and rent expense
7.5

 
7.7

Professional liability
2.3

 
2.6

General and administrative
6.4

 
6.6

Depreciation and amortization
2.0

 
2.2

Total expenses
99.1

 
99.9

OPERATING INCOME (LOSS)
0.9

 
0.1

OTHER INCOME (EXPENSE):
 
 
 
Equity in net losses of unconsolidated affiliate
0.1

 

Interest expense, net
(1.0
)
 
(1.1
)
 
(0.9
)
 
(1.1
)
INCOME (LOSS) FROM CONTINUING OPERATIONS BEFORE INCOME TAXES
0.1

 
(1.0
)
BENEFIT FOR INCOME TAXES

 
0.5

INCOME (LOSS) FROM CONTINUING OPERATIONS
0.1
%
 
(0.5
)%

24



Three Months Ended March 31, 2015 Compared With Three Months Ended March 31, 2014
Patient Revenues
Patient revenues were $95.2 million in 2015 and $77.8 million in 2014. This increase is primarily attributable to the acquisition of new facilities during the period. The following table summarizes the revenue increases attributable to our portfolio growth (in thousands):
 
Period Ended
March 31,
 
2015
 
2014
 
Change
Same-store revenue
$
81,727

 
$
76,825

 
$
4,902

2014 acquisition revenue
11,743

 
974

 
10,769

2015 acquisition revenue
1,755

 

 
1,755

Total revenue
$
95,225

 
$
77,799

 
$
17,426

The overall increase in revenue of $17.4 million is primarily attributable to incremental revenue contributions from acquisition activity in 2014 of $10.8 million, as well as the contribution from the newly acquired nursing centers in Glasgow, Kentucky and Hutchinson, Kansas. The two nursing centers acquired to date in 2015 contributed $1.8 million in revenues since the Company assumed operations on February 1, 2015.
The same-store revenues increased by $4.9 million in 2015 compared to the same period in 2014. Overall same-store Medicare census increased 9.4% in 2015 resulting in same-store revenue increase of $1.8 million compared to 2014. Managed Care average daily census increased 17.3% resulting in a revenue increase at our same-store nursing centers of $0.9 million in revenue. The increases in revenue associated with our census increases were partially offset by a decrease in Medicaid census resulting in a revenue decrease of $1.2 million in same-store nursing centers as compared to 2014.
The average Medicaid rate per patient day at same-store nursing centers for 2015 increased 5.0% compared to 2014, resulting in an increase in revenue of $1.8 million. This average rate per day for Medicaid patients is the result of rate increases in certain states and increasing patient acuity levels. The average Medicare rate per patient day for same-store nursing centers increased 3.0% for 2015 compared to 2014, resulting in an increase in revenue of $0.6 million. Additionally, the average Managed Care rate per patient day at same-store nursing centers increased 3.5% over the prior year period resulting in $0.2 million of additional same-store revenue.
The following table summarizes key revenue and census statistics for continuing operations for each period:
 
 
Three Months Ended
March 31,
 
 
 
2015
 
 
 
2014
 
 
Skilled nursing occupancy
77.1
%
 

 
77.8
%
 

As a percent of total census:
 
 
 
 
 
 
 
Medicare census
13.6
%
 
 
 
12.5
%
 
 
Managed Care census
4.0
%
 
 
 
3.8
%
 
 
As a percent of total revenues:
 
 
 
 
 
 
 
Medicare revenues
31.0
%
 
 
 
28.7
%
 
 
Medicaid revenues
47.0
%
 
 
 
49.2
%
 
 
Managed Care revenues
7.2
%
 
 
 
7.0
%
 
 
Average rate per day:
 
 
 
 
 
 
 
Medicare
$
453.84

 
  
 
$
437.64

 
 
Medicaid
$
164.39

 
  
 
$
157.83

 
 
Managed Care
$
392.41

 
  
 
$
377.78

 
 
Operating Expense
Operating expense increased in the first quarter of 2015 to $77.1 million as compared to $62.8 million in the first quarter of 2014, driven primarily by the $9.1 million increase in operating costs attributable to the nursing center operations acquired in 2014, as well as $1.6 million of operating expense associated with the nursing center operations assumed in the first quarter of 2015. The following table summarizes the expense increases attributable to our portfolio growth (in thousands):

25



 
Period Ended
March 31,
 
2015
 
2014
 
Change
Same-store operating expense
$
65,828

 
$
62,183

 
$
3,645

2014 acquisition expense
9,710

 
641

 
9,069

2015 acquisition expense
1,607

 

 
1,607

Total expense
$
77,145

 
$
62,824

 
$
14,321

Operating expense increased slightly as a percentage of revenue at 81.0% for the first quarter of 2015 as compared to 80.8% for the first quarter of 2014. The largest component of operating expenses is wages. Considering the aforementioned addition of the new centers, we experienced an increase to $44.3 million in the first quarter of 2015 as compared to $36.0 million in the first quarter of 2014, an increase of $8.3 million, or 23.1%. Wages as a percentage of revenue slightly increased in the first quarter of 2015 to 46.5% as compared to 46.3% in the first quarter of 2014, an increase of 0.2%.
While the majority of the $14.3 million increase in operating expenses is attributable to the $9.1 million of incremental operating expenses from 2014 acquisitions and $1.6 million from 2015 acquisitions, the same-store nursing centers also experienced an increase of $3.6 million in the first quarter of 2015 as compared to the first quarter of 2014. The increase in operating expenses for our same-store nursing centers is primarily driven by a $2.9 million increase in salaries and related payroll taxes in 2015 compared to the prior year. Additionally, we experienced a $0.6 million increase in Nursing and Ancillary services in 2015 compared to 2014. Both of these increases are primarily attributable to increased census at the nursing centers requiring additional resources to provide care, as well as overall merit increases from the prior year.
Lease Expense
Lease expense increased in the first quarter of 2015 to $7.1 million as compared to $6.0 million in the first quarter of 2014. The increase in lease expense was primarily attributable to $1.2 million in incremental lease expense for the eight newly leased nursing centers in 2014.
Professional Liability
Professional liability expense was $2.2 million in the first quarter of 2015 compared to $2.1 million in the first quarter of 2014, an increase of $0.1 million. We were engaged in 45 professional liability lawsuits as of March 31, 2015, compared to 61 as of March 31, 2014. Our quarterly cash expenditures for professional liability costs of continuing operations were $0.8 million and $1.1 million for 2015 and 2014, respectively. Professional liability expense and cash expenditures fluctuate from year to year based respectively on the results of our third-party professional liability actuarial studies and on the costs incurred in defending and settling existing claims. See “Liquidity and Capital Resources” for further discussion of the accrual for professional liability.

General and Administrative Expense
General and administrative expense was $6.1 million in the first quarter of 2015 as compared to $5.1 million in the first quarter of 2014, an increase of $1.0 million, but decreased as a percentage of revenue from 6.6% in 2014 to 6.4% in 2015. The increase in general and administrative expense is primarily attributable to an increase in salaries and related taxes of $0.7 million in the first quarter of 2015.
Depreciation and Amortization
Depreciation and amortization expense was approximately $1.9 million in the first quarter of 2015 as compared to $1.7 million in 2014. The increase in depreciation expense relates to fixed assets at the newly leased and acquired centers.
Interest Expense, Net
Interest expense was $1.0 million in the first quarter of 2015 and $0.9 million in the first quarter of 2014, an increase of $0.1 million. The increase was primarily attributable to higher debt balances in 2015 as a result of higher outstanding borrowings on the revolving credit facility as a result of the increase in centers undergoing the change in ownership process, as well as the addition of the Glasgow term loan during the first quarter of 2015.
Income (Loss) from Continuing Operations before Income Taxes; Loss from Continuing Operations per Common Share
As a result of the above, continuing operations reported nearly break-even income before income taxes for the first quarter of 2015 as compared to a loss of $0.8 million for the first quarter of 2014. As a result of the near break-even performance, the

26



provision for income taxes was inconsequential for 2015 as compared to a tax benefit of $0.4 million in the first quarter of 2014. The basic and diluted income per common share from continuing operations were both $0.00 for the first quarter of 2015 as compared to a basic and diluted loss per common share from continuing operations of $0.08 in the first quarter of 2014.
Liquidity and Capital Resources
Liquidity
Our primary source of liquidity is the net cash flow provided by the operating activities of our centers. We believe that these internally generated cash flows will be adequate to service existing debt obligations, fund required capital expenditures as well as provide cash flows for investing opportunities. In determining priorities for our cash flow, we evaluate alternatives available to us and select the ones that we believe will most benefit us over the long-term. Options for our cash include, but are not limited to, capital improvements, dividends, purchase of additional shares of our common stock, acquisitions, payment of existing debt obligations, preferred stock redemptions as well as initiatives to improve nursing center performance. We review these potential uses and align them to our cash flows with a goal of achieving long-term success.
Net cash provided by operating activities of continuing operations totaled $0.3 million in the three months ended March 31, 2015, as compared to net cash used of $4.9 million in the same period of 2014.
Our cash expenditures related to professional liability claims of continuing operations were $0.8 million and $1.1 million for three months ended March 31, 2015 and 2014, respectively. Although we work diligently to limit the cash required to settle and defend professional liability claims, a significant judgment entered against us in one or more legal actions could have a material adverse impact on our cash flows and could result in our being unable to meet all of our cash needs as they become due.
Investing activities of continuing operations used cash of $5.9 million and $0.7 million in 2015 and 2014, respectively. The increase is primarily attributable to the $7.0 million of assets purchased in the Glasgow transaction, offset partially by the $2.5 million change in restricted cash.
Financing activities of continuing operations provided cash of $7.0 million in 2015 as compared to cash provided of $2.7 million in 2014 primarily due to draws on the Company's revolving credit facility and the new debt associated with the Company's purchase of the Glasgow nursing center in 2015.

Dividends
On May 6, 2015, the Board of Directors declared a quarterly dividend of $0.055 per common share payable to shareholders of record as of June 30, 2015, to be paid on July 14, 2015. While the Board of Directors intends to pay quarterly dividends, the Board will make the determination of the amount of future cash dividends, if any, to be declared and paid based on, among other things, the Company’s financial condition, funds from operations, the level of its capital expenditures and its future business prospects and opportunities.
Redeemable Preferred Stock
Effective August 14, 2014, the Company redeemed all of its outstanding shares of Series C Preferred Stock (“Preferred Stock”) from the holder, Omega. The redemption was affected as a result of Omega’s exercise of its pre-existing option to require the Company to redeem the Preferred Stock as provided in the Company’s Certificate of Designation. Following the redemption, the Company no longer has any Series C Preferred Stock outstanding.
Professional Liability
The Company has professional liability insurance coverage for its nursing centers that, based on historical claims experience, is likely to be substantially less than the claims that are expected to be incurred. Effective July 1, 2013, the Company established a wholly-owned, offshore limited purpose insurance subsidiary, SHC Risk Carriers, Inc. (“SHC”), to replace some of the expiring commercial policies. SHC covers losses up to specified limits per occurrence. On a per claim basis, coverage for losses in excess of those covered by SHC are maintained through unaffiliated commercial reinsurance carriers. All of the Company's nursing centers in Florida and Tennessee, as well as the Company’s formerly operated Arkansas and West Virginia facilities, are now covered under the captive insurance policies along with most of the nursing centers in Alabama, Kentucky, Ohio, and Texas. The insurance coverage provided for these centers under the SHC policy include coverage limits of $0.5 million per medical incident with a sublimit per center of $1.0 million and total annual aggregate policy limits of $5.0 million. All other centers within the Company’s portfolio are covered through various commercial insurance policies which provide similar coverage limits per medical incident, per location, and on an aggregate basis for covered centers. 

27



As of March 31, 2015, we have recorded total liabilities for reported and settled professional liability claims and estimates for incurred, but unreported claims of $24.9 million. Our calculation of this estimated liability is based on an assumption that the Company will not incur a severely adverse judgment with respect to any asserted claim; however, a significant judgment could be entered against us in one or more of these legal actions, and such a judgment could have a material adverse impact on our financial position and cash flows.
Capital Resources
As of March 31, 2015, we had $55.6 million of outstanding long-term debt and capital lease obligations. The $55.6 million total includes $0.5 million in capital lease obligations, $7.0 million currently outstanding on the revolving credit facility, and $5.0 million in a note payable for the asset purchase of the Glasgow nursing center in Kentucky. The balance of the long-term debt is comprised of $43.1 million owed on our mortgage loan.
On May 1, 2013, the Company executed an Amended and Restated Credit Agreement (the "Credit Agreement") which modified the terms of the Original Mortgage Loan and the Original Revolver Agreements dated February 28, 2011. The Credit Agreement increases the Company's borrowing capacity to $65.0 million allocated between a $45.0 million Mortgage Loan ("Amended Mortgage Loan") and a $20.0 million Revolver ("Amended Revolver"). Loan acquisition costs associated with the Amended Mortgage Loan and the Amended Revolver were capitalized in the amount of $1.3 million and are being amortized over the five-year term of the agreements.
Under the terms of the amended agreements, the syndicate of banks provided the Amended Mortgage Loan with an original balance of $45.0 million with a five-year maturity through April 30, 2018, and a $20.0 million Amended Revolver through April 30, 2018. The Amended Mortgage Loan has a term of five years, with principal and interest payable monthly based on a 25-year amortization. Interest is based on LIBOR plus 4.5%, which was 4.70% at March 31, 2015, but a portion of the outstanding principal balance under the Amended Mortgage Loan is effectively fixed at 6.87% as a result of the interest rate swap described below. The Amended Mortgage Loan is secured by thirteen owned nursing centers, related equipment and a lien on the accounts receivable of these centers. The Amended Mortgage Loan and the Amended Revolver are cross-collateralized. The Company’s Amended Revolver has an interest rate of LIBOR plus 4.5%.
Effective March 31, 2014, the Company entered into the Second Amendment to the Amended and Restated Revolver ("Second Amendment"). The Second Amendment temporarily increased the Amended Revolver capacity from the $20.0 million in the original Amended Revolver to $27.5 million through September 30, 2014, as a result of the increase in receivables related to new facilities that continue to progress through the change in ownership process. Effective July 1, 2014, the Company entered into the Third Amendment to the Amended and Restated Revolver ("Third Amendment"). The Third Amendment makes the previously temporary increase to the Amended Revolver capacity from the $20.0 million in the original Amended Revolver to $27.5 million, a permanent change to the borrowing capacity as a result of the increase in receivables related to new facilities that continue to progress through the change in ownership process.
As of March 31, 2015, the Company had $7.0 million borrowings outstanding under the revolving credit facility compared to $4.5 million outstanding as of December 31, 2014. The outstanding borrowings on the revolver primarily reflect the Company's approach to accumulated Medicaid and Medicare receivables at recently acquired facilities as these facilities proceed through the change in ownership process with CMS. Annual fees for letters of credit issued under this Revolver are 3.00% of the amount outstanding. The Company has eleven letters of credit with a total value of $8.1 million outstanding as of March 31, 2015. Considering the balance of eligible accounts receivable, the letters of credit, the amounts outstanding under the revolving credit facility and the maximum loan amount of $27.5 million, the balance available for borrowing under the revolving credit center is $11.5 million at March 31, 2015.
Our lending agreements contain various financial covenants, the most restrictive of which relate to minimum cash deposits, cash flow and debt service coverage ratios. We are in compliance with all such covenants at March 31, 2015.
Our calculated compliance with financial covenants is presented below:
 
 
Requirement
  
Level at
March 31, 2015
Minimum fixed charge coverage ratio
1.00:1.00
 
1.15:1.00
Minimum adjusted EBITDA
$10.0 million
 
$20.2 million
EBITDAR (mortgaged centers)
$6.15 million
 
$10.08 million
As part of the debt agreements entered into in March 2011, we entered into an interest rate swap agreement with a member of the bank syndicate as the counterparty. The interest rate swap agreement has the same effective date and maturity date as the

28



Amended Mortgage Loan, and carries a notional equivalent to half of the outstanding principal on the Amended Mortgage Loan. The interest rate swap agreement requires us to make fixed rate payments to the bank calculated on the applicable notional amount at an annual fixed rate of 6.87% while the bank is obligated to make payments to us based on LIBOR on the same notional amounts. We entered into the interest rate swap agreement to mitigate the variable interest rate risk on our outstanding mortgage borrowings.
On February 1, 2015, in conjunction with the acquisition of Diversicare of Glasgow, a 94-bed skilled nursing facility in Glasgow, Kentucky, the Company entered into the $5.0 million Glasgow term loan with The PrivateBank in order to finance the purchase of the assets. The Glasgow term loan is an interest-only loan and has an 18-month maturity dated August 1, 2016, and a variable interest rate based on LIBOR, with a minimum base rate of 4.75%.
Receivables
Our operations could be adversely affected if we experience significant delays in reimbursement from Medicare, Medicaid or other third-party revenue sources. Our future liquidity will continue to be dependent upon the relative amounts of current assets (principally cash, accounts receivable and inventories) and current liabilities (principally accounts payable and accrued expenses). In that regard, accounts receivable can have a significant impact on our liquidity. Continued efforts by governmental and third-party payors to contain or reduce the acceleration of costs by monitoring reimbursement rates, by increasing medical review of bills for services, or by negotiating reduced contract rates, as well as any delay by us in the processing of our invoices, could adversely affect our liquidity and results of operations.
Accounts receivable attributable to patient services of continuing operations totaled $50.0 million at March 31, 2015 compared to $47.5 million at December 31, 2014, representing approximately 45 days and 43 days revenue in accounts receivable, respectively. The increase in accounts receivable is due to increases in payor sources with longer payment cycles, including Managed Care payors, as well as an increase in Medicaid patients undergoing the initial qualification process.
Our accounts receivable included approximately $6.6 million and $5.5 million at March 31, 2015 and December 31, 2014, respectively of unbilled accounts, primarily attributable to newly acquired facilities.  During the change of ownership process, we were required to hold these accounts while waiting for final Medicare and Medicaid approvals.
The allowance for bad debt was $6.5 million at March 31, 2015 as compared to $6.0 million at December 31, 2014. We continually evaluate the adequacy of our bad debt reserves based on patient mix trends, aging of older balances, payment terms and delays with regard to third-party payors, collateral and deposit resources, as well as other factors. We continue to evaluate and implement additional procedures to strengthen our collection efforts and reduce the incidence of uncollectible accounts.
Off-Balance Sheet Arrangements
We have eleven letters of credit outstanding with an aggregate value of approximately $8.1 million as of March 31, 2015, the first of which serves as a security deposit for our facility lease with Omega in the amount of $4.6 million. The second letter of credit serves our initial funding of insurance policies with a captive insurance company in the amount of $1.0 million. The balance of the outstanding letters of credit relate to deposits at various leased facilities where the Company opted to issue letters of credit as a deposit in lieu of cash. These letters of credit were issued under our revolving credit facility. Our accounts receivable serve as the collateral for this revolving credit facility.


29



Forward-Looking Statements
The foregoing discussion and analysis provides information deemed by management to be relevant to an assessment and understanding of our consolidated results of operations and financial condition. This discussion and analysis should be read in conjunction with our consolidated financial statements included herein. Certain statements made by or on behalf of us, including those contained in this “Management’s Discussion and Analysis of Financial Condition and Results of Operations” and elsewhere, are forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995. Actual results could differ materially from those contemplated by the forward-looking statements made herein. In addition to any assumptions and other factors referred to specifically in connection with such statements, other factors, many of which are beyond our ability to control or predict, could cause our actual results to differ materially from the results expressed or implied in any forward-looking statements including, but not limited to, our ability to successfully operate the new nursing centers in Alabama, Kansas, Kentucky, Ohio, and Indiana, our ability to increase census at our renovated centers, changes in governmental reimbursement, including the impact of the CMS final rule that has resulted in a reduction in Medicare reimbursement as of October 2012 and our ability to mitigate the impact of the revenue reduction, government regulation, the impact of the recently adopted federal health care reform or any future health care reform, any increases in the cost of borrowing under our credit agreements, our ability to comply with covenants contained in those credit agreements, the outcome of professional liability lawsuits and claims, our ability to control ultimate professional liability costs, the accuracy of our estimate of our anticipated professional liability expense, the impact of future licensing surveys, the outcome of proceedings alleging violations of state or Federal False Claims Acts, laws and regulations governing quality of care or other laws and regulations applicable to our business including laws governing reimbursement from government payors, impacts associated with the implementation of our electronic medical records plan, the costs of investing in our business initiatives and development, our ability to control costs, changes to our valuation of deferred tax assets, changes in occupancy rates in our centers, changing economic and competitive conditions, changes in anticipated revenue and cost growth, changes in the anticipated results of operations, the effect of changes in accounting policies as well as others. Investors also should refer to the risks identified in this “Management’s Discussion and Analysis of Financial Condition and Results of Operations” as well as risks identified in “Risk Factors” in our annual report on Form 10-K for the year ended December 31, 2014, for a discussion of various risk factors of the Company and that are inherent in the health care industry. Given these risks and uncertainties, we can give no assurances that these forward-looking statements will, in fact, transpire and, therefore, caution investors not to place undue reliance on them. These assumptions may not materialize to the extent assumed, and risks and uncertainties may cause actual results to be different from anticipated results. These risks and uncertainties also may result in changes to the Company’s business plans and prospects. Such cautionary statements identify important factors that could cause our actual results to materially differ from those projected in forward-looking statements. In addition, we disclaim any intent or obligation to update these forward-looking statements.

ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK
The chief market risk factor affecting our financial condition and operating results is interest rate risk. As of March 31, 2015, we had outstanding borrowings of approximately $55.1 million, $28.6 million of which was subject to variable interest rates. In connection with our May 2013 financing agreement, we entered into an interest rate swap with respect to one half of the Amended Mortgage Loan to mitigate the floating interest rate risk of a portion of such borrowing. In the event that interest rates were to change 1%, the impact on future pre-tax cash flows would be approximately $286,000 annually, representing the impact of increased or decreased interest expense on variable rate debt.

ITEM 4. CONTROLS AND PROCEDURES
As required by Rule 13a-15(b) of the Securities Exchange Act of 1934, as amended (the Exchange Act), our management, including our chief executive officer and chief financial officer, conducted an evaluation of the effectiveness of the design and operation of our disclosure controls and procedures (as defined in Exchange Act Rule 13a-15(e)) as of March 31, 2015. Disclosure controls and procedures include controls and procedures designed to ensure that information required to be disclosed in our reports filed or submitted under the Exchange Act, such as this Quarterly Report on Form 10-Q, is properly recorded, processed, summarized and reported within the time periods required by the Securities and Exchange Commission’s rules and forms. Management necessarily applied its judgment in assessing the costs and benefits of such controls and procedures that, by their nature, can provide only reasonable assurance regarding management’s control objectives. Management does not expect that its disclosure controls and procedures will prevent all errors and fraud. A control system, irrespective of how well it is designed and operated, can only provide reasonable assurance, and cannot guarantee that it will succeed in its stated objectives.
Based on an evaluation of the effectiveness of the design and operation of disclosure controls and procedures, our chief executive officer and chief financial officer concluded that, as of March 31, 2015, our disclosure controls and procedures were effective in reaching a reasonable level of assurance that information required to be disclosed by us in the reports that we file or

30



submit under the Exchange Act is recorded, processed, summarized and reported within the time period specified in the Securities and Exchange Commission’s rules and forms.

PART II — OTHER INFORMATION
ITEM 1. LEGAL PROCEEDINGS.
The provision of health care services entails an inherent risk of liability. Participants in the health care industry are frequently subject to lawsuits, many of which involve large claims and significant defense costs. Like many other companies engaged in the long-term care profession in the United States, we have numerous pending claims, disputes and legal actions for professional liability, negligence and other related issues. It is expected that we will continue to be subject to such suits as a result of the nature of our business. Further, as with all health care providers, we are periodically subject to state and federal regulatory investigations, proceedings, and actions related to our compliance with laws governing health care fraud, reimbursement for services provided, patient care standards, elder abuse, employment, and other issues related to the operation of our business. Like other health care providers, in the ordinary course of our business, we are also subject to claims made by employees and other disputes and litigation arising from the conduct of our business.
As of March 31, 2015, we are engaged in 45 professional liability lawsuits. Four lawsuits are currently scheduled for trial or arbitration during the next twelve months, and it is expected that additional cases will be set for trial or hearing. The ultimate results of any of our professional liability claims and disputes cannot be predicted with certainty. A significant judgment entered against us in one or more of these legal actions could have a material adverse impact on our financial position and cash flows.
In July 2013, the Company learned that the United States Attorney for the Middle District of Tennessee (DOJ) had commenced a civil investigation of potential violations of the False Claims Act (FCA) at two of the Company's facilities. Notice to the Company came in the form of a civil investigative demand (CID), a form of subpoena, to produce certain documents relating to our practices and policies for rehabilitation and other services since 2010 at those two facilities. The Company responded to this limited CID and has cooperated with the DOJ in connection with its investigation. In October 2014, the Company received a second CID indicating that the DOJ’s investigation now covers all of the Company’s facilities, but only directing the Company to produce material related to a total of six of the Company's facilities. The Company has also received from the OIG requests for the medical records of certain patients. The Company intends to respond to the most recent requests and to continue cooperating with the DOJ and the OIG in the investigation. The Company cannot predict the outcome of this investigation or any possible related proceedings, and the outcome could have a materially adverse effect on the Company, including the imposition of damages, fines, penalties and/or a corporate integrity agreement, but the Company is committed to provide caring and professional services to its patients and residents in compliance with applicable laws and regulations.
In November 2012, a purported stockholder class action complaint was filed in the Chancery Court for Williamson County, Tennessee (21st Judicial District) against the Company's Board of Directors. This action alleges that the Board of Directors breached its fiduciary duties to stockholders related to its response to certain expressions of interest in a potential strategic transaction from Covington Investments, LLC (“Covington”). The complaint asserts that the Board failed to negotiate or otherwise appropriately consider Covington's proposals. Plaintiff has filed a motion seeking to certify the action as a class action, which is not currently set for hearing. On May 23, 2014, the plaintiff and defendants entered into a memorandum of understanding outlining the terms of a settlement subject to the execution of definitive documentation and court approval. The agreement provides that the Company will adopt and maintain certain corporate governance procedures for a period of at least three years. This settlement has not yet been approved by the court. The settlement hearing is scheduled for May 22, 2015.
In June 2012, a collective action complaint was filed in the U.S. District Court for the U.S. District Court for the Western District of Arkansas against us and certain of our subsidiaries.  The complaint alleges that the defendants violated the Fair Labor Standards Act (FLSA) and seeks unpaid overtime wages as well as liquidated damages.  The Court conditionally certified a nationwide class of all of the Company's hourly employees, but recently decertified the class.  After the class was decertified, the law firm initiating the action filed three new separate actions in federal courts in Arkansas, Tennessee, and Texas, naming as plaintiffs many of the individuals who had filed claims in the first Arkansas action. The new actions assert the same claim as was asserted in the original Arkansas action. The original action has been settled and dismissed. The Company intends to defend the remaining lawsuits vigorously.
We cannot currently predict with certainty the ultimate impact of any of the above cases on our financial condition, cash flows, or results of operations. Our reserve for professional liability expenses does not include any amounts for any of the collective actions and investigations specifically described above. An unfavorable outcome in any of these lawsuits or any of our professional liability actions, any regulatory action, any investigation or lawsuit alleging violations of fraud and abuse laws or of elderly abuse laws or any state or Federal False Claims Act case could subject us to fines, penalties and damages, including

31



exclusion from the Medicare or Medicaid programs, and could have a material adverse impact on our financial condition, cash flows or results of operations.

ITEM 6. EXHIBITS
The exhibits filed as part of this report on Form 10-Q are listed in the Exhibit Index immediately following the signature page.

32



SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
 
 
 
 
 
 
Diversicare Healthcare Services, Inc.
 
 
 
May 7, 2015
 
 
 
 
 
 
 
By:
 
/s/ Kelly J. Gill
 
 
 
Kelly J. Gill
 
 
 
President and Chief Executive Officer, Principal Executive Officer and
 
 
 
An Officer Duly Authorized to Sign on Behalf of the Registrant
 
 
 
 
By:
 
/s/ James R. McKnight, Jr.
 
 
 
James R. McKnight, Jr.
 
 
 
Executive Vice President and Chief Financial Officer and
 
 
 
An Officer Duly Authorized to Sign on Behalf of the Registrant

33



 
 
 
Exhibit
Number
  
Description of Exhibits
3.1

  
Certificate of Incorporation of the Registrant (incorporated by reference to Exhibit 3.1 to the Company’s Registration Statement No. 33-76150 on Form S-1).
 
 
3.2

  
Certificate of Designation of Registrant (incorporated by reference to Exhibit 3.5 to the Company’s quarterly report on Form 10-Q for the quarter ended September 30, 2006).
 
 
3.3

  
Bylaws of the Company (incorporated by reference to Exhibit 3.2 to the Company’s Registration Statement No. 33-76150 on Form S-1).
 
 
3.4

  
Bylaw Amendment adopted November 5, 2007 (incorporated by reference to Exhibit 3.4 to the Company’s annual report on Form 10-K for the year ended December 31, 2007).
 
 
3.5

  
Amendment to Certificate of Incorporation dated March 23, 1995 (incorporated by reference to Exhibit A of Exhibit 1 to the Company’s Form 8-A filed March 30, 1995).
 
 
3.6

  
Certificate of Designation of Registrant (incorporated by reference to Exhibit 3.4 to the Company’s quarterly report on Form 10-Q for the quarter ended March 31, 2001).
 
 
3.7

 
Certificate of Ownership and Merger of Diversicare Healthcare Services, Inc. with and into Advocat Inc. (incorporated by reference to Exhibit 3.1 to the Company's current report on Form 8-K filed March 14, 2013).
 
 
 
4.1

  
Form of Common Stock Certificate (incorporated by reference to Exhibit 4 to the Company’s Registration Statement No. 33-76150 on Form S-1).
 
 
10.1

 
Asset Purchase Agreement dated February 1, 2015 by and between Diversicare Healthcare Services, Inc. and Barren County Health Care Center, Inc.
 
 
 
10.2

 
Term Loan and Security Agreement dated as of February 2, 2015 by and between Diversicare Glasgow Property, LLC and The PrivateBank And Trust Company.
 
 
 
31.1

  
Certification of Chief Executive Officer pursuant to Rule 13a-14(a) or Rule 15d-14(a).
 
 
31.2

  
Certification of Chief Financial Officer pursuant to Rule 13a-14(a) or Rule 15d-14(a).
 
 
32

  
Certification of Chief Executive Officer and Chief Financial Officer pursuant to Rule 13a-14(b) or Rule 15d-14(b).
 
 
101.INS

  
XBRL Instance Document
 
 
101.SCH

  
XBRL Taxonomy Extension Schema Document
 
 
101.CAL

  
XBRL Taxonomy Extension Calculation Linkbase Document
 
 
101.LAB

  
XBRL Taxonomy Extension Labels Linkbase Document
 
 
101.PRE

  
XBRL Taxonomy Extension Presentation Linkbase Document
 
 


34
EX-10.1 2 dvcr-ex101x33115barrencoun.htm EXHIBIT 10.1 DVCR-EX10.1 - 3.31.15 Barren County Asset Purchase Agreement

ASSET PURCHASE AGREEMENT
THIS ASSET PURCHASE AGREEMENT (“Agreement”), is made effective as of January 29, 2015, by and among BARREN COUNTY HEALTH CARE CENTER, INC., a Kentucky corporation (“Seller”), DIVERSICARE OF GLASGOW, LLC, a Delaware limited liability company (“Buyer”), and, solely for the purposes of Sections 5.18 and 11.2, Steve Brown, John L. Beam, Linda Beam, Nancy A. Mollett, James B. Hurst, Thomas S. Hurst, Jr., Peggy Hurst Greenwell, Beth Hurst Hawkins and Sallie Hurst Schrieber, individuals and residents of the Commonwealth of Kentucky (collectively, the “Shareholders”).
A.    Seller owns and operates a certain skilled nursing facility located at 300 Westwood Street, Glasgow, Kentucky 42141, known as “Barren County Health Care Center” (the “Facility”).
B.    Seller desires to sell and transfer the assets of the Facility including all rights in the Real Estate (as defined below) and Buyer (or an affiliate of Buyer) desires to purchase the same from Seller subject to the terms and conditions of this Agreement.
In consideration of the mutual covenants contained in this Agreement and of other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the parties intending to be legally bound hereby agree as follows:
ARTICLE 1. PURCHASE AND SALE
1.1.    Purchase and Sale. Seller agrees at Closing (as defined herein), to sell, transfer, assign, convey and deliver to Buyer, and Buyer agrees to purchase, acquire and accept from Seller all right, title and interest in and to certain assets of Seller related to the Facility (collectively, the “Assets”), as set forth below, but expressly excluding the “Excluded Assets” (as defined in Section 1.2 below):
(1)    All right, title and interest, in and to all of the land and real estate owned by Seller and used in connection with the Facility as described on Exhibit 1.1(1) attached hereto and in and to all structures, improvements, fixed assets and fixtures including fixed machinery and fixed equipment situated thereon or forming a part thereof (collectively, the “Real Estate”), together with all appurtenances, easements and rights-of-way related thereto;
(2)    All tangible personal property, medical and other equipment, machinery, data processing and computer hardware and software, furniture, furnishings, appliances, vehicles and other tangible personal property and located at the Facility (collectively, the “Equipment and Furnishings”);
(3)    All inventory of goods and supplies used or maintained in connection with the Facility including food, cleaning materials, disposables, linens, consumables, office supplies, and medical supplies (collectively, the “Inventory”);
(4)    All personnel, resident/occupant and other records related to the Facility (including hard, electronic and microfiche copies) and all manuals, books and records used in operating the Facility including, without limitation, personnel policies and files and manuals, accounting records, and computer files;
(5)    To the extent transferable, all licenses, permits, registrations, certificates, accreditations and approvals necessary to operate the Facility;
(6)    All plans and surveys, including “as-built” plans, those relating to utilities, easements and roads, and plats, specifications, engineers’ drawings, architectural renderings and similar items in Seller’s possession;
(7)    All goodwill and, to the extent assignable by Seller, all warranties (express or implied) and, except as otherwise excluded hereinbelow, rights and claims related to the Assets or the operation of the Facility, including the “Barren County Health Care Center” name;
(8)    All resident escrows and deposits of any prepaid rent or any other fees paid by Facility residents related to the Facility (the “Deposits”), as set forth on Exhibit 1.1(8) attached hereto;
(9)    The Assumed Contracts, as defined in Section 3.9, and as set forth on Exhibit 3.9 attached hereto;
(10)    all other properties and assets of every kind, character and description, tangible or intangible, owned by Seller and used in connection with the Facility, whether or not similar to the items specifically set forth above;
(11)    Seller’s Medicare provider number; and
(12)    All interests in the admissions agreements with residents of the Facilities (“Admission Agreements”).
1.2.    Excluded Assets. Seller is not selling and Buyer is not purchasing or assuming obligations with respect to the following (collectively, the “Excluded Assets”):
(1)    Seller’s corporate and fiscal records and other records that Seller is required by law to retain in its possession and that are not included in Section 1.1(4) above;
(2)    All accounts not included in Section 1.1(8) above, notes and other receivables, specifically including but not limited to, promissory notes from residents and accounts receivable for services provided to residents at the Facility prior to the Closing, including those from non-governmental third party payors and those from governmental third-party, including Medicare and Medicaid;
(3)    All cash, cash equivalents, cash deposits and escrows, bank accounts, money market accounts, other accounts, certificates of deposit and other investments of Seller other than the Facility’s petty cash;
(4)    Seller’s provider agreements with Medicaid or any other state governmental payor program and any corresponding provider numbers;
(5)    All Contracts not included in the Assumed Contracts;
(6)    Seller’s provider agreements with Medicaid or any other state governmental payor program and any corresponding provider numbers;
(7)    Rights to settlements and retroactive adjustments, if any, whether arising under a cost report of Seller or otherwise, for cost reporting periods ending on or before the Closing Date, whether open or closed, arising from or against the United States government under the terms of the Medicare program or the TRICARE, formerly Civilian Health and Medical Program of the Uniformed Services (“CHAMPUS”), or against the State of Kentucky under the Medicaid program, and against any third party payor programs which settle upon a basis other than an individual claims basis;
(8)    All inventory and prepaid expenses disposed of or exhausted prior to the Closing in the ordinary course of business;
(9)    Any records related solely to Excluded Assets or Excluded Liabilities;
(10)    Any records which Seller is required by law to retain in its possession;
(11)    Any proprietary information of Seller, including without limitation that information contained in Seller’s employee or operations manuals, Seller’s third-party reimbursement systems and manuals and all information that does not pertain to the continuing operations of the Facility;
(12)    Claims against third parties related to the operation of the Facility prior to the Closing;
(13)    Rights to tax refunds or claims related to the Seller, the Facility or the Assets for the periods ending prior to Closing;
(14)    Computer software and programs which are licensed from third party providers and/or are proprietary to Seller, including but not limited to, PointClickCare and other billing programs;
(15)    Any reimbursement from Medicaid and Medicare as a result of any loss by Seller on the disposal of the Assets for purposes of Medicaid and Medicare reimbursement;
(16)    Subject to Sections 5.5 and 5.6, rights to insurance proceeds or the equivalent relative to the Assets; and
(17)    Any other items listed on Exhibit 1.2 attached hereto.
1.3.    Disclaimer of Warranties. Except as expressly set forth in Article 3 hereof, the Assets will be transferred to Buyer and Buyer agrees to accept said Assets and their condition as of the date of Closing “AS IS”, “WHERE IS” AND “WITH ALL FAULTS”, “WITH NO WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES REGARDING HABITABILITY, FITNESS FOR HABITATION OR CONDITION, WITH RESPECT TO LAND, BUILDINGS AND IMPROVEMENTS, AND WITH NO WARRANTIES, INCLUDING WITHOUT LIMITATION, THE WARRANTIES OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE, WITH RESPECT TO THE MACHINERY, EQUIPMENT AND INVENTORY, AND SUPPLIES, ANY AND ALL OF WHICH WARRANTIES (BOTH EXPRESS AND IMPLIED) SELLER HEREBY DISCLAIMS.
1.4.    Assumed Contracts and Liabilities.
(1)    At Closing, Buyer will assume and agree to pay or perform, as the case may be, those obligations of Seller (i) arising after Closing under the Assumed Contracts and (ii) arising from all accrued vacation, sick leave and paid time off (vested and unvested) for Employees (as defined in Section 3.13) who are hired by Buyer or Buyer’s agent at Closing, to the extent that Buyer receives a credit for such liabilities against the Purchase Price (as defined in Section 2.1 below) (herein, the “Employee Obligations”) (items (i) and (ii) are collectively, the “Assumed Liabilities”).
(2)    Except for the Assumed Liabilities, Buyer shall not assume, and shall not be liable for, any debt, liability or obligation of Seller of any type or description whatsoever, whether related or unrelated to the Assets, the Facility or the transactions contemplated within this Agreement and Seller shall remain liable and responsible for the payment or performance, as the case may be, of all such debts, liabilities and obligations.
1.5.    Excluded Liabilities. Without limiting the foregoing, Seller shall remain responsible for all debts, liabilities and obligations not expressly assumed by Buyer (collectively, the “Excluded Liabilities”), including but not limited to the following:
(1)    All obligations pursuant to or related to any loan or debt obligations;
(2)    Liabilities, indebtedness, commitments or obligations and responsibilities of any kind whatsoever (other than the Assumed Liabilities) of Seller arising from operations of the Facility relating to the time prior to Closing;
(3)    All liabilities and commitments relating to the time periods through Closing for income tax and other taxes; all employee (and former employee) wages, salaries and benefits (unless specifically referred to in Section 1.3(1)),
(4)    any liability of the Seller arising out of the injury to or death of any person, or damage to or destruction of any property, whether based on negligence, breach of warranty, strict liability, enterprise liability or any other legal or equitable theory arising from or related to services provided by the Seller, to the extent any of such liabilities arose on or prior to the Closing; and
(5)    amounts owed by Seller to any third party payors, including Medicare and Medicaid, for the periods through Closing as a result of any settlement or other adjustment process used by such third party payors, including cost reports filed or to be filed.
ARTICLE 2.     PURCHASE PRICE; ALLOCATIONS;
ACCOUNTS RECEIVABLE AND RESIDENT FUNDS
2.1.    Purchase Price.
(18)    The purchase price payable by Buyer to Seller for the Assets shall be Seven Million and No/100 Dollars ($7,000,000.00) (the “Purchase Price”) minus an amount equal to One Hundred Fifty Thousand Dollars ($150,000.00) (the “Escrow Holdback”), which shall be paid to First Tennessee Bank, N.A. (the “Escrow Agent”) and held in accordance with the Escrow Agreement (herein so called) in the form attached as Exhibit A. The Purchase Price, plus or minus credits and prorations as set forth in this Agreement, shall be payable at Closing by wire transfer to an account designated by Seller of immediately available, same day funds. For purposes of determining the credit given to Buyer at Closing for assuming the Employee Obligations, the amount of Employee Obligations assumed by Buyer shall be estimated in good faith by the parties at Closing, subject to a final adjustment in accordance with Section 2.2 in the event of any variation in the amounts estimated at Closing and the actual amount of Employee Obligations assumed by Buyer.
(19)    Upon execution of this Agreement, Buyer shall deliver to a nationally recognized title insurance company reasonably acceptable to Buyer (the “Title Company”), as escrow agent (the “Escrow Agent”), the sum of Fifty Thousand and No/100 Dollars ($50,000.00) as a deposit (the “Earnest Money Deposit”), which shall be held in an escrow account and paid by Title Company in accordance with this Agreement. All interest accrued on the Earnest Money Deposit shall be added to and become a part of the Earnest Money Deposit. If Closing occurs, at the Closing the Escrow Agent shall release the Earnest Money Deposit and any accrued interest to Seller to be applied in partial satisfaction of the Purchase Price. If the Agreement is terminated pursuant to Section 6.2(1)(b), the Escrow Agent shall release the Earnest Money Deposit and any accrued interest to Seller. If the Agreement is terminated for any other reason, the Escrow Agent shall release the Earnest Money Deposit and any accrued interest to Buyer.
2.2.    Apportionable Income and Expenses. All income and expense attributable to the operation of the Facility (measured on an accrual basis) through 11:59 p.m. on the day preceding the Closing Date shall be for the account of Seller. Thereafter, such income and expense shall be for the account of Buyer. All apportionable items of operating income and expense applicable to any periods commencing before Closing and continuing after Closing shall be prorated between Seller and, to the extent they are included within the Assumed Liabilities, Buyer. Apportionable operating income and expenses shall include, but shall not be limited to, such items as prepaid income, power and utility charges, personal property taxes, real estate taxes and rents. Buyer will be responsible for any and all sales taxes incurred as a result of this transaction.
If final prorations cannot be made at Closing for any item being prorated under this Section 2.2, Buyer and Seller agree to allocate such items on a fair and equitable basis as soon as invoices or bills are available and applicable reconciliation have been completed, with final adjustment to be made as soon as reasonably possible after the Closing (but in no event later than ninety (90) days after the Closing, except that adjustments arising from any tax protest shall not be subject to such ninety (90) day limitation, but shall be made as soon as reasonably possible), to the effect that income and expenses are received and paid by the parties on an accrual basis with respect to their period of ownership. Payments in connection with the final adjustment shall be due no later than ninety (90) days after the Closing, except that adjustments arising from any tax protest shall not be subject to such 90-day limitation, but shall be made as soon as reasonably possible. Seller shall have reasonable access to, and the right to inspect and audit, Buyer’s books to confirm the final prorations for a period of one (1) year after the Closing. To the extent invoices or bills for the current real estate tax year are not yet issued, the parties shall prorate such taxes on the basis of the most recent tax year and will adjust such proration within five (5) business days after Seller or Buyer receive the real estate tax invoice for the current tax year.
2.3.    Allocation of Purchase Price. The Purchase Price shall be allocated among the Assets in the manner set forth in Exhibit 2.3 attached hereto (the “Allocation”). The parties to this Agreement agree that the Allocation shall be used by them for all purposes including tax, reimbursement and other purposes. Each party to this Agreement agrees that it will report the transaction completed pursuant to this Agreement in accordance with the Allocation, including any report made under Section 1060 of the Internal Revenue Code of 1986, as amended (the “Code”), and that no party will take a position inconsistent with the Allocation except with the prior written consent of the other parties hereto.
2.4.    Accounts Receivable.
(6)    Seller is not selling, and shall retain all right, title and interest in and to all unpaid accounts receivable with respect to the Facility which relate to the period prior to the Closing Date, including, but not limited to, any accounts receivable arising from rate adjustments which relate to the period prior to the Closing Date even if such adjustments occur after the Closing Date (“Seller’s A/R”). Buyer (i) shall not interfere with any of Seller’s rights with respect to the Seller’s A/R, including but not limited to, the right to collect the same and to enforce any and all of Seller’s rights with respect to Seller’s A/R; provided the Seller shall not initiate any litigation for collections against parties who continue to be residents of the Facility after Closing without Buyer’s consent, with the exception of Seller enforcing any promissory notes signed by, or for the benefit of, residents in favor of Seller for amounts due for services rendered prior to Closing, and (ii) agrees that if it receives any proceeds with respect to the Seller’s A/R, Buyer will hold such proceeds in trust for Seller and shall promptly turn over those proceeds to Seller without demand, in the form received.
(7)    Within thirty (30) days following the Closing Date, Seller shall provide Buyer with a schedule setting forth by patient its outstanding accounts receivable with respect to the Facility as of the Closing Date.
(8)    In furtherance and not in limitation of the requirements set forth in Section 2.4, payments received by Buyer from and after the Closing Date from third party payors, including but not limited to Medicare, Medicaid, managed care and health insurance, shall be handled as follows:
(a)    If such payments specifically indicate on the accompanying remittance advice, or the parties otherwise agree, that they relate to the period prior to the Closing Date, the payments (if received by Buyer) shall be forwarded to Seller by Buyer, along with the applicable remittance advice, promptly, but in no event more than five (5) business days, after receipt thereof;
(b)    If such payments indicate on the accompanying remittance advice, or the parties otherwise agree, that they relate to the period on or after the Closing Date, they shall be retained by Buyer if received by Buyer, and paid to Buyer promptly but in no event later than five (5) business days, if received by Seller; and
(c)    If the period(s) for which such payments are made is not indicated on the accompanying remittance advice, and the parties are unable to agree as to the periods for which such payments relate, the parties shall assume that each payment received within ninety (90) days after the Closing Date relates to the oldest outstanding unpaid receivables for reimbursement and, based on such assumption, the portion thereof which relates to the period on and after the Closing Date shall be retained by Buyer and the balance shall be remitted to Seller promptly, but in no event more than five (5) business days, after receipt thereof. After said ninety (90) day period, such payments which fail to designate the period to which they relate shall be first applied to current balances with any excess applied to reduce pre-Closing balances and, based on such assumption, the portion thereof which relates to the post-Closing period shall be retained by or promptly (within five (5) business days) remitted to Buyer and the balance shall be retained by or promptly (within five (5) business days) remitted to Seller.
(9)    Any payments received within ninety (90) days after the Closing Date from or on behalf of private pay patients with outstanding balances as of the Closing Date which fail to designate the period to which they relate, will first be applied to reduce the patients’ pre-Closing Date balances owed to Seller, with any excess applied to reduce any balances due for services rendered by Buyer after the Closing Date, except, however, those amounts due and paid on any promissory note executed by any resident in favor of Seller for services rendered prior to Closing, which shall be paid to Seller under the terms of said note.
(10)    In the event the parties mutually determine that they misapplied any payment hereunder, or any remittance was made to the wrong party, the party that erroneously received the payment shall remit it to the other party promptly, but in no event more than five (5) business days, after the determination of misapplication is made. For a period of one (1) year after the Closing, Buyer and Seller shall, upon reasonable notice and during normal business hours and at reasonable intervals, have the right to inspect all cash receipts of the other respective party in order to confirm the other party’s compliance with the obligations imposed on it under this Section 2.4.
(11)    The obligations of the parties to forward the accounts receivable payments pursuant to this Section 2.4 are absolute and unconditional and irrespective of any circumstances whatsoever which might constitute a legal or equitable discharge, offset, counterclaim or defense of the parties, the right to assert any of which is hereby waived.
2.5.    Transfer of Resident Trust Funds.
(1)    Upon execution of this Agreement, Seller shall prepare and deliver to Buyer a current true, correct, and complete accounting and inventory (properly reconciled) of any resident trust funds and residents’ property held by Seller in trust for residents at the Facility (collectively the “Resident Trust Funds”). Not less than ten (10) days prior to Closing, Seller shall prepare and deliver to Buyer an updated true, correct and complete accounting and inventory (properly reconciled as of the previous month-end) of the Resident Trust Funds.
(2)    As of the Closing Date, Seller hereby agrees to transfer to Buyer the Resident Trust Funds and Buyer hereby agrees that it will accept such Resident Trust Funds in trust for the residents/responsible parties and be solely accountable to the residents/responsible parties for such Resident Trust Funds in accordance with the terms of this Agreement and applicable statutory and regulatory requirements.
(3)    Within five (5) days after the Closing Date, Seller shall prepare a final reconciliation comparing the actual Resident Trust Fund balance on the Closing Date to the amount of the Resident Trust Funds transferred to Buyer at the Closing and to the extent the former exceeds the latter, Seller shall remit such excess to Buyer or to the extent the latter exceeds the former, Buyer shall remit such excess to Seller.
(4)    Seller shall have no responsibility to the applicable resident/responsible party and regulatory authorities with respect to any Resident Trust Funds delivered to Buyer, and Buyer will hold Seller harmless for same.
ARTICLE 3.    REPRESENTATIONS AND WARRANTIES OF SELLER
As a material inducement to Buyer to enter into this Agreement and to consummate the transactions contemplated herein, Seller hereby represents and warrants to Buyer and its permitted assignees, which representations and warranties shall be true and correct on the date hereof and as of the date of Closing, as follows:
3.1.    Organization, Qualification and Authority. Seller is a corporation organized, validly existing and in good standing in the Commonwealth of Kentucky. Seller has full power and authority to own and operate the Facility and its Assets as presently owned and operated and to carry on its business as it is now being conducted. Seller has the full right, power and authority to execute, deliver and carry out the terms of this Agreement and all documents and agreements necessary to give effect to the provisions of this Agreement and to consummate the transactions contemplated on the part of Seller hereby. The execution, delivery and consummation of this Agreement, and all other agreements and documents executed in connection herewith by Seller, have been duly authorized by all necessary action on the part of Seller and Seller has provided Buyer certified copies of resolutions or consents of Seller evidencing such authorizations. Except as set forth on Exhibit 3.1-A, no other action, consent or approval on the part of Seller or any other person or entity is necessary to authorize Seller’s due and valid execution, delivery and consummation of this Agreement and all other agreements and documents executed in connection herewith. The Shareholders are, collectively, the holders of all outstanding equity ownership of any kind of the Company, and their respective ownership is set forth on Exhibit 3.1-B. This Agreement and all other agreements and documents executed in connection herewith by Seller, upon execution and delivery thereof, constitute the valid and binding obligations of Seller, enforceable in accordance with their respective terms.
3.2.    Absence of Default. The execution, delivery and consummation of this Agreement and all other agreements and documents executed in connection herewith by Seller will not constitute a material violation of, or be in conflict with, and will not, with or without the giving of notice or the passage of time, or both, result in a material breach of, constitute a material default under, or create or cause the acceleration of the maturity of any material debt, indenture, obligation or liability affecting the Assets or the Facility pursuant to, or result in the creation or imposition of any security interest, lien, charge or other encumbrance upon any of the Assets under: (1) any term or provision of the governing documents of Seller; (2) any contract, lease, purchase order, agreement, document, instrument, indenture, mortgage, pledge, assignment, permit, license, approval or other commitment to which Seller is a party or by which Seller and/or the Assets are bound; (3) any judgment, decree, order, regulation or rule of any court or regulatory authority; or (4) any law, statute, rule, regulation, order, writ, injunction, judgment or decree of any court or governmental authority or arbitration tribunal to which Seller and/or the Assets are subject.
3.3.    Financial Statements. Attached hereto as Exhibit 3.3 are true and correct copies of the unaudited balance sheets for the Facility as of the fiscal years ending September 30, 2012 and 2013, and unaudited income statements for the fiscal years then ending, and the interim unaudited balance sheet and income statement of the Facility for the one (1) month period ended October 31, 2014 (collectively, the “Financial Statements”). The Financial Statements are based on the books and records of Seller and present fairly and accurately the financial position of the Facility as of the periods specified, the results of its operation, and all costs and expenses for the periods specified. The Financial Statements are true, complete and correct and contain no untrue or misleading statements and do not omit anything which would cause them to be misleading or inaccurate in any respect. The Financial Statements have been prepared in compliance with generally accepted accounting principles on an accrual basis, except that they (a) are subject to year-end audit adjustments, (b) do not contain footnotes, (c) were prepared without physical inventories, (d) are not restated for subsequent events, (e) may not contain a statement of construction in process, and (f) may not fully reflect the following liabilities: (i) liabilities payable in connection with workers’ compensation claims, (ii) liabilities payable to any employee welfare benefit plan (within the meaning of Section 3(1) of ERISA) maintained by Seller or its affiliates on account of Seller’s employees, (iii) federal, state and local income or franchise taxes and (iv) bonuses payable to certain employees.
3.4.    Operations Since June 30, 2014. To the knowledge of Seller, since June 30, 2014, there has been no:
(5)    Material change in the condition, financial or otherwise, of Seller, the Facility or the Assets that has, or could reasonably be expected to have, a material adverse effect on any of the Assets, the Facility or future prospects of the Facility, or the results of the operations of Seller;
(6)    Uninsured loss, damage or destruction in excess of $10,000.00 of or to any of the Assets;
(7)    Sale, lease, transfer or other disposition by Seller of, or mortgages or pledges of or the imposition of any lien or encumbrance on, any portion of the Assets;
(8)    Material increase in the compensation payable by Seller to any of its employees other than those made in the ordinary course of business, or any increase in, or institution of, any bonus, insurance, pension, profit-sharing or other employee benefit plan or arrangements;
(9)    Strike, work stoppage or other labor dispute at the Facility;
(10)    Material amendment to or change in the terms of any of the Assumed Contracts or termination, waiver or cancellation of any rights or claims of Seller thereunder;
(11)    Assumption or creation of any liability outside of Seller’s ordinary course of business in excess of $10,000.00; or
(12)    Institution or settlement of any litigation, action or proceeding before any court or governmental body relating to Seller, the Facility or the Assets, except as set forth on Exhibit 3.4(8) attached hereto.
3.5.    Employment Discrimination. Except as disclosed in Exhibit 3.5 attached hereto, no person or party (including, without limitation, any governmental agency) has asserted, or to Seller’s knowledge, threatened to assert, any claim for any action or proceeding against Seller (or any officer, director, employee, agent or member of Seller) arising out of any statute, ordinance or regulation relating to wages, collective bargaining, discrimination in employment or employment practices or occupational safety and health standards including, without limitation, the Fair Labor Standards Act, Title VII of the Civil Rights Act of 1964, as amended, the Occupational Safety and Health Act, the Age Discrimination in Employment Act of 1967, the Americans With Disabilities Act and the Family and Medical Leave Act, and Seller has no knowledge of any acts or omissions which could give rise to any such claims.
3.6.    Licenses and Permits. The Facility has all licenses, permits, registrations, certificates and accreditations (collectively, the “Licenses and Permits”) necessary for Seller to occupy and operate the Facility as a skilled nursing and rehabilitation facility. There is no material default under any of the Licenses and Permits, nor does Seller know of any grounds for revocation, suspension or limitation of any of the Licenses or Permits. No written or verbal notices have been received by Seller with respect to any pending or, to Seller’s knowledge, threatened or pending revocation, termination, suspension or limitation of any of the Licenses and Permits.
3.7.    Compliance with Zoning, Land Use and Other Laws. None of the Real Estate is in violation, in any material respects, of any zoning, public health, building code or other similar law applicable thereto or to the ownership, occupancy and/or operation thereof, or there exist applicable variances, conditional use permits, waivers or exemptions relating to the Real Estate with respect to any non-conforming use or other zoning or building codes matters. To Seller’s knowledge, the consummation of the transactions contemplated herein will not result in the termination of any applicable zoning variance, conditional use permit, waiver or exemption relating to the Real Estate with respect to any such non-conforming use or other zoning, land use or building codes matters. There are no conditions, restrictions, ordinances or other limitations that would make the Real Estate unusable for its current use or materially restrict or impair its current use.
3.8.    Title to Assets.
(1)    Seller is the sole legal and beneficial owner of, or has the exclusive, unrestricted right and authority to use and transfer to Buyer, the personal property included in the Assets, free and clear of all mortgages, security interests, liens, leases, covenants, assessments, easements, options, rights of refusal, restrictions, reservations, defects in the title, encroachments and other encumbrances. The Inventory and Equipment and Furnishings are: (i) in good repair and good operating condition, ordinary wear and tear excepted; (ii) suitable for immediate use in the ordinary course of business; and (iii) to Seller’s knowledge, free from latent and patent defects. No item of Inventory or Equipment and Furnishings is in need of repair or replacement other than as part of routine maintenance in the ordinary course of business. All Inventory and Equipment and Furnishings are in the possession or control of Seller.
(2)    The descriptions of the Real Estate contained in Exhibit 1.1(1) hereto include all real property owned by Seller in connection with the Facility. At Closing, Seller will be the sole and exclusive holder of all right, title and interest in the Real Estate and at Closing will convey to Buyer good and marketable title, free and clear of all mortgages and liens, subject to (i) any lien to secure the payment of real estate taxes, including special assessments, not delinquent, (ii) all applicable laws, ordinances, rules and governmental regulations affecting the use and occupancy of the Real Estate, (iii) easements, restrictions and other matters applicable to the Real Estate that do not hinder, interfere with or prohibit the use and occupancy of the Real Estate as a skilled nursing facility, and (iv) matters shown by the Existing Title Work deemed to be Permitted Exceptions under Section 3.8(2) hereof and those additional matters described on Exhibit 3.8(2) attached hereto (the “Permitted Exceptions”). Seller has, and will at Closing have, the full right and authority to transfer and convey the Real Estate to Buyer (or an affiliate of Buyer) as contemplated by the terms of this Agreement, and to vest in Buyer good, marketable and fee simple title and the lawful right to possess and use the Real Estate.
(3)    No other person or entity owns any interest in any of the Assets.
3.9.    Contracts.
(1)    Exhibit 3.9 attached hereto sets forth a complete and accurate list of all contracts, agreements, purchase orders, and commitments, oral or written, and all assignments, amendments, schedules, exhibits and appendices thereof, affecting or relating to the Facility or any Asset to which either Seller is a party or by which Seller, the Assets or the Facility is bound or affected, including, without limitation, service contracts, management agreements and equipment leases (collectively, the “Contracts”). At least five (5) business days after the end of the date of the execution of this Agreement, Buyer shall notify Seller of which Contracts it intends to assume, and such Contracts shall hereinafter be the “Assumed Contracts”; provided, however that any Contracts not included in the Assumed Contracts shall be retained by Seller. Neither the Facility nor any of the Assets are subject to any leases, subleases or options to purchase or sell.
(2)    None of the Contracts have been modified, amended, assigned, transferred or subordinated except as described on Exhibit 3.9 and each is in full force and effect and is valid, binding and enforceable in accordance with its respective terms.
(3)    To Seller’s knowledge, no event or condition has happened or presently exists that (i) constitutes a default or breach by Seller or against any other party thereto, or (ii) after notice or lapse of time or both, would constitute a default or breach by Seller or against any other party thereto, under any of the Assumed Contracts. To Seller’s knowledge, there are no counterclaims or offsets under any of the Assumed Contracts.
3.10.    Environmental Matters.
(1)    Hazardous Substances. As used in this Section, the term “Hazardous Substances” means any hazardous or toxic substance, medical or biologic material or waste or other material or waste including, but not limited to, those substances, materials, and wastes defined in Section 101 of the Comprehensive Environmental Response, Compensation and Liability Act of 1980, as amended (“CERCLA”), listed in the United States Department of Transportation Table (49 CFR 172.101) or by the Environmental Protection Agency as hazardous substances pursuant to 40 CFR Part 302, or which are regulated under any other Environmental Law (as defined herein), or any hydrocarbons, petroleum, petroleum products, asbestos, polychlorinated biphenyls, formaldehyde, radioactive substances, flammables or explosives.
(2)    Compliance with Laws and Regulations. All operations, use or occupancy of the Real Estate, or any portion thereof, by Seller and any agent, contractor or employee of any agent or contractor of Seller (collectively, “Agents”), or any tenant or subtenant of Seller of any part of the Real Estate, have been in compliance in all material respects with any and all federal, state or local laws, statutes, regulations, orders, codes, judicial decisions, decrees, licenses, permits and other applicable requirements of governmental authorities with respect to Hazardous Substances, pollution or protection of human health and safety (collectively, “Environmental Law”) including, but not limited to, the release, emission, discharge, storage and removal of Hazardous Substances. Seller, its affiliates and Agents have kept the Real Estate free of any lien imposed pursuant to Environmental Law.
(3)    No Investigation or Inquiry. Seller: (i) has not either received or been issued a notice, demand, request for information, citation, summons or complaint regarding an alleged failure to comply with Environmental Law; or (ii) is not subject to any existing, pending, or, to Seller’s knowledge, threatened investigation or inquiry by any governmental authority for failure to comply with, or any remedial obligations under, Environmental Law, and there are no circumstances known to Seller which could serve as a basis therefor. Seller has not assumed any liability of any third party for clean up under, or noncompliance with, Environmental Law.
(4)    No Disposal, Discharge or Release. Seller has not disposed of, discharged or released any Hazardous Substances on, in, under or upon, or from the Real Estate, except for uses and temporary storage of Hazardous Substances reasonably necessary to the customary operation of a skilled nursing facility in compliance with applicable Environmental Laws.
(5)    OSHA. To Seller’s knowledge there is no asbestos located in or on the Facility.
Seller shall promptly notify Buyer in writing of any order of which either is aware, receipt of any notice of violation or noncompliance with any Environmental Law, any threatened or pending action of which either is aware by any regulatory agency or governmental authority, or any claims made by any third party of which it is aware relating to Hazardous Substances on, emanations on or from, releases on or from, the Real Estate; and shall promptly furnish Buyer with copies of any written correspondence, notices or legal pleadings and written summaries of any oral communications or notices in connection therewith.
3.11.    Condemnation. No part of the Real Estate is currently subject to condemnation proceedings and, to Seller’s knowledge, no condemnation or taking is threatened or contemplated. To Seller’s knowledge, no part of the Real Estate is subject to any pending or threatened plans to modify or realign any street or highway that would result in the taking of all or any part of any adjacent street or highway that would adversely affect the current use of the Real Estate.
3.12.    Litigation. Seller has received no notice of any violation of any law, rule, regulation, ordinance or order of any court or federal, state, municipal or other governmental department, commission, board, bureau, agency or instrumentality. There are no lawsuits, proceedings, actions, arbitrations, governmental investigations, claims, inquiries or proceedings pending or, to Seller’s knowledge, threatened involving Seller, any of the Assets or the Facility and Seller knows of no basis therefor. A list of each lawsuit, administrative proceeding, governmental investigation, arbitration or other action commenced against Seller or involving the Real Estate or Assets commenced or pending during the past five (5) years is set forth on Exhibit 3.12 attached hereto. Seller is not a party to nor otherwise bound by any order, judgment, injunction, decree or settlement agreement under which it may have continuing obligations as of the date hereof.
3.13.    Seller’s Employees. Exhibit 3.13 attached hereto sets forth: (1) a complete list of all of Seller’s employees at the Facility, including all employees on leave of absence, including but not limited to leaves arising from injury or workers compensation claims, Family and Medical Leave Act, or similar basis, (collectively, the “Employees”) and rates of pay; (2) categorization of each such person as a full-time or part-time employee of Seller; (3) the employment dates and job titles of each such person; and (4) true and complete copies of any and all fringe benefits and personnel policies. For purposes of this Section, “part-time employee” means an employee who is employed for an average of fewer than twenty (20) hours per week or who has been employed for fewer than six (6) of the twelve (12) months preceding the date on which notice is required pursuant to the Worker Adjustment and Retraining Notification Act (“WARN”), 29 U.S.C. § 2102 et seq. Seller has no employment agreements with the Employees and all such Employees are employed on an “at will” basis. Seller will terminate all of the Employees at Closing. The parties expressly agree that Seller shall retain responsibility for and timely pay all salaries and wages, related payroll taxes and all retention bonuses, retirement and other fringe benefits that have accrued to the Employees through Closing; provided that Buyer shall assume accrued vacation and paid time off obligations (vested and unvested) pursuant to Section 1.3(1) above. No officer, director, agent or managing employee (as that term is defined in 42 U.S.C. § 1320a-5(b)) of the Seller has been (i) excluded from participating in the Programs (as defined in Section 3.23 below), (ii) subject to sanction pursuant to 42 U.S.C. § 1320a-7a or 1320a-8, (iii) convicted of, a criminal offense under the Anti-Kickback Statute (42 U.S.C. § 1320a-7b) or (iv) charged with or, to the Seller’s knowledge, investigated, for any violation of laws related to fraud, theft, embezzlement, breach of fiduciary responsibility, financial misconduct, obstruction of any investigation, or controlled substances.
3.14.    Labor Relations. Seller is not a party to any labor contract, collective bargaining agreement, contract, Letter of Understanding, or any other arrangement, with any labor union or organization which obligates such Seller to compensate its employees at prevailing rates or union scale nor are any of its employees represented by any labor union or organization. To Seller’s knowledge, there is no pending or threatened labor dispute, work stoppage, unfair labor practice complaint, strike, administrative or court proceeding or order between Seller and any present or former employee(s) of Seller.
3.15.    Insurance. A complete list of all insurance policies held by Seller with respect to the Facility is set forth on Exhibit 3.15 attached hereto. True and complete copies of such policies have previously been provided to Buyer. Exhibit 3.15 also sets forth a summary of Seller’s current insurance coverage (listing type, carrier and limits), and includes a list of any pending insurance claims relating to Seller. Seller is not in default or breach with respect to any provision of any such insurance policies nor has Seller failed to give any notice or to present any claim thereunder in due and timely fashion. In the event Seller’s professional and general liability insurance is written on a claims made basis, Seller shall purchase or provide continuing coverage, otherwise known as an Extended Reporting Endorsement or “tail” coverage, for the mutual benefit of both Buyer and Seller, with minimum limits of no less than $1 million per occurrence and $3 million in the annual aggregate. Such required liability coverage will remain in force for a minimum of two (2) years from the date of Closing. In the event any of such aggregate liability insurance limits are eroded during the two (2) year period when such insurance is required to be maintained, Seller agrees to reinstate such limits at the beginning of each year during the two (2) year period. Seller further agrees to add Buyer as an Additional Insured to any of its required liability coverage.
3.16.    Broker’s or Finder’s Fee. Neither Seller nor Buyer has employed and neither is liable for the payment of any fee to any finder, broker, consultant or similar person in connection with the transactions contemplated by this Agreement.
3.17.    Motor Vehicles. No motor vehicles are including in the Assets.
3.18.    Employee Benefit Plans.
(1)    Welfare Benefit Plans. Exhibit 3.18(1) attached hereto contains a true, accurate and complete list of each “employee welfare benefit plan” (as defined in Section 3(1) of the Employee Retirement Income Security Act of 1974 as amended (“ERISA”)) maintained by Seller or to which Seller contributes or is required to contribute (such employee welfare benefit plans being hereinafter collectively referred to as the “Welfare Benefit Plans”). Complete and accurate copies of all Welfare Benefit Plans have previously been provided to Buyer.
(2)    Pension Benefit Plans. Exhibit 3.18(2) attached hereto contains a true and complete list of each “employee pension benefit plan” (as defined in Section 3(2) of ERISA) maintained by Seller, to which Seller contributes or is required to contribute, or which covered any employee of Seller during the period of their employment with any predecessor of Seller, including any multi-employer pension plan as defined under Section 414(f) of the Code (such employee pension benefit plans being hereinafter collectively referred to as the “Pension Benefit Plans”). Complete and accurate copies of all Pension Benefit Plans have previously been provided to Buyer.
(3)    Liabilities. There are no unfunded liabilities under any Welfare Benefit Plans or Pension Benefit Plans. Buyer shall not be liable or responsible for any debt, obligation, responsibility or liability of Seller under any such plans. Seller shall be liable under its Welfare Benefit Plans and Pension Benefit Plans for all claims due and unpaid at Closing and for all claims incurred before Closing, whether or not paid or presented before Closing.
(4)    COBRA Coverage. Seller has provided or caused to be provided notice of the availability of continuation coverage within the meaning of Section 4980B of the Code (“COBRA coverage”) for all of either present and former employees and their dependents entitled to such notice because of a qualifying event occurring before Closing, and for providing COBRA coverage as required by law for all such employees, or their dependents, who elect or have elected such coverage. As of the day after Closing, Buyer agrees to have in place its health insurance program providing benefits substantially equivalent to those of the Seller; provided that Seller acknowledges that Buyer will not continue Seller’s employer funding program.
3.19.    Compliance with Laws. Seller has received no written or, to Seller’s knowledge, verbal notices of non-compliance with any laws, rules and regulations applicable to the Assets or Facility. To Seller’s knowledge, Seller is in compliance with all federal, state and local laws, rules and regulations which relate to the operations of the Facility.
3.20.    WARN Act. Within the period ninety (90) days prior to Closing, Seller has not temporarily or permanently closed or shut down any single site of employment or any facility or any operating unit, department or service within a single site of employment, as such terms are used in WARN.
3.21.    Tax Returns; Taxes. Seller is current with its filings of required federal, state and local tax returns and tax reports and will continue to keep current on its required filings. To Seller’s knowledge, there is no pending tax examination or audit of, nor any action, suit, investigation or claim asserted or, to the knowledge of Seller, threatened against Seller by any federal, state or local authority. All tax returns are (and with respect to the final returns will be) at the time of filing complete and accurate and in accordance with the tax laws applicable thereto and disclose all taxes required to be paid for the periods covered thereby. Seller has not committed any material violation of any federal, state or local tax laws. Proper amounts have been collected or withheld by Seller for all income, franchise, property, sales, employment or other taxes payable or anticipated to be payable and for the payment of all other taxes (including without limitation all employment, sales or use taxes). Proper amounts have been withheld or collected from each payment made or to be made to each employee of Seller for all taxes required to be withheld therefrom.
3.22.    Deposits. The Deposits currently held by Seller are listed on Exhibit 3.22 attached hereto. All funds held with respect to such Deposits are in balance and will be in balance at Closing. Exhibit 3.22 will be updated to Closing by Seller for purposes of crediting any additional Deposits to Buyer’s account.
3.23.    Medicaid. In connection with the Facility, Seller participates in the Medicaid Program (the “Program”) under valid Medicaid contracts and reimbursement agreements (collectively, the “Program Agreements”). Seller is in compliance, in all material respects, with rules and policies respecting the Program, including all certification, billing, reimbursement and documentation requirements, and there is no threatened or pending revocation, suspension, termination, probation, restriction, limitation or non-renewal affecting any of Seller’s Program Agreements or third-party payor contracts.
3.24.    Accreditation; Survey Reports. Seller has not received any written notice of material deficiency from The Joint Commission or any other crediting organization with respect to the Facility’s current accreditation period that require any material action or response by the Seller that have not been corrected or otherwise remedied. Seller has made available to Buyer a true and complete copy of (i) Facility’s most recent Joint Commission or other accreditation survey report and deficiency list, if any and (ii) Facility’s (A) most recent Statement and Deficiencies and Plan of Correction on Form HCFA-2567, (B) most recent state licensing report and list of deficiencies, if any, and (C) the most recent fire marshal’s survey and deficiency list, if any, and the corresponding plans of correction or other responses.
3.25.    Intellectual Property. Seller is the sole and exclusive owner of all of Seller’s right, title and interest in and to all of the Intellectual Property Assets (defined below). “Intellectual Property Assets” means all trade secrets, names, assumed names, registered or unregistered trade names, patents, inventions or discoveries that may be patentable, registered or unregistered trademarks, registered or unregistered service marks, registered or unregistered copyrights, registered or unregistered brands, applications for any of the foregoing, and proprietary rights in internet web sites and internet domain names, as owned, used or licensed by Seller in connection with the Facility. Intellectual Property Assets shall not include any computer hardware or software. The Intellectual Property Assets owned by Seller have not been subject to any adverse claim, or challenged or to Seller’s knowledge, threatened in any way, and to Seller’s knowledge, do not infringe, misappropriate, violate or conflict with any patent, copyright, trademark, trade secret or any other intellectual property or proprietary right of any other person.
3.26.    Workers’ Compensation. Seller is in good standing and compliance, in all material respects, with coverage for workers’ compensation and unemployment compensation of the Commonwealth of Kentucky and all other jurisdictions in which Seller engages in business or has employees. Except as set forth on Exhibit 3.26, there are no outstanding or pending, and to the knowledge of Seller no threatened claims against Seller for workers’ compensation or unemployment compensation, and no workers’ compensation claims which can be reopened. Seller shall remain responsible for all workers’ compensation claims which arise out of any workplace injury occurring on or before the Closing Date.
3.27.    Residency Agreements; Admission Agreements. A true, correct and complete copy of the Facility’s standard form of residency agreement and/or admission agreement has been made available to Buyer and, except for agreements whose material terms are consistent with such standard residency agreement and/or admission agreement, there are no agreements or contracts between Seller and any Patient or resident of the Facility.
3.28.    Compliance with Medicare and Other Third Party Payor Programs. With respect to the federal Medicare programs and other third party payor programs:
(1)    The Facility is qualified as a provider of, and is in compliance, in all material respects, with all conditions for participation in Medicare.
(2)    Seller has timely filed all cost reports required to be filed in connection with Medicare, and has delivered to Buyer true, correct and complete copies of all such cost reports filed for each of the last three (3) completed fiscal years of Seller, together with all claims and adjustments asserted by the applicable governmental authority and any settlement thereof.
(3)    Except for reviews conducted by the applicable regulatory authorities in the ordinary course of business, Seller has not been notified of any validation review or program integrity review related to the Facility, and no such review has been conducted or is currently pending by any regulatory authority relating to Medicare.
(4)    Neither Seller nor, to the Seller’s knowledge any employee of Seller, has been convicted of or pleaded guilty or no contest to any criminal offense related to the operation of the Facility, and, to the knowledge of Seller, no person has committed any offense that could serve as the basis for suspension, restriction or exclusion of the Facility from Medicare.
(5)    Seller has not received written notice of any proceeding, and Seller has no knowledge or reason to believe that any proceeding has been recommended or is threatened by any applicable regulatory authority to investigate, revoke, limit, suspend or take any adverse action against Seller’s participation in Medicare.
3.29.    Intentionally omitted
3.30.    Absence of Certain Business Practices; Fraud and Abuse Matters. To Seller’s knowledge, no former or present partner, officer, employee or agent of Seller or persons who provide professional services under agreements with Seller, acting alone or together, has, directly or indirectly, overtly or covertly, (i) knowingly and willfully received any prohibited remuneration, rebates, payments, commissions, promotional allowances or any other prohibited gifts or benefits, from any customer, supplier, physician, health care employee, governmental employee or other person with whom Seller has done business directly or indirectly; (ii) knowingly and willfully given or agreed to give any prohibited remuneration, rebates, payments, commissions, promotional allowances, or any other prohibited gifts or benefits to any customer, supplier, physician, health care employee, governmental employee or other person who is or may be in a position to help or hinder the business of Seller (or Seller in connection with any actual or proposed transaction) or (iii) engaged in any activities that are prohibited, or are cause for civil penalties or permissive exclusion from Medicare or Medicaid, under Title 42 of the United States Code (“Title 42”) or Title 31 of the United States Code, or the regulations promulgated thereunder, that, in the case of any of clause (i), (ii) or (iii), (A) would subject Seller to any claims, liabilities or penalties in any civil, criminal or governmental investigation, litigation or proceeding brought by any regulatory authority, (B) if continued in the future, would have a material adverse effect or (C) are prohibited by any private accrediting organization from which the Facility seeks or has accreditation or by generally recognized professional standards of care or conduct, including without limitation the following activities:
(1)    knowingly and willfully making or causing to be made a false statement or representation of a material fact in any application for any benefit or payment;
(2)    knowingly and willfully making or causing to be made any false statement or representation of a material fact for use in determining rights to any benefit or payment;
(3)    presenting or causing to be presented a claim for reimbursement under Medicare, Medicaid or other federal or state health care program that is (i) for an item or service that the person presenting or causing to be presented knows or should know was not provided as claimed, (ii) for an item or service that the person presenting knows or should know that the claim is false or fraudulent or (iii) for an item or service that the person presenting knows or should know is not medically necessary;
(4)    knowingly and willfully making or causing to be made or inducing or seeking to induce the making of any false statement or representation (or omitting to state a material fact required to be stated therein or necessary to make the statements contained therein not misleading) or a material fact with respect to (i) the conditions or operations of the Facility in order that such Facility may qualify for Medicare, Medicaid or other federal or state health care program certification or (ii) information required to be provided under Section 1320a-7 of Title 42 or any regulations promulgated thereunder; or
(5)    currently is, or within the preceding five (5) years, been subject to any corporate integrity agreement with the Office of Inspector General, or any other type of oversight program that could cause the facility to incur obligations or liabilities or that could restrict, impair, limit, jeopardize, or suspend participation in the Medicare program.
3.31.    Undisclosed Liabilities. All material liabilities of Seller related to the Facility and the Business are identified on the Financial Statements, or the Schedules to this Agreement except for (a) liabilities reflected or reserved against in the financial statement balance sheets of Seller, (b) current liabilities incurred in the ordinary course of business of Seller, (c) expenses incurred by the Seller in connection with the transactions contemplated by this Agreement, or (d) contractual and similar liabilities incurred in the ordinary course of business consistent with past practice which are not required to be reflected on a balance sheet (including in the notes thereto) prepared in accordance with GAAP as historically applied by Seller, and Seller knows of no other material liabilities.
ARTICLE 4.    REPRESENTATIONS AND WARRANTIES OF BUYER
As an inducement to Seller to enter into this Agreement and to consummate the transactions contemplated herein, Buyer hereby represents and warrants to Seller, which representations and warranties shall be true and correct on the date hereof and on the date of Closing, as follows:
4.1.    Organization, Qualification and Authority. Buyer is a limited liability company duly organized under the laws of the State of Delaware, and qualified to do business under the laws of the Commonwealth of Kentucky. Buyer has the full power and authority to own, lease and operate its properties and assets as presently owned, leased and operated and to carry on its business as it is now being conducted. Buyer has the full right, power and authority to execute, deliver and carry out the terms of this Agreement and all documents and agreements necessary to give effect to the provisions of this Agreement and to consummate the transactions contemplated on the part of Buyer hereby. The execution, delivery and consummation of this Agreement and all other agreements and documents executed in connection herewith by Buyer has been duly authorized by all necessary action on the part of Buyer. No other action on the part of Buyer or any other person or entity is necessary to authorize the execution, delivery and consummation of this Agreement and all other agreements and documents executed in connection herewith. This Agreement, and all other agreements and documents executed in connection herewith by Buyer, upon due execution and delivery thereof, shall constitute the valid binding obligations of Buyer, enforceable in accordance with their respective terms.
4.2.    Absence of Default. The execution, delivery and consummation of this Agreement and all other agreements and documents executed in connection herewith by Buyer will not constitute a violation of, be in conflict with, or, with or without the giving of notice or the passage of time, or both, result in a breach of, constitute a default under, or create (or cause the acceleration of the maturity of) any debt, indenture, obligation or liability or result in the creation or imposition of any security interest, lien, charge or other encumbrance upon any of the Assets (except in the ordinary course pursuant to Buyer’s existing credit agreements) under: (1) any term or provision of the governing documents of Buyer; (2) any contract, lease, agreement, indenture, mortgage, pledge, assignment, permit, license, approval or other commitment to which Buyer is a party or by which Buyer is bound; (3) any judgment, decree, order, regulation or rule of any court or regulatory authority; or (4) any law, statute, rule, regulation, order, writ, injunction, judgment or decree of any court or governmental authority or arbitration tribunal to which Buyer is subject.
4.3.    Broker’s or Finder’s Fee. Buyer has not employed and is not liable for the payment of any fee to any finder, broker, government official, consultant or similar person in connection with the transactions contemplated by this Agreement. Buyer shall indemnify and hold Seller harmless from any breach of this representation.
4.4.    Financing. As of the date of this Agreement, Buyer has received reasonable assurances from its primary lender that it will provide the financing necessary to effect the purchase of the Assets pursuant to the terms hereof.
ARTICLE 5.    COVENANTS OF PARTIES
5.1.    Inspection; Preservation of Facility and Assets. Buyer, its agents, employees, consultants and contractors (“Buyer Parties”), shall have the right to come onto the Real Estate and to have access to the Assets and the Facility from time to time for the purpose of conducting its due diligence investigation and review of the Assets and the Facility; provided, that any inspection, examination, test or study conducted by or on behalf of Buyer shall be solely at Buyer’s expense, shall be conducted at reasonable times and upon reasonable advance notice, and shall not interfere with the operation of the Facility by Seller. Seller shall have a right to have a representative present during any visits to or inspections of the Facility by Buyer Parties. From the date hereof through Closing, Seller shall use its best efforts and shall do or cause to be done all such acts and things as may be necessary to preserve, protect and maintain intact the operation of the Facility and Assets as a going concern consistent with prior practice and not other than in the ordinary course of business and to preserve, protect and maintain for Buyer the goodwill of the clinical staff, suppliers, employees, clientele, patients and others having business relations with the Facility. Seller shall use its best efforts to obtain all documents called for by this Agreement. Buyer and Seller shall use its best efforts to facilitate the consummation of the transactions contemplated under this Agreement. Until termination of this Agreement, Seller agrees that it will not sell or transfer, or negotiate the sale or transfer of, the Assets or the Facility. From the date hereof until Closing, Seller will not sell, discard or dispose of any of the Assets other than in the ordinary course of business. From the date hereof through Closing, Seller will not perform any material grading or excavation, construction or removal of any improvement, or make any other material change or improvement upon or about the Real Estate without the prior written consent of Buyer. From the date hereof through Closing, Seller and any party in possession of all or any part of the Assets will maintain and keep the Assets in a sanitary, well-maintained condition and in good order and repair.
5.2.    Absence of Material Change. From the date hereof through Closing, Seller shall not make any material change in the operations of the Facility or and in the utilization of the Assets and shall not enter into any other material contract or commitment or any other transaction with respect to the Facility or the Assets without the prior written consent of Buyer.
5.3.    WARN Act. Buyer shall be required to and shall employ such number of Seller’s employees at the Facility, and shall retain for a period of ninety (90) days following the Closing such number of Seller’s employees at the Facility, as shall be necessary to avoid any potential liability by Seller for a violation of the Workers Adjustment Retraining and Notification Act (the “WARN Act”) (or any similar law of the Commonwealth of Kentucky) attendant to Seller’s failure to notify such employees of a “mass layoff” or “plant closing” as defined in the WARN Act (or any similar law of the Commonwealth of Kentucky). For purposes of determining compliance by Buyer with the foregoing provisions, employees terminated by Seller at the Facilities during the period of ninety (90) days immediately prior to the Closing for other than cause, retirement or voluntary departure, shall be taken into consideration so long as Seller notifies Buyer of such terminations. Seller shall notify Buyer in writing regarding all employees terminated by Seller during said ninety (90) day period. In order to determine compliance with this Section 5.3, Buyer shall advise Seller in writing on or before five (5) days prior to the Closing of those employees of Seller that Buyer has elected not to employ. Nothing herein contained shall be deemed either to affect or to limit in any way the management prerogatives of Buyer with respect to employees, or to create or to grant to such employees any third party beneficiary rights or claims or causes of action of any kind or nature. The provisions of this Section 5.3 shall survive the closing of the transactions contemplated herein. Notwithstanding the foregoing Buyer shall be entitled to offer employment to therapists who work at the Facility and are employees of Seller or its affiliates, and Seller and/or its affiliates shall consent to such employment and shall release Buyer and its affiliates, and the affected employees, from any non-competition covenants or similar restrictions.
5.4.    Access to Books and Records.
(1)    From the date hereof through Closing, Seller shall give Buyer and Buyer’s counsel, accountants and other representatives full access to all of Seller’s offices, properties, books, contracts, commitments, records and affairs relating to the Assets or the Facility so that Buyer may inspect and audit them and shall furnish to Buyer a copy of all documents and information concerning the properties and affairs of Seller, the Facility or the Assets as Buyer may request. If any such books, records and materials are in the custody of third parties, Seller shall direct such third parties to promptly provide them to Buyer. Copies of documents furnished to Buyer by Seller will be returned by Buyer upon request if the transaction is not consummated. The Buyer and Seller currently have in place a Non-Disclosure Agreement, the terms of which are incorporated herein by reference, and all information exchanged related in any way to this transaction shall be subject to the terms of said Agreement. Seller shall provide Buyer promptly with interim financial statements of Seller and any other management reports, as and when they are available.
(2)    Following Closing, Buyer shall permit Seller’s representatives (including, without limitation, its counsel and auditors), during normal business hours, to have reasonable access to, and examine and make copies of, all books and records of the Facility which relate to transactions or events occurring through Closing. Buyer’s reasonable out-of-pocket costs associated with the delivery of the requested documents shall be paid by Seller.
(3)    Following Closing, Seller shall permit Buyer and its representatives (including, without limitation, its counsel and auditors), to have access to, and examine and make copies of, all books and records relating to the Facility or Assets, which books and records are retained by Seller and which relate to transactions or events occurring prior to Closing. For a period of five (5) years after Closing or such longer period as may be mandated by law, Seller agrees that, prior to the destruction or disposition of any such books or records, Seller shall provide not less than forty-five (45) days, nor more than ninety (90) days, prior written notice to Buyer of such proposed destruction or disposal. If Buyer desires to obtain any such documents or records, it may do so by notifying Seller in writing at any time prior to the date scheduled for such destruction or disposal. In such event, Seller shall not destroy such documents or records and the parties shall then promptly arrange for the delivery of such documents or records to Buyer, its successors or assigns. Seller’s reasonable out-of-pocket costs associated with the delivery of the requested documents or records shall be paid by Buyer.
(4)    For a period of eighteen (18) months following Closing, to the extent requested by Buyer in connection with (a) any audit of the financial statements of Seller relating to the Facility; (b) any separate presentation to be prepared by Buyer or any of its affiliates of the financial statements relating to the Facility (including, without limitation, any such separate presentation of the Facility as a “significant subsidiary” or a “Facility acquired” within the meaning of the accounting rules of the Securities Act and/or the Exchange Act (each as defined below), and/or the rules and regulations promulgated under either such act); or (c) any presentation to be prepared by Buyer or any of its affiliates of the pro forma effects of Buyer’s acquisition of the Facility, in each case, Seller shall, and shall cause its accountants to, (i) cooperate in the preparation of such financial statements or pro forma presentation, including, the execution and delivery of any management or other audit letters reasonably requested by Buyer’s auditors, and (ii) provide, or cause to be provided, any records or other information requested by Buyer or any of its affiliates in connection therewith, to the extent they are not included in the Assets, as well as access to, and the cooperation of, Seller’s accountants and work papers relating to financial statements of Seller, at the cost and expense of Buyer.
5.5.    Risk of Loss. In the event there is any damage to or loss of any of the Assets (whether by fire, theft, vandalism, terrorism, act of God or other cause or casualty, damage or loss) between the date hereof and Closing, the Purchase Price shall be reduced by the amount necessary to repair the damage, which reduction shall be offset by any amounts paid by Seller’s insurance company and assigned to Buyer; provided, however, that in the event of a material casualty that affects the Facility and renders it unusable for its intended purposes, Buyer may elect to either: (i) terminate this Agreement in its entirety, without any further penalty or obligation and no remaining obligations of either party to the other; or (ii) complete the Closing on the terms stated herein, subject to the right to either receive all insurance proceeds, or obtain a reduction in the Purchase Price with regard to such insurance proceeds received by Seller.
5.6.    Condemnation. From the date hereof through Closing, in the event the Facility becomes subject to or is threatened with any condemnation or eminent domain proceedings that threatens to render the Facility unusable for its intended purposes then Buyer, in its sole discretion, may elect to terminate this Agreement in its entirety without obligation or penalty. In the event Buyer does not elect to terminate the Agreement, the transaction shall proceed towards Closing, provided that the Purchase Price shall be reduced by any condemnation award received by Seller or Buyer shall be assigned all such claims. In the event that the Facility becomes subject to or is threatened with any condemnation or eminent domain proceedings which do not threaten to render the Facility unusable for its intended purposes, then the parties shall proceed to Closing and Buyer shall be entitled to any condemnation award or damages paid with respect to such proceeding.
5.7.    Preserve Accuracy of Representations and Warranties. Seller shall refrain from taking any action which would render any representation and warranty contained in Article 3 hereof untrue, inaccurate or misleading as of Closing. Seller will promptly notify Buyer of any lawsuit, claim, administrative action or other proceeding asserted or commenced against Seller that may involve or relate in any way to Seller, the Assets or the operation of the Facility. Seller shall promptly notify Buyer of any facts or circumstances that come to Seller’s attention and that cause, or through the passage of time or the giving of notice or either, may cause any of Seller’s representations and warranties to be untrue or misleading at any time from the date hereof through Closing.
5.8.    Maintain Books and Accounting Practices. From the date hereof through Closing, Seller shall maintain its books of account in the usual, regular and ordinary manner on a basis consistent with prior years and shall make no change in its accounting methods or practices.
5.9.    Indebtedness; Liens. Other than in the ordinary course of Seller’s business consistent with past practice, from the date hereof through Closing, Seller shall not create, incur, assume, guarantee or otherwise become liable or obligated with respect to any indebtedness for borrowed money, nor make any loan or advance to, or any investment in, any person or entity, nor create any lien, security interest, mortgage, right or other encumbrance in any of the Assets, without Buyer’s prior written approval.
5.10.    Compliance with Laws and Regulatory Consents. From the date hereof through Closing: (1) Seller shall comply with all applicable statutes, laws, ordinances and regulations; (2) Seller shall keep, hold and maintain all certificates, accreditations, participations, licenses, and other permits necessary for operation of the Facility; (3) Seller shall use reasonable efforts and shall cooperate with Buyer to obtain all consents, approvals, exemptions and authorizations of third parties, whether governmental or private, necessary to consummate the transactions contemplated by this Agreement; and (4) Seller shall make and cause to be made all filings and give and cause to be given all notices which may be necessary or desirable under all applicable laws and under applicable contracts, agreements and commitments in order to consummate the transactions contemplated by this Agreement.
5.11.    Maintain Insurance Coverage. From the date hereof through Closing, Seller shall maintain and cause to be maintained the existing insurance on the Assets and the operations of the Facility.
5.12.    Licensure and Certification. Buyer shall within ten (10) business days of the date hereof file all initial applications and other documents required by the Commonwealth of Kentucky (the “State”) for the issuance of the licenses, certificates of need, certifications and approvals required by the State for the operation of the Facility by Buyer (the “Licensure Approvals”) and Buyer shall diligently proceed with securing the Licensure Approvals, including providing the State with any supplemental or additional information required for the State to deem any such applications to be complete. Buyer shall not use or bill under any Medicaid provider numbers used by Seller, and Buyer shall be responsible for obtaining a new Medicaid provider agreement and number and/or Medicaid certification as may be necessary for the continued operations of the Facility (“New Provider Number”). Seller’s Medicaid provider account numbers for the Facility shall remain the sole and exclusive property of Seller.
5.13.    Performance. Seller and Buyer shall take all appropriate steps to satisfy their respective obligations, and the conditions to Closing, including without limitation the application for necessary licenses and permits.
5.14.    WARN Act; Hiring of Employees. Prior to Closing, Seller will not temporarily or permanently close or shut down any “single” site of “employment” or any “facility” or any “operating unit,” department or service within a single site of employment, as such terms are used in WARN. At Closing, Buyer shall offer employment to a sufficient number of the Employees, and on such terms, and for such periods, as may be necessary to avoid triggering any obligations on behalf of either Seller under WARN or any similar state law or regulation. Buyer shall also offer group health plan coverage to such Employees that accept employment and are otherwise eligible for such coverage under the terms of Buyer’s plan effective immediately after Closing.
5.15.    Consents. Seller shall use reasonable efforts to obtain all consents required in form and substance for the assignment of the Assumed Contracts and Buyer shall assist Seller in such efforts. Anything contained herein to the contrary notwithstanding, this Agreement shall not constitute an agreement to assign any of the Contracts if an attempted assignment thereof without the consent of another party thereto would constitute a breach thereof, unless such consent is obtained. If such consent is not obtained, or if an attempted assignment would be ineffective or would materially affect Seller’s rights thereunder so that Buyer would not in fact receive all such rights, Seller shall cooperate in any reasonable arrangement designed to provide Buyer the benefit under any such Assumed Contracts, including without limitation enforcement, at no out-of-pocket cost to Seller, of any and all rights of Seller against the other party or parties thereto arising out of the breach or cancellation by such other party or otherwise.
5.16.    Medicare/Medicaid Cost Reports.
(5)    Seller acknowledges and agrees that it shall be responsible for all Medicare and Medicaid billing and cost reports filed with Medicare and Medicaid with respect to the Facilities prior to the Closing Date and is responsible for terminating cost reports that include periods up to the Closing Date. Seller acknowledges and agrees that it shall remain liable for any claims for overpayments under any of Seller’s Medicare or Medicaid provider agreements for periods prior to the Closing Date. Seller shall timely file all required Medicare credit balance reports, responses to open cost report audits and settlements, and terminating cost reports. Buyer acknowledges and agrees that following the Closing Date, Seller shall continue to be entitled to receive any refund or other benefit which may result from the filing of said reports, including, without limitation, rights to settlements and retroactive adjustments and the Seller Bad Debt (as defined below), if any, arising under a cost report of Seller or its affiliates, for cost report periods ending on or prior to the Closing Date, whether open or closed. After the Closing Date, Buyer shall assist Seller in any way reasonably necessary or required of Buyer to complete such cost reports in a timely manner; provided that any costs or expenses related thereto shall be borne by Seller.
(6)    After the Closing Date, Seller shall promptly and diligently provide Buyer with reasonable and appropriate documentation regarding the Medicare bad debts associated with the Facility incurred by Seller for dates of services prior to the Closing Date (the “Seller Bad Debt”) for purposes of facilitating Buyer’s preparation of related cost reports.
(7)    Buyer shall timely prepare and file with the CMS and the appropriate state agency, its initial cost report for the fiscal year commencing with the fiscal year in which the Closing Date occurs, and will include in its initial cost report the Seller Bad Debt.
(8)    Seller shall provide to Buyer for filing by the day following closure of the certificate of need file, a completed and signed CMS 855A (Sections 1A, 2F, 13, 15 or 16, assuming the Seller has submitted an 855 application at some point such as revalidation and the Authorized/Delegated Person has not changed from the last submission). If the Authorized/Delegated Person has changed or if none is on file with the MAC, then Section 6 shall be completed for both the old and new Authorized/Delegated Person. As an alternative, the Seller can provide all the information needed to complete the Seller’s CMS 855A and a completed and signed Section 15 or 16.
(9)    In the event Buyer receives any notices of settlement of claims from Medicaid and/or Medicare for dates of services rendered prior to Closing, Buyer shall notify Seller within ten (10) business days.
5.17.    Prohibited Actions Pending Closing. Unless otherwise expressly provided for herein or approved by Buyer in writing, from the date of this Agreement until the Closing Date, Seller shall not:
(1)    Accept any advance payment for more than thirty (30) days of any rent or residents’ occupancy fees under any lease included in the Assumed Contracts or occupancy agreement; or waive, reduce or forgive any rent or occupancy fees required to be paid under any occupancy agreement, or grant any lease or other concessions or free rent periods under any occupancy agreement;
(2)    Make any capital improvements to the Real Estate in excess of $10,000 or incur any other obligations in excess of $10,000;
(3)    Make any commitments or representations to any applicable governmental authority, any adjoining or surrounding property owners, any civic association, any utility or any other person or entity that would in any manner be binding upon Buyer;
(4)    Sell or otherwise dispose of, or agree to sell or dispose of any of the Assets, except in the ordinary course of business as permitted by this Agreement; and
(5)    Take any action prior to the Closing Date which would breach any of the representations and warranties contained in this Agreement or otherwise take any action outside of the ordinary course of business of Seller.
5.18.    Restrictive Covenants. In consideration of the Purchase Price and the benefits the Seller and the Shareholders will receive under this Agreement, and to protect Buyer’s legitimate business interests in the operation of the Facility, Seller and the Shareholders shall not, directly or indirectly, do any of the following:
(1)    For a period beginning at Closing and ending on the third anniversary of Closing, engage in, or invest in (other than as a passive shareholder of less than five percent (5%) of the securities of a publicly traded entity), own, manage, operate, finance, control, be employed by, associated with or in any manner connected with, or render services or advice or other aid to, any person engaged in or planning to become engaged in, any Competing Business (defined below) within the Restricted Area (defined below); or
(2)    For a period beginning at Closing and ending on the first anniversary of Closing, induce or attempt to induce any employee or independent contractor of Buyer or any of its affiliates to leave the employ or service of Buyer or any of its affiliates, in any way interfere with the relationship between Buyer or any of its affiliates and any such employee or independent contractor, or solicit, offer employment to, otherwise attempt to hire, employ, or otherwise engage as an employee, independent contractor, or otherwise, any such employee or independent contractor.
For purposes hereof, (i) “Competing Business” shall mean any business engaged in the ownership and/or operation of skilled nursing facilities, and (ii) “Restricted Area” shall mean any area within a ten (10) mile radius of the Facility
Buyer and Seller agree that this Section 5.18 shall not restrict Steve Brown from working for Buyer at the Facility after Closing.
5.19.    Medicare Billing Assistance. Following the Closing Date, Buyer will cooperate and assist Seller in the preparation and execution of Medicare billings for services provided by Seller to residents of the Facility for months (or portions of months) ending prior to the Closing Date and any associated forms for new or discharged residents, which may need to be signed by the Facility’s administrator. After the Closing Date, Buyer shall allow the field auditor/accountant of Seller to have reasonable onsite access to the Facility and the records of the Facility for the billing month in question for the purpose of preparing, completing and submitting the Medicare billings and any associated forms to the appropriate Medicare offices for payment to the account of Seller. Buyer will allow Seller to utilize its biller and any other staff and/or employees on a reasonable basis and as may be necessary by Seller for billing and collection purposes for up to ninety (90) days following Closing.
5.20.    Collection Assistance. Buyer shall cooperate with Seller in collecting accounts receivable which relate to periods prior to the Closing Date, but shall not be responsible for actively collecting such receivables for Seller. Until the earlier of: (i) Seller receives payment of all of Seller’s A/R; or (ii) the date which is twelve (12) months after the Closing Date, Buyer shall provide Seller with an accounting by the 20th day of each month setting forth all amounts received by Buyer during the preceding month with respect to Seller’s A/R which are set forth in the schedule provided by Seller pursuant to Section 2.4. Seller shall have the right to inspect all cash receipts of Buyer related to payment for services rendered to residents of the Facility prior to the Closing Date, during weekday business hours, in order to confirm Buyer’s compliance with the obligations imposed on it under this Section.
5.21.    Notices. Buyer agrees to notify Seller within ten (10) business days of its receipt of any correspondence received by Buyer after the Closing which relates in any way to periods of time, events, services, and/or operations prior to Closing.
ARTICLE 6.    CLOSING
6.1.    Closing. If all of the conditions to Closing set forth in Articles 7 and 8 hereof are satisfied, then the closing of the transaction contemplated by this Agreement (the “Closing”) shall occur promptly following the satisfaction or waiver of the closing conditions set forth in Articles 7 and 8 (the “Closing Date”). The parties shall use commercially reasonable efforts to close the transactions contemplated hereby on or before February 1, 2015 Closing shall take place at the offices of Harwell Howard Hyne Gabbert & Manner, P.C., Nashville, Tennessee, or at such other time or place as the parties may mutually agree. Upon consummation, the Closing shall be deemed to be effective, and the transfer of the Assets shall be deemed to have occurred, as of 12:01 a.m. local time on the Closing Date. On the day of Closing, Buyer shall pay to Seller or their designee (pursuant to wire instructions given to Buyer by Seller) funds in an amount equal to the Purchase Price.
6.2.    Termination. Notwithstanding anything in this Agreement to the contrary, this Agreement and the obligations of the parties hereunder may be terminated at or prior to Closing as follows:
(1)    By Seller: (a) in the event the transactions contemplated by this Agreement have been prohibited or enjoined by reason of any final judgment, decree or order entered or issued by a court of competent jurisdiction in litigation or proceedings involving either Buyer or Seller; or (b) in the event Buyer breaches or violates any material provision of this Agreement or fails to perform any material covenant or agreement to be performed by Buyer under the terms of this Agreement and such breach, violation or failure is not cured prior to Closing or waived by Seller at or prior to Closing.
(2)    By Buyer: (a) in the event the transactions contemplated by this Agreement have been prohibited or enjoined by reason of any final judgment, decree or order entered or issued by a court of competent jurisdiction in litigation or proceedings involving either Buyer or Seller; (b) pursuant to Section 5.5, 5.6 or 5.12; or (c) in the event Seller breaches or violates any material provision of this Agreement or fails to perform any material covenant or agreement to be performed by either under the terms of this Agreement and such breach, violation or failure is not cured prior to Closing or waived by Buyer at or prior to Closing.
(3)    By Buyer or Seller if Closing hereunder shall not have taken place within ninety (90) days after the date of this Agreement, or by such later date as shall be agreed upon by an appropriate amendment to this Agreement if the parties agree in writing to an extension, provided that a party shall not have the right to terminate under this Section 6.2(3) if the conditions precedent to such party’s obligation to close have been fully satisfied and such party has failed or refused to close after being requested in writing to close by the other party.
ARTICLE 7.    SELLER’S CONDITIONS TO CLOSE
The obligations of Seller under this Agreement are subject to the satisfaction on or prior to Closing, of the following conditions (which may be waived in writing by Seller in whole or in part):
7.1.    Representations and Warranties True at Closing; Compliance with Agreement. The representations and warranties of Buyer contained in this Agreement (including the Exhibits hereto) or in any certificate or document delivered by Buyer to Seller pursuant hereto shall be deemed to have been made again at Closing and shall then be true in all material respects; and Buyer shall have performed and complied with all material covenants, agreements and conditions required by this Agreement to be performed or complied with by it prior to or at Closing.
7.2.    No Action/Proceeding. No action or proceeding before a court or any other governmental agency or body shall have been instituted to restrain or prohibit the transaction herein contemplated, and no governmental agency or body or other entity shall have taken any other action as a result of which to proceed with the transactions hereunder will constitute a violation of law.
7.3.    Order Prohibiting Transaction. No order shall have been entered in any action or proceeding before any court or governmental agency, and no preliminary or permanent injunction by any court shall have been issued which would have the effect of: (1) making the transactions contemplated by this Agreement illegal; or (2) otherwise preventing consummation of such transactions. There shall have been no United States federal or state statute, rule or regulations enacted or promulgated after the date of this Agreement that results in any of the consequences referred to in this Section.
ARTICLE 8.    BUYER’S CONDITIONS TO CLOSE
The obligations of Buyer under this Agreement are subject to the satisfaction, on or prior to Closing, of the following conditions (which may be waived in writing by Buyer in whole or in part):
8.1.    Representations and Warranties True at Closing; Compliance with Agreement. The representations and warranties of Seller contained in this Agreement (including the Exhibits hereto) or in any certificate or document delivered to Buyer in connection herewith, shall be deemed to have been made again at Closing and shall then be true in all material respects; and Seller shall have performed and complied with all material covenants, agreements and conditions required by this Agreement to be performed or complied with by them prior to or at Closing.
8.2.    No Loss, Damage of Destruction. In the event there is any damage to or loss of any of the Assets (whether by fire, theft, vandalism or other cause or casualty), the terms of Sections 5.5 and 5.6 shall have been complied with.
8.3.    Regulatory Approvals. Buyer shall have obtained or have reasonable assurance that it will obtain (at its own cost) (a) certification for participation in the Medicaid Programs of the State under a new provider agreement and provider number, and (b) all other licenses, permits, approvals or certificates necessary for the ownership and operation of the Facility; provided that Buyer has promptly made application for such certifications, consents, licenses, etc. Buyer acknowledges and agrees that it shall not be entitled to use Seller’s Medicaid provider account numbers for the Facility, which shall remain the sole and exclusive property of the Seller.
8.4.    No Action/Proceeding. No action or proceeding before a court or any other governmental agency or body shall have been instituted to restrain or prohibit the transaction herein contemplated, and no governmental agency or body or other entity shall have taken any other action as a result of which to proceed with the transactions hereunder constitute a violation of law.
8.5.    Material Adverse Change. There shall not have occurred a material adverse change with respect to the assets, financial condition or operations of the Facility, taken as a whole. Expressly excluded from the definition of “material adverse change” hereunder are changes (a) generally affecting the skilled nursing and nursing home industries, including changes due to actual or proposed changes in law or regulations, (b) that result from political or economic turmoil, or (c) that result from the announcement or pendency of the transaction contemplated by this Agreement.
8.6.    Status of License and Certification. Buyer shall be satisfied in its sole but reasonable discretion that the nursing home license, and Medicare/Medicaid certification, for the operation of the Facility is in substantial compliance and valid and in good standing, and not subject to any regulatory or remedial conditions or restrictions nor otherwise subject to or in risk of suspension or termination. In the event Closing cannot occur due to the inability of Buyer to receive the licenses or certifications as a result of lack of the Facility’s substantial compliance with Medicare or Medicaid requirements for skilled nursing facilities, then Seller agrees to use its best efforts to correct such issues and the Closing Date will be extended for such additional time as may be reasonably necessary for such corrective measures.
8.7.    Title Work and Surveys; Defects and Cure; Title Policy; Environmental Inspections. The obligations of Buyer to consummate the transactions contemplated by this Agreement shall be subject to the fulfillment prior to or at Closing of each of the following conditions, any and all of which may be waived, in whole or in part, by Buyer to the extent permitted by applicable Law:
(1)    Title Work. Seller has furnished to Buyer copies of all existing title work in Seller’s possession or control insuring title to the Real Estate listed on Exhibit 8.7 attached hereto (the “Existing Title Work”). Within five (5) days following the date of this Agreement, Buyer may, at Buyer’s option and expense, order commitments from the title insurance company issuing the existing Title Work (the “Title Company”) to issue (i) updates to the Existing Title Work or (ii) new policies of title insurance for those portions of the Real Estate as to which there is no existing Title Work, together with legible copies of all exceptions to title referenced therein (the “New Title Work”). The New Title Work shall set forth the state of title as of each commitment’s Closing to the Real Estate together with all exceptions or conditions to such title, and all other encumbrances of record affecting such Real Estate, which would appear in an owner’s or lender’s title policy of title insurance, if issued. Buyer shall furnish Seller with copies of any updated title work and New Title Work.
(2)    Survey. Seller has furnished to Buyer copies of all existing land title surveys of the Real Estate in Seller’s possession or control listed on Exhibit 8.7 (the “Existing Surveys”). Within five (5) days following the date of this Agreement, Buyer may, at Buyer’s option and expense, order (i) updates to the Existing Surveys or (ii) current, as-built surveys for those portions of the Real Estate as to which there are no Existing Surveys (the “New Surveys”) meeting the 2011 Minimum Standard Detail Requirements for ALTA/ACSM Land Title Survey of comparable properties, including such Table A optional items as Buyer elects. The updated surveys and New Surveys shall contain the surveyor’s ALTA/ACSM certification to Buyer, Buyer’s lender, Seller and the Title Company. Buyer shall furnish Seller with copies of any updated surveys and New Surveys.
(3)    Defects and Cure. The Existing Title Work, the New Title Work, the Existing Survey and the New Survey are collectively referred to as “Title Evidence”. Buyer shall notify Seller in writing within five (5) days after its receipt of the last of the Title Evidence of any claims, encumbrances, exceptions or defects disclosed in the Title Evidence, other than Permitted Exceptions, to which Buyer objects (the “Defects”). Any matters disclosed in the Title Evidence as to which Buyer does not so object shall be deemed to be Permitted Exceptions. For purposes of this Agreement, any encumbrance, exception or other matter reflected on any Existing Title Work or Existing Survey, other than mortgages or liens to be released at Closing, shall be deemed a Permitted Exception. Seller, at its sole cost and expense, may elect to cure any such Defects on or before Closing (“cure” shall include, but is not limited to, an endorsement by the Title Company reasonably acceptable to Buyer or its lender, either eliminating the Defect, insuring over the Defect or insuring against the effect of the Defect) or Seller may elect to not cure the Defect and shall give written notice to Buyer within ten (10) days of its receipt of Buyer’s notice of Defects of its decision. Within ten (10) days of Buyer’s receipt of Seller’s election not to cure any Defects, Buyer may, at its election, (i) waive such uncured Defects and close, or (ii) terminate this Agreement. If Seller fails to timely give such notice, Seller shall be deemed to have elected not to cure the Defects, whereupon Buyer may waive such Defects and close or may terminate this Agreement as provided in the immediately preceding sentence.
(4)    Title Policy. At the Closing, Buyer may obtain a current ALTA Form Owner’s Policy of Title Insurance (the “Title Policy”) for the Real Estate issued by the Title Company. The Title Policy shall be issued as of the Closing Date in an amount equal to the portion of the Purchase Price being allocated to the Real Estate and shall insure to Buyer good and marketable fee simple title to the Real Estate, subject only to (i) Permitted Exceptions and (ii) taxes for the current and subsequent years “not yet due and payable.” At Buyer’s request, the Title Policy shall have all standard and general exceptions deleted so as to afford full “extended form coverage” and shall contain such available endorsements as Buyer or Buyer’s lender shall reasonably require in connection with its review of the Title Evidence. Seller shall execute such certificates and affidavits as may be reasonably necessary in connection with the issuance of the Title Policy as described in this Section 8.7(4). Buyer shall pay all premiums, costs and expenses of the Title Policy, including the premiums, costs and expenses of any mortgage title insurance required of any lender of Buyer.
(5)    Environmental Inspections. For a period of forty-five (45) days following the execution of this Agreement (the “Environmental Inspection Period”), Buyer and Buyer’s agents, representatives and contractors (or those of Buyer’s lender) shall have the right to enter upon the Real Estate for the purpose of conducting such tests, assessments, evaluations and investigations as Buyer may determine in its sole discretion, in order to evaluate and determine the current environmental condition of the Real Estate, including without limitation Phase I or Phase II environmental assessments of the Real Estate. Within five (5) days after the expiration of the Environmental Inspection Period, Buyer shall give written notice to Seller if Buyer has identified any existing, potential or suspect environmental conditions, risks or liabilities on or in respect of the Real Estate (“Environmental Conditions”). Buyer shall provide Seller with a copy of Buyer’s Environmental Inspections reflecting such Environmental Conditions. If Buyer gives notice of any Environmental Conditions to Seller, then Seller (i) shall, at its sole cost and expense, cure or remedy such Environmental Conditions to Buyer’s reasonable satisfaction on or before Closing or (ii) may elect not to cure or remedy such Environmental Conditions, and shall give written notice of its election to Buyer within ten (10) days after Buyer’s notice of Environmental Conditions. Within ten (10) days of Buyer’s receipt of Seller’s notice that Seller has elected not to cure or remedy any Environmental Conditions, Buyer may elect to (i) waive such Environmental Conditions and close or (ii) elect to terminate this Agreement. If Seller fails to timely give notice of its election as herein provided, Seller shall be deemed to have elected not to cure or remedy the Environmental Conditions, whereupon Buyer may elect to waive such Environmental Conditions and close or terminate this Agreement as provided in the immediately preceding sentence.
8.8.    Financing. Buyer shall have obtained the financing necessary to effect the purchase of the Assets pursuant to the terms hereof.
8.9.    [Deleted].
8.10.    Admission Agreements. Buyer and Seller will enter into an Assignment and Assumption Agreement in the form attached hereto, pursuant to which Seller will assign to Buyer, and Buyer will assume all of Seller’s right, title and interest in and to and obligations arising after the Closing Date under the Admissions Agreements with the persons who are residing at the Facility on the Closing Date (“Assigned Admission Agreements”). Any claims arising under the Assigned Admission Agreements prior to the Closing shall be and remain the liability and obligation of Seller as provided in Sections 1.3(2) and 11.2.
ARTICLE 9.    OBLIGATIONS OF SELLER AT CLOSING
At Closing, Seller shall deliver or cause to be delivered to Buyer the following in form and substance reasonably satisfactory to Buyer:
9.1.    Performance of Covenants. Seller shall have performed the covenants and obligations required of Seller by this Agreement in all material respects.
9.2.    Documents Relating to Title. Seller shall execute, acknowledge, deliver and cause to be executed, acknowledged and delivered to Buyer, or to its designee:
(4)    A special warranty deed, duly executed and acknowledged by Seller, in recordable form conveying fee simple title to the Real Estate to Buyer (or an affiliate of Buyer) free and clear of all liens, claims and encumbrances made, created or suffered by Seller or those claiming by, through or under Seller, except for Permitted Exceptions.
(5)    One or more Bill of Sale and Assignment Agreements, in form and substance satisfactory to Buyer, warranting and conveying to Buyer (or an affiliate of Buyer) good, valid and marketable title to all Assets, free and clear of all liens, mortgages, pledges, encumbrances, security interests, covenants, easements, rights of way, equities, options, rights of first refusal restrictions, special tax or governmental assessments, defects in title, encroachments and other burdens, except for those expressly acceptable to Buyer.
(6)     Intentionally omitted
(7)    Assignment of Admission Agreements, in the form and substance satisfactory to Buyer.
9.3.    Possession. Seller shall deliver to Buyer full possession and control of the Facility and Assets, free and clear of all liens, mortgages, pledges, security interests, restrictions, encumbrances and burdens of any kind whatsoever, including, without limitation, limitations on use and rights of reclamation by donees, subject only to the Permitted Exceptions.
9.4.    Corporate Good Standing and Resolutions. Seller shall deliver to Buyer a certificate of good standing from the Commonwealth of Kentucky, certified copy of the Certificate of Organization and other governing documentation of Seller (all dated the most recent practical date prior to Closing), certified copies of the resolutions of the shareholders of Seller authorizing the execution, delivery and consummation of this Agreement and the execution, delivery and consummation of all other agreements and documents executed in connection herewith.
9.5.    Closing Certificate. Seller shall deliver to Buyer certificates of officers of Seller, dated as of Closing, certifying that: (1) each covenant and obligation of Seller has been complied with by Seller; and (2) each representation and warranty of Seller is true and correct at Closing as if made on and as of Closing.
9.6.    Taxes and Other Payments. Seller shall deliver to Buyer:
(6)    A certificate of non-foreign status signed by the appropriate party and sufficient in form and substance to relieve Buyer of all withholding obligations under Section 1445 of the Code. In the event that Seller cannot furnish such a certificate or Buyer is not entitled to rely upon such a certificate under the provisions of Section 1445 and the regulations thereunder, Seller shall take and/or permit Buyer or Buyer’s nominee to take any and all steps necessary to allow Buyer or Buyer’s nominee to satisfy the requirements of Section 1445.
(7)    Executed releases of all mortgages, security interests, liens, pledges, restrictions or other encumbrances on or applicable to the Assets, other than the Permitted Exceptions.
9.7.    Closing Statement. The parties shall execute a mutually agreeable form of Closing Statement as of the Closing Date of this transaction.
9.8.    Escrow Agreement. The parties shall execute and deliver the Escrow Agreement.
ARTICLE 10.    OBLIGATIONS OF BUYER AT CLOSING
At Closing, Buyer shall deliver or cause to be delivered to Seller the following in a form and substance reasonably satisfactory to Seller:
10.1.    Performance of Covenants. Buyer shall have performed the covenants and obligations required of Buyer by this Agreement in all material respects.
10.2.    Purchase Price. Buyer shall pay to Seller the Purchase Price upon the terms specified in Section 2.1 hereof.
10.3.    Certificate of Existence and Resolutions. Buyer shall deliver to Seller certificates of good standing from the Secretary of State of Delaware and Kentucky, dated the most recent practical date prior to Closing, together with a certified copy of the resolutions of Buyer approving this Agreement and the consummation of the transactions intended hereby.
10.4.    Closing Certificate. Buyer shall deliver to Seller a certificate of officers of Buyer, dated as of Closing, certifying that: (1) each covenant and obligation of Buyer has been complied with by Buyer; and (2) each representation and warranty of Buyer is true and correct at Closing as if made on and as of Closing.
10.5.    Assumption of Liabilities. Buyer shall covenant to perform and comply with all of the Assumed Liabilities, subject to the provisions of this Agreement, from and after Closing.
ARTICLE 11.    SURVIVAL OF PROVISIONS AND INDEMNIFICATION
11.1.    Survival. The covenants, obligations, representations and warranties of Buyer and Seller contained in this Agreement, or in any certificate or document delivered pursuant to this Agreement, shall be deemed to be material and to have been relied upon by the parties hereto notwithstanding any investigation prior to Closing, and shall not be merged into any documents delivered in connection with Closing.
11.2.    Indemnification by Seller and Shareholders. Subject to Section 11.4, Seller and Shareholders individual shall, jointly and severally, promptly indemnify, defend, and hold harmless Buyer, the directors, officers, shareholders, employees and agents of Buyer (the “Buyer Indemnified Parties”), and the Assets against any and all losses, costs, and expenses (including reasonable costs of investigation, court costs and legal fees) and other damages resulting from: (1) any breach by Seller or Shareholders of any of the covenants, obligations, representations or warranties contained in this Agreement or any certificate or document of Seller delivered pursuant to this Agreement; (2) the Excluded Liabilities or any liability of Seller not expressly assumed by Buyer pursuant to Section 1.3 hereof; (3) the determination by Medicare, Medicaid, any fiscal intermediary, or any federal or state governmental authority that any amounts paid to Seller by Medicare, Medicaid, any fiscal intermediary, or any federal or state governmental authority for any services provided by the Facility prior to the Closing resulted in an overpayment or other determination by Medicare, Medicaid, any fiscal intermediary, or any federal or state governmental authority that funds previously paid by Medicare, Medicaid, any fiscal intermediary, or any federal or state governmental authority to Seller must be repaid, which determination results in (i) an offset against amounts owed to Buyer, or (ii) any penalty, sanction or repayment obligations being assessed against Buyer and (4) any claim (whether or not disclosed herein) that is brought or asserted by any third party(s) against Buyer arising out of the ownership, licensing, operation, or conduct of the Facility or Assets or the conduct of any of Seller’s employees, agents or independent contractors, relating to all periods of time prior to Closing.
11.3.    Indemnification by Buyer. Subject to Section 11.4, Buyer shall promptly indemnify, defend, and hold Seller harmless against any and all losses, costs, and expenses (including reasonable cost of investigation, court costs and legal fees) and other damages resulting from: (1) any breach by Buyer of any of its covenants, obligations, representations or warranties or breach or untruth of any representation, warranty, fact or conclusion contained in this Agreement or any certificate or document of Buyer delivered pursuant to this Agreement; (2) any claim which is brought or asserted by any third party(s) against Seller for failure to pay or perform any of the Assumed Liabilities; and (3) subject to the other provisions of this Agreement, any claim that is brought or asserted by any third party(s) against Seller arising out of or relating to the ownership, licensing, operation or conduct of the Facility or Assets or the conduct of any of Buyer’s employees, agents or independent contractors, relating to all periods of time subsequent to Closing.
11.4.    Procedure for Indemnification.
(8)    Notice. Unless otherwise stated herein, within thirty (30) days after receipt of written or actual notice of any action or claim (the “Claim”) as to which it asserts a right to indemnification, the party seeking indemnification hereunder (the “Indemnitee”) shall give written notice thereof (the “Notice”) to the person from whom indemnification is sought (the “Indemnitor”), provided that the failure of the Indemnitee to give the Indemnitor notice within the specified number of days shall not relieve the Indemnitor of any of its obligations hereunder, but may create a cause of action for breach for damages directly attributable to such delay.
(9)    Third Party Claims.
(a)    If any claim for indemnification by Indemnitee arises out of a Claim by a person other than Indemnitee, the Indemnitor shall be entitled to assume the defense thereof, by written notice to the Indemnitee within ten (10) days after receipt of the Notice. Indemnitor shall thereupon undertake to take all steps or proceedings to defeat or compromise any such Claim, including retaining counsel reasonably satisfactory to the Indemnitee. Except as otherwise provided herein, all costs, fees and expenses with respect to any such Claim shall be borne by Indemnitor. If the Indemnitor assumes the defense of a Claim, it shall not settle such Claim unless such settlement includes as an unconditional term thereof a release by the claimant of the Indemnitee, reasonably satisfactory to the Indemnitee and except that Indemnitor shall not, without the prior written consent of Indemnitee, directly or indirectly require Indemnitee to take or refrain from taking any action, or make any public statement, or consent to any settlement, which it reasonably considers to be against its interest. Indemnitee shall have the right to participate at its own expense, in such proceedings, but control of such proceedings shall remain exclusively with Indemnitor.
(b)    If the Indemnitor shall fail to notify the Indemnitee of its desire to assume the defense of any such claim or action within the prescribed period of time, then the Indemnitee may assume such defense in such manner as it may deem appropriate, and the Indemnitor shall be bound by any determinations made or any settlements thereof effected by the Indemnitee. The Indemnitor shall be permitted, at its own expense, to join in such defense and to employ its own counsel but control of such proceedings shall remain exclusively with Indemnitee.
(c)    Indemnitor and Indemnitee agree to make available to each other, their counsel and other representatives, all information and documents reasonably available to them reasonably requested by the other which relate to any such claim or action, and to render to each other such reasonable assistance as may be reasonably requested in order to insure the proper and adequate defense of such claim or action, but any costs or expenses related thereto shall be borne by Indemnitor; and provided that any failure (after written notice with specificity and an opportunity to cure) shall not relieve the Indemnitor of any of its obligations hereunder but may create a cause of action for breach for damages directly attributable to such failure.
(10)    Straddle Resident Claims. Any claim by a resident relating to professional negligence or similar matters involving a resident of Facility served both prior to and subsequent to the Closing Date will be the responsibility of either Buyer or Seller in accordance with the following guidelines: (a) if it is a claim in which the incident giving rise to liability arose prior to the Closing Date, Seller shall be obligated for such claim and shall pay the defense expenses and damages assessed; (b) if it is a claim in which the incident giving rise to liability arose subsequent to the Closing Date, then Buyer shall be obligated for such claim and shall pay the defense expenses and damages assessed; and (c) in the event that it is not clear whether or not the incident giving rise to liability occurred prior to or subsequent to the Closing Date, then Seller and Buyer will jointly defend the case and each will fully cooperate with the other in such defense. In the event of any joint defense hereunder, the parties will (x) attempt in good faith to agree upon a single counsel to represent both parties in the defense of such claim, and (y) share equally in all costs incurred and damages assessed against the parties in connection with such claim. Once the case is resolved, if Seller and Buyer cannot agree to the allocation of both liability and expenses, then the issue shall be submitted to binding arbitration in accordance with the rules and procedures of the American Health Lawyers Association.
(11)    Payment of Claims. Amounts payable by the Indemnitor to the Indemnitee shall be payable by the Indemnitor as incurred by the Indemnitee. In the event Indemnitor fails to pay, timely and fully, any such amounts, Indemnitee may pay such Claim. In such event, the Indemnitee may recover from the Indemnitor, in an addition to the amount so paid, reasonable attorneys’ fees in connection with the enforcement of any payment due hereunder.
(12)    Limitations on Indemnification. No Indemnitor shall have any liability for any Claims hereunder until the total of all Claims against such Indemnitor exceeds Ten Thousand Dollars ($10,000.00) (the “Threshold”) after which Indemnitor shall be liable for Claims above said Threshold. No claim for indemnification may be asserted hereunder unless the party seeking indemnification gives the other party notice of such claim on or before eighteen (18) months after the Closing Date. The total aggregate amount of claims to which any Indemnitor shall be subject hereunder shall be capped at Two Million Dollars ($2,000,000.00) (the “Cap”). Notwithstanding the forgoing, the Threshold and the Cap shall not apply to Claims arising under Section 11.2(2), (3) or (4), or Section 11.3(2) or (3). In addition to the limitations specified above, the maximum liability of any Shareholder under this Article 11 shall not exceed the Purchase Price multiplied by the ownership percentage of such Shareholder set forth on Exhibit 3.1-B.
(13)    Insurance Benefit. No Indemnitor shall have any liability for Claims hereunder to the extent of any Claim that is covered by insurance policy held by the Indemnitee (or to the extent Indemnitee has been named as an additional insured) with respect to cash proceeds of such policy actually received by Indemnitee; provided, however, that (i) this provision shall not apply and the Indemnitee shall be entitled to indemnification with respect to the amount of any Claim that is in excess of the cash proceeds actually received by such Indemnitee (after deducting reasonable costs and expenses incurred in connection with the recovery of such insurance proceeds, including attorneys’ fees and premium increases) pursuant to such insurance, (ii) this limitation shall not apply to any self-insurance arrangement maintained by Indemnitee, and (iii) this provision shall not be deemed to require Indemnitee to file a claim with respect to any insurance coverage if Indemnity reasonably determines that such claim would result in a cancellation of any policy held by or benefiting Indemnitee or any of its affiliates.
(14)    Damages. Neither party, nor any of its affiliates, shall have any liability hereunder for consequential, incidental, special or punitive damages.
(15)    Escrow Holdback. The Escrow Holdback shall be applied to Claims payable to any Buyer Indemnified Party in accordance with the terms of the Escrow Agreement. Eighteen (18) months after the Closing Date, the Escrow Holdback, minus (i) any amount paid to any Buyer Indemnified Party under this Article 11, plus (ii) the amount of any pending claims by any Buyer Indemnified Party under this Article 11 shall be released to Seller. In the event that any amount is withheld by the Escrow Agent due to any pending claim, the portion of such amount that is not applied to a pending claim shall be released to Seller as soon as practicable following resolution of such Claim
(16)    Exclusive Remedy. The sole and exclusive remedy for any damages incurred by either party as a result of any breach of the representations, warranties, covenants and agreements of the other party contained in this Agreement shall be the remedies contained in this Article 11.
ARTICLE 12.    SHAREHOLDER REPRESENTATIVE
12.1.    Appointment. All of the Shareholders collectively and irrevocably constitute and appoint the Shareholder Representative as their agent and representative to take all actions contemplated to be taken by the Shareholder Representative hereunder and otherwise to act from and after the date hereof and to do any and all things and execute any and all documents on behalf of the Shareholders which may be necessary, convenient or appropriate to facilitate the consummation of the transactions contemplated by this Agreement, including: (1) execution of the documents and certificates pursuant to this Agreement; (1) administration of the provisions of this Agreement; (1) giving or agreeing to, on behalf of all or any of the Shareholders, any and all consents, waivers, amendments or modifications under this Agreement and the execution or delivery of any documents in connection therewith; (1) amending this Agreement or any of the instruments to be delivered to the Buyer pursuant to this Agreement; (1) (A) disputing or refraining from disputing, on behalf of each Shareholder relative to any amounts to be received by such Shareholder under this Agreement or any agreements contemplated hereby, any claim made by the Buyer under this Agreement or other agreements contemplated hereby, (B) negotiating and compromising, on behalf of each such Shareholder, any dispute that may arise under, and exercising or refraining from exercising any remedies available under, this Agreement or any other agreement contemplated hereby and (C) executing, on behalf of each such Shareholder, any settlement agreement, release or other document with respect to such dispute or remedy and (1) engaging attorneys, accountants, agents or consultants on behalf of the Shareholders in connection with this Agreement or any other agreement contemplated hereby and paying any fees related thereto; provided, however, that, except to the extent otherwise set forth in Section 12.2, the Shareholder Representative shall not take any actions on behalf of the Shareholders pursuant to the powers delegated to the Shareholder Representative hereunder that require the Shareholder Representative to exercise discretion without the prior approval of the Shareholders given in accordance with the provisions of Section 12.2 hereof. For the avoidance of doubt, the following actions shall not constitute the exercise of discretion by the Shareholder Representative and thus may be taken by the Shareholder Representative without the approval of Shareholders: (i) the receipt of payments under or pursuant to this Agreement and disbursement thereof to the Shareholders and others, as contemplated by this Agreement; (ii) payment of any undisputed amounts due to the Buyer under this Agreement; and (iii) the receipt of written notices and communications hereunder and the forwarding of such written notices and communications to the Shareholders pursuant to this Agreement.
12.2.    Direction. Whenever the Shareholder Representative believes that it is advisable to take an action hereunder requiring the exercise of discretion, or in the event the Shareholder Representative desires to seek the direction of the Shareholders, the Shareholder Representative shall notify the Shareholders requesting direction as to the course of action to be taken, and to the extent the Shareholder Representative in good faith so acts or refrains from acting in accordance with any directions provided by the Shareholders pursuant hereto, the Shareholder Representative shall be authorized hereunder to take such action and shall not be liable on account of such action to the Shareholders or any other Person. If the Shareholder Representative shall not have received appropriate directions within three (3) Business Days of such notice (or within such shorter period of time as reasonably may be specified in such notice or may be necessary under the circumstances), the Shareholder Representative may, but shall be under no duty to, take or refrain from taking such action as he shall deem to be in the best interests of the Shareholders, and the Shareholder Representative shall have no liability to the Shareholders or any other Person for such action or inaction, so long as such action or inaction does not constitute fraud, gross negligence or willful misconduct. With respect to any action for which the Shareholder Representative seeks directions from the Shareholders hereunder, the determination by Shareholders owning two-thirds or more of the Company’s stock prior to Closing shall be binding on all of the Shareholders and shall constitute the authorization by the Shareholders. Upon receiving a determination from the Shareholders in the manner set forth in this Section 12.2, the Shareholder Representative shall be authorized to act in reliance on such determination and shall be deemed to have been granted all power and authority to take any action reasonably necessary or prudent to accomplish the purpose and intent of such determination and the Shareholder Representative shall have no liability to the Shareholders or any other Person for such action or inaction, so long as such action or inaction does not constitute fraud or willful misconduct.
12.3.    Capacity. All acts of the Shareholder Representative hereunder in his capacity as such taken in accordance with the provisions of this Section 12.3 shall be deemed to be acts on behalf of the Shareholders and not of the Shareholder Representative individually. The Shareholder Representative shall not be liable to the Buyer in his capacity as the Shareholder Representative, for any liability of a Shareholder or otherwise or for anything, which he may do or refrain from doing in connection with this Agreement. The Shareholder Representative shall not be liable to the Shareholders, in his capacity as the Shareholder Representative, for any liability of a Shareholder or otherwise or for any error of judgment, or any act done or step taken or omitted by him in good faith or for any mistake in fact or law, or for anything which he may do or refrain from doing in connection with this Agreement except in the case of the Shareholder Representative’s fraud, gross negligence or willful misconduct. The Shareholder Representative may seek the advice of legal counsel in the event of any dispute or question as to the construction of any of the provisions of this Agreement or its duties hereunder, and it shall incur no liability in its capacity as the Shareholder Representative to the Buyer, the Consolidated Companies or the Shareholders and shall be fully protected with respect to any action taken, omitted or suffered by it in good faith in accordance with the advice of such counsel and in accordance with the provisions of this Article 12. The Shareholder Representative shall not by reason of this Agreement have a fiduciary relationship in respect of any Shareholder, except in respect of amounts received on behalf of the Shareholders.
12.4.    Expenses. Any reasonable expenses or taxable income incurred by the Shareholder Representative in connection with the performance of his duties under this Agreement shall not be the personal obligation of the Shareholder Representative but shall be payable by and attributable to the Shareholders based on each such Shareholder’s Pro Rata Share (determined as of the date on which such expense or taxable income was incurred). Notwithstanding anything to the contrary in this Agreement and without the requirement for any approval of the Shareholders, the Shareholder Representative shall be entitled and is hereby granted the right to set off and deduct any unpaid or non-reimbursed reasonable expenses and unsatisfied liabilities incurred by the Shareholder Representative in connection with the performance of his duties hereunder from amounts delivered to the Shareholder Representative pursuant to this Agreement. Additionally, in connection with any unpaid or non-reimbursed reasonable expenses and unsatisfied liabilities incurred by the Shareholder Representative in connection with the performance of his duties hereunder, the Shareholder Representative, without the requirement for any approval of the Shareholders, shall be entitled and is hereby granted the right to direct any funds that would otherwise be payable to Shareholders from the Escrow Account to itself. The Shareholder Representative may also from time to time submit invoices to Shareholders covering such expenses and liabilities and, upon the request of any Shareholder, shall provide such Shareholder with an accounting of all expenses and liabilities paid. The Shareholder Representative shall, within twenty (20) Business Days of the end of each calendar quarter in which any amounts have been paid or received by the Shareholder Representative on behalf of the Shareholder, deliver to each Shareholder a statement setting forth in reasonable detail and with reasonable supporting documentation any amounts paid or received by the Shareholder Representative on behalf of the Shareholders during such calendar quarter.
12.5.    Notice. Notices or communications to or from the Shareholder Representative provided in accordance with the terms of this Article 12 shall constitute notice to or from each of the Shareholders. The Shareholder Representative shall use commercially reasonable efforts to promptly deliver copies of any written notices or written communications received or made by him in his capacity as the Shareholder Representative to all Shareholders. All decisions, acts, consents or instructions of the Shareholder Representative that are made or taken in accordance with the provisions of this Section 12.5 shall be deemed to be decisions, acts, consents or instructions of the Shareholders and shall be final, binding and conclusive upon each of the Shareholders. The Buyer may rely upon any decision, act, consent or instruction of the Shareholder Representative as being the decision, act, consent or instruction of each and every Shareholder. Notwithstanding anything in this Agreement to the contrary, the rights and obligations between and among the Shareholders and the Shareholder Representative set forth in this Article 12 are agreements between and among the Shareholders and the Shareholder Representative, and the Shareholders and the Shareholder Representative acknowledge and agree that the Buyer shall have no obligations or liabilities with respect to such agreements between and among the Shareholders and the Shareholder Representative.
12.6.    Indemnity. The Shareholders jointly and severally hereby agree to indemnify and hold, harmless the Shareholder Representative against any out-of-pocket loss, reasonable expense (including reasonable attorneys’ fees) or other liability arising out of its service as Shareholder Representative under this Agreement, other than for harm directly caused by his fraud or willful misconduct.
ARTICLE 13.    MISCELLANEOUS
13.1.    Assignment. Except as otherwise provided below, neither Seller nor Buyer may assign any rights or delegate any obligations under this Agreement without the prior written consent of the other party, and any prohibited assignment or delegation will be null and void. Notwithstanding the foregoing, Buyer may assign some or all of its rights, including its right to take title to some or all of the Assets at Closing, to one or more affiliates so long as Buyer remains obligated hereunder. This Agreement shall be binding upon and shall inure to the exclusive benefit of the parties hereto and their respective permitted heirs, legal representatives, successors and assigns.
13.2.    Other Expenses. Except as otherwise provided in this Agreement, Seller shall pay all of its expenses in connection with the negotiation, execution, and implementation of the transactions contemplated by this Agreement and Buyer shall pay all of its expenses in connection with the negotiation, execution, and implementation of the transactions contemplated by this Agreement. Seller will pay any applicable real estate documentary or transfer taxes and recording costs for the recording of Buyer’s deed to the Real Estate. All costs associated with any real property surveys, environmental reports, title insurance or document recording fees incurred in connection with the transactions contemplated within this Agreement shall be borne solely by Buyer and paid by Closing. Real estate and personal property taxes and assessments (“Taxes”) imposed by any governmental authority with respect to the Real Estate and Seller’s personal property of the relevant tax year in which the Closing occurs and that are not yet due and payable shall be prorated as of the Closing Date based upon the most recent ascertainable assessed values and tax rates. Seller shall receive a credit for any Taxes already paid by Seller and applicable to any period after the Closing Date. Seller shall pay any unpaid Taxes for tax years prior to the relevant tax year in which Closing occurs. All other costs incurred in connection with the transactions contemplated within this Agreement shall be prorated at Closing.
13.3.    Notices. All notices, requests, demands, waivers and other communications required or permitted to be given under this Agreement shall be in writing and shall be deemed to have been duly given: (1) if delivered personally or sent by facsimile, on the date received; (2) if delivered by overnight courier, on the day after mailing; and (3) if mailed, five (5) days after mailing with postage prepaid. Any such notice shall be sent as follows:
To Buyer:

c/o Diversicare Healthcare Services, Inc.
1621 Galleria Boulevard
Brentwood, Tennessee 37027
Attn: President
(615) 771-7409 (fax)

with a copy to:

Harwell Howard Hyne Gabbert & Manner, P.C.
333 Commerce Street, Suite 1500
Nashville, Tennessee 37201
Attn: Michael R. Hill
(615) 251-1059 (fax)

To Seller prior to the Closing:

Barren County Health Care Center
300 Westwood Street
Glasgow, KY 42141
Attn: Steve Brown, Administrator

with a copy to:

Thacker, Hodskins, Thacker, Searcy & Knight, LLP
209 W. 4th Street
PO Box 39
Owensboro, KY 42302
Attn: Terra W. Knight
(270) 926-4576 (fax)

To Shareholders, and to Seller after the Closing:

Steve Brown
105 Wingate
Glasgow, KY 42141

13.4.    Confidentiality; Public Announcements. All parties agree to maintain the confidentiality of the existence of this Agreement and the transactions contemplated hereunder, unless disclosure is required by law, except for regulatory filings and except that Buyer shall be entitled to disclose the terms of this Agreement to its attorneys, accountants, financing sources, third party agents, investors, and other advisors, provided, such persons agree to keep the terms of this Agreement confidential. Except as otherwise required by law, all public announcements prior to and on the Closing Date relating to this Agreement or the transactions contemplated hereby, including announcements to employees, will be made only as may be agreed upon jointly by the parties.
13.5.    Controlling Law. This Agreement shall be construed, interpreted and enforced in accordance with the laws of the Commonwealth of Kentucky without regard to its choice or conflicts of law provisions. Seller and Buyer hereby consent to the jurisdiction and venue of courts located in Owensboro, Kentucky, for the resolution of any disputes arising under this Agreement for which a dispute resolution mechanism has not been specified herein.
13.6.    Headings. Table of contents and Section headings in this Agreement are for convenience of reference only and shall not be considered or referred to in resolving questions of interpretation.
13.7.    Partial Invalidity. The invalidity or unenforceability of any particular provision of this Agreement shall not affect the other provisions hereof, and this Agreement shall be construed in all respects as if such invalid or unenforceable provisions were omitted.
13.8.    Waiver. Neither the failure nor any delay on the part of any party hereto in exercising any rights, power or remedy hereunder shall operate as a waiver thereof, or of any other right, power or remedy; nor shall any single or partial exercise of any right, power or remedy preclude any further or other exercise thereof, or the exercise of any other right, power or remedy. No waiver of any of the provisions of this Agreement shall be valid unless it is in writing and signed by the party against which it is sought to be enforced.
13.9.    Counterparts. This Agreement may be executed simultaneously in two or more counterparts each of which shall be deemed an original and all of which together shall constitute but one and the same instrument.
13.10.    Interpretation; Knowledge. All pronouns and any variation thereof shall be deemed to refer to the masculine, feminine, neuter, singular or plural as the identity of the person or entity, or the context, may require. Further, it is acknowledged by the parties that this Agreement has undergone several drafts with the negotiated suggestions of both; and, therefore, no presumptions shall arise favoring either party by virtue of the authorship of any of its provisions or the changes made through revisions. Whenever in this Agreement the term “to the knowledge of Seller” or the like is used, Seller shall be deemed to have the knowledge of Seller’s executive officers, managers and directors.
13.11.    Entire Agreement. This Agreement, including the Exhibits hereto, constitutes the entire agreement between the parties hereto with regard to the matters contained herein and it is understood and agreed that all previous undertakings, negotiations, letters of intent and agreements between the parties are merged herein. This Agreement may not be modified orally, but only by an agreement in writing signed by Buyer and Seller.
13.12.    Legal Fees and Costs. In the event any party incurs legal expenses to enforce or interpret any provision of this Agreement, the prevailing party will be entitled to recover such legal expenses, including, without limitation, attorney’s fees, costs and necessary disbursements, in addition to any other relief to which such party shall be entitled.
13.13.    No Third Party Beneficiaries. The provisions of this Agreement are solely for the benefit of the parties hereto. It shall create no rights in any persons other than as set forth in the immediately preceding sentence.
13.14.    Exclusivity. Until and unless this Agreement is terminated by Buyer or Seller as provided herein, Seller will not solicit any offers or proposals, or enter into letters of intent, negotiations or contracts with any third-party with respect to a transaction relating to the sale, transfer, conveyance, merger or any other transaction of similar import with respect to Seller or any of the Assets.
13.15.    Waiver of Jury Trial. EACH OF THE PARTIES HEREBY KNOWINGLY, VOLUNTARILY AND INTENTIONALLY WAIVES, TO THE FULLEST EXTENT PERMITTED BY LAW, ANY RIGHT TO TRIAL BY JURY IN ANY LEGAL ACTION BROUGHT ON OR WITH RESPECT TO THIS AGREEMENT, INCLUDING TO ENFORCE OR DEFEND ANY RIGHTS HEREUNDER, AND AGREES THAT ANY SUCH ACTION SHALL BE TRIED BEFORE A COURT AND NOT BEFORE A JURY.

The parties hereto have executed this Agreement as of the date first above written.
BUYER:

DIVERSICARE OF GLASGOW, LLC

BY:    DIVERSICARE HOLDING COMPANY, LLC,     its sole member


By: /s/ Kelly J. Gill                
Name:    Kelly J. Gill    
Title:    President and Chief Executive Officer



SELLER:

BARREN COUNTY HEALTH CARE CENTER, INC.


By: /s/ Steve Brown                    

Title:    President                        


SHAREHOLDERS:


/s/ Steve Brown                        
STEVE BROWN


/s/ John L. Beam                        
JOHN L. BEAM


/s/ Linda Beam                        
LINDA BEAM


/s/ Nancy A. Mollett                    
NANCY A. MOLLETT


/s/ James B. Hurst                        
JAMES B. HURST


/s/ Thomas S. Hurst, Jr.                    
THOMAS S. HURST, JR.


/s/ Peggy Hurst Greenwell                
PEGGY HURST GREENWELL


/s/ Beth Hurst Hawkins                    
BETH HURST HAWKINS


/s/ Sallie Hurst Schrieber                    
SALLIE HURST SCHRIEBER



EX-10.2 3 dvcr-ex102x33115termloanan.htm EXHIBIT 10.2 DVCR-EX10.2 - 3.31.15 Term Loan and Security Agreement - Glasgow


TERM LOAN AND SECURITY AGREEMENT
dated as of February 2, 2015
by and between
DIVERSICARE GLASGOW PROPERTY, LLC,
as Borrower
and
THE PRIVATEBANK AND TRUST COMPANY,
as Lender


TERM LOAN AND SECURITY AGREEMENT
This TERM LOAN AND SECURITY AGREEMENT (this “Agreement”), dated as of February 2, 2015, is by and between DIVERSICARE GLASGOW PROPERTY, LLC, a Delaware limited liability company (“Borrower”), and THE PRIVATEBANK AND TRUST COMPANY, an Illinois banking corporation (“Lender”), its successors and assigns.
RECITALS
WHEREAS, Borrower is, or as of the date hereof shall be, the owner of certain improved real estate located at 300 Westwood Street, Glasgow, Barren County, Kentucky 42141, as more fully described on Exhibit A attached hereto and made a part hereof (the “Real Property”), which Real Property is improved with a ninety-four (94) bed skilled nursing facility (the “Facility”).
WHEREAS, Borrower has requested that Lender provide Borrower with a term loan in the original maximum principal amount of Five Million and No/100 Dollars ($5,000,000.00) (the “Term Loan”), which Term Loan shall be for the purpose of acquiring the Real Property and all improvements located thereon.
WHEREAS, Lender is willing to make such Term Loan to Borrower upon the terms and provisions and subject to the conditions set forth herein.
NOW, THEREFORE, in consideration of the mutual agreements contained herein, and of the Term Loan to be made to or for the benefit of Borrower by Lender, and for other good and valuable consideration, the receipt and adequacy of which is hereby acknowledged, the parties hereto (intending to be legally bound) hereby agree as follows:
1.DEFINITIONS.
1.1    General Terms. When used herein, the following terms shall have the following meanings:
Acquisition” means Borrower’s acquisition of the Real Property.
Acquisition Agreement” means the Asset Purchase Agreement dated January 29, 2015, between Borrower, as tenant, and Seller, as landlord, granting Borrower the right to purchase the Real Estate.
Acquisition Documents” means, collectively, the Acquisition Agreement, bill of sale, assignment and assumption agreement, special warranty deed, and any and all of the other documents, instruments and agreements executed or delivered in connection therewith or otherwise in connection with the Acquisition.
Adjusted Borrower EBITDA” means the sum of (a) Borrower EBITDA, and (b) the amounts deducted (or less amounts added) in computing Borrower EBITDA for the period for (i) the non-cash provision (benefit) for self-insured professional and general liability expenses, (ii) non-cash rent expense, (iii) non-cash stock based compensation expense, (iv) non-cash debt retirement, and (v) all other non-cash expenses reasonably approved by Lender, less (c) the Cash Cost of Self-Insured Professional and General Liability.
Adjusted Operator EBITDAR” means the sum of (a) Operator EBITDAR, and (b) the amounts deducted (or less amounts added) in computing Operator EBITDAR for the period for (i) the non-cash provision (benefit) for self-insured professional and general liability expenses, (ii) non-cash rent expense, (iii) non-cash stock based compensation expense, (iv) non-cash debt retirement, and (v) all other non-cash expenses reasonably approved by Lender, less (c) the Cash Cost of Self-Insured Professional and General Liability.
Adjusted Parent EBITDA” means the sum of (a) Parent EBITDA, and (b) the amounts deducted (or less amounts added) in computing Parent EBITDA for the period for (i) the non-cash provision (benefit) for self-insured professional and general liability expenses, (ii) non-cash rent expense, (iii) non-cash stock based compensation expense, (iv) non-cash debt retirement, and (v) all other non-cash expenses reasonably approved by Lender, less (c) the Cash Cost of Self-Insured Professional and General Liability.
Affiliate” means, with respect to any Person, any other Person directly or indirectly controlling (including, without limitation, all shareholders, members, directors, partners, managers, and officers of such Person), controlled by, or under direct or indirect common control with, such Person. A Person shall be deemed to control another Person if such first Person possesses, directly or indirectly, the power to direct or cause the direction of the management and policies of such other Person, whether through ownership of voting securities, by contract or otherwise; provided, however, Lender shall not be deemed an Affiliate of any Credit Party.
Agreement” means this Term Loan and Security Agreement, as the same may be restated, modified, supplemented or amended from time to time.
Applicable Base Rate Margin” means, with respect to Base Rate Loans, one hundred fifty (150) basis points.
Applicable Libor Margin” means, with respect to Libor Loans, an amount equal to four hundred fifty (450) basis points.
Appraisal” means a complete, self-contained appraisal of the Real Property performed in accordance with FIRREA and Lender’s appraisal requirements by an independent appraiser MAI licensed in the state in which the Real Property is located and selected and retained by Lender.
Asset Disposition” means the sale, lease, assignment or other transfer for value of greater than Fifty Thousand and No/100 Dollars ($50,000.00) by Borrower to any Person of any personal property of Borrower, other than (a) the sale of any personal property asset which is to be replaced, and is in fact replaced, within sixty (60) days thereof with another of equal or substantially similar value and used in the ordinary course of business of Borrower, (b) the sale or lease of Inventory in the ordinary course of business, and (c) sales in the ordinary course of business of personal property that is obsolete, unmerchantable or otherwise unsalable, unusable or unnecessary to Borrower’s business.
Assignment of Membership Interests” means that certain Collateral Assignment of Membership Interests including Negative Pledge Agreement between Diversicare Property Co., LLC, a Delaware limited liability company, as assignor, and Lender, as assignee.
Assignment of Rents and Leases” means that certain Assignment of Rents and Leases dated of even date herewith made by Borrower in favor of Lender, with respect to the Real Property, in form and substance reasonably satisfactory to Lender, as the same may be amended, supplemented, and modified from time to time.
Bank Product” means any service provided to, facility extended to, or transaction entered into with, any Credit Party by Lender or its Affiliates consisting of, (a) deposit accounts, (b) cash and treasury management services, including, controlled disbursement, lockbox, electronic funds transfers (including, book transfers, fedwire transfers, ACH transfers), online reporting and other services relating to accounts maintained with Lender or its Affiliates, (c) debit cards, purchase cards, and credit cards, (d) Hedging Agreements, or (e) so long as prior written notice thereof is provided by Lender (or its Affiliate) providing such service, facility or transaction and Lender consents in writing to its inclusion as a Bank Product, any other service provided to, facility extended to, or transaction entered into with, any Credit Party by Lender or its Affiliates.
Bank Product Agreements” means those agreements entered into from time to time between any Credit Party and Lender or its Affiliates in connection with the obtaining of any of the Bank Products, including, without limitation, Hedging Agreements.
Bank Product Obligations” means all obligations, liabilities, reimbursement obligations, contingent reimbursement obligations, fees, or expenses owing by any Credit Party to Lender or its Affiliates pursuant to or evidenced by a Bank Product Agreement and irrespective of whether for the payment of money, whether direct or indirect, absolute or contingent, due or to become due, now existing or hereafter arising, and including all such amounts that a Credit Party is obligated to reimburse to Lender as a result of Lender purchasing participations or executing indemnities or reimbursement obligations with respect to the Bank Products provided to the Credit Parties pursuant to the Bank Product Agreements.
Base Rate” means, subject to Sections 2.2(d), solely with respect to Section 2.9(b), 2.9(c) and 2.9(f) hereof, the greater of (a) the corporate base rate of interest per annum identified from time to time by Lender, as its base or prime rate, which rate shall not necessarily be the lowest rate of interest which Lender charges its customers, and (b) the greater of (i) four and three-quarters percent (4.75%) per annum, and (ii) the Libor Rate as in effect immediately before such time as the Libor Base Rate became unavailable. Any change in the Base Rate shall be effective as of the effective date of such change.
Base Rate Loan” means, solely with respect to Sections 2.9(b), 2.9(c) and 2.9(f) hereof, a Loan that bears interest at an interest rate based on the Base Rate (plus the Applicable Base Rate Margin, subject to Section 2.4).
Blocked Persons List” shall have the meaning ascribed to such term in Section 7.24 hereof.
Borrower Cash Management Program” means the business practice of Borrower whereby cash receipts for Borrower are transferred/swept into a central concentration account and all cash disbursements are funded by transfers from such central concentration account.
Borrower EBITDA” means with respect to Borrower, for any period of determination, the net earnings of Borrower (without duplication or double-counting) from the Facility before nonrecurring items (in accordance with GAAP and as reasonably agreed to by Lender), interest, taxes, depreciation, and amortization (including amortized transaction expense), all as determined in accordance with GAAP, consistently applied.
Borrower Fixed Charge Coverage Ratio” means, on any date of determination, the ratio of (a) Adjusted Borrower EBITDA for the period of twelve (12) consecutive months then ended, to (b) Fixed Charges, for Borrower, all as determined in accordance with GAAP, consistently applied.
Borrowing Date” means a date on which a Libor Loan is made hereunder.
Business Day” means (a) with respect to any borrowing, payment or rate selection of Libor Loans, a day other than Saturday or Sunday on which banks are open for business in Chicago, Illinois and on which dealings in United States dollars are carried on in the London interbank market, and (b) for all other purposes, a day other than Saturday or Sunday on which banks are open for business in Chicago, Illinois.
Capital Expenditures” means, as to any Person, any and all expenditures of such Person for fixed or capital assets, including, without limitation, the incurrence of Capitalized Lease Obligations, all as determined in accordance with GAAP, except that Capital Expenditures shall not include (i) expenditures for fixed or capital assets to the extent such expenditures are paid for or reimbursed from the proceeds of insurance, condemnation awards and other settlements in respect of lost, destroyed, damaged, condemned or stolen assets, (ii) expenditures for assets purchased substantially concurrently with the trade-in of existing assets to the extent of the trade-in credit thereof; and (iii) any incurrence of Indebtedness comprising the purchase price for the acquisition, whether by purchase, merger, consolidation or otherwise, by Borrower of the assets of, or the equity interest in, a Person or a division, line of business or other business unit of a Person engaged in a business of the type conducted by Borrower as of the date hereof or in a business reasonably related thereto.
Capitalized Lease Obligations” means any amount payable with respect to any lease of any tangible or intangible property (whether real, personal or mixed), however denoted, which either (a) is required by GAAP to be reflected as a liability on the face of the balance sheet of the lessee thereunder, or (b) based on actual circumstances existing and ascertainable, either at the commencement of the term of such lease or at any subsequent time at which any property becomes subject thereto, can reasonably be anticipated to impose on such lessee substantially the same economic risks and burdens, having regard to such lessee’s obligations and the lessor’s rights thereunder both during and at the termination of such lease, as would be imposed on such lessee by any lease which is required to be so reflected or by the ownership of the leased property. For avoidance of doubt, prepaid leases shall not be deemed “Capital Lease Obligations” except to the extent required under GAAP.
Cash Cost of Self-Insured Professional and General Liability” means the total cash expenditures associated with professional and general liability related settlements, legal fees and administration costs for the Facility.
CERCLA” means the Comprehensive Environmental Release Compensation and Liability Act, 42 U.S.C. § 9601 et seq., as amended.
Certificates” shall have the meaning ascribed to such term in Section 5.1(d)(7) hereof.
CHAMPUS” means the Civilian Health and Medical Program of the Uniformed Service, a part of TRICARE, a medical benefits program supervised by the U.S. Department of Defense.
Closing Date” means February 2, 2015.
Closing Fee” shall have the meaning ascribed to such term in Section 2.12 hereof.
CMS” means the Centers for Medicare and Medicaid Services of HHS and any Person succeeding to the functions thereof.
Collateral” shall have the meaning ascribed to such term in Section 6.1 hereof.
Commodity Exchange Act” means the Commodity Exchange Act (7 U.S.C. § 1 et seq.), as amended from time to time, and any successor statute.
Compliance Certificate” shall have the meaning ascribed to such term in Section 8.1(b) hereof.
CON” shall have the meaning ascribed to such term in Section 10.1 hereof.
Credit Party” means Borrower and each other Person that is or becomes primarily or secondarily liable for the Liabilities, whether as a principal, surety, guarantor, endorser or otherwise.
Credit Termination Date” means the earlier of (i) the Stated Maturity Date, (ii) such other date on which the Term Loan Commitment shall terminate pursuant to Section 11.2 hereof, or (iii) such other date as is mutually agreed in writing between Borrower and Lender.
Default” means an event, circumstance or condition which through the passage of time or the service of notice or both would (assuming no action is taken to cure the same) mature into an Event of Default.
Default Rate” shall have the meaning ascribed to such term in Section 2.4 hereof.
Deposit Accounts” means any deposit, securities, operating, lockbox, blocked or cash collateral account, together with any funds, instruments or other items credited to any such account from time to time, and all interest earned thereon.
Duly Authorized Officer” means the Chief Executive Officer, the President, the Chief Operating Officer, the Chief Financial Officer and the Assistant Secretary of the sole member of Borrower.
Environmental Indemnity Agreement” means that certain Environmental Indemnity Agreement of even date herewith made by Borrower in favor of Lender, in form and substance acceptable to Lender, as the same may be amended or modified from time to time.
Environmental Laws” means all federal, state, local, and foreign statutes, regulations, ordinances, and similar provisions having the force or effect of law, all judicial and administrative orders and determinations, and all common law concerning public health and safety, worker health and safety, pollution, or protection of the environment, including all those relating to the presence, use, production, generation, handling, transportation, treatment, storage, disposal, distribution, labeling, testing, processing, discharge, release, threatened release, control, or cleanup of any hazardous materials, substances, or wastes, chemical substances, or mixtures, pesticides, pollutants, contaminants, toxic chemicals, petroleum products or byproducts, asbestos, polychlorinated biphenyls, noise, or radiation, including, without limitation, the Resource Conservation and Recovery Act, 42 U.S.C. § 6901 et seq., as amended; CERCLA; the Toxic Substance Act, 15 U.S.C. § 2601 et seq., as amended; the Clean Water Act, 33 U.S.C. § 466 et seq., as amended; the Clean Air Act, 42 U.S.C. § 7401 et seq., as amended; state and federal superlien and environmental cleanup programs; and U.S. Department of Transportation regulations.
Environmental Notice” means any summons, citation, directive, information request, notice of potential responsibility, notice of violation or deficiency, order, claim, complaint, investigation, proceeding, judgment, letters or other communication, written or oral to Borrower or any officer thereof, actual or threatened, from the United States Environmental Protection Agency or other federal, state or local agency or authority, or any other entity or individual, public or private, concerning any intentional or unintentional act or omission which involves Management of Hazardous Substances on or off the property of Borrower which could result in Borrower incurring a material liability or which could have a Material Adverse Effect, or the imposition of any Lien on property, or any alleged violation of or responsibility under Environmental Laws which could result in Borrower incurring a material liability or which could have a Material Adverse Effect, and, after due inquiry and investigation, any knowledge of any facts which could give rise to any of the foregoing.
Equipment” means “equipment” as defined in the Code, including, without limitation, any and all of Borrower’s machinery, equipment, vehicles, fixtures, furniture, computers, appliances, tools, and other tangible personal property (other than Inventory), whether located on Borrower’s premises or located elsewhere, together with any and all accessions, parts and appurtenances thereto, whether presently owned or hereafter acquired by Borrower.
ERISA” means the Employee Retirement Income Security Act of 1974, as amended, together with the regulations thereunder.
ERISA Affiliate” means any corporation, trade or business, which together with Borrower would be treated as a single employer under Section 4001 of ERISA.
Event of Default” shall have the meaning ascribed to such term in Section 11.1 hereof.
Excluded Swap Obligation” means, with respect to any guarantor of the Liabilities, any Swap Obligation if, and to the extent that, the applicable guaranty or collateral pledge provided by such Person with respect to the Liabilities becomes illegal under the Commodity Exchange Act or any rule, regulation or order of the Commodity Futures Trading Commission (or the application or official interpretation of any thereof) by virtue of such Person’s failure for any reason to constitute an “eligible contract participant” as defined in the Commodity Exchange Act at the time such applicable guaranty or pledge agreement or similar collateral document becomes effective with respect to such related Swap Obligation, but such exclusion shall only be effective for so long as it would otherwise be so impermissible.
Facility” shall have the meaning ascribed to such term in the Recitals.
FCPA” means the Foreign Corrupt Practices Act, 15 U.S.C. §§ 78dd-1, et seq., as amended, and the rules and regulations thereunder.
Financing Agreements” means any and all agreements, instruments, certificates and documents, including, without limitation, security agreements, loan agreements, notes, guarantees, keep well agreements, landlord waivers, mortgages, deeds of trust, subordination agreements, intercreditor agreements, pledges, powers of attorney, consents, assignments, collateral assignments, perfection certificates, interest rate protection agreements, reimbursement agreements, contracts, notices, leases, subordination and attornment agreement, collateral assignments of key man life insurance policies, financing statements and all other written matter (including, without limitation, this Agreement, the Term Note, the Mortgage, the Assignment of Rents and Leases, the Assignment of Membership Interests, the Environmental Indemnity Agreement, the Subordination of Management Agreement, the Certificates, each Hedging Agreement and any other Bank Product Agreement), in each case evidencing, securing or relating to the Term Loan and the Liabilities, whether heretofore, now, or hereafter executed by or on behalf of Borrower, any Affiliate, or any other Person, and delivered to or in favor of Lender, together with all agreements and documents referred to therein or contemplated thereby, as each may be amended, modified or supplemented from time to time.
FIRREA” means the Financial Institutions Reform, Recovery And Enforcement Act of 1989, as amended from time to time.
Fiscal Quarter” means the three (3) month period ending on March 31, June 30, September 30 and December 31 of each calendar year.
Fiscal Year” means the twelve (12) month period commencing on January 1 and ending on December 31 of each calendar year.
Fixed Charges” means, for any period of determination, the sum of, without duplication: (a) regularly scheduled payments of principal with respect to all Indebtedness for borrowed money; plus (b) cash interest expense of Borrower or Operator, as applicable for its Indebtedness that has been paid during such period (including, without limitation, interest attributable to issued and outstanding Letters of Credit); plus (c) Net Capital Expenditures; plus (d) cash rent expense that has been paid during such period; plus (e) dividends on stock; plus (f) cash paid income taxes of Borrower or Operator, as applicable, during such period, all of the foregoing as determined in accordance with GAAP, consistently applied.
GAAP” means generally accepted accounting principles set forth in the opinions and pronouncements of the Accounting Principles Board of the American Institute of Certified Public Accountants and statements and pronouncements of the Financial Accounting Standards Board (or any successor authority) that are applicable to the circumstances as of the date of determination.
General Intangibles” means “general intangibles” as defined in the Code, including, without limitation, any and all general intangibles, choses in action, causes of action, rights to the payment of money (other than Accounts), and all other intangible personal property of Borrower of every kind and nature wherever located and whether currently owned or hereafter acquired by Borrower (other than Accounts), including, without limitation, corporate or other business records, inventions, designs, patents, patent applications, service marks, service mark applications, trademark applications, brand names, trade names, trademarks and all goodwill symbolized thereby and relating thereto, trade styles, trade secrets, registrations, domain names, websites, computer software, advertising materials, distributions on certificated and uncertificated securities, investment property, securities entitlements, goodwill, operational manuals, product formulas for industrial processes, blueprints, drawings, copyrights, copyright applications, rights and benefits under contracts, licenses, license agreements, permits, approvals, authorizations which are associated with the operation of Borrower’s business and granted by any Person, franchises, customer lists, deposit accounts, tax refunds, tax refund claims, and any letters of credit, guarantee claims, security interests or other security held by or granted to Borrower to secure payment by an Account Debtor of any of Borrower’s Accounts, and, to the maximum extent permitted by applicable Law, any recoveries or amounts received in connection with any litigation or settlement of any litigation.
Governing Documents” shall have the meaning ascribed to such term in Section 9.14 hereof.
Governmental Approvals” means, collectively, all consents, licenses, and permits and all other authorizations or approvals required from any Governmental Authority to operate the Facility.
Governmental Authority” means and includes any federal, state, commonwealth, District of Columbia, county, municipal, or other government and any political subdivision, department, commission, board, bureau, agency or instrumentality thereof, whether domestic or foreign.
Hazardous Substances” means hazardous substances, materials, wastes, and waste constituents and reaction by-products, pesticides, oil and other petroleum products, and toxic substances, including, without limitation, asbestos and PCBs, as those terms are defined pursuant to Environmental Laws.
Healthcare Laws” means all applicable Laws relating to the possession, control, warehousing, marketing, sale and distribution of pharmaceuticals, the operation of medical or senior housing facilities (such as, but not limited to, nursing homes, skilled nursing facilities, rehabilitation hospitals, intermediate care facilities, assisted living and adult care facilities), patient healthcare, patient healthcare information, patient abuse, the quality and adequacy of medical care, rate setting, equipment, personnel, operating policies, fee splitting, including, without limitation, (a) all federal and state fraud and abuse laws, including, but not limited to the federal Anti-Kickback Statute (42 U.S.C. §1320a-7b(6)), the Stark Law (42 U.S.C. §1395nn), the civil False Claims Act (31 U.S.C. §3729 et seq.); (b) TRICARE; (c) CHAMPUS, (d) Medicare; (e) Medicaid; (f) HIPAA; (g) quality, safety and accreditation standards and requirements of all applicable state laws or regulatory bodies; (h) all laws, policies, procedures, permits, requirements, certifications, and regulations pursuant to which licenses, approvals and accreditation certificates are issued in order to operate medical, senior housing facilities, assisted living facilities, or skilled nursing facilities; and (i) any and all other applicable health care laws, regulations, manual provisions, policies and administrative guidance, each of (a) through (i) as may be amended from time to time.
Hedging Agreement” means any interest rate, currency or commodity swap agreement, cap agreement or collar agreement, and any other agreement or arrangement designed to protect a Person against fluctuations in interest rates, currency exchange rates or commodity prices, in each case in form and substance satisfactory to Lender, as the same may be amended or modified from time to time; provided, Borrower will only enter into any such Hedging Agreement with PrivateBank or another Lender reasonably approved by Lender.
HHS” means the United States Department of Health and Human Services and any Person succeeding to the functions thereof.
HIPAA” means the Health Insurance Portability and Accountability Act of 1996, as the same may be amended, modified or supplemented from time to time, and any successor statute thereto, and any and all rules or regulations promulgated from time to time thereunder.
Indebtedness” with respect to any Person means, as of the date of determination thereof, (a) all of such Person’s indebtedness for borrowed money, (b) all indebtedness of such Person or any other Person secured by any Lien with respect to any property or asset owned or held by such Person, regardless whether the indebtedness secured thereby shall have been assumed by such Person or such Person has become liable for the payment thereof, (c) all Capitalized Lease Obligations of such Person and obligations or liabilities created or arising under conditional sale or other title retention agreement with respect to property used and/or acquired by Borrower even though the rights and remedies of the lessor, seller and/or lender thereunder are limited to repossession of such property, (d) all unfunded pension fund obligations and liabilities, (e) all obligations of such Person evidenced by bonds, debentures, notes or similar instruments, (f) all obligations in respect of letters of credit, whether or not drawn, and bankers’ acceptances issued for the account of such Person, (g) deferred and/or accrued taxes and all unfunded pension fund obligations and liabilities, (h) all guarantees by such Person, or any undertaking by such Person to be liable for, the debts or obligations of any other Person, described in clauses (a) through (h), (i) any Stock of such Person, whether or not mandatorily redeemable, that under GAAP is characterized as debt, whether pursuant to Financial Accounting Standards Board Issuance No. 150 or otherwise, and (j) all Bank Product Obligations of such Person.
Indemnified Liabilities” shall have the meaning ascribed to such term in Section 12.16 hereof.
Indemnified Parties” shall have the meaning ascribed to such term in Section 12.16 hereof.
Intellectual Property” means all of the following in any jurisdiction throughout the world: (a) all inventions (whether patentable or unpatentable and whether or not reduced to practice), all improvements thereto, and all patents, patent applications, and patent disclosures, together with all reissuances, continuations, continuations-in-part, revisions, extensions, and reexaminations thereof, (b) all trademarks, service marks, trade dress, logos, slogans, trade names, corporate names, Internet domain names, and rights in telephone numbers, together with all translations, adaptations, derivations, and combinations thereof and including all goodwill associated therewith, and all applications, registrations, and renewals in connection therewith, (c) all copyrightable works, all copyrights, and all applications, registrations, and renewals in connection therewith, (d) all mask works and all applications, registrations, and renewals in connection therewith, (e) all trade secrets and confidential business information (including ideas, research and development, know-how, formulas, compositions, manufacturing and production processes and techniques, technical data, designs, drawings, specifications, customer and supplier lists, pricing and cost information, and business and marketing plans and proposals), (f) all computer software (including source code, executable code, data, databases, and related documentation), (g) all material advertising and promotional materials, (h) all other proprietary rights, and (i) all copies and tangible embodiments thereof (in whatever form or medium).
Inventory” means “inventory” as defined in the Code, including, without limitation, any and all inventory and goods of Borrower, wheresoever located, whether now owned or hereafter acquired by Borrower, which are held for sale or lease, furnished under any contract of service or held as raw materials, work-in-process or supplies, and all materials used or consumed in Borrower’s business, and shall include such property the sale or other disposition of which has given rise to Accounts and which has been returned to or repossessed or stopped in transit by Borrower.
Laws” means, collectively, all federal, state, commonwealth and local laws, statutes, codes, ordinances, orders, rules and regulations, including judicial opinions or presidential authority in the applicable jurisdiction and Healthcare Laws and Environmental Laws, now or hereafter in effect, and in each case as amended or supplemented from time to time.
Lease Agreement” means that certain Lease Agreement dated February 1, 2015, by Borrower, as landlord, and Operator, as tenant, as it may be modified, amended or restated from time to time.
Leases” means all leases, subleases, licenses, concessions and other agreements (written or oral), including all amendments, extensions, renewals, guaranties, and other agreements with respect thereto, pursuant to which Borrower holds any leased real property.
Lender Parties” shall have the meaning ascribed to such term in Section 12.23 hereof.
Liabilities” means any and all of Borrower’s Indebtedness, liabilities and obligations, to Lender under this Agreement (whether relating to the Term Loan or otherwise and including, without limitation, all of Borrower’s Bank Product Obligations) or each Hedging Agreement (but excluding any Excluded Swap Obligation), the Term Note, and any and all other Financing Agreements to which Borrower is a party, and any refinancings, substitutions, extensions, renewals, replacements and modifications for or of any or all of the forgoing, of any and every kind and nature, whether heretofore, now or hereafter owing, arising, due or payable and howsoever evidenced, created, incurred, acquired, or owing, whether primary, secondary, direct, indirect, contingent, absolute, fixed or otherwise (including, without limitation, payments of or for principal, interest, default interest, reimbursement obligations, interest rate hedging obligations, fees, costs, expenses, and/or indemnification, and obligations of performance, and the Closing Fee, any other fee due or payable to Lender in connection with any Financing Agreement, and all Bank Product Obligations, and any interest that accrues after commencement of any insolvency or bankruptcy proceeding regardless of whether allowed or allowable in whole or in part as a claim in any such insolvency or bankruptcy proceeding) and whether arising or existing under written agreement, oral agreement, or by operation of law, including, without limitation, all of Borrower’s Indebtedness, liabilities and obligations to Lender under this Agreement (whether relating to the Term Loan or otherwise and including, without limitation, all of Borrower’s Bank Product Obligations) or each Hedging Agreement and any and all other Financing Agreements to which Borrower is a party, and any refinancings, substitutions, extensions, renewals, replacements and modifications for or of any or all of the foregoing; provided, however, that, with respect to any guarantor of the Liabilities, the Liabilities shall not include any Excluded Swap Obligation in respect of such Person.
Libor Base Rate” means a rate of interest equal to (a) the per annum rate of interest at which United States dollar deposits in an amount comparable to the amount of the relevant Libor Loan and for a period equal to the Libor Interest Period are offered in the London Interbank Eurodollar market at 11:00 A.M. (London time) two (2) Business Days prior to the commencement of such Libor Interest Period (or three (3) Business Days prior to the commencement of such Libor Interest Period if banks in London, England were not open and dealing in offshore United States dollars on such second preceding Business Day), as displayed in the Bloomberg Financial Markets system (or other authoritative source selected by Lender in its sole discretion) or, if the Bloomberg Financial Markets system or another authoritative source is not available, as the Libor Base Rate is otherwise determined by Lender in its sole and absolute discretion, divided by (b) a number determined by subtracting from 1.00 the then stated maximum reserve percentage for determining reserves to be maintained by member banks of the Federal Reserve System for Eurocurrency funding or liabilities as defined in Regulation D (or any successor category of liabilities under Regulation D), such rate to remain fixed for such Libor Interest Period. Lender’s determination of the Libor Base Rate shall be conclusive, absent manifest error.
Libor Interest Period” means, with respect to any Libor Loan, successive one (1) month periods; provided, however, that: (a) each Libor Interest Period occurring after the initial Libor Interest Period of any Libor Loan shall commence on the day on which the preceding Libor Interest Period for such Libor Loan expires, with interest for such day to be calculated at the Libor Rate in effect for the new Libor Interest Period; (b) whenever the last day of any Libor Interest Period would otherwise occur on a day other than a Business Day, the last day of such Libor Interest Period shall be extended to occur on the next succeeding Business Day; (c) whenever the first day of any Libor Interest Period occurs on a date for which there is no numerically corresponding date in the month in which such Libor Interest Period terminates, such Libor Interest Period shall end on the last day of such month, unless such day is not a Business Day, in which case the Libor Interest Period shall terminate on the first Business Day of the following month, provided, further, that so long as the Libor Rollover remains in effect, all subsequent Libor Interest Periods shall terminate on the date of the month numerically corresponding to the date on which the initial Libor Interest Period commenced; and (d) if at any time the Libor Interest Period for a Libor Loan expires less than one month before the Stated Maturity Date, such Libor Loan shall automatically renew at the then current Libor Rate for a Libor Interest Period terminating on the Stated Maturity Date.
Libor Loan” means a Loan which bears interest at a Libor Rate.
Libor Rate” means, with respect to a Libor Loan for the relevant Libor Interest Period, the sum of the Libor Base Rate applicable to that Libor Interest Period, plus the Applicable Libor Margin, subject to Section 2.4.
Libor Rollover” means that each Libor Loan shall automatically renew for the Libor Interest Period at the then current Libor Rate, except that a Libor Interest Period for a Libor Loan shall not automatically renew with respect to any principal amount which is scheduled to be repaid before the last day of the applicable Libor Interest Period, and any such amounts shall bear interest at the Base Rate plus the Applicable Base Rate Margin, until repaid.
Licenses” shall have the meaning ascribed to such term in Section 10.1 hereof
Lien” means any lien, security interest, mortgage, pledge, hypothecation, collateral assignment, or other charge, encumbrance or preferential arrangement, including, without limitation, the retained security title of a conditional vendor or lessor.
Loan Account” shall have the meaning ascribed to such term in Section 2.2 hereof.
Manage” or “Management” means to generate, handle, manufacture, process, treat, store, use, re-use, refine, recycle, reclaim, blend or burn for energy recovery, incinerate, accumulate speculatively, transport, transfer, dispose of, release, threaten to release or abandon Hazardous Substances.
Management Agreement” means that certain Management Agreement dated as of January 27, 2015, between Manager and Operator for the operation and management of the Facility.
Manager” means Diversicare Management Services Co., a Tennessee corporation.
Material Adverse Change” or “Material Adverse Effect” means, with respect to any event, act, condition or occurrence of whatever nature (including any adverse determination in any litigation, arbitration, or governmental investigation or proceeding), whether singly or in conjunction with any other event or events, act or acts, condition or conditions, occurrence or occurrences, whether or not related, any of the following: (a) a material adverse change in, or a material adverse effect upon, the financial condition, operations, business or properties of the Credit Parties, taken as a whole, (b) a material adverse change in, or a material adverse effect upon, the rights and remedies of Lender under any Financing Agreement or the ability of the Credit Parties, taken as a whole, to perform their payment or other obligations under any Financing Agreement to which they are parties, (c) a material adverse change in, or a material adverse effect upon, the legality, validity or enforceability of any Financing Agreement, (d) a material adverse change in, or a material adverse effect upon, the existence, perfection or priority of any security interest granted in any Financing Agreement or the value of any material Collateral not resulting from any action or inaction by Lender, or (e) any liability of the Credit Parties, or any one or more of them, in excess of Five Hundred Thousand and No/100 Dollars ($500,000.00) in the aggregate as a result the final adjudication of one or more violations of any Healthcare Law which remains unpaid for a period of thirty (30) days, unless such liability is being contested or appealed by appropriate proceedings and Borrower has established appropriate reserves adequate for payment in the event such appeal or contest is ultimately unsuccessful, provided further that in the event such contest or appeal is ultimately unsuccessful, Borrower shall pay the assessment no later than the deadline set forth by the applicable agency.
Maximum Term Facility” means an amount equal to Five Million and No/100 Dollars ($5,000,000.00).
Medicaid” mean collectively all federal statutes (whether set forth in Title XIX of the Social Security Act or elsewhere) affecting the health insurance program established by Title XIX of the Social Security Act (42 U.S.C. §§ 1396, et seq.), together with all applicable provisions of all rules, regulations, manuals, final orders and administrative, reimbursement and other applicable guidelines of all governmental authorities, including HHS, CMS or the Office of the Inspector General of HHS, or any Person succeeding to the functions of any of the foregoing (whether or not having the force of law).
Medicare” mean collectively all federal statutes (whether set forth in Title XVIII of the Social Security Act or elsewhere) affecting the health insurance program for the aged and disabled established by Title XVIII of the Social Security Act (42 U.S.C. § 1395, et seq.), together with all applicable provisions of all rules, regulations, manuals, final orders and administrative, reimbursement and other applicable guidelines of all governmental authorities, including HHS, CMS or the Office of the Inspector General of HHS, or any Person succeeding to the functions of any of the foregoing (whether or not having the force of law).
Mortgage” means that certain Mortgage, Security Agreement, Assignment of Rents and Leases and Fixture Filing dated of even date herewith made by Borrower to and for the benefit of Lender, granting and conveying to Lender a first mortgage Lien on the Real Property, as the same may be amended, restated, supplemented or modified from time to time.
Multiemployer Plan” shall have the meaning ascribed to such term in Section 7.18 hereof.
Net Capital Expenditures” means Capital Expenditures minus the sum of (a) any financing used in connection with such expenditures (including, without limitation, any financing of capital improvements provided by a landlord and recovered through rental payments), and (b) amounts actually incurred in connection with Capital Expenditures made in connection with the Facility.
OFAC Lists” means, collectively, the Specially Designated Nationals and Blocked Persons List maintained by the Office of Foreign Asset Control, the Department of the Treasury pursuant to Executive Order No. 13224, 66 Fed. Reg. 49079 (Sept. 25, 2001) and/or any other list of terrorists or terrorist organizations maintained pursuant to any of the rules and regulations of or by the Office of Foreign Asset Control, the Department of the Treasury or pursuant to any other applicable Executive Orders, as such lists may be amended or supplemented from time to time.
Operator” means Diversicare of Glasgow, LLC, a Delaware limited liability company.
Operator EBITDAR” means with respect to Operator, for any period of determination, the net earnings of Operator (without duplication or double-counting) from the Facility (measured after taking into account the greater of (i) the actual management fees paid during such period and (ii) an imputed management fee of five percent (5%) of Operator’s total revenue derived from the operation of the Facility) before nonrecurring items (in accordance with GAAP and as reasonably agreed to by Lender), interest, taxes, depreciation, and amortization (including amortized transaction expense) and rent payments, all as determined in accordance with GAAP, consistently applied.
Operator Fixed Charge Coverage Ratio” means, on any date of determination, the ratio of (a) Adjusted Operator EBITDAR for the period of twelve (12) consecutive months then ended, to (b) Fixed Charges, for Operator, all as determined in accordance with GAAP, consistently applied.
Parent” means Diversicare Healthcare Services, Inc. (f/k/a Advocat Inc.), a Delaware corporation.
Parent EBITDA” means with respect to Parent, for any period of determination, the net earnings of Parent (without duplication or double-counting) from all of its properties before nonrecurring items (in accordance with GAAP and as reasonably agreed to by Lender), interest, taxes, depreciation, and amortization (including amortized transaction expense), all as determined in accordance with GAAP, consistently applied.
Parent Fixed Charge Coverage Ratio” means, on any date of determination, the ratio of (a) Adjusted Parent EBITDA for the period of twelve (12) consecutive months then ended, to (b) Fixed Charges, for Parent, all as determined in accordance with GAAP, consistently applied.
Participant” shall have the meaning ascribed to such term in Section 12.15(c) hereof.
Patriot Act” shall have the meaning ascribed to such term in Section 8.16 hereof.
Payment In Full” means (a) the indefeasible payment in full in cash of all Loans and other Liabilities, other than contingent indemnification obligations for which no claims have been asserted, and (b) the termination of the Term Loan Commitment in accordance with the terms and conditions hereof.
PBGC” shall have the meaning ascribed to such term in Section 7.18 hereof.
Permitted Liens” shall have the meaning ascribed to such term in Section 9.1 hereof.
Person” means any individual, sole proprietorship, partnership, joint venture, trust, limited liability company, unincorporated organization, association, corporation, institution, entity, party, or government (whether national, federal, state, provincial, county, city, municipal or otherwise, including, without limitation, any instrumentality, division, agency, body or department thereof).
Plan” shall have the meaning ascribed to such term in Section 7.18 hereof.
Prohibited Transaction” shall have the meaning ascribed to such term in ERISA.
Real Property” shall have the meaning ascribed to such term in the Recitals.
Release” means any actual or threatened spilling, leaking, pumping, pouring, emitting, emptying, discharging, injecting, escaping, leaching, dumping or disposing of Hazardous Substances into the environment, as “environment” is defined in CERCLA.
Released Parties” shall have the meaning ascribed to such term in Section 12.23 hereof.
Releasing Parties” shall have the meaning ascribed to such term in Section 12.23 hereof.
Respond” or “Response” means any action taken pursuant to Environmental Laws to correct, remove, remediate, cleanup, prevent, mitigate, monitor, evaluate, investigate or assess the Release of a Hazardous Substance.
Restricted Agreements” means, collectively, the Lease, the Management Agreement, each agreement, document or instrument entered into in connection with (directly or indirectly) Borrower Cash Management Program, the Acquisition Documents, and any other agreement, document or instrument between or among the Credit Parties and any agreement, document or instrument pertaining to (directly or indirectly) any of the foregoing.
Restrictions” shall have the meaning ascribed to such term in Section 10.2 hereof.
Seller” means Barren County Health Care Center, Inc., a Kentucky corporation.
Service Fee” shall have the meaning ascribed to such term in Section 8.9 hereof.
Solvent” means, with respect to any Person on a particular date, that on such date (a) the fair value of the property of such Person is greater than the total amount of liabilities, including contingent liabilities, of such Person; (b) the present fair salable value of the assets of such Person is not less than the amount that will be required to pay the probable liability of such Person on its debts as they become absolute and matured; (c) such Person does not intend to, and does not believe that it will, incur debts or liabilities beyond such Person’s ability to pay as such debts and liabilities mature; and (d) such Person is not engaged in a business or transaction, and is not about to engage in a business or transaction, for which such Person’s property would constitute an unreasonably small capital. The amount of contingent liabilities (such as litigation, guaranties and pension plan liabilities) at any time shall be computed as the amount that, in light of all the facts and circumstances existing at the time, represents the amount that can be reasonably be expected to become an actual or matured liability, but shall not include incurred but not reported professional liability claims.
Stated Maturity Date” means August 1, 2016.
Stock” shall mean all certificated and uncertificated shares, stock, options, warrants, general or limited partnership interests, membership interests or units, limited liability company interests, participation or other equivalents (regardless of how designated) of or in a corporation, partnership, limited liability company or equivalent entity whether voting or nonvoting, including common stock, preferred stock, or any other “equity security” (as such term is defined in Rule 3a11‑1 of the General Rules and Regulations promulgated by the Securities and Exchange Commission under the Securities Exchange Act of 1934).
Subordinated Debt” means any and all Indebtedness owing by Borrower to a third party that has been subordinated to the Liabilities in writing on terms and conditions satisfactory to Lender in its sole and absolute discretion.
Subordination Agreement” means, collectively, any subordination agreements entered into from time to time by holders of Subordinated Debt and Lender, each in form and substance satisfactory to Lender in its sole and absolute discretion, each as the same may be modified, supplemented, amended or restated from time to time.
Subordination of Management Agreement” means that certain Subordination of Management Agreement of even date herewith made by the Manager in favor of Lender, in form and substance reasonable satisfactory to Lender, as the same may be modified, restated, supplemented or amended from time to time in accordance with the terms thereof.
Subsidiary” means, with respect to any Person, (i) any corporation of which an aggregate of more than fifty percent (50%) of the outstanding Stock having ordinary voting power to elect a majority of the board of directors of such corporation (irrespective of whether, at the time, Stock of any other class or classes of such corporation shall have or might have voting power by reason of the happening of any contingency) is at the time, directly or indirectly, owned legally or beneficially by such Person and/or one or more Subsidiaries of such Person, or with respect to which any such Person has the right to vote or designate the vote of fifty percent (50%) or more of such Stock whether by proxy, agreement, operation of law or otherwise, and (ii) any partnership or limited liability company in which such Person or one or more Subsidiaries of such Person has an equity interest (whether in the form of voting or participation in profits or capital contribution) of more than fifty percent (50%) or of which any such Person is a general partner, managing member or manager or may exercise the powers of a general partner, managing member or manager.
Swap Obligation” means any Hedging Agreement or related obligation that constitutes a “swap” within the meaning of section 1a(47) of the Commodity Exchange Act.
Tax Code” shall have the meaning ascribed to such term in Section 7.18 hereof.
Taxes” shall have the meaning ascribed to such term in Section 3.2 hereof.
Tenant” means any tenant, resident or occupant under any Lease.
Term Loan” shall have the meaning ascribed to such term in the Recitals.
Term Note” shall have the meaning ascribed to such term in Section 2.1 hereof.
Term Loan Commitment” means Lender’s commitment to make the Term Loan under this Agreement.
TRICARE” means the medical program for active duty members, qualified family members, CHAMPUS eligible retirees and their family members and survivors, of all uniformed services.
Uniform Commercial Code” or “UCC” or “Code” means the Uniform Commercial Code as the same may, from to time, be in effect in the State of Illinois; provided, however, that if, by reason of mandatory provisions of law, any or all of the attachment, perfection or priority of, or remedies with respect to, Lender’s Lien on the Collateral is governed by the Uniform Commercial Code as in effect in a jurisdiction other than the State of Illinois, the term “Uniform Commercial Code” or “UCC” or “Code” shall mean the Uniform Commercial Code as in effect in such other jurisdiction for purposes of the provisions of this Agreement or the other Financing Agreements relating to such attachment, perfection, priority or remedies and for purposes of definitions related to such provisions; provided further that, to the extent that the Uniform Commercial Code of a particular jurisdiction is used to define a term herein or in any Financing Agreement and such term is defined differently in different Articles or Divisions of such Uniform Commercial Code, then the definition of such term contained in Article or Division 9 of such Uniform Commercial Code shall control.
1.2    Interpretation.
(a)    All accounting terms used in this Agreement or the other Financing Agreements shall have, unless otherwise specifically provided herein or therein, the meaning customarily given such term in accordance with GAAP, and all financial computations thereunder shall be computed, unless otherwise specifically provided therein, in accordance with GAAP consistently applied; provided, however, that all financial covenants and calculations in the Financing Agreements shall be made in accordance with GAAP as in effect on the Closing Date unless Borrower and Lender shall otherwise specifically agree in writing. That certain items or computations are explicitly modified by the phrase “in accordance with GAAP” shall in no way be construed to limit the foregoing. Unless otherwise specified, references in this Agreement or any of the attachments hereto or appendices hereof to a Section, subsection or clause refer to such Section, subsection or clause as contained in this Agreement. The words “herein,” “hereof” and “hereunder” and other words of similar import refer to this Agreement as a whole, including all exhibits attached hereto, as the same may from time to time be amended, restated, modified or supplemented, and not to any particular section, subsection or clause contained in this Agreement or any such exhibit.
(b)    Wherever from the context it appears appropriate, each term stated in either the singular or plural shall include the singular and the plural, and pronouns stated in the masculine, feminine or neuter gender shall include the masculine, feminine and neuter genders. The words “including”, “includes” and “include” shall be deemed to be followed by the words “without limitation”; the word “or” is not exclusive; references to Persons include their respective successors and assigns (to the extent and only to the extent permitted by the Financing Agreements) or, in the case of governmental Persons, Persons succeeding to the relevant functions of such Persons; and all references to statutes and related regulations shall include any amendments of the same and any successor statutes and regulations. Whenever any provision in any Financing Agreement refers to the knowledge (or an analogous phrase) of Borrower, except as otherwise expressly provided for herein, such words are intended to signify that a Duly Authorized Officer of Borrower has actual knowledge or awareness of a particular fact or circumstance or that a prudent individual in the position of such Duly Authorized Officer of Borrower, would reasonably be expected to have known or been aware of such fact or circumstance in the course of performing his or her duties.
2.    TERM LOAN COMMITMENT; INTEREST; FEES.
2.1    Term Loan. On the terms and subject to the conditions set forth in this Agreement, and provided there does not then exist a Default or an Event of Default, Lender agrees to make in U.S. Dollars the Term Loan in one advance to Borrower on the Closing Date in the amount of the Maximum Term Facility. Any amounts paid or applied to the principal balance of the Term Loan (whether by mandatory prepayment or otherwise) may not be reborrowed hereunder.
(c)    The advance to Borrower under this Section 2.1 shall be deposited, in immediately available funds, in Borrower’s demand deposit account with Lender, or in such other account as Borrower designates in writing with Lender’s approval.
(d)    The Term Loan shall be evidenced by a separate Term Note (hereinafter, as the same may be amended, restated, modified or supplemented from time to time, and together with any renewals or extensions thereof or exchanges or substitutions therefor, called the “Term Note”), duly executed and delivered by Borrower, substantially in the form set forth in Exhibit B attached hereto, with appropriate insertions, dated the Closing Date, payable to the order of Lender, in the principal amount equal to the Maximum Term Facility. THE PROVISIONS OF THE TERM NOTE NOTWITHSTANDING, THE TERM LOAN THEN OUTSTANDING SHALL BECOME IMMEDIATELY DUE AND PAYABLE ON UPON THE EARLIEST TO OCCUR OF (X) STATED MATURITY DATE; (Y) THE ACCELERATION OF THE LIABILITIES PURSUANT TO SECTION 11.2 HEREOF; AND (Z) TERMINATION OF THIS AGREEMENT (WHETHER BY PREPAYMENT OR OTHERWISE) IN ACCORDANCE WITH ITS TERMS.
(e)    Accrued interest on the Term Loan shall be due and payable and shall be made by Borrower to Lender in accordance with Section 2.5 hereof. Monthly interest payments on the Term Loan shall be computed using the interest rate(s) then in effect and based on the outstanding principal balance of the Term Loan. Upon maturity, the outstanding principal balance of the Term Loan shall be immediately due and payable, together with any remaining accrued interest thereon.
2.2    Borrower’s Loan Account. Lender shall maintain a loan account (the “Loan Account”) on its books for Borrower in which shall be recorded (a) the Term Loan made by Lender to Borrower pursuant to this Agreement, (b) all payments made by Borrower on the Term Loan, and (c) all other appropriate debits and credits as provided in this Agreement, including, without limitation, all fees, charges, expenses and interest. All entries in the Loan Account shall be made in accordance with Lender’s customary accounting practices as in effect from time to time. Borrower promises to pay the amount reflected as owing by Borrower under its Loan Account and all of its other obligations hereunder as such amounts become due or are declared due pursuant to the terms of this Agreement. Notwithstanding the foregoing, the failure so to record any such amount or any error in so recording any such amount shall not limit or otherwise affect Borrower’s obligations under this Agreement or under the Term Note to repay the outstanding principal amount of the Term Loan together with all interest accruing thereon.
2.3    Statements. The Term Loan to Borrower, and all other debits and credits provided for in this Agreement, shall be evidenced by entries made by Lender in its internal data control systems showing the date, amount and reason for each such debit or credit. Until such time as Lender shall have rendered to Borrower written statements of account as provided herein, the balance in the Loan Account, as set forth on Lender’s most recent computer printout, shall be rebuttably presumptive evidence of the amounts due and owing Lender by Borrower. From time to time Lender shall render to Borrower a statement setting forth the balance of the Loan Account, including principal, interest, expenses and fees. Each such statement shall be subject to subsequent adjustment by Lender but shall, absent manifest errors or omissions, be presumed correct and binding upon Borrower.
2.4    Interest. Borrower agrees to pay to Lender interest on the daily outstanding principal balance of that portion of the Libor Loan at the Libor Rate (or, if and as applicable in accordance with Sections 2.9(b), 2.9(c) or 2.9(f) hereof, at the Base Rate from time to time in effect, plus the Applicable Base Rate Margin); provided, however, for all purposes of this Agreement, under no circumstances at any time shall the sum of the Base Rate plus the Applicable Base Rate Margin be less than four and three-quarters percent (4.75%) per annum; provided, further, that immediately following the occurrence and during the continuance of an Event of Default, and notwithstanding any other provisions of this Agreement to the contrary, unless Lender otherwise waives in writing, Borrower agrees to pay to Lender, interest on the outstanding principal balance of the Loan at the per annum rate of two percent (2%) plus the rate otherwise payable hereunder with respect to the Loan (the “Default Rate”). Accrued interest on that portion of the Mortgage Loan that is a Libor Loan shall be payable on the last day of the Libor Interest Period relating to such Libor Loan, upon a prepayment of such loan and at maturity, commencing with the first such last day of the initial Libor Interest Period. If at any time applicable in accordance with Sections 2.9(b), 2.9(c) or 2.9(f) hereof, accrued interest on each Base Rate Loan shall be payable on the first calendar day of each month and at maturity. Monthly interest payments on the Mortgage Loan shall be computed using the interest rate then in effect and based on the outstanding principal balance of the applicable Loan. Upon maturity, the outstanding principal balance of the Mortgage Loan shall be immediately due and payable, together with any remaining accrued interest thereon. All accrued interest shall be computed on the basis of a year of three hundred sixty days (360) for the actual number of days elapsed. If any payment of principal of, or interest on, the Term Note falls due on a day that is not a Business Day, then such due date shall be extended to the next following Business Day, and additional interest shall accrue and be payable for the period of such extension. Each determination by Lender of an interest rate hereunder shall be conclusive and binding for all purposes, absent manifest error.
2.5    Method for Making Payments. All payments of principal, interest, fees and costs and expenses (including, without limitation, pursuant to Section 12.2) hereunder shall be paid by automatic debit from Borrower’s concentration account, wire transfer, check or in coin or currency which, at the time or times of payment, is the legal tender for public and private debts in the United States of America and shall be made at such place as Lender may from time to time appoint or direct in the payment invoice or otherwise in writing, and in the absence of such appointment or direction, then, not later than 1:00 p.m. (Chicago time) on the date of payment, at the offices of Lender at 120 South LaSalle Street, Chicago, Illinois 60603, Attn: Commercial Loan Department. Payment made by check shall be deemed paid on the date two Business Days after Lender receives such check; provided, however, that if such check is subsequently returned to Lender unpaid due to insufficient funds or otherwise, the payment shall not be deemed to have been made and shall continue to bear interest until collected. If at any time requested by Borrower (including via electronic transmission), principal, interest, fees and costs and expenses (including, without limitation, pursuant to Section 12.2) hereunder owed to Lender from time to time will be deducted by Lender automatically on the due date or date declared due from Borrower’s concentration account with Lender. Borrower shall maintain sufficient funds in the account on the dates Lender enters debits authorized hereby. If there are insufficient funds in the concentration account on the date Lender enters any debit authorized hereby, the debit will be reversed. Borrower may terminate this direct debit arrangement at any time by sending written notice to Lender at the address specified above. Notwithstanding the foregoing in this Section, Borrower hereby irrevocably authorizes and instructs Lender after the occurrence and during the continuance of any Default or Event of Default to direct debit any of Borrower’s operating accounts with Lender for all principal, interest, costs, and any and all fees, costs and expenses due hereunder or pursuant hereto with respect to the Term Loan and the Liabilities (including, without limitation, reasonable attorneys’ fees). Payments made after 1:00 p.m. (Chicago time) shall be deemed to have been made on the next succeeding Business Day.
2.6    Term of this Agreement. Borrower shall have the right to terminate this Agreement (subject to survival of Sections 12.9 and 12.16 and any other term hereof surviving by its terms hereof) following prepayment of all of the Liabilities as provided under Section 2.10 hereof; provided, however, that (a) all of Lender’s rights and remedies under this Agreement, and (b) the Liens created under Section 6.1 hereof and under any of the other Financing Agreements, shall survive such termination until Payment in Full. In addition, the Liabilities may be accelerated as set forth in Section 11.2 hereof. Upon the effective date of termination, all of the Liabilities shall become immediately due and payable on a joint and several basis without notice or demand. Notwithstanding any termination, until Payment in Full, Lender shall be entitled to retain its Liens in and to all existing and future Collateral.
2.7    Optional Prepayment of Loan. Borrower may, at its option, permanently prepay, at any time during the term of this Agreement the Term Loan or any portion thereof but in minimum amounts of no less than Five Hundred Thousand and No/100 Dollars ($500,000.00), subject to the following condition: not less than ten (10) days prior to the date upon which Borrower desires to make any such prepayment, Borrower shall deliver to Lender a written notice of its intention to prepay all or such portion of the Term Loan, which notice shall be revocable (provided, that any and all costs or expenses incurred or suffered by Lender as a result of the revocation of notice by Borrower shall be borne solely by Borrower) and state the amount of the prepayment and the prepayment date.
2.8    Limitation on Charges. It being the intent of the parties that the rate of interest and all other charges to Borrower be lawful, if for any reason the payment of a portion of the interest or other charges otherwise required to be paid under this Agreement would exceed the limit which Lender may lawfully charge Borrower, then the obligation to pay interest or other charges shall automatically be reduced to such limit and, if any amounts in excess of such limit shall have been paid, then such amounts shall at the sole option of Lender either be refunded to Borrower or credited to the principal amount of the Liabilities (or any combination of the foregoing) so that under no circumstances shall the interest or other charges required to be paid by Borrower hereunder exceed the maximum rate allowed by applicable Laws, and Borrower shall not have any action against Lender for any damages arising out of the payment or collection of any such excess interest.
2.9    Libor Loan Specific Items. (a) If any payment of a Libor Loan occurs on a date that is not the last day of the applicable Libor Interest Period, whether because of acceleration, prepayment or otherwise, or a Libor Loan is not made on the date specified by Borrower, Borrower shall on demand indemnify Lender for any loss or cost incurred by it resulting therefrom, including, without limitation, any loss or cost in liquidating or employing deposits acquired to fund or maintain the Libor Loan.
(b)    If Lender determines that maintenance of any of its Libor Loans would violate any applicable law, rule, regulation or directive of any government or any division, agency, body or department thereof, whether or not having the force of law, Lender may suspend the availability of the Libor Base Rate and require any Libor Loans outstanding to be promptly converted to a Base Rate Loan subject to Borrower’s compliance with clause (c) below; or if Lender determines that (i) deposits of a type or maturity appropriate to match fund Libor Loans are not available, Lender may suspend the availability of the Libor Base Rate after the date of any such determination, or (ii) the Libor Base Rate does not accurately reflect the cost of making a Libor Loan, then, Lender may, at its option, suspend the availability of the Libor Base Rate after the date of any such determination (and thereafter charge interest on the Mortgage Loan at the Base Rate from time to time in effect, plus the Applicable Base Rate Margin) or permit (solely in the case of clause (ii)) Borrower to pay Lender for any increased cost it may incur.
(c)    If: (i) Lender reasonably determines (which determination shall be binding and conclusive on Borrower) that by reason of circumstances affecting the interlender Libor Base Rate market adequate and reasonable means do not exist for ascertaining the applicable Libor Base Rate; or (ii) the Libor Base Rate as determined by Lender will not adequately and fairly reflect the cost to Lender of maintaining or funding Libor Loans for such Libor Interest Period or that the making or funding of Libor Loans has become impracticable as a result of an event occurring after the date of this Agreement which in the opinion of Lender materially affects such loans; then Lender shall promptly notify Borrower thereof and, so long as such circumstances shall continue, on the last day of the current Libor Interest Period for each Libor Loan, such loan shall, unless then repaid in full, automatically thereafter be charged interest at the Base Rate from time to time in effect, plus the Applicable Base Rate Margin.
(d)    Borrower hereby agrees that upon demand by Lender (which demand shall be accompanied by a statement setting forth the basis for the amount being claimed, a copy of which shall be furnished to Lender), Borrower will indemnify Lender against any net loss or expense which Lender may sustain or incur (including any net loss or expense incurred by reason of the liquidation or reemployment of deposits or other funds acquired by Lender to fund or maintain any Libor Loan), as reasonably determined by Lender, as a result of (i) any payment, conversion or prepayment of any Libor Loan of Lender on a date other than the last day of a Libor Interest Period for such loan, or (ii) any failure of any Borrower to borrow, convert or continue any portion of the Mortgage Loan on a date specified therefor in a notice of borrowing, conversion or continuation pursuant to this Agreement. For this purpose, all notices to Lender pursuant to this Agreement shall be deemed to be irrevocable.
(e)    Lender may, if it so elects, fulfill its commitment as to any Libor Loan by causing a foreign branch or Affiliate of Lender to make such loan; provided that in such event for the purposes of this Agreement such loan shall be deemed to have been made by Lender and the obligation of Borrower to repay such loan shall nevertheless be to Lender and shall be deemed held by it, to the extent of such loan, for the account of such branch or Affiliate.
(f)    If any applicable law or regulation, or any interpretation thereof by any court or any governmental or other regulatory body charged with the administration thereof, should make it unlawful for Lender to make, maintain or fund any Libor Loan, then the obligation of Lender to make, convert into or continue such Libor Loan shall, upon the effectiveness of such event, be suspended for the duration of such unlawfulness, and on the last day of the current Libor Interest Period for such Libor Loan (or, in any event, if Lender so requests, on such earlier date as may be required by the relevant law, regulation or interpretation), the Libor Loans shall, unless then paid in full in cash, automatically convert to Base Rate Loans.
2.10    Setoff. (a) Borrower agrees that Lender has all rights of setoff and banker’s liens provided by applicable law. Borrower agrees that, if at any time (i) any amount owing by it under this Agreement or any Financing Agreement is then due and payable to Lender, or (ii) or an Event of Default shall have occurred and be continuing, then Lender, in its sole discretion, may set off against and apply to the payment of any and all Liabilities, any and all balances, credits, deposits, accounts or moneys of Borrower then or thereafter with Lender.
(b)    Without limitation of Section 2.10(a) hereof, Borrower agrees that, upon and after the occurrence of any Event of Default, Lender is hereby authorized, at any time and from time to time, without prior notice to Borrower (provided, however, prior to an Event of Default Lender shall use reasonable efforts to provide notice of any such action within a reasonable time thereafter but Lender shall not be liable for any failure to provide such notice), (i) to set off against and to appropriate and apply to the payment of any and all Liabilities any and all amounts which Lender is obligated to pay over to Borrower (whether matured or unmatured, and, in the case of deposits, whether general or special, time or demand and however evidenced), and (ii) pending any such action, to the extent necessary, to deposit such amounts with Lender as Collateral to secure such Liabilities and to dishonor any and all checks and other items drawn against any deposits so held as Lender in its sole discretion may elect.
(c)    The rights of Lender under this Section 2.10 are in addition to all other rights and remedies which Lender may otherwise have in equity or at law.
2.11    Termination of Term Loan Commitment. On the date on which the Term Loan Commitment terminates pursuant to Section 11.2 hereof, the Term Loan and other Liabilities shall become immediately due and payable, without presentment, demand or notice of any kind.
2.12    Closing Fee. On the Closing Date, Borrower shall pay to Lender a one-time closing fee of Twenty-Five Thousand and No/100 Dollars ($25,000.00) in immediately available funds, which fee shall be nonrefundable and deemed fully earned as of such date (“Closing Fee”).
2.13    Late Charge. If any installment of principal or interest due hereunder shall become overdue for five (5) days after the date when due, Borrower shall pay to Lender on demand a “late charge” of five cents ($.05) for each dollar so overdue in order to defray part of the increased cost of collection occasioned by any such late payment, as liquidated damages and not as a penalty.
2.14    Mandatory Prepayments. Upon receipt by Borrower of the proceeds of any (a) Asset Disposition, or (b) sale or issuance of any Stock of Borrower (excluding (i) any issuance of Stock pursuant to any employee, officer or director option program or agreement, benefit plan or compensation program or agreement, or (ii) any issuance of Stock pursuant to the exercise of options or warrants, or (iiii) any issuance in connection with any dividend reinvestment plan or direct stock purchase plan, if applicable), in each case, Borrower shall prepay the outstanding principal amount of the Liabilities in an amount equal to one hundred percent (100%) of the cash proceeds of such transaction net of (A) the direct reasonably and actually incurred costs relating thereto, such as sales commissions and legal, accounting and investment banking fees and out-of-pocket costs, and (B) taxes paid or reasonably estimated by Borrower to be payable as a result thereof. Nothing contained in this Section 2.14 shall be construed to permit Borrower to consummate any transaction in violation of any other provision contained in this Agreement, including, without limitation, Section 9.6 hereof.
3.    CHANGE IN CIRCUMSTANCES.
3.1    Yield Protection. If, after the date of this Agreement (for purposes of this Agreement, the Dodd-Frank Wall Street Reform and Consumer Protection Act and all guidelines and regulations adopted in connection therewith are deemed to have been adopted after the date hereof), the adoption of any law or any governmental or quasi-governmental rule, regulation, policy, guideline or directive (whether or not having the force of law), or any change therein, or any change in the interpretation or administration thereof, or the compliance of Lender therewith, or Regulation D of the Board of Governors of the Federal Reserve System,
(a)    subjects Lender to any tax, duty, charge or withholding on or from payments due from Borrower (excluding taxation of the overall net income or receipts of Lender or any branch profits taxes), or changes the basis of taxation of payments to Lender in respect of the Term Loan or other amounts due it hereunder, or
(b)    imposes, modifies, or increases or deems applicable any reserve, assessment, insurance charge, special deposit or similar requirement against assets of, deposits with or for the account of, or credit extended by, Lender (other than reserves and assessments taken into account in determining the interest rate applicable to Libor Loans), or
(c)    imposes any other condition the result of which is to increase the cost to Lender of making, funding or maintaining advances or reduces any amount receivable by Lender in connection with advances, or requires Lender to make any payment calculated by reference to the amount of advances held or interest received by it, by an amount deemed material by Lender, or
(d)    affects the amount of capital required or expected to be maintained by Lender or any corporation controlling Lender and Lender determines the amount of capital required is increased by or based upon the existence of this Agreement or its obligation to make the Term Loan hereunder or of commitments of this type, then, within three (3) Business Days of demand by Lender, Borrower agrees to pay Lender that portion of such increased expense incurred (including, in the case of clause (d), any reduction in the rate of return on capital to an amount below that which it could have achieved but for such law, rule, regulation, policy, guideline or directive and after taking into account Lender’s policies as to capital adequacy) or reduction in an amount received which Lender determines is attributable to making, funding and maintaining the Term Loan.
3.2    Taxes. All payments by Borrower under this Agreement shall be made free and clear of, and without deduction for, any present or future income, excise, stamp or other taxes, fees, levies, duties, withholdings or other charges of any nature whatsoever, now or hereafter imposed by any taxing authority, other than franchise taxes and taxes imposed on or measured by Lender’s net income or receipts or branch profits taxes (such non-excluded items being called “Taxes”). If any withholding or deduction from any payment to be made by Borrower hereunder is required in respect of any Taxes pursuant to any applicable law, rule or regulation, then Borrower shall:
(a)    pay directly to the relevant authority the full amount required to be so withheld or deducted;
(b)    promptly forward to Lender an official receipt or other documentation satisfactory to Lender evidencing such payment to such authority; and
(c)    pay to Lender such additional amount or amounts as is necessary to ensure that the net amount actually received by Lender will equal the full amount Lender would have received had no such withholding or deduction been required.
Moreover, if any Taxes are directly asserted against Lender with respect to any payment received by Lender hereunder, Lender may pay such Taxes and Borrower agrees to promptly pay such additional amounts (including, without limitation, any penalties, interest or expenses) as is necessary in order that the net amount received by Lender after the payment of such Taxes (including, without limitation, any Taxes on such additional amount) shall equal the amount Lender would have received had not such Taxes been asserted.
The provisions of and undertakings of Borrower set out in this Section 3.2 shall survive the satisfaction and payment of the Liabilities of Borrower and the termination of this Agreement.
3.3    Funding Indemnification. If any payment of a Libor Loan occurs on a date that is not the last day of the applicable Libor Interest Period, whether because of acceleration, prepayment, or otherwise, or a Libor Loan is not made on the date specified by Borrower, Borrower shall indemnify Lender for any loss or cost incurred by it resulting therefrom, including, without limitation, any loss or cost in liquidating or employing deposits acquired to fund or maintain the Libor Loan.
3.4    Lender Statements. Lender shall deliver a written statement to Borrower as to the amount due, if any, under Sections 3.1, 3.2 or 3.3 hereof. Such written statement shall set forth in reasonable detail the calculations upon which Lender determined such amount and shall be final, conclusive and binding on Borrower in the absence of demonstrable error. Unless otherwise provided herein, the amount specified in the written statement shall be payable on demand after receipt by Borrower of the written statement.
3.5    Basis for Determining Interest Rate Inadequate or Unfair. If with respect to any Libor Interest Period: (a) Lender reasonably determines, which determination shall be binding and conclusive on Borrower, that by reason of circumstances affecting the interbank Libor Base market adequate and reasonable means do not exist for ascertaining the applicable Libor Base Rate; or (b) Lender reasonably determines that the Libor Base Rate will not adequately and fairly reflect the cost to Lender of maintaining or funding the Term Loan or any portion thereof for such Libor Interest Period, or that the making or funding of Libor Loans has become impracticable as a result of an event occurring after the date of this Agreement which in the opinion of Lender adversely affects such loan, then, in either case, so long as such circumstances shall continue: (i) Lender shall not be under any obligation to make, maintain, convert into or continue Libor Loans and (ii) on the last day of the then current Libor Interest Period for each Libor Loan, each such loan shall, unless then repaid in full, automatically convert to a Base Rate Loan. Each affected Lender shall promptly give Borrower written notice of any determination made by it under this Section accompanied by a statement setting forth in reasonable detail the basis of such determination.
3.6    Illegality. If any applicable law or regulation, or any interpretation thereof by any court or any governmental or other regulatory body charged with the administration thereof, should make it unlawful for Lender or its lending office to make, maintain or fund any Libor Loan, then the obligation of Lender to make, convert into or continue such Libor Loan shall, upon the effectiveness of such event, be suspended for the duration of such unlawfulness, and on the last day of the current Libor Interest Period for such Libor Loan (or, in any event, if Lender so request, on such earlier date as may be required by the relevant law, regulation or interpretation), the Libor Loans shall, unless then repaid in full, automatically convert to Base Rate Loans.
3.7    Right of Lender to Fund through Other Offices. Lender may, if it so elects, fulfill its commitment as to any Libor Loan by causing a foreign branch or Affiliate of Lender to make such loan; provided that such election shall not increase the costs to Borrower hereunder and that in such event for the purposes of this Agreement such loan shall be deemed to have been made by Lender and the obligation of Borrower to repay such loan shall nevertheless be to Lender and shall be deemed held by it, to the extent of such loan, for the account of such branch or Affiliate.
3.8    Discretion of Lender as to Manner of Funding; No Match Funding. Notwithstanding any provision of this Agreement to the contrary, Lender shall be entitled to fund and maintain its funding of its portion of the Term Loan in any manner it sees fit, it being understood, however, that for the purposes of this Agreement all determinations hereunder shall be made as if Lender had actually funded and maintained each Libor Loan during each Libor Interest Period for such loan through the purchase of deposits having a maturity corresponding to such Libor Interest Period and bearing an interest rate equal to the Libor Rate for such Libor Interest Period.
3.9    Further Documentation; Loss of Note. If any further documentation or information is (a) required by Lender or any prospective transferee in connection with selling, transferring, delivering, assigning, or granting a participation in the Term Loan (or transferring the servicing of the Term Loan), or (b) deemed necessary or appropriate by Lender to correct patent mistakes in the Financing Agreements, Borrower shall provide, or cause to be provided to Lender, and, in the case of (b), unless such patent mistake is due to the gross negligence, willful misconduct or illegal activity of Lender at Borrower’s cost and expense, such documentation or information as Lender or any prospective transferee may reasonably request. Upon notice from Lender of the loss, theft, or destruction of the Term Note and upon receipt of indemnity reasonably satisfactory to Borrower from the applicable Lender, or in the case of mutilation of the Term Note, upon surrender of the mutilated Term Note, Borrower shall promptly make and deliver a new promissory note of like tenor in lieu of the then to be superseded Term Note.
4.    ATTORNEY-IN-FACT.
4.1    Appointment of Lender as Borrower’s Attorney-in-Fact. Borrower hereby irrevocably designates, makes, constitutes and appoints Lender (and all Persons designated by Lender in writing to Borrower) as Borrower’s true and lawful attorney-in-fact, and authorizes Lender, in Borrower’s or Lender’s name, after an Event of Default has occurred and is continuing to do the following: (a) at any time, (i) endorse Borrower’s name upon any items of payment or proceeds thereof and deposit the same in Lender’s account on account of Borrower’s Liabilities, and (ii) do all other acts and things which are necessary, in Lender’s reasonable discretion, to fulfill Borrower’s obligations under this Agreement. Borrower hereby ratifies and approves all acts under such power of attorney and neither Lender nor any other Person acting as Borrower’s attorney hereunder will be liable for any acts or omissions or for any error of judgment or mistake of fact or law made in good faith except as result of its gross negligence, willful misconduct or illegal activity as finally determined in a non-appealable judicial proceeding. The appointment of Lender (and any of Lender’s officers, employees or agents designated by Lender) as Borrower’s attorney, and each and every one of Lender’s rights and powers, being coupled with an interest, are irrevocable until all of the Liabilities have been fully repaid and this Agreement shall have expired or been terminated in accordance with the terms hereunder. Without restricting the generality of the foregoing, after an Event of Default has occurred and is continuing, Borrower hereby appoints and constitutes Lender its lawful attorney-in-fact with full power of substitution in the Real Property to advance funds in excess of the face amount of the Term Note, to pay, settle or compromise all existing bills and claims, which may be liens or security interests, or to avoid such bills and claims becoming liens against the Collateral; to execute all applications and certificates in the name of Borrower prosecute and defend all actions or proceedings in connection with the Collateral (including any Leases pertaining to Real Property); and to do any and every act which Borrower might do in its own behalf; it being understood and agreed that this power of attorney shall be a power coupled with an interest and cannot be revoked.
5.    CONDITIONS OF LOAN.
5.1    Conditions to Loan. Notwithstanding any other term or provision contained in this Agreement, Lender’s obligation to make the Term Loan hereunder is subject to the satisfaction of each of the following conditions precedent:
(a)    No Default. Neither a Default nor an Event of Default shall have occurred or be in existence.
(b)    Representations and Warranties. All of the representations and warranties contained in the Financing Agreements to which Borrower is a party and in this Agreement (including, without limitation, those set forth in Section 7 hereof), are true and correct.
(c)    Fees and Expenses. Borrower shall have paid all fees owed to Lender and reimburse Lender for all costs, disbursements, fees and expenses due and payable hereunder on or before the Closing Date, including, without limitation, all fees and costs identified in Section 12.2(a) hereof.
(d)    Documents. Lender shall have received all of the following, each duly executed and delivered and dated the Closing Date, or such earlier date as shall be satisfactory to Lender, each in form and substance reasonably satisfactory to Lender in its sole determination:
(1)    Financing Agreements. This Agreement, the Term Note, the Mortgage, the Assignment of Rents and Leases, the Assignment of Membership Interests, the Environmental Indemnity Agreement, the Subordination of Management Agreement, and such other Financing Agreements as Lender may require.
(2)    Resolutions; Incumbency and Signatures. Copies of resolutions of the Board of Directors of the sole member of Borrower, authorizing or ratifying the execution, delivery and performance by Borrower of this Agreement, the Financing Agreements to which Borrower is a party and any other document provided for herein or therein to be executed by Borrower, certified by a Duly Authorized Officer. A certificate of a Duly Authorized Officer certifying the names of the officers of Borrower authorized to make a borrowing request and sign this Agreement and the Financing Agreements to which Borrower is a party, together with a sample of the true signature of each such officer; Lender may conclusively rely on each such certificate until formally advised by a like certificate of any changes therein.
(3)    Consents. Certified copies of all documents evidencing any necessary consents and governmental approvals, if any, with respect to this Agreement, the Financing Agreements, and any other documents provided for herein or therein to be executed by Borrower.
(4)    Opinions of Counsel. An opinion of Harwell Howard Hyne Gabbert & Manner, the legal counsel to Borrower, and a local counsel opinion in the jurisdiction where the Facility is located with respect to the Mortgage, each in form and substance reasonably satisfactory to Lender.
(5)    Certain Restricted Agreements. Correct and complete copies of the fully executed Lease, the Management Agreement, the Acquisition Documents, the skilled nursing home license of Borrower, and any other Restricted Agreement, together with all applicable amendments thereto.
(6)    Financial Condition Certificate. A Financial Condition Certificate, in form and substance reasonably satisfactory to Lender, signed on behalf of Borrower by a Duly Authorized Officer of Borrower.
(7)    Governing Documents and Good Standings. Lender shall have received (i) copies, certified as correct and complete by the state of organization of Borrower, of the certificate of incorporation, certificate of formation or certificate of limited liability partnership, as applicable, of Borrower, with any amendments to any of the foregoing, (ii) copies, certified as correct and complete by an authorized officer, member or partner of Borrower, of all other documents necessary for performance of the obligations of Borrower under this Agreement and the other Financing Agreements, and (iii) certificates of good standing for Borrower, Operator and Manager issued by the state of organization of Borrower, Operator and Manager and certificates of authority to do business by the commonwealth in which the Facility is located for each of Borrower and Manager (such certificates set forth in (i) through (iii), the “Certificates”).
(8)    UCC Financing Statements; Termination Statements; UCC Searches. A UCC Financing Statement naming Borrower as debtor and Lender as secured party with respect to the Collateral, together with such UCC termination statements necessary to release all Liens (other than Permitted Liens) and other rights in favor of any Person in any of the Collateral except Lender, and other documents as Lender deems necessary or appropriate, shall have been filed in all jurisdictions that Lender deems necessary or advisable. UCC tax, lien, bankruptcy, pending suit and judgment searches for Borrower and each dated a date reasonably near to the Closing Date in all jurisdictions deemed necessary by Lender, the results of which shall be satisfactory to Lender in its sole and absolute determination.
(9)    Insurance Certificates. Certificates from Borrower’s insurance carriers evidencing that all required insurance coverage is in effect, each designating Lender as an additional insured and “lender’s loss payee” thereunder (and any reasonably required endorsements thereof).
(10)    Certificate of Occupancy. To the extent available, a true and complete copy of the certificate of occupancy with respect to the Facility.
(11)    Environmental Assessment. A Phase I environmental report of the Real Property addressed to Lender prepared by an environmental audit firm reasonably acceptable to Lender, the form and results of which shall be satisfactory to Lender in its sole and absolute determination.
(12)    Title Insurance. A title insurance policy in the form of ALTA Form Mortgagee Title Insurance Policy shall be issued by an insurer (reasonably acceptable to Lender) in favor of Lender for the Real Property. The title insurance policy shall contain such endorsements as deemed appropriate by Lender that are available in the commonwealth where the Real Property is located. Copies of all documents of record concerning the Real Property as identified on the commitment for the ALTA Policy referred to above.
(13)    Survey. An ALTA plat of survey shall be prepared on the Real Property (certified to the 2011 ALTA standards).
(14)    Appraisal. An Appraisal prepared by an independent appraiser of the Real Property engaged by Lender, which appraisal shall satisfy the requirements of the FIRREA, if applicable, and shall evidence compliance with the supervisory loan-to-value limits set forth in the Federal Deposit Insurance Corporation Improvement Act of 1991 (including a loan-to-value ratio on a “stabilized value” not to exceed 80%). Such appraisal (and the results thereof) shall be satisfactory to Lender in its sole and absolute determination.
(15)    Flood Insurance. A flood insurance policy concerning the Real Property, reasonably satisfactory to Lender, as required by the Flood Disaster Protection Act of 1973.
(16)    Property Condition Report. A Property Condition Report for the Real Property, the form, substance and results of which shall be satisfactory to Lender in its sole and absolute determination.
(17)    Operating Agreement. Correct and complete certified copy of the duly executed Limited Liability Company Agreement of Borrower, as amended.
(18)    Other. Lender shall have received, in form and substance reasonably satisfactory to Lender, all certificates, orders, authorities, consents, affidavits, schedules, instruments, agreements, financing statements, and other documents which are provided for hereunder or under or in connection with any Financing Agreement, which Lender may reasonably request on or prior to the Closing Date.
(e)    Field Examinations. At Lender’s sole option, Lender shall have completed its field examinations of Borrower’s books and records, assets, and operations which examinations will be satisfactory to Lender in its sole and absolute discretion.
(f)    Certificate. Lender shall have received a certificate signed on behalf of Borrower by a Duly Authorized Officer and dated the Closing Date certifying satisfaction of the conditions specified in this Section 5.
(g)    Closing Fee. Borrower shall have paid Lender the Closing Fee.
(h)    Bank Meetings. Borrower’s senior management shall have made themselves and Borrower’s facilities reasonably available (through scheduled bank meetings, company visits, or other venues) to Lender and its representatives.
(i)    Acquisition Agreement. The closing of the transaction contemplated by the Acquisition Agreement (including all material conditions precedent thereto, including, without limitation, the obtaining of any and all consents and approvals) shall occur in accordance with its terms concurrently with the transactions contemplated by this Agreement.
(j)    Solvency. On the Closing Date, Borrower is Solvent.
(k)    No Material Adverse Change. No Material Adverse Change, as reasonably determined by Lender, in the business, assets, liabilities, properties, condition (financial or otherwise), prospects or results of operations of Borrower shall have occurred from December 31, 2014, through the Closing Date.
(l)    Litigation. There shall not have been instituted or threatened any litigation or proceeding in any court or administrative forum to which Borrower is, or is threatened to be, a party which has, or is reasonably likely to result in, a Material Adverse Change.
6.    COLLATERAL.
6.1    Security Interest. As security for the prompt and complete payment and performance of all of the Liabilities when due or declared due, Borrower hereby grants, pledges, conveys and transfers to Lender a continuing security interest in and to all of Borrower’s right, title and interest in and to the following property and interests in property, whether now owned or existing or hereafter owned, arising or acquired, and wheresoever located (collectively, the “Collateral”): (a) all of Borrower’s accounts receivable, including, without limitation, Accounts and Health-Care-Insurance Receivables (each as defined in the Code), (b) all of Borrower’s General Intangibles, including, without limitation, General Intangibles related to accounts receivable and money; (c) all of Borrower’s Deposit Accounts and other deposit accounts (general or special) with, and credits and other claims against Lender or any other financial institution with which Borrower maintains deposits, including without limitation, any and all lease deposit accounts with Lender; (d) all of Borrower’s contracts, licenses, chattel paper, instruments, notes, letters of credit, contract rights, bills of lading, warehouse receipts, shipping documents, permits, tax refunds, documents and documents of title, and all of Borrower’s Tangible Chattel Paper, Documents, Electronic Chattel Paper, Letter-of-Credit Rights, letters of credit, Software, Supporting Obligations, Payment Intangibles, and Goods (each as defined in the Code); (e) all of Borrower’s Inventory and Equipment and motor vehicles and trucks; (f) all of Borrower’s monies, and any and all other property and interests in property of Borrower, including, without limitation, Investment Property, Instruments, Security Entitlements, Uncertificated Securities, Certificated Securities, Chattel Paper, and Financial Assets (each as defined in the Code), now or hereafter coming into the actual possession, custody or control of Lender or any agent or Affiliate thereof in any way or for any purpose (whether for safekeeping, deposit, custody, pledge, transmission, collection or otherwise), and, independent of and in addition to Lender’s rights of setoff (which Borrower acknowledges), the balance of any account or any amount that may be owing from time to time by Lender to Borrower; (g) all insurance proceeds of or relating to any of the foregoing property and interests in property, and any key man life insurance policy covering the life of any officer or employee of Borrower; (h) all proceeds and profits derived from the operation of Borrower’s business; (i) all of Borrower’s books and records, computer printouts, manuals and correspondence relating to any of the foregoing and to Borrower’s business; and (j) all accessions, improvements and additions to, substitutions for, and replacements, products, profits and proceeds of any of the foregoing.
6.2    Preservation of Collateral and Perfection of Security Interests Therein. Borrower agrees that it shall execute and deliver to Lender, concurrently with the execution of this Agreement, and promptly at any time or times hereafter at the reasonable request of Lender instruments and documents as Lender may reasonably request, in a form and substance satisfactory to Lender, to establish, create, perfect and keep perfected the Liens in the Collateral or to otherwise protect and preserve the Collateral and Lender’s Liens therein (including, without limitation, if and as applicable, financing statements, and Borrower shall pay the cost of filing or recording the same in all public offices deemed necessary by Lender). If Borrower fails to do so, Lender is authorized to file such financing statements. Borrower further agrees that a carbon, photographic, photostatic or other reproduction of this Agreement or of a financing statement is sufficient as a financing statement.
6.3    Loss of Value of Collateral. Borrower agrees to immediately notify Lender of any material loss or depreciation in the value of the Collateral or any portion thereof.
6.4    Right to File Financing Statements. Notwithstanding anything to the contrary contained herein, Lender may at any time and from time to time file financing statements, continuation statements and amendments thereto that describe the Collateral as “all assets” or in particular and which contain any other information required by the Code for the sufficiency or filing office acceptance of any financing statement, continuation statement or amendment, including whether Borrower is an organization, the type of organization and any organization identification number issued to Borrower. Borrower agrees to furnish any such information to Lender promptly upon request. Any such financing statements, continuation statements or amendments may be signed (if at any time required) by Lender on behalf of Borrower and may be filed at any time with or without signature and in any jurisdiction as reasonably determined by Lender. Lender agrees to use its reasonable efforts to notify Borrower of Lender taking any such action provided in this Section; provided, however, Borrower agrees that the failure of Lender to so notify Borrower for any reason shall not in any way invalidate the actions taken by Lender pursuant to this Section.
6.5    Third Party Agreements. Borrower shall at any time and from time to time take such steps as Lender may reasonably require for Lender: (i) to obtain an acknowledgment, in form and substance reasonably satisfactory to Lender, of any third party having possession of any of the Collateral that the third party holds for the benefit of Lender, (ii) to obtain “control” (as defined in the Code) of any Investment Property, Deposit Accounts, Letter of Credit Rights or Electronic Chattel Paper (each as defined in the Code), with any agreements establishing control to be in form and substance reasonably satisfactory to Lender, and (iii) otherwise to ensure the continued perfection and priority of Lender’s security interest in any of the Collateral and of the preservation of its rights therein.
6.6    All Loans One Obligation. All Liabilities of Borrower under this Agreement and each of the Financing Agreements, are cross-collateralized and cross-defaulted. Payment of all sums and indebtedness to be paid by Borrower to Lender under this Agreement shall be secured by, among other things, the Financing Agreements. All loans or advances made to Borrower under this Agreement shall constitute one Loan, and all of Borrower’s Liabilities and other liabilities of Borrower to Lender shall constitute one general obligation secured by Lender’s Lien on all of the Collateral of Borrower and by all other liens heretofor, now, or at any time or times granted to Lender to secure the Term Loan and other Liabilities. Borrower agrees that all of the rights of Lender set forth in this Agreement shall apply to any amendment, restatement or modification of, or supplement to, this Agreement, any supplements or exhibits hereto and the Financing Agreements, unless otherwise agreed in writing by Lender.
6.7    Commercial Tort Claim. If Borrower shall at any time hereafter acquire a Commercial Tort Claim (as defined in the Code), Borrower shall promptly notify Lender of same in a writing signed by Borrower (describing such claim in reasonable detail) and grant to Lender in such writing (at the sole cost and expense of Borrower) a continuing, first-priority security interest therein (subject only to the Permitted Liens) and in the proceeds thereof, with such writing to be in form and substance satisfactory to Lender in its sole and absolute determination.
7.    REPRESENTATIONS AND WARRANTIES.
Borrower represents and warrants to Lender that as of the date of this Agreement, and continuing as long as any Liabilities remain outstanding, and (even if there shall be no such Liabilities outstanding) as long as this Agreement remains in effect:
7.1    Existence. Borrower is a limited liability company duly organized, validly existing and in good standing under the laws of the state of its incorporation or formation. Borrower is duly (a) qualified and in good standing as a foreign corporation or foreign limited liability company and (b) authorized to do business in each jurisdiction where such qualification is required because of the nature of its activities or properties. Borrower has all requisite power to carry on its business as now being conducted and as proposed to be conducted.
7.2    Company Authority. The execution and delivery by Borrower of this Agreement and all of the other Financing Agreements to which Borrower is a party and the performance of its obligations hereunder and thereunder: (i) are within its powers; (ii) are duly authorized by the board of directors, manager or members of Borrower, each as applicable; and (iii) are not in contravention of the terms of its operating agreement, bylaws, or of an indenture, agreement or undertaking to which it is a party or by which it or any of its property is bound. The execution and delivery by Borrower of this Agreement and all of the other Financing Agreements to which it is a party and the performance of its obligations hereunder and thereunder: (i) do not require any governmental consent, registration or approval; (ii) do not contravene any contractual or governmental restriction binding upon it; and (iii) will not, except in favor of Lender, result in the imposition of any Lien upon any property of Borrower under any existing indenture, mortgage, deed of trust, loan or credit agreement or other material agreement or instrument to which it is a party or by which it or any of its property may be bound or affected. Borrower is not bound by any contractual obligation, or subject to any restriction in any organizational document, that could reasonably be expected to have a Material Adverse Effect. This Agreement and all of the other Financing Agreements to which Borrower is a party have been duly executed.
7.3    Binding Effect. This Agreement and all of the other Financing Agreements to which Borrower is a party are the legal, valid and binding obligations of Borrower and are enforceable against Borrower in accordance with their respective terms, subject to bankruptcy, insolvency, reorganization, moratorium or other similar laws affecting the enforcement of creditor’s rights and remedies generally.
7.4    Financial Data.
(a)    All income statements, balance sheets, cash flow statements, statements of operations, and other financial data which have been or shall hereafter be furnished to Lender for the purposes of or in connection with this Agreement do and will present fairly in all material respects in accordance with GAAP, consistently applied, the financial condition of Borrower as of the dates thereof and the results of its operations for the period(s) covered thereby. The foregoing notwithstanding all unaudited financial statements furnished or to be furnished to Lender by or on behalf of Borrower are not and will not be prepared in accordance with GAAP to the extent that such financial statements (a) are subject to cost report and other year-end audit adjustments, (b) do not contain footnotes, (c) were prepared without physical inventories, (d) are not restated for subsequent events, (e) may not contain a statement of construction in process, and (f) may not fully reflect the following liabilities: (i) vacation, holiday and similar accruals, (ii) liabilities payable in connection with workers’ compensation claims, (iii) liabilities payable to any employee welfare benefit plan (within the meaning of Section 3(1) of ERISA) maintained by Borrower or its affiliates on account of Borrower’s employees, (iv) federal, state and local income or franchise taxes and (v) bonuses payable to certain employees (collectively, the “GAAP Exceptions”).
(b)    Since December 31, 2014, there has been no Material Adverse Change with respect to Borrower.
7.5    Collateral. Except for the Permitted Liens, all of Borrower’s assets and property (including, without limitation, the Collateral) is and will continue to be owned by Borrower (except for items of Inventory disposed of in the ordinary course of business and sales of Equipment being replaced in the ordinary course of business, or as a result of casualty loss or condemnation, with other Equipment with a value equal to or greater than the Equipment being sold), has been fully paid for and is free and clear of all Liens. No financing statement or other document similar in effect covering all or any part of the Collateral is on file in any recording or filing office, other than those identifying Lender as the secured creditor or except for Permitted Liens. The organizational number assigned by the Secretary of State of Borrower’s state of incorporation or formation, as applicable, is 5623793, as also identified on the UCC Financing Statement filed in connection with this Agreement.
7.6    Solvency. Borrower is Solvent. Borrower will not be rendered insolvent by the execution and delivery of this Agreement or any Financing Agreement, or by completion of the transactions contemplated hereunder or thereunder.
7.7    Principal Place of Business; State of Organization. As of the Closing Date, (a) the principal place of business and chief executive office of Borrower is 1621 Galleria Boulevard, Brentwood, Tennessee 37027, and (b) Borrower’s state of incorporation or formation is the State of Delaware. The books and records of Borrower are at the principal place of business and chief executive office of Borrower.
7.8    Other Names. As of the Closing Date Borrower is not using, and shall not thereafter use, any name (including, without limitation, any trade name, trade style, assumed name, division name or any similar name).
7.9    Tax Liabilities. Borrower has filed all material federal, state and local tax reports and returns required by any law or regulation to be filed by it, except for extensions duly obtained, and taxes that are being contested in good faith by appropriate proceedings duly conducted, and has either duly paid all taxes, duties and charges indicated due on the basis of such returns and reports, or made adequate provision for the payment thereof, and the assessment of any material amount of additional taxes in excess of those paid and reported is not reasonably expected.
7.10    Loans. Borrower is not obligated on any loans or other Indebtedness (except for the Lease Agreement).
7.11    Margin Securities. No part of the proceeds of the Term Loan will be used, and whether immediately, incidentally or ultimately, for any purposes that violates or results in directly or indirectly, a violation of Regulations U, T or X of the Board of Governors of the Federal Reserve System (assuming, in the case of Regulation T, that no broker-dealer or other “creditor” as defined in Regulation T extends or maintains credit to Borrower under this Agreement). Borrower does not own any margin securities and the Term Loan advanced hereunder will not be used for the purpose of purchasing or carrying any margin securities or for the purpose of reducing or retiring any Indebtedness which was originally incurred to purchase any margin securities or for any other purpose not permitted by Regulation U of the Board of Governors of the Federal Reserve System.
7.12    Litigation and Proceedings. As of the Closing Date, no judgments are outstanding against Borrower that could be an Event of Default under clause (e) of Section 11.1, nor is there as of such date pending, or to the best of Borrower’s knowledge, threatened as of the Closing Date, except as shown on Schedule 7.12, any (i) litigation, suit, action or contested claim (other than a personal injury tort claim), or federal, state or municipal governmental proceeding, by or against Borrower or any of its property which if adversely determined could have a Material Adverse Effect, or (ii) any tort claim for personal injury, including death, against Borrower as to which (a) litigation has been instituted and is pending or (b) or a request for medical records has been made upon Borrower by an attorney for the claimant.
7.13    Other Agreements. Borrower is not in default under or in breach of any agreement, contract, lease, or commitment to which it is a party or by which it is bound which could reasonably be expected to have a Material Adverse Effect. Borrower does not know of any dispute regarding any agreement, contract, instrument, lease or commitment to which it is a party which could reasonably be expected to have a Material Adverse Effect.
7.14    Compliance with Laws and Regulations. The execution and delivery by Borrower of this Agreement and all of the other Financing Agreements to which it is a party and the performance of Borrower’s obligations hereunder and thereunder are not in contravention of any applicable law, rule or regulation. Borrower has obtained all licenses, authorizations, approvals, licenses and permits necessary in connection with the operation of its business, except to the extent the failure to obtain any of the foregoing could reasonably be expected to not result in a Material Adverse Effect. Borrower is in compliance with all laws, orders, rules, regulations and ordinances of all federal, foreign, state and local governmental authorities applicable to it and its business, operations, property, and assets, except to the extent any such non-compliance could reasonably be expected to not result in a Material Adverse Effect.
7.15    Intellectual Property. As of the Closing Date, Borrower does not own or otherwise possess any material Intellectual Property. To Borrower’s best knowledge, none of its Intellectual Property infringes on the rights of any other Person; provided that the name “Diversicare” is shared in Canada with various Diversicare entities that were sold in 2004.
7.16    Environmental Matters. Borrower has not Managed Hazardous Substances on or off the Real Property other than in compliance with applicable Environmental Laws, except to the extent any such non-compliance could reasonably be expected to not result in a Material Adverse Effect. Borrower has complied in all material respects with applicable Environmental Laws regarding transfer, construction on and operation of its business and the Real Property, including, but not limited to, notifying authorities, observing restrictions on use, transferring, modifying or obtaining permits, licenses, approvals and registrations, making required notices, certifications and submissions, complying with financial liability requirements, and Managing Hazardous Substances and Responding to the presence or Release of Hazardous Substances connected with operation of its business or the Real Property. Borrower does not have any contingent liability with respect to the Management of any Hazardous Substance that could reasonably be expected to result in a Material Adverse Effect. As of the Closing Date, Borrower has not received any Environmental Notice that could reasonably be expected to result in a Material Adverse Effect.
7.17    Disclosure. As of the Closing Date, none of the representations or warranties made by Borrower herein or in any Financing Agreement to which Borrower is a party and no other written information provided or statements made by Borrower or its representatives to Lender contains any untrue statement of a material fact or omits to state a material fact necessary to make the statements therein, in light of the circumstances under which they were made, not misleading. As of the Closing Date, Borrower has disclosed to Lender all facts of which Borrower has knowledge which might result in a Material Adverse Effect either prior or subsequent to the consummation of the transactions contemplated hereby or which, to Borrower’s knowledge, at any time hereafter might reasonably be expected to result in a Material Adverse Effect.
7.18    Pension Related Matters. Each employee pension plan (other than a multiemployer plan within the meaning of Section 3(37) of ERISA and to which Borrower or any ERISA Affiliate has or had any obligation to contribute (a “Multiemployer Plan”)) maintained by Borrower or any of its ERISA Affiliates to which Title IV of ERISA applies and (a) which is maintained for employees of Borrower or any of its ERISA Affiliates or (b) to which Borrower or any of its ERISA Affiliates made, or was required to make, contributions at any time within the preceding five (5) years (a “Plan”), complies, and is administered in accordance, with its terms and all material applicable requirements of ERISA and of the Internal Revenue Code of 1986, as amended, and any successor statute thereto (the “Tax Code”), and with all material applicable rulings and regulations issued under the provisions of ERISA and the Tax Code setting forth those requirements. No “Reportable Event” or “Prohibited Transaction” (as each is defined in ERISA) or withdrawal from a Multiemployer Plan caused by Borrower has occurred and no funding deficiency described in Section 302 of ERISA caused by Borrower exists with respect to any Plan or Multiemployer Plan which could have a Material Adverse Effect. Borrower and each ERISA Affiliate has satisfied all of their respective funding standards applicable to such Plans and Multiemployer Plans under Section 302 of ERISA and Section 412 of the Tax Code and the Pension Benefit Guaranty Corporation and any entity succeeding to any or all of its functions under ERISA (“PBGC”) has not instituted any proceedings, and there exists no event or condition caused by Borrower which would reasonably be expected to constitute grounds for the institution of proceedings by PBGC, to terminate any Plan or Multiemployer Plan under Section 4042 of ERISA which could have a Material Adverse Effect.
7.19    Perfected Security Interests. The Lien in favor of Lender provided pursuant to Section 6.1 hereof is a valid and perfected first priority security interest in the Collateral (subject only to the Permitted Liens), and all filings and other actions necessary to perfect such Lien have been or will be duly taken.
7.20    Broker’s Fees. Borrower does not have any obligation to any Person in respect of any finder’s, brokers or similar fee in connection with the Term Loan or this Agreement.
7.21    Investment Company Act. Borrower is not an “investment company” or a company “controlled” by an “investment company”, within the meaning of the Investment Company Act of 1940, as amended.
7.22    Offenses and Penalties Under the Medicare/Medicaid Programs. As of the Closing Date, Neither Borrower nor any employee of Borrower is currently, to the best knowledge of Borrower, after due inquiry, under investigation or prosecution for, nor has Borrower or, to the best knowledge of Borrower, after due inquiry, any current employee of Borrower been convicted of: (a) any offense related to the delivery of an item or service under the Medicare or Medicaid programs; (b) a criminal offense related to neglect or abuse of patients in connection with the delivery of a health care item or service; (c) fraud, theft, embezzlement or other financial misconduct; (d) the obstruction of an investigation of any crime referred to in subsections (a) through (c) of this Section; or (e) unlawful manufacture, distribution, prescription, or dispensing of a controlled substance. As of the Closing Date, Neither Borrower nor, to the best knowledge of Borrower, after due inquiry, any current employee of Borrower has been required to pay any civil money penalty under applicable laws regarding false, fraudulent or impermissible claims or payments to induce a reduction or limitation of health care services to beneficiaries of any state or federal health care program, nor, to the best knowledge of Borrower, after due inquiry, is Borrower and/or to the best knowledge of Borrower, after due inquiry, any current employee of Borrower currently the subject of any investigation or proceeding that may result in such payment.
7.23    Medicaid/Medicare. Neither Borrower nor any Affiliate of Borrower nor any current officer or director of the foregoing has engaged in any of the following: (i) knowingly and willfully making or causing to be made a false statement or representation of a material fact in any application for any benefit or payment under Medicare or Medicaid; (ii) knowingly and willfully making or causing to be made any false statement or representation of a material fact for use in determining rights to any benefit or payment under Medicare or Medicaid; (iii) failing to disclose knowledge by a claimant of the occurrence of any event affecting the initial or continued right to any benefit or payment under Medicare or Medicaid on its own behalf or on behalf of another, with intent to secure such benefit or payment fraudulently; or (iv) knowingly and willfully soliciting or receiving any remuneration (including any kickback, bribe or rebate), directly or indirectly, overtly or covertly, in cash or in kind or offering to pay such remuneration: (A) in return for referring any individual to a Person for the furnishing or arranging for the furnishing of any item or service for which payment may be made in whole or in part by Medicare or Medicaid; or (B) in return for purchasing, leasing or ordering or arranging for or recommending the purchasing, leasing or ordering of any good, facility, service or item for which payment may be made in whole in part by Medicare or Medicaid.
7.24    USA Patriot Act. Neither Borrower nor any of its Affiliates is identified in any list of known or suspected terrorists published by any United States government agency (collectively, as such lists may be amended or supplemented from time to time, referred to as the “Blocked Persons Lists”) including, without limitation, (a) the annex to Executive Order 13224 issued on September 23, 2001, and (b) the Specially Designated Nationals List published by the Office of Foreign Assets Control. No part of the proceeds of any Loan will be used directly or indirectly for any payments to any government official or employee, political party, official of a political party, candidate for political office, or anyone else acting in an official capacity, in order to obtain, retain or direct business or obtain any improper advantage, in violation of the United States Foreign Corrupt Practices Act of 1977, as amended.
7.25    Absence of Foreign or Enemy Status. Neither Borrower nor any Affiliate of Borrower is an “enemy” or an “ally of the enemy” within the meaning of Section 2 of the Trading with the Enemy Act (50 U.S.C. App. §§ 1 et seq.), as amended. Neither Borrower nor any Affiliate of Borrower is in violation of, nor will the use of the Term Loan violate, the Trading with the Enemy Act, as amended, or any executive orders, proclamations or regulations issued pursuant thereto, including, without limitation, regulations administered by the Office of Foreign Asset Control of the Department of the Treasury (31 C.F.R. Subtitle B, Chapter V).
7.26    Acquisition. Borrower has delivered true, correct and complete copies of the fully-signed Acquisition Documents to Lender on or prior to the Closing Date. On the Closing Date and concurrently with the making of the Term Loan hereunder, the Acquisition will have been consummated in accordance with the terms of the Acquisition Documents and in accordance in all material respects with all applicable laws. As of the Closing Date, to Borrower’s knowledge, the Seller is not in default or breach of or under the Acquisition Documents to which Seller is a party. All consents and approvals of, and filings and registrations with, and all other actions by, any Governmental Authority and (except where the failure to obtain or make the same could not reasonably be expected to have an adverse effect on the Acquisition or any portion thereof or a Material Adverse Effect) to the best of Borrower’s knowledge each other Person required in order to make or consummate the Acquisition have been obtained, given, filed or taken and are or will be in full force and effect.
7.27    Labor Matters. There are no strikes or other labor disputes or grievances pending or, to the knowledge of Borrower, threatened against Borrower. All payments due from Borrower on account of wages and employee and retiree health and welfare insurance and other benefits have been paid or accrued as a liability on its books. The consummation of the transactions contemplated by the Financing Agreements will not give rise to a right of termination or right of renegotiation on the part of any union under any collective bargaining agreement to which Borrower is a party or by which it is bound.
7.28    Government Contracts. Borrower is not a party to any contract or agreement (including, but not limited to, any Lease) that requires Borrower to comply with the Federal Assignment of Claims Act, as amended (31 U.S.C. Section 3727) or, to the best of Borrower’s knowledge, any similar state or local law.
7.29    OFAC. Neither Borrower, nor any beneficial owner of Borrower, is currently listed on the OFAC Lists. Neither Borrower nor, to the best knowledge of Borrower, its Affiliates, are in violation of (a) the Trading with the Enemy Act, and each of the foreign assets control regulations of the United States Treasury Department (31 CFR, Subtitle B Chapter V, as amended) and any other enabling legislation or executive order relating thereto, (b) the Patriot Act and (c) other federal or state laws relating to “know your customer” and anti-money laundering rules and regulations.
7.30    Leases. As of the Closing Date, there are no Leases as to which Borrower is the lessee.
7.31    Title to Property. Except as could not reasonably be expected to have a Material Adverse Effect, Borrower owns good and, in the case of real property, marketable title to all of its properties and assets, real and personal, tangible and intangible, of any nature whatsoever, free and clear of all Liens (except for Permitted Liens), and except for minor defects in title that do not interfere with in any material respect with the ability of Borrower to conduct its business as currently conducted or utilize such properties and assets for their intended purposes.
7.32    Management Fees. The management fees payable by Operator to Manager pursuant to the Management Agreement is entirely used to cover and pay for actually incurred, ordinary course costs and does not include any amount of profit.
7.33    FCPA. Neither Borrower nor any of its Subsidiaries nor, to knowledge of Borrower, any director, manager, officer, agent, employee or other Person acting on behalf of Borrower or any of its Subsidiaries is aware of or has taken any action, directly or indirectly, that would result in a violation by such persons of the FCPA or any other applicable anti-corruption law, and Borrower has instituted and maintains policies and procedures designed to ensure continued compliance therewith.
8.    AFFIRMATIVE COVENANTS.
Borrower covenants and agrees on a joint and several basis with Lender that, as long as any Liabilities remain outstanding, and (even if there shall be no such Liabilities outstanding) as long as this Agreement remains in effect:
8.1    Reports, Certificates and Other Information. Borrower shall deliver to Lender:
(a)    Financial Statements. On or before (i) the forty-fifth (45th) day after the end of each calendar month during the first (1st), second (2nd) and third (3rd) Fiscal Quarters of each Fiscal Year, (ii) the seventy-fifth (75th) day after the end of the calendar month ending the Borrower’s final Fiscal Quarter, and (iii) the thirtieth (30th) day after the end of each calendar month, a copy of the internally prepared consolidated monthly financial statement of Borrower and Operator, prepared in conformity with GAAP, signed on behalf of Borrower and Operator by Duly Authorized Officers and consisting of balance sheets and statements of income and cash flow for such period, including without limitation schedules thereto breaking out the financials for the Facility, as at the close of such calendar month and statements of earnings for such calendar month and for the period from the beginning of such Fiscal Year to the close of such calendar month, each of which must be in form, scope and substance reasonably satisfactory to Lender.
(b)    Compliance Certificates. On or before the forty-fifth (45th) day after each Fiscal Quarter, a duly completed compliance certificate with appropriate insertions (a “Compliance Certificate”), dated the date of such annual financial statement or such Fiscal Quarter and signed on behalf of Borrower by a Duly Authorized Officer, which Compliance Certificate shall state that no Default or Event of Default has occurred and is continuing, or, if there is any such event, describes it and the steps, if any, being taken to cure it. Each Compliance Certificate shall contain a computation of, and show compliance with, each of the financial ratios and restrictions set forth in Section 9.12 hereof (each such computation and calculation to be in form and substance acceptable to Lender), and each Compliance Certificate must otherwise be in form, scope and substance reasonably satisfactory to Lender.
(c)    Real Estate Taxes. As paid, evidence of timely payment of real estate taxes owed on the Real Property.
(d)    Notice of Default, Regulatory Matters, Litigation Matters or Adverse Change in Business. Forthwith upon learning of the occurrence of any of the following, written notice thereof which describes the same and the steps being taken by Borrower with respect thereto: (i) the occurrence of a Default or an Event of Default; (ii) the institution or threatened institution of, or any adverse determination in, any litigation (other than a personal injury tort claim), arbitration proceeding or governmental proceeding in which any injunctive relief or money damages is sought which if adversely determined could have a Material Adverse Effect; (iii) the receipt of any notice from any governmental agency concerning any violation or potential violation of any regulations, rules or laws applicable to Borrower which could have a Material Adverse Effect; or (iv) any Material Adverse Change. With regard to personal injury tort claims, upon request by Lender, Borrower shall review with Lender the occurrence of any personal injury or other action which could reasonably give rise to a personal injury tort claim against Borrower as to which (i) litigation has been instituted and is pending or (ii) a request for medical records has been made upon Borrower by an attorney for the claimant.
(e)    Insurance Reports. (i) At any time after a Default and upon the request of Lender, a certificate signed by a Duly Authorized Officer that summarizes the property, casualty, liability and malpractice insurance policies carried by Borrower, and (ii) written notification of any material change in any such insurance by Borrower within five (5) Business Days after receipt of any notice (whether formal or informal) of such change by any of its insurers.
(f)    Operating Budget. No later than thirty (30) days after the end of each Fiscal Year, a copy of Borrower’s Fiscal Year operating budget.
(g)    Affiliate Transactions. Upon Lender’s reasonable request from time to time, a reasonably detailed description of each of the material transactions between Borrower and any of its Affiliates during the time period reasonably requested by Lender, which shall include, without limitation, the amount of money either paid or received, as applicable, by Borrower in such transactions.
(h)    Interim Reports. Promptly upon receipt thereof, copies of any reports submitted to Borrower by the independent accountants in connection with any interim audit of the books of any such Person and copies of each management control letter provided to Borrower by independent accountants.
(i)    Reports to the SEC. Upon Lender’s reasonable request from time to time, copies of any and all regular, annual, periodic or special reports of Borrower or any Affiliate thereof filed with the Securities and Exchange Commission (“SEC”); copies of any and all registration statements of Borrower or any Affiliate thereof filed with the SEC; and copies of any and all proxy statements or other written communications made to security holders generally.
(j)    Other Information. Such other information, certificates, schedules, exhibits or documents (financial or otherwise) concerning Borrower and its operations, business, properties, condition or otherwise as Lender may reasonably request from time to time.
8.2    Inspection; Audit Fees. Borrower shall keep proper books of record and account in accordance with GAAP in which full, true and correct entries shall be made of all dealings and transactions in relation to its business and activities; and shall permit (at the expense of Borrower provided Borrower shall be responsible for such reasonable expenses no more than one (1) time per year unless an Event of Default has occurred and is continuing), representatives of Lender or any Person appointed by Lender to visit and inspect the Facility, to examine and make abstracts or copies from any of its books and records (in each case excluding patient medical records and other records to the extent confidential or where such examination is prohibited under applicable Laws, including without limitation HIPAA), to conduct a collateral audit and analysis of its Inventory and Accounts and to discuss its affairs, finances and accounts with its officers, employees and independent public accountants as often as may reasonably be desired. In the absence of an Event of Default, Lender shall give Borrower commercially reasonable prior written notice of such exercise; provided, no notice shall be required during the existence and continuance of any Event of Default. All such costs, expenses and fees incurred or charged by Lender under this Section 8.2 shall bear interest at the Default Rate and shall be additional Liabilities of Borrower to Lender, secured by the Collateral, if not promptly paid upon the request of Lender.
8.3    Conduct of Business. Borrower shall maintain its corporate existence, shall maintain in full force and effect all licenses, permits, authorizations, bonds, franchises, leases, patents, trademarks and other Intellectual Property, contracts and other rights necessary to the conduct of its business, shall continue in, and limit its operations to, the same general line of business as that currently conducted and shall comply with all applicable laws (including, without limitation, Healthcare Laws and Environmental Laws), orders, regulations and ordinances of all federal, foreign, state and local governmental authorities, except to the extent any such non-compliance could reasonably be expected to result in a Material Adverse Effect. Borrower shall keep proper books of record and account in which full and true entries will be made of all dealings or transactions of or in relation to the business and affairs of Borrower, in accordance with GAAP (subject, however, to the GAAP Exceptions), consistently applied.
8.4    Claims and Taxes. Borrower agrees to pay or cause to be paid all license fees, bonding premiums and related taxes and charges and shall pay or cause to be paid all of Borrower’s real and personal property taxes, assessments and charges and all of Borrower’s franchise, income, unemployment, payroll, use, excise, old age benefit, withholding, sales and other taxes and other governmental charges assessed against Borrower, or payable by Borrower, at such times and in such manner as to prevent any penalty from accruing or any Lien from attaching to its property, provided that Borrower shall have the right to contest in good faith, by an appropriate proceeding promptly initiated and diligently conducted, the validity, amount or imposition of any such tax, assessment or charge, and upon such good faith contest to delay or refuse payment thereof, if (a) Borrower establishes adequate reserves to cover such contested taxes, assessments or charges, and (b) such contest does not have a Material Adverse Effect.
8.5    State of Incorporation or Formation. Borrower’s state of incorporation or formation, as applicable, shall remain Borrower’s state of incorporation or formation, as applicable, unless: (a) Borrower provides Lender with at least thirty (30) days prior written notice of any proposed change, (b) no Event of Default then exists or will exist immediately after such proposed change, and (c) Borrower provides Lender with, at Borrower’s sole cost and expense, such financing statements, and such other agreements and documents as Lender shall reasonably request in connection therewith.
8.6    Liability Insurance. Borrower shall (or shall cause Operator to) maintain, at its or Operator’s expense, general liability and professional insurance through commercial insurance in such amounts and with such deductibles consistent with its past practices, and shall deliver to Lender the original (or a certified) copy of each policy of insurance and evidence of the payment of all premiums therefor. Such policies of insurance shall contain an endorsement showing Lender as additional insured thereunder to the general liability coverage and, where such an endorsement is available from Borrower’s or Operator’s carrier at commercially affordable rates, to the professional liability coverage. Borrower (or Operator) has in place and will maintain general liability and professional liability insurance with single limit coverage of One Million and No/100 Dollars ($1,000,000.00) per occurrence and Three Million and No/100 Dollars ($3,000,000.00) aggregate. Borrower shall provide Lender, (a) on an annual basis, information from its insurance representative, insurance carrier or from comparable insurance carriers regarding availability of insurance and (b) with respect to the insurance policies contemplated by this Section 8.6 and those certain insurance policies contemplated by Section 8.7 below, prompt (but in any event, within five (5) Business Days of any such occurrence) written notice of any alteration or cancellation of such insurance policy. Lender acknowledges that professional liability insurance coverage may from time to time be unavailable generally in the nursing home industry at commercially affordable rates. In the event that at any time the professional liability insurance coverage required under Section 8.6 is not generally available to operators of similar healthcare facilities to that of the Facility in the market area in which the Facility is located at commercially affordable rates and on commercially reasonable terms and conditions, then Borrower (or Operator) may obtain in place thereof to cover the risk either or a combination of (i) professional liability insurance limits and coverages that are generally available to operators of similar healthcare facilities to that of the Facility in the market area in which the Facility is located at commercially affordable rates and on commercially reasonable terms and conditions, and/or (ii) a security deposit, self-insurance by Borrower, the establishment of a loss reserve to be funded by Borrower and held by Lender, captive insurance program or other alternative containing commercially reasonable terms and conditions. Prior to making any such switch, Borrower shall be obligated to provide Lender with supporting evidence from its (or Operator’s) insurance broker or carrier demonstrating the existence of the conditions set forth herein permitting Borrower (or Operator) to do so. At such time as the professional liability insurance coverages required under Section 8.6 are available at commercially affordable rates and on commercially reasonable terms and conditions, then Borrower (or Operator) shall immediately purchase and provide Lender with evidence of professional liability insurance coverage necessary to meet the requirements of this Section 8.6. In the event that, as a result of the professional liability coverage not being available as provided herein, the general liability insurance coverage required herein is also not available at commercially affordable rates and on commercially reasonable terms and conditions, then the provisions of this Section 8.6 shall likewise apply to and include the general liability coverage required herein.
8.7    Property and Other Insurance. Borrower shall, at its expense, keep and maintain its assets material to the Business of Borrower insured against (i) loss or damage by fire, theft, explosion, flood, earthquake, spoilage and all other hazards and risks and (ii) business interruption, in such amounts with such deductibles (which may include self-insurance trusts) ordinarily insured against by other owners or users of such properties in similar businesses of comparable size operating in the same or similar locations. Borrower, at Borrower’s expense, shall keep and maintain workers compensation insurance as may be required by applicable Laws. Borrower shall deliver to Lender the original (or a certified) copy of each policy of insurance and evidence of payment of all premiums therefor. All such policies of insurance shall be in form and substance reasonably satisfactory to Lender. Such policies of insurance shall contain an endorsement, in form and substance satisfactory to Lender, showing Lender as “Lender’s Loss Payee” and all loss payable to Lender, as its interests may appear, as provided in this Section. Such endorsement shall provide that such insurance company will give Lender at least thirty (30) days prior written notice before any such policy or policies of insurance shall be altered or canceled and that no act or default of Borrower or any other Person shall affect the right of Lender to recover under such policy or policies of insurance in case of loss or damage. Borrower hereby directs all insurers under such policies of insurance to pay all proceeds of insurance policies directly to Lender and Lender shall absent an Event of Default permit Borrower to use such proceeds to restore or rebuild the damaged property as Borrower shall determine in its reasonable and good faith determination.
Upon the occurrence of an Event of Default under this Agreement, Borrower irrevocably makes, constitutes and appoints Lender (and all officers, employees or agents designated by Lender in writing to Borrower) as Borrower’s true and lawful attorney-in-fact for the purpose, of making, settling and adjusting claims on behalf of Borrower under all such policies of insurance, endorsing the name of Borrower on any check, draft, instrument or other item of payment received by Borrower or Lender pursuant to any such policies of insurance, and for making all determinations and decisions of Borrower with respect to such policies of insurance.
UNLESS BORROWER PROVIDES LENDER WITH EVIDENCE OF THE INSURANCE COVERAGE REQUIRED BY THIS AGREEMENT WITHIN THREE BUSINESS DAYS FOLLOWING LENDER’S REQUEST, LENDER MAY PURCHASE INSURANCE AT BORROWER’S EXPENSE TO PROTECT LENDER’S INTERESTS IN THE COLLATERAL. THIS INSURANCE MAY, BUT NEED NOT, PROTECT THE INTERESTS IN THE COLLATERAL. THE COVERAGE PURCHASED BY LENDER MAY NOT PAY ANY CLAIMS THAT BORROWER MAKES OR ANY CLAIM THAT IS MADE AGAINST BORROWER IN CONNECTION WITH THE COLLATERAL. BORROWER MAY LATER CANCEL ANY SUCH INSURANCE PURCHASED BY LENDER, BUT ONLY AFTER PROVIDING LENDER WITH EVIDENCE THAT BORROWER HAS OBTAINED INSURANCE AS REQUIRED BY THIS AGREEMENT. IF LENDER PURCHASES INSURANCE FOR THE COLLATERAL, BORROWER WILL BE RESPONSIBLE FOR THE COSTS OF THAT INSURANCE, INCLUDING INTEREST AND ANY OTHER CHARGES THAT LENDER MAY IMPOSE IN CONNECTION WITH THE PLACEMENT OF THE INSURANCE, UNTIL THE EFFECTIVE DATE OF THE CANCELLATION OR EXPIRATION OF THE INSURANCE. THE COSTS OF THE INSURANCE MAY BE ADDED TO THE LIABILITIES SECURED HEREBY. THE COSTS OF THE INSURANCE MAY BE MORE THAN THE COST OF INSURANCE BORROWER MAY BE ABLE TO OBTAIN ON ITS OWN.
8.8    Environmental. Borrower shall promptly notify and furnish Lender with a copy of any and all Environmental Notices which are received by it. Borrower shall take prompt and appropriate action in response to any and all such Environmental Notices and shall promptly furnish Lender with a description of Borrower’s Response thereto. Borrower shall (a) obtain and maintain all permits required under all applicable federal, state, and local Environmental Laws, except as to which the failure to obtain or maintain would not have a Material Adverse Effect; and (b) keep and maintain the Real Property and each portion thereof in compliance with, and not cause or permit the Real Property or any portion thereof to be in violation of, any Environmental Law, except as to which the failure to comply with or the violation of which, would not have a Material Adverse Effect. During the term of this Agreement, Borrower shall not permit others to, Manage, whether on or off Borrower’s Property, Hazardous Substances, except to the extent such Management does not or is not reasonably likely to result in or create a Material Adverse Effect. Borrower shall take prompt action in material compliance with applicable Environmental Laws to Respond to the on-site or off-site Release of Hazardous Substances connected with operation of its business or the Real Property.
8.9    Banking Relationship. Borrower shall at all times maintain all of its primary deposit and operating accounts with Lender and Lender will act as the principal depository and remittance agent for Borrower. Borrower agrees to pay to Lender reasonable and customary fees for banking services/cash management services of Borrower (the “Service Fee”). Lender shall be and hereby is authorized to charge any deposit or operating account of Borrower in respect of the Service Fee.
8.10    Intellectual Property. If after the Closing Date Borrower shall own or otherwise possess any registered patents, copyrights, trademarks, trade names, or service marks, Borrower shall promptly notify Lender in writing of same and execute and deliver any documents or instruments (at Borrower’s sole cost and expense) reasonably required by Lender to perfect a security interest in and lien on any such federally registered Intellectual Property in favor of Lender and assist in the filing of such documents or instruments with the United States Patent and Trademark Office and/or United States Copyright Office or other applicable registrar.
8.11    Change of Location; Etc. Any of the Collateral may be moved to another location within the continental United States so long as: (i) Borrower provides Lender with at least thirty (30) days prior written notice, (ii) no Event of Default then exists, and (iii) Borrower provides Lender with, at Borrower’s sole cost and expense, such financing statements, landlord waivers, bailee and processor letters and other such agreements and documents as Lender shall reasonably request. Borrower shall defend and protect the Collateral against and from all claims and demands of all Persons at any time claiming any interest therein adverse to Lender. If Borrower desires to change its principal place of business and chief executive office or its name, Borrower shall notify Lender thereof in writing no later than thirty (30) days prior to such change and Borrower shall provide Lender with, at Borrower’s sole cost and expense, such financing statements, amendment statements and other documents as Lender shall reasonably request in connection with such change. If Borrower shall decide to change the location where its books and records are maintained, Borrower shall notify Lender thereof in writing no later than thirty (30) days prior to such change.
8.12    Health Care Related Matters. To the extent applicable, Borrower shall cause all licenses, permits, certificates of need, reimbursement contracts and programs, and any other agreements necessary for the use and operation of its business or as may be necessary for participation in Medicaid and other applicable reimbursement programs, to remain in full force and effect, except to the extent that the failure to do so would not cause a Material Adverse Effect.
8.13    US Patriot Act. Borrower covenants to Lender that if Borrower becomes aware that it or any of its Affiliates is identified on any Blocked Persons List (as identified in Section 7.29 hereof), Borrower shall immediately notify Lender in writing of such information. Borrower further agrees that in the event any of them or any Affiliate is at any time identified on any Blocked Persons List, such event shall be an Event of Default, and shall entitle Lender to exercise any and all remedies provided in any Financing Agreements or otherwise permitted by Law. In addition, Lender may immediately contact the Office of Foreign Assets Control and any other government agency Lender deem appropriate in order to comply with its obligations under any Law regulating or relating to terrorism and international money laundering.
8.14    Single Purpose Entity Provisions. (a) The business and purposes of Borrower is and will continue to be limited to the following: (i) to acquire, own, hold, lease, operate, manage, maintain, develop and/or improve the Real Property; (ii) to enter into and perform its obligations under this Agreement and the other Financing Agreements; (iii) to sell, transfer, service, convey, dispose of, pledge, assign, borrow money against, finance or otherwise deal with the Real Property to the extent permitted under this Agreement and the other Financing Agreements; and (iv) to engage in any lawful act or activity and to exercise any powers permitted to entities of its type pursuant to the laws of its state of organization that are related or incidental to and necessary, convenient or advisable for the accomplishment of the above mentioned purposes.
(b)    Borrower shall do all of the following: (i) maintain its intention to remain Solvent and pay its debts and liabilities (including, as applicable, shared personnel and overhead expenses) from its assets, to the extent of its assets, as the same shall become due; (ii) do or cause to be done all things necessary to observe organizational formalities of Borrower and preserve its existence; and (iii) to the extent of cash flow available from operations, intend to maintain adequate capital for the normal obligations reasonably foreseeable in a business of its size and character and in light of its contemplated business operations.
8.15    Further Assurances. Borrower shall, at its own cost and expense, cause to be promptly and duly taken, executed, acknowledged and delivered all such further acts, documents and assurances as may from time to time be necessary or as Lender may from time to time reasonably request in order to carry out the intent and purposes of this Agreement and the other Financing Agreements and the transactions contemplated hereby and thereby, including, without limitation, all such actions to establish, create, preserve, protect and perfect a first-priority Lien (subject only to the Permitted Liens) in favor of Lender on the Collateral (including Collateral acquired after the date hereof), including on any and all unencumbered assets of Borrower whether now owned or hereafter acquired.
8.16    Compliance with Anti-Terrorism Orders. Lender hereby notifies Borrower that pursuant to the requirements of the USA Patriot Act (Title III of Pub. L. 107-56, signed into law October 26, 2001) (the “Patriot Act”), and the policies and practices of Lender, Lender is required to obtain, verify and record certain information and documentation that identifies Borrower, which information includes the name and address of Borrower and such other information that will allow Lender to identify Borrower in accordance with the Patriot Act. In addition, Borrower shall (a) ensure that no Person who owns a controlling interest in or otherwise controls Borrower is or shall be listed on the OFAC Lists, (b) not use or permit the use of the proceeds of the Term Loan to violate any of the foreign asset control regulations of OFAC or any enabling statute or Executive Order relating thereto, and (c) comply with all applicable Bank Secrecy Act laws and regulations, as amended. Borrower shall not permit the transfer of any interest in Borrower to any Person (or any beneficial owner of such entity) who is listed on the OFAC Lists. Borrower shall not knowingly enter into a Lease with any party who is listed on the OFAC Lists. Borrower shall immediately notify Lender if Borrower has knowledge that Borrower or any manager, member or beneficial owner of Borrower is listed on the OFAC Lists or (i) is indicted on or (ii) arraigned and held over on charges involving money laundering or predicate crimes to money laundering. Borrower shall immediately notify Lender if Borrower knows that any Tenant is listed on the OFAC Lists or (A) is convicted on, (B) pleads nolo contendere to, (C) is indicted on or (D) is arraigned and held over on charges involving money laundering or predicate crimes to money laundering.
8.18    ERISA. Borrower shall maintain, or cause its ERISA Affiliates to maintain, each Plan in compliance in all material respects with all material applicable requirements of ERISA and the Tax Code.
8.17    FCPA. No part of the proceeds of the Term Loan will be used, directly or indirectly, in furtherance of an offer, payment, promise to pay, or authorization of the payment or giving of money, or anything else of value, to any Person in violation of the FCPA or any other applicable anti-corruption law. Borrower shall maintain in effect policies and procedures designed to promote compliance by Borrower, its Subsidiaries and their respective directors, managers, officers, employees, and agents with the FCPA and any other applicable anti-corruption laws.
9.    NEGATIVE COVENANTS.
Borrower covenants and agrees that as long as any Liabilities remain outstanding, and (even if there shall be no such Liabilities outstanding) as long as this Agreement remains in effect (unless Lender shall give prior written consent thereto):
9.1    Encumbrances. Borrower shall not create, incur, assume or suffer to exist any Lien of any nature whatsoever on any of its assets or property, including, without limitation, the Collateral, other than the following (“Permitted Liens”): (i) Liens securing the payment of taxes, either not yet due or the validity of which is being contested in good faith by appropriate proceedings, and as to which Borrower shall, if appropriate under GAAP, have set aside on its books and records adequate reserves, provided, that such contest does not have a material adverse effect on the ability of Borrower to pay any of the Liabilities, or the priority or value of Lender’s Lien in the Collateral; (ii) deposits under workmen’s compensation, unemployment insurance, social security and other similar laws made in ordinary course of business; (iii) Liens in favor of Lender; (iv) liens imposed by law, such as mechanics’, materialmen’s, landlord’s, warehousemen’s, carriers’ and other similar liens, securing obligations incurred in the ordinary course of business that are not past due for more than thirty (30) calendar days, or that are being diligently contested in good faith by appropriate proceedings and for which appropriate reserves have been established, or that are not yet due and payable; (v) purchase money security interests upon or in any property acquired or held by Borrower in the ordinary course of business to secure the purchase price of such property so long as: (a) the aggregate indebtedness relating to such purchase money security interests and Capitalized Lease Obligations does not at any time exceed One Million and No/100 Dollars ($1,000,000.00) in the aggregate at any time, (b) each such lien shall only attach to the property to be acquired; and (c) the indebtedness incurred shall not exceed one hundred percent (100%) of the purchase price of the item or items purchased; (v) pledges and deposits made in the ordinary course of business in compliance with workmen’s compensation laws, unemployment insurance and other social security laws or regulations, or deposits to secure performance of tenders, statutory obligations, trade contracts (other than for Indebtedness), leases (other than Capital Lease Obligations), surety and appeal bonds, performance bonds and other obligations of a like nature incurred in the ordinary course of Borrower’s business as presently conducted; (vi) any Lien securing a judgment; provided, that any Lien securing a judgment in excess of Five Hundred Thousand and No/100 Dollars ($500,000.00) that remains unsatisfied or undischarged for more than thirty (30) days shall not be a Permitted Lien, unless such judgment is either (x) fully insured and such insurer has admitted liability or (y) is being contested or appealed by appropriate proceedings and the enforcement of such judgment is stayed during the course of such contest or appeal, provided that Borrower has established reserves adequate for payment of such judgment and in the event such contest or appeal is ultimately unsuccessful pays such judgment within ten (10) days of the final, non-appealable ruling rendered in such contest or appeal; and (vii) financing statements with respect to a lessor’s rights in and to personal property leased to Borrower in the ordinary course of business other than through a Capitalized Lease Obligations.
9.2    Indebtedness; Capital Expenditures. Borrower shall not incur, create, assume, become or be liable in any manner with respect to, or permit to exist, any Indebtedness, except (i) the Liabilities, (ii) trade obligations and normal accruals in the ordinary course of business not yet due and payable, (iii) the indebtedness not to at any time exceed One Million and No/100 Dollars ($1,000,000.00) relating to the purchase money security interests and Capitalized Lease Obligations permitted pursuant to Section 9.1 hereof, and (iv) intercompany Indebtedness of Borrower to the extent permitted under Section 9.4.
9.3    Consolidations, Mergers or Transactions; Subsidiary. Borrower shall not be a party to any merger, consolidation, recapitalization or other exchange of Stock, or purchase or otherwise acquire all or substantially all of the assets or Stock of any class of, or any other evidence of an equity interest in, or any partnership, limited liability company, or joint venture interest in, any other Person (whether in one transaction or a series of related transactions); provided, that, with prior written notice to Lender, Borrower may merge or consolidate with, or dissolve into, another Borrower so long as the surviving entity remains Borrower for all purposes under this Agreement and the other Financing Agreements. Borrower shall not form or establish any Subsidiary without Lender’s prior written consent. With prior notice to Lender, Borrower may dissolve an inactive Subsidiary that does not conduct any business operations and has assets with a book value not in excess of Ten Thousand and No/100 Dollars ($10,000.00) (“Inactive Subsidiary”).
9.4    Investments or Loans. Borrower shall not make, incur, assume or permit to exist any loans or advances, or any investments in or to any other Person, except (i) investments in short-term direct obligations of the United States Government, agency or instrumentality thereof; or any (ii) investments in negotiable certificates of deposit issued by Lender or by any other bank reasonably satisfactory to Lender, payable to the order of Borrower or to bearer, (iii) investments in commercial paper rated at least A-1 by Standard & Poor’s Corporation or P-1 by Moody’s Investors Service, Inc., or carrying an equivalent rating by a nationally recognized rating agency if both of the two named rating agencies cease publishing ratings of investments, (iv) investments in money market funds which invest substantially all their assets in securities of the types described in clauses (i) through (iii), above; provided that, in each case, such investment is reasonably acceptable to Lender, (iv) other short-term investments as may be permitted by Lender, (vi) loans and advances to employees permitted under Section 9.8; and (vii) investments by Borrower in its Subsidiaries existing on the date hereof.
9.5    Guarantees. Borrower shall not guarantee, endorse or otherwise in any way become or be responsible for obligations of any other Person, whether by agreement to purchase the Indebtedness of any other Person or through the purchase of goods, supplies or services, or maintenance of working capital or other balance sheet covenants or conditions, or by way of stock purchase, capital contribution, advance or loan for the purpose of paying or discharging any Indebtedness or obligation of such other Person or otherwise, except (i) endorsements of negotiable instruments for collection in the ordinary course of business, and (ii) the Indebtedness permitted under Section 9.2, above.
9.6    Disposal of Property. Borrower shall not sell, assign, lease, convey, lease, transfer or otherwise dispose of (whether in one transaction or a series of transactions) all or any substantial part of its properties, assets and rights (or sell or assign, with or without recourse, any receivables) to any Person except (a) sales of Inventory in the ordinary course of business, (b) sales of Equipment being replaced in the ordinary course of business with other Equipment with a fair market value and orderly liquidation value equal to or greater than the Equipment being replaced, and (c) sales in the ordinary course of business of personal property that is obsolete, unmerchantable or otherwise unsalable, unusable or unnecessary to Borrower’s business.
9.7    Use of Proceeds. Borrower shall use the proceeds of the Term Loan only for the following purposes: (a) to consummate the Acquisition; and (b) to pay reasonable and actually incurred transaction costs and expenses in connection with this Agreement, the Acquisition Agreement and the transactions contemplated hereby and thereby.
9.8    Loans to Officers; Consulting and Management Fees. Borrower shall not make any loans to its officers, directors, equity holders, manager, member, or employees or to any other Person, and Borrower shall not pay any consulting, management fees or similar fees to its officers, directors, equity holders, member, manager, employees, or Affiliates or any other Person, whether for services rendered to Borrower or otherwise; provided, however, Borrower shall be permitted to (i) make advances to its employees in an aggregate amount not to exceed One Hundred Thousand and No/100 Dollars ($100,000.00) in any Fiscal Year of Borrower for all such employees collectively, in each case, provided that both immediately before such contemplated payment(s) or after giving effect to any such payment(s) no Default or Event of Default shall exist or have occurred or result therefrom; (ii) pay reasonable outside directors fees; and (iii) pay the management fees permitted by the Management Agreement (with an absolute cap on the payment of any and all management fees notwithstanding anything to the contrary contained in the Management Agreement of five percent (5.0%) of the total revenues of Operator during any Fiscal Year). Lender acknowledges that travel advances issued in the ordinary course of business do not constitute loans for purposes of this Section 9.8.
9.9    Dividends, Distributions and Stock Redemptions. Borrower shall not (a) declare, make or pay any dividend or other distribution (whether in cash, property or rights or obligations) to or for the benefit of any officer, member, equity holder, director, or any Affiliate or any other Person other than (i) to Diversicare Healthcare Services, Inc. (“Parent”, provided that both immediately before such contemplated payment(s) or after giving effect to such Payment(s) Borrower is in compliance with Section 9.12(a) hereof, (ii) distributions under Borrower Cash Management Program, including distributions for Parent’s normal quarterly dividends to common shareholders, and (iii) payment of the management fees under the Management Agreement (subject to subsection (iii) of Section 9.8 above), or (b) purchase or redeem any of the Stock of Borrower or any options or warrants with respect thereto, declare or pay any dividends or distributions thereon, or set aside any funds for any such purpose. Notwithstanding the foregoing or anything to the contrary contained herein, the foregoing declarations, payments, distributions, purchases or redemptions set forth in this Section 9.9 shall, in each case, be in both manner and amount consistent with Borrower’s historical practices.
9.10    Payments in Respect of Subordinated Debt. Borrower shall not make any payment in respect of any Indebtedness for borrowed money that is subordinated to the Liabilities (including, without limitation, the Subordinated Debt); provided, however, Borrower shall be permitted to make solely those payments expressly permitted pursuant to the terms of any Subordination Agreements, in each case, as long as Borrower is in compliance with Section 9.12 hereof both immediately before and after any such contemplated or actual payment, provided, further, that both immediately before any such contemplated payment or after giving effect to any such payments no Default or Event of Default shall exist or have occurred or result therefrom, unless otherwise permitted expressly under the terms of such Subordination Agreements.
9.11    Transactions with Affiliates. Except as expressly permitted under this Agreement, and except for the Management Agreement and payment of the fee permitted by the terms of the Management Agreement (subject to subsection (iii) of Section 9.8 above), and Borrower Cash Management Program, Borrower shall not transfer any cash or property to any Affiliate or enter into any transaction, including, without limitation, the purchase, lease (other than the Lease Agreement), sale or exchange of property or the rendering of any service to any Affiliate; provided, however, except as otherwise expressly restricted under this Agreement, that Borrower may transfer cash or property to Affiliates and enter into transactions with Affiliates for fair value in the ordinary course of business pursuant to terms that are no less favorable to Borrower than the terms upon which such transfers or transactions would have been made had such transfers or transactions been made to or with a Person that is not an Affiliate.
9.12    Financial Ratios. Commencing with the Fiscal Quarter ending June 30, 2015, and continuing thereafter:
(a)    Minimum Operator EBITDAR. Borrower shall not permit the Operator EBITDAR to be less than (a) as of June 30, 2015, One Hundred Seventy-Five Thousand and No/100 Dollars ($175,000.00), (b) as of September 30, 2015, Three Hundred Fifty Thousand and No/100 Dollars ($350,000.00), (c) as of December 31, 2015, Five Hundred Twenty-Five Thousand and No/100 Dollars ($525,000.00), and (d) as of March 31, 2016, and as of the last day of each Fiscal Quarter thereafter, Seven Hundred Thousand and No/100 Dollars ($700,000.00), measured as of the last day of the trailing twelve (12) month period. Such ratio shall be tested on or before the forty-fifth (45th) day after the last day of each Fiscal Quarter, using the information contained in the Compliance Certificate most recently delivered to Lender pursuant to the requirements of Section 8.1(b) hereof.
(b)    Minimum Fixed Charge Coverage Ratio.
(1)    Borrower shall not permit the Borrower Fixed Charge Coverage Ratio for each Fiscal Quarter during the term of the Term Loan to be less than 1.00 to 1.00, measured as of the last day of the trailing twelve (12) month period. Such ratio shall be tested on or before the forty-fifth (45th) day after the last day of each Fiscal Quarter, using the information contained in the Compliance Certificate most recently delivered to Lender pursuant to the requirements of Section 8.1(b) hereof.
(2)    Borrower shall not permit the Parent Fixed Charge Coverage Ratio for each Fiscal Quarter during the term of the Term Loan to be less than 1.00 to 1.00, measured as of the last day of the trailing twelve (12) month period. Such ratio shall be tested on or before the forty-fifth (45th) day after the last day of each of the first, second and third Fiscal Quarters, and on or before the seventy-fifth (75th) day after the last day of the fourth Fiscal Quarter, using the information contained in the Compliance Certificate most recently delivered to Lender pursuant to the requirements of Section 8.1(b) hereof.
(c)    Minimum Parent EBITDA. Borrower shall not permit the Parent EBITDA to be less than Ten Million and No/100 Dollars ($10,000,000.00) during the term of the Term Loan, measured as of the last day of the trailing twelve (12) month period. Such ratio shall be tested on or before the forty-fifth (45th) day after the last day of each of the first, second and third Fiscal Quarters, and on or before the seventy-fifth (75th) day after the last day of the fourth Fiscal Quarter, using the information contained in the Compliance Certificate most recently delivered to Lender pursuant to the requirements of Section 8.1(b) hereof.
(d)    Minimum Liquidity of Parent. Parent shall maintain a liquidity, in the form of unencumbered: (i) unrestricted cash deposits, and (ii) US Government & listed securities, in an amount not less than Four Million and No/100 Dollars ($4,000,000.00), tested on a quarterly basis commencing June 30, 2015, and each September 30, December 31, March 31 and June 30 thereafter during the term of the Term Loan.
9.13    Change in Nature of Business. Borrower shall not engage, directly or indirectly, in any business other than owning and operating the Facility and matters incidental or directly related thereto.
9.14    Other Agreements. Borrower shall not enter into any agreement containing any provision which would be violated or breached by the performance of its obligations hereunder or under any Financing Agreement to which Borrower is a party or which would violate or breach any provision hereof or thereof, or that would or is reasonably likely to adversely affect Lender’s interests or rights under this Agreement and the other Financing Agreements to which Borrower is a party or the likelihood that the Liabilities will be paid in full when due, nor shall Borrower’s certificate of formation, bylaws, articles of incorporation, operating agreement, partnership agreement or other governing document (each a “Governing Document”), as applicable, be amended or modified in any way that would violate or breach any provision hereof or of any Financing Agreement to which Borrower is a party, or that would or is reasonably likely to adversely affect Lender’s interests or rights under this Agreement and the other Financing Agreements to which Borrower is a party or the likelihood that the Liabilities will be paid in full when due; provided, prior to any amendment or modification of any of Borrower’s Governing Documents, Borrower shall furnish a correct and complete copy of any such proposed amendment or modification to Lender.
9.15    Blocked Accounts and Lock Box Accounts. Borrower shall not establish or open any blocked account or any lock box accounts after the Closing Date unless in favor of and with Lender.
9.16    Amendments to Restricted Agreements. Borrower shall not amend, modify or supplement any Restricted Agreement in any manner that would or is reasonably likely to adversely affect Lender’s interests under this Agreement and the other Financing Agreements to which Borrower is a party, without Lender’s prior written consent. Within three (3) Business Days after entering into any non-adverse amendment, modification or supplement to any Restricted Agreement, Borrower shall deliver to Lender a complete and correct copy of such amendment, modification or supplement.
9.17    State of Incorporation or Formation. Borrower shall not change its state of incorporation or formation, as applicable.
9.18    Environmental. Borrower shall not permit the Real Property or any portion thereof to be involved in the use, generation, manufacture, storage, disposal or transportation of Hazardous Substances except in compliance in all material respects with all Environmental Laws.
9.19    Fiscal Year. Borrower shall not change its Fiscal Year.
9.20    Restrictions on Fundamental Changes. Without duplication of any of the foregoing, Borrower shall not:
(a)    except as expressly permitted in accordance with Section 9.3 hereof, liquidate, wind-up or dissolve itself (or suffer any liquidation or dissolution);
(b)    transfer, assign, convey or grant to any other Person, other than another Borrower, the right to operate or control the Facility, whether by lease, sublease, management agreement, joint venture agreement or otherwise;
(c)    without providing Lender with thirty (30) days’ prior written notice, change its legal name (and Borrower shall provide Lender with, at Borrower’s sole cost and expense, such amendment and financing statements and other documents as Lender shall reasonably request in connection with such contemplated change);
(d)    except as expressly permitted in accordance with Section 9.3 hereof, suffer or permit to occur any change in the legal or beneficial ownership of the capital stock, partnership interests or membership interests, or in the capital structure, or any material change in the organizational documents or governing documents, of Borrower;
(e)    change the licensed operator, manager or property manager for the Real Property; or
(f)    consent to or acknowledge any of the foregoing.
9.21    Margin Stock. Borrower shall not carry or purchase any “margin security” within the meaning of Regulations U, T or X of the Board of Governors of the Federal Reserve System.
9.22    Truth of Statements and Certificates. Borrower shall not furnish to Lender any certificate or other document that contains any untrue statement of a material fact or that omits to state a material fact necessary to make it not misleading in light of the circumstances under which it was furnished.
9.23    Leases. Except for resident agreements entered into in the normal course of business, Borrower shall not enter into any Leases at the Facility without the prior written consent of Lender, which consent will not be unreasonably withheld. Lender acknowledges approval of Borrower entering into the Lease Agreement.
9.24    ERISA. Borrower shall not, and shall not cause or permit any ERISA Affiliate to, cause or permit to occur an unfunded pension fund obligation and liability to the extent such unfunded pension fund obligation and liability would reasonably be expected to result in taxes, penalties and other liability in excess of Two Hundred Fifty Thousand and No/100 Dollars ($250,000.00) in the aggregate.
9.25    Miscellaneous. Borrower shall not (a) voluntarily cancel any claim or debt owing to it, except for reasonable consideration or in the ordinary course of business, the effect of which would be a Material Adverse Change, (b) enter into any agreement containing any provision that would (i) be violated or breached by any borrowing by Borrower hereunder or the performance by Borrower of any of its Liabilities hereunder or under any other Financing Agreement to which it is a party, or (ii) prohibit Borrower from granting to Lender a Lien on any of Borrower’s assets as contemplated hereunder, except for (w) any restrictions imposed by any Permitted Lien pursuant to Section 9.1; (x) any restrictions imposed by any agreement relating to any Indebtedness permitted by Section 9.2; (y) customary provisions contained in leases and licenses entered into in the ordinary course of Borrower’s business restricting the assignment thereof; and (z) any restrictions imposed by applicable Laws. Without the prior written consent of Lender, the management fees payable by Operator to Manager pursuant to the Management Agreement shall not include any amount of profit (but shall entirely be used to cover and pay for actually incurred, ordinary course costs).
Borrower agrees that compliance with this Article 9 is a material inducement to Lender’s advancing credit under this Agreement. Borrower further agrees that in addition to all other remedies available to Lender, Lender shall be entitled to specific enforcement of the covenants in this Article 9, including injunctive relief.
10.    HEALTH CARE MATTERS.
Without limiting the generality of any representation or warranty made in Article 7 or any covenant made in Articles 8 or 9, Borrower represents and warrants to and covenants with Lender, that:
10.1    Certificate of Need. If required under applicable Law, Borrower has, or Borrower shall cause Operator to have, and shall maintain in full force and effect a valid certificate of need (“CON”) or similar certificates, license, permit, registration, certification or approval issued by the State/Commonwealth Regulator for the requisite number of beds in the Facility (the “Licenses”). Borrower shall cause to be operated the Facility in a manner such that the Licenses shall remain in full force and effect at all times. True and complete copies of the Licenses have been delivered to Lender.
10.2    Licenses. The Licenses: (i) are and shall continue in full force and effect at all times throughout the term of this Agreement and are and shall be free from restrictions or known conflicts which would materially impair the use or operation of the Real Property for its current use, and if any Licenses become provisional, probationary, conditional or restricted in any way (collectively “Restrictions”), Borrower shall take or cause to be taken prompt action to correct such Restrictions; (ii) may not be, and have not been, and will not be transferred to any location other than the Real Property; and (iii) have not been and will not be pledged as collateral security for any other loan or indebtedness. Borrower shall not do (or suffer to be done by Operator or any other party) any of the following:
(d)    Rescind, withdraw, revoke, amend, modify, supplement, or otherwise alter the nature, tenor or scope of the Licenses for the Facility without Lender’s prior written consent;
(e)    Amend or otherwise change the Facility’s licensed beds capacity and/or the number of beds approved by the State/Commonwealth Regulator without Lender’s prior written consent; or
(f)    Replace, assign or transfer all or any part of the Facility’s beds to another site or location without Lender’s prior written consent.
11.    DEFAULT, RIGHTS AND REMEDIES OF LENDER.
11.1    Event of Default. Any one or more of the following shall constitute an “Event of Default” under this Agreement:
(g)    Borrower fails to pay (i) any principal or interest payable hereunder or under the Term Note on the date due, declared due or demanded (including, without limitation, any amount due under Section 2.14); or (ii) any other amount payable to Lender under this Agreement or under any other Financing Agreement to which Borrower is a party (including, without limitation, the Term Note) within five (5) calendar days after the date when any such payment is due and, with respect to clause (ii) only, such failure is not cured within five (5) calendar days after notice to Borrower by Lender;
(h)    Borrower fails or neglects to perform, keep or observe any of the covenants, conditions or agreements set forth in (i) Sections 8.1(a), 8.1(b), 8.1(c), 8.2, 8.5, 8.6, 8.7, 8.9, 8.11, or 8.12, hereof, (ii) any Section of Article 9 hereof (other than Section 9.18 hereof), or (iii) any Section of Article 10 hereof and, with respect to such Sections in Article 10 only, such failure or neglect shall continue for a period of five (5) calendar days after the earlier of (1) the date Borrower actually knew of such failure or neglect and (2) notice to Borrower by Lender.
(i)    Borrower fails or neglects to perform, keep or observe any of the covenants, conditions, promises or agreements contained in this Agreement (which is not otherwise specifically referenced in this Section 11.1) and such failure or neglect shall continue for a period of thirty (30) calendar days after the earlier of (i) the date Borrower actually knew of such failure or neglect and (ii) notice to Borrower by Lender;
(j)    any representation or warranty heretofore, now or hereafter made by Borrower in connection with this Agreement or any of the other Financing Agreements to which Borrower is a party is untrue, misleading or incorrect in any material respect, or any schedule, certificate, statement, report, financial data, notice, or writing furnished at any time by Borrower to Lender is untrue, misleading or incorrect in any material respect, on the date as of which the facts set forth therein are stated or certified;
(k)    a judgment, decree or order requiring payment in excess of Five Hundred Thousand and No/100 Dollars ($500,000.00) shall be rendered against Borrower and such judgment or order shall remain unsatisfied or undischarged and in effect for thirty (30) consecutive days without a stay of enforcement or execution, provided that this clause (e) shall not apply to any judgment, decree or order for which Borrower is fully insured and with respect to which the insurer has admitted liability, or such judgment, decree or order is being contested or appealed by appropriate proceedings;
(l)    a notice of Lien, levy or assessment is filed or recorded with respect to any of the assets of Borrower (including, without limitation, the Collateral), by the United States, or any department, agency or instrumentality thereof, or by any state, county, municipality or other governmental agency or any taxes or debts owing at any time or times hereafter to any one or more of them become a Lien, upon any of the assets of Borrower (including, without limitation, the Collateral), provided that this clause (f) shall not apply to any Liens, levies, or assessments which Borrower is diligently contesting in good faith (provided Borrower has complied with the provisions of clauses (a) and (b) of Section 8.4 hereof) or which relate to current taxes not yet due and payable;
(m)    any material portion of the Collateral is attached, seized, subjected to a writ or distress warrant, or is levied upon, or comes within the possession of any receiver, trustee, custodian or assignee for the benefit of creditors;
(n)    a proceeding under any bankruptcy, reorganization, arrangement of debt, insolvency, readjustment of debt or receivership law or statute is filed against Borrower or any guarantor of the Liabilities, and any such proceeding is not dismissed within sixty (60) days of the date of its filing, or a proceeding under any bankruptcy, reorganization, arrangement of debt, insolvency, readjustment of debt or receivership law or statute is filed by Borrower or any guarantor of the Liabilities, or Borrower or any guarantor of the Liabilities makes an assignment for the benefit of creditors, or Borrower or any guarantor of the Liabilities takes any action to authorize any of the foregoing;
(o)    except as permitted for an Inactive Subsidiary or Borrower voluntarily or involuntarily dissolves or is dissolved, or its existence terminates or is terminated; provided that in the case of an administrative dissolution or revocation of existence for failure to file the proper reports or returns with the applicable governmental authorities, no Event of Default shall be deemed to have occurred if an application for reinstatement is (i) filed promptly (but in any event, within fifteen (15) calendar days) upon Borrower receiving notice of such dissolution or revocation from the applicable Governmental Authority and (ii) diligently pursued to completion (if reasonably capable of being completed), as determined by Lender in its sole and absolute discretion;
(p)    the Credit Parties, taken as a whole, fail, at any time, to be Solvent;
(q)    Borrower or any guarantor of the Liabilities is enjoined, restrained, or in any way prevented by the order of any court or any administrative or regulatory agency from conducting all or any material part of its business affairs;
(r)    a breach by Borrower shall occur under any agreement, document or instrument (other than an agreement, document or instrument evidencing the lending of money), whether heretofore, now or hereafter existing between Borrower and any other Person and the effect of such breach if not cured within any applicable cure period will or is likely to have or create a Material Adverse Effect;
(s)    Borrower shall fail to make any payment due on any other obligation for borrowed money or shall be in breach of any agreement evidencing the lending of money and the effect of such failure or breach if not cured within any applicable cure period would be to permit the acceleration of any obligation, liability or indebtedness in excess of Five Hundred Thousand and No/100 Dollars ($500,000.00);
(t)    there shall be instituted in any court criminal proceedings against Borrower, or Borrower shall be indicted for any crime, in either case for which forfeiture of a material amount of its property is a potential penalty, unless (i) such actions are being contested or appealed in good faith by appropriate proceedings, (ii) the potential forfeiture has been stayed during the pendency of such proceedings, and (iii) no Medicare or Medicaid reimbursement obligations are materially adversely affected by such proceedings;
(u)    (Intentionally Omitted);
(v)    any Lien securing the Liabilities shall, in whole or in part, cease to be a perfected first priority Lien (subject only to the Permitted Liens); this Agreement or any of the Financing Agreements to which Borrower is a party, shall (except in accordance with its terms), in whole or in part, terminate, cease to be effective or cease to be the legally valid, binding and enforceable obligations of Borrower; or Borrower shall directly or indirectly, contest in any manner such effectiveness, validity, binding nature or enforceability;
(w)    any breach, non-compliance, default or event of default shall occur under or pursuant to any Subordination Agreement, or any other Financing Agreement (including, without limitation, any Hedging Agreement, or the Mortgage by any party thereto (other than by Lender), and the same is not cured or remedied within any applicable cure period, provided that if such default or event of default, breach, noncompliance or default, requires the giving of notice by Lender to any party in addition to or other than Borrower, Lender shall have provided Borrower with such notice at the same time as it provides such notice to such other party;
(x)    any material adverse breach by Borrower that would materially adversely affect Lender or its rights or remedies hereunder shall occur under or pursuant to the Acquisition Documents, after expiration of any applicable notice or cure period provided therein, if any;
(y)    institution by the PBGC, Borrower or any ERISA Affiliate of steps to terminate any Plan or to organize, withdraw from or terminate a Multiemployer Plan if as a result of such reorganization, withdrawal or termination, Borrower or any ERISA Affiliate could be required to make a contribution to such Plan or Multiemployer Plan, or could incur a liability or obligation to such Plan or Multiemployer Plan, in excess of Two Hundred Fifty Thousand and No/100 Dollars ($250,000.00), or (ii) a contribution failure occurs with respect to any Plan sufficient to give rise to a Lien under ERISA, which Lien is not fully discharged within fifteen (15) days;
(z)    a Material Adverse Change shall occur;
(aa)    Borrower or any Affiliate of Borrower, shall challenge or contest, in any action, suit or proceeding, the validity or enforceability of this Agreement, or any of the other Financing Agreements, the legality or the enforceability of any of the Liabilities or the perfection or priority of any Lien granted to Lender;
(bb)    Borrower shall be prohibited or otherwise restrained from conducting the business theretofore conducted by it in any manner that has or could reasonably be expected to have or result in a Material Adverse Effect;
(cc)    there shall occur any Medicare or Medicaid survey deficiencies at Level I, J, K, L or worse (i) which deficiencies are not cured within the amount of time permitted by the applicable reviewing agency; (ii) which result in the imposition by any Government Authority or the applicable state survey agency of sanctions in the form of either a program termination, temporary management, denial of payment for new admission (which continues for thirty (30) days or more) or facility closure and (iii) which sanctions could have a Material Adverse Effect as determined by Lender in its reasonable discretion. Upon the occurrence of such event, Borrower shall submit to Lender its plan of correction for dealing with such event, and shall periodically review its progress under the plan of correction with Lender. Provided that Lender remains satisfied with the progress under the plan of correction, then such Event shall not be an Event of Default unless formal notice is given by Lender to Borrower;
(dd)    a state or federal regulatory agency shall have revoked any license, permit, certificate or Medicaid or Medicare qualification pertaining to the Real Property, regardless of whether such license, permit, certificate or qualification was held by or originally issued for the benefit of Borrower, a tenant or any other Person, the revocation of which could reasonably be expected to have a Material Adverse Effect;
(ee)    any material default by Borrower under the terms of any material Lease following the expiration of any applicable notice and cure period (if any);
(ff)    Kelly J. Gill or James R. McKnight, Jr. shall not be senior officers of Borrower and devote significant time and energy to the business of Borrower; provided, however, it shall not constitute an Event of Default if any such individual shall fail for any reason to be a senior officer of Borrower or fail to devote significant time and energy to the business of Borrower, and such individual shall be promptly replaced by Borrower, whether on an interim or permanent basis, with an individual with substantially similar skills and experience (but in no event later than within 90 calendar days of the former individual’s resignation, termination, permanent disability or death) and otherwise acceptable to Lender in its reasonable and good faith determination;
(gg)    any subordination provision in any document or instrument governing Subordinated Debt, or any subordination provision in any guaranty by any Subsidiary of any Subordinated Debt, shall cease to be in full force and effect, or any Credit Party or any other Person (including the holder of any applicable Subordinated Debt) shall contest in any manner the validity, binding nature or enforceability of any such provision;
Notwithstanding the foregoing, in the situations described in clauses (l), (t), (x) and (z), above, where an Event of Default is triggered by the occurrence of a Material Adverse Change or a Material Adverse Effect, events which could reasonably be expected to have or result in a Material Adverse Effect or Material Adverse Change, such occurrence shall not be deemed to be an Event of Default hereunder provided that Borrower shall within forty-eight (48) hours after the occurrence thereof submit to Lender in writing a plan of correction for dealing with such Material Adverse Change or Material Adverse Effect that is acceptable to Lender in its sole and absolute discretion, and, if such plan of correction is so acceptable, for so long as Lender remains satisfied in all respects with the progress under such plan of correction and until written notice that Lender is not so satisfied is given by Lender to Borrower.
11.2    Acceleration. Upon the occurrence of any Event of Default described in Sections 11.1(h), (i), or (j), the Term Loan Commitment (if it has not theretofore terminated) shall automatically and immediately terminate and all of the Liabilities shall immediately and automatically, without presentment, demand, protest or notice of any kind (all of which are hereby expressly waived), be immediately due and payable; and upon the occurrence of any other Event of Default, Lender may declare the Term Loan Commitment (if it has not theretofore terminated) to be terminated and any or all of the Liabilities may, at the option of Lender, and without presentment, demand, protest or notice of any kind (all of which are hereby expressly waived), be declared, and thereupon shall become, immediately due and payable, whereupon the Term Loan Commitment shall immediately terminate.
11.3    Rights and Remedies Generally.
(a)    Upon the occurrence of any Event of Default, Lender shall have, in addition to any other rights and remedies contained in this Agreement and in any of the other Financing Agreements, all of the rights and remedies of a secured party under the Code or other applicable laws, all of which rights and remedies shall be cumulative, and non-exclusive, to the extent permitted by Laws, including, without limitation, the right of Lender to sell, assign, or lease any or all of the Collateral. The exercise of any one right or remedy shall not be deemed a waiver or release of any other right or remedy, and Lender, upon the occurrence of an Event of Default, may proceed against Borrower, and/or the Collateral, at any time, under any agreement, with any available remedy and in any order. All sums received from Borrower and/or the Collateral in respect of the Term Loan may be applied by Lender to any Liabilities in such order of application and in such amounts as Lender shall deem appropriate in its discretion (subject to Section 12.8). Borrower waives any right it may have to require Lender to pursue any Person for any of the Liabilities.
(b)    Upon notice to Borrower after an Event of Default, Borrower at its own expense shall assemble all or any part of the Collateral as determined by Lender and make it available to Lender at any location designated by Lender. In such event, Borrower shall, at its sole cost and expense, store and keep any Collateral so assembled at such location pending further action by Lender and provide such security guards and maintenance services as shall be necessary to protect and preserve such Collateral. In addition to all such rights and remedies, the sale, lease or other disposition of the Collateral, or any part thereof, by Lender after an Event of Default may be for cash, credit or any combination thereof, and Lender may purchase all or any part of the Collateral at public or, if permitted by law, private sale, and in lieu of actual payment of such purchase price, may set-off the amount of such purchase price against the Liabilities of Borrower then owing. Any sales of such Collateral may be adjourned from time to time with or without notice. Lender may, in its sole discretion, cause the Collateral to remain on Borrower’s premises, at Borrower’s expense, pending sale or other disposition of such Collateral. Lender shall have the right after an Event of Default to conduct such sales on Borrower’s premises, at Borrower’s expense, or elsewhere, on such occasion or occasions as Lender may see fit.
11.4    Entry Upon Premises and Access to Information. Upon the occurrence of any Event of Default, Lender shall have the right to enter upon the premises of Borrower where the Collateral is located without any obligation to pay rent to Borrower, or any other place or places where such Collateral is believed to be located and kept, and remove such Collateral therefrom to the premises of Lender or any agent of Lender, for such time as Lender may desire, in order to effectively collect or liquidate such Collateral. Upon the occurrence of any Event of Default, Lender shall have the right to obtain access to Borrower’s data processing equipment, computer hardware and software relating to the Collateral and subject to the privacy requirements and regulations of HIPAA and of any applicable state or federal patients bill of rights, to use all of the foregoing and the information contained therein in any manner Lender deems appropriate. Upon the occurrence of any Event of Default, Lender shall have the right to receive, open and process all mail addressed to Borrower and relating to the Collateral.
11.5    Sale or Other Disposition of Collateral by Lender. Any notice required to be given by Lender of a sale, lease or other disposition or other intended action by Lender, with respect to any of the Collateral, which is deposited in the United States mails, postage prepaid and duly addressed to Borrower at the address specified in Section 12.12 hereof, at least ten (10) calendar days prior to such proposed action shall constitute fair and reasonable notice to Borrower of any such action. The net proceeds realized by Lender upon any such sale or other disposition, after deduction for the expense of retaking, holding, preparing for sale, selling or the like and the attorneys’ and paralegals’ fees and legal expenses incurred by Lender in connection therewith, shall be applied as provided herein toward satisfaction of the Liabilities, including, without limitation, such Liabilities described in Sections 8.2 and 11.2 hereof. Lender shall account to Borrower for any surplus realized upon such sale or other disposition, and Borrower shall remain liable for any deficiency. The commencement of any action, legal or equitable, or the rendering of any judgment or decree for any deficiency shall not affect Lender’s Liens in the Collateral until Payment in Full. Borrower agrees that Lender has no obligation to preserve rights to the Collateral against any other Person. If and to the extent applicable, Lender is hereby granted a license or other right to use, without charge, Borrower’s labels, patents, copyrights, rights of use of any name, trade secrets, trade names, trade styles, trademarks, service marks and advertising matter or any property of a similar nature, as it pertains to the Collateral, in completing production of, advertising for sale and selling any such Collateral, and Borrower’s rights and benefits under all licenses and franchise agreements, if any, shall inure to Lender’s benefit until Payment in Full. Borrower covenants and agrees not to interfere with or impose any obstacle to Lender’s exercise of its rights and remedies with respect to the Collateral.
11.6    Waivers (General).
(a)    Except as otherwise provided for in this Agreement and to the fullest extent permitted by applicable Law, Borrower hereby waives: (i) presentment, demand and protest, and notice of presentment, dishonor, intent to accelerate, acceleration, protest, default, nonpayment, maturity, release, compromise, settlement, extension or renewal of any or all Financing Agreements, the Term Note or any other notes, commercial paper, Accounts, contracts, documents, instruments, chattel paper and guaranties at any time held by Lender on which Borrower may in any way be liable, and hereby ratifies and confirms whatever Lender may do in this regard; (ii) all rights to notice and a hearing prior to Lender’s taking possession or control of, or to Lender’s replevy, attachment or levy upon, any Collateral or any bond or security which might be required by any court prior to allowing Lender to exercise any of its remedies; and (iii) the benefit of all valuation, appraisal and exemption Laws. Borrower acknowledges that it has been advised by counsel of its choice and decision with respect to this Agreement, the other Financing Agreements and the transactions evidenced hereby and thereby.
(b)    Borrower for itself and all endorsers, guarantors and sureties and their heirs, legal representatives, successors and assigns, (i) agrees that its liability shall not be in any manner affected by any indulgence, extension of time, renewal, waiver, or modification granted or consented to by Lender; (ii) consents to any indulgences and all extensions of time, renewals, waivers, or modifications that may be granted by Lender with respect to the payment or other provisions of this Agreement, the Term Note, and to any substitution, exchange or release of the Collateral, or any part thereof, with or without substitution, and agrees to the addition or release of Borrower, endorsers, guarantors, or sureties, or whether primarily or secondarily liable, without notice to Borrower and without affecting its liability hereunder; (iii) agrees that its liability shall be unconditional and without regard to the liability of any other tax; and (iv) expressly waives the benefit of any statute or rule of law or equity now provided, or which may hereafter be provided, which would produce a result contrary to or in conflict with the foregoing.
(c)    Subject to Section 12.1, each and every covenant and condition for the benefit of Lender contained in this Agreement and the other Financing Agreements may be waived by Lender. Any forbearance by Lender in exercising any right or remedy under any of the Financing Agreements, or otherwise afforded by applicable Law, including any failure to accelerate the Stated Maturity Date shall not be a waiver of or preclude the exercise of any right or remedy nor shall it serve as a novation of the Term Note or as a reinstatement of the Term Loan or a waiver of such right of acceleration or the right to insist upon strict compliance of the terms of the Financing Agreements. Lender’s acceptance of payment of any sum secured by any of the Financing Agreements after the due date of such payment shall not be a waiver of Lender’s right to either require prompt payment when due of all other sums so secured or to declare a default for failure to make prompt payment. The procurement of insurance or the payment of taxes or other liens or charges by Lender shall not be a waiver of Lender’s right to accelerate the maturity of the Term Loan, nor shall Lender’s receipt of any condemnation awards, insurance proceeds, or damages under this Agreement operate to cure or waive Borrower’s default in payment of sums secured by any of the Financing Agreements.
(d)    Without limiting the generality of anything contained in this Agreement or the other Financing Agreements, Borrower agrees that if an Event of Default is continuing (i) Lender is not subject to any “one action” or “election of remedies” law or rule, and (ii) all liens and other rights, remedies or privileges provided to Lender shall remain in full force and effect until Lender has exhausted all of its remedies against the Collateral and any other properties owned by Borrower and the Financing Agreements and other security instruments or agreements securing the Liabilities has been foreclosed, sold and/or otherwise realized upon in satisfaction of the Liabilities.
(e)    Nothing contained herein or in any other Financing Agreement shall be construed as requiring Lender to resort to any part of the Collateral for the satisfaction of any of Borrower’s obligations under the Financing Agreements in preference or priority to any other Collateral, and Lender may seek satisfaction out of all of the Collateral or any part thereof, in its absolute discretion in respect of Borrower’s obligations under the Financing Agreements. In addition, Lender shall have the right from time to time to partially foreclose upon any Collateral in any manner and for any amounts secured by the Financing Agreements then due and payable as determined by Lender, including, without limitation, the following circumstances: (i) if Borrower defaults beyond any applicable grace period in the payment of one or more scheduled payments of principal and interest, Lender may foreclose upon all or any part of the Collateral to recover such delinquent payments, or (ii) if Lender elects to accelerate less than the entire outstanding principal balance of the Term Note, Lender may foreclose all or any part of the Collateral to recover so much of the principal balance of the Term Note as Lender may accelerate and such other sums secured by one or more of the Financing Agreements as Lender may elect. Notwithstanding one or more partial foreclosures, any unforeclosed Collateral shall remain subject to the Financing Agreements to secure payment of sums secured by the Financing Agreements and not previously recovered.
(f)    To the fullest extent permitted by Law, Borrower, for itself and its successors and assigns, waives in the event of foreclosure of any or all of the Collateral any equitable right otherwise available to Borrower which would require the separate sale of any of the Collateral or require Lender to exhaust its remedies against any part of the Collateral before proceeding against any other part of the Collateral; and further in the event of such foreclosure Borrower does hereby expressly consent to and authorize, at the option of Lender, the foreclosure and sale either separately or together of each part of the Collateral.
11.7    Waiver of Notice. UPON THE OCCURRENCE OF AN EVENT OF DEFAULT, BORROWER HEREBY WAIVES ALL RIGHTS TO NOTICE AND HEARING OF ANY KIND PRIOR TO THE EXERCISE BY LENDER OF ITS RIGHTS TO REPOSSESS THE COLLATERAL WITHOUT JUDICIAL PROCESS OR TO REPLEVY, ATTACH OR LEVY UPON THE COLLATERAL WITHOUT PRIOR NOTICE OR HEARING.
11.8    Injunctive Relief. The parties acknowledge and agree that, in the event of a breach or threatened breach of any Credit Party’s obligations under any Financing Agreements, Lender may have no adequate remedy in money damages and, accordingly, shall be entitled to an injunction (including without limitation, a temporary restraining order, preliminary injunction, writ of attachment, or order compelling an audit) against such breach or threatened breach. However, no specification in this Agreement of a specific legal or equitable remedy shall be construed as a waiver or prohibition against any other legal or equitable remedies in the event of a breach or threatened breach of any provision of this Agreement. Each Credit Party waives the requirement of the posting of any bond in connection with such injunctive relief.
11.9    Marshalling; Recourse to Borrower. Lender shall have no obligation to marshal any assets in favor of any Credit Party, or against or in payment of any of the other Liabilities or any other obligation owed to Lender by any Credit Party. Notwithstanding anything to the contrary contained herein or in any other Financing Agreement, the Term Loan and other Liabilities shall be fully recourse to Borrower, and Lender shall be authorized, in its sole and absolute discretion, to enforce any or all of its remedies hereunder against Borrower, including all present and future revenue and assets of Borrower, whether or not such assets have been pledged as collateral for the Term Loan.
11.10    Advice of Counsel. Borrower acknowledges that it has been advised by its counsel with respect to this transaction and this Agreement, including, without limitation, all waivers contained herein.
11.11    Credit Bidding. Without limiting the foregoing, Borrower and Lender hereby irrevocably authorize (and by entering into a Bank Product Agreement, each Bank Product provider shall be deemed to authorize) Lender to Credit Bid (as defined below) and purchase (either directly or through one or more acquisition vehicles) all or any portion of the Collateral (and Borrower shall approve Lender as a qualified bidder and such Credit Bid as a qualified bid) at any sale thereof conducted by Lender to Credit Bid (as defined below) and purchase (either directly or through one or more acquisition vehicles) all or any portion of the Collateral (and Borrower shall approve Lender as a qualified bidder and such Credit Bid as a qualified bid) at any sale thereof conducted by Lender, (a) under any provisions of the UCC, including pursuant to Sections 9-610 or 9-620 of the UCC, (b) under the provisions of the Bankruptcy Code, including pursuant to Section 363 thereof, or any applicable insolvency, reorganization or similar law, or (c) at any other sale or foreclosure conducted by (or with the consent or at the direction of) Lender (whether by judicial action or otherwise) in accordance with applicable law or by the exercise of any legal or equitable remedy; provided, however, that (i) the acquisition documents shall be commercially reasonable and contain customary protections for minority holders, such as anti-dilution and tag-along rights, (ii) the exchanged debt or equity securities must be freely transferable, without restriction (subject to applicable securities laws) and (iii) reasonable efforts shall be made to structure the acquisition in a manner that causes the governance documents pertaining thereto to not impose any obligations or liabilities upon Lender individually (such as indemnification obligations).
For purposes of the preceding sentence, the term “Credit Bid” shall mean, an offer submitted at a public or private sale of all or any portion of the Collateral by Lender, to acquire all of the Collateral of Borrower or any portion thereof in exchange for and in full and final satisfaction of all or a portion of the Liabilities owing to Lender under this Agreement and the other Financing Agreements.
12.    MISCELLANEOUS.
12.1    Waiver; Amendment. Lender’s failure, at any time or times hereafter, to require strict performance by Borrower of any covenant, condition or provision of this Agreement shall not waive, affect or diminish any right of Lender thereafter to demand strict compliance and performance therewith. Any suspension or waiver by Lender of an Event of Default under this Agreement or a default under any of the other Financing Agreements shall not suspend, waive or affect any other Event of Default under this Agreement or any other default under any of the other Financing Agreements, whether the same is prior or subsequent thereto and whether of the same or of a different kind or character. None of the undertakings, agreements, warranties, covenants and representations of Borrower contained in this Agreement or any of the other Financing Agreements and no Event of Default under this Agreement or default under any of the other Financing Agreements shall be deemed to have been suspended or waived by Lender unless such suspension or waiver is in writing signed by an officer of Lender, and directed to Borrower specifying such suspension or waiver.
Except as otherwise set forth herein, no amendment or modification or waiver of, or consent with respect to (as reasonably determined by Lender) any provision of this Agreement or the other Financing Agreements shall in any event be effective unless the same shall be in writing and acknowledged by Borrower and Lender.
12.2    Costs and Attorneys’ Fees.
(c)    Borrower agrees to pay on demand all of the costs and expenses of Lender (including, without limitation, the reasonable fees and out-of-pocket expenses of Lender’s counsel, all UCC tax, lien, judgment, pending suit, and bankruptcy search fees and costs, UCC filing fee and costs, recording, filing and registration fees and charges, mortgage or documentary taxes, all costs of Intralinks, DebtX or other similar transmission system, if applicable, all corporate search fees and certified documents, all financial and legal due diligence expenses, all audit, field exam and appraisal costs and fees, costs incurred by Lender in connection with travel expenses of its associates, background checks on members of management of Borrower, and real estate appraisal fees, survey fees, recording and title insurance costs, and any environmental report or analysis) in connection with the structuring, preparation, negotiation, execution, delivery and closing of: (i) this Agreement, the other Financing Agreements and all other instruments, agreements, certificates or documents provided for herein or delivered or to be delivered hereunder, and (ii) any and all amendments, modifications, supplements and waivers executed and delivered pursuant hereto or any other Financing Agreement or in connection herewith or therewith. Borrower further agrees that Lender, in its sole discretion, may deduct all such unpaid amounts from the aggregate proceeds of the Term Loan or debit such amounts from the operating accounts of Borrower maintained with Lender.
(d)    The costs and expenses that Lender incurs in any manner or way with respect to the following shall be part of the Liabilities, payable by Borrower on demand if at any time after the date of this Agreement Lender: (i) employs counsel in good faith for advice or other representation, (ii) with respect to the amendment, modification or enforcement of this Agreement or the other Financing Agreements, or with respect to any Collateral hereunder or other collateral under the other Financing Agreements securing the Liabilities hereunder, (iii) to represent Lender and Lender in any work-out or any type of restructuring of the Liabilities, or any litigation, contest, dispute, suit or proceeding or to commence, defend or intervene or to take any other action in or with respect to any litigation, contest, dispute, suit or proceeding (whether instituted by Lender, Borrower or any other Person) in any way or respect relating to this Agreement, the other Financing Agreements, Borrower’s affairs or any Collateral hereunder or under any other Financing Agreement, (iv) to protect, preserve, or enforce any of the rights of Lender with respect to Borrower provided in this Agreement, under any of the other Financing Agreements, or otherwise (whether at law or in equity) (including any foreclosure sale, deed in lieu transaction or costs incurred in connection with any litigation or bankruptcy or administrative hearing and any appeals therefrom and any post-judgment enforcement action including, without limitation, supplementary proceedings in connection with the enforcement of this Agreement); (v) takes any action to protect, preserve, store, ship, appraise, prepare for sale, collect, sell, liquidate or otherwise dispose of any Collateral hereunder or any other collateral under any other Financing Agreement; and/or (vi) seeks to enforce or enforces any of the rights and remedies of Lender with respect to Borrower or any guarantor of the Liabilities. Without limiting the generality of the foregoing, such expenses, costs, charges and fees include: reasonable fees, costs and expenses of attorneys, accountants, environmental consultants, and other consultants (whether work out, financial or otherwise); court costs and expenses; court reporter fees, costs and expenses; long distance telephone charges; and courier and telecopier charges.
(e)    Borrower further agrees to pay, and to save Lender harmless from all liability for, any documentary stamp tax, intangible tax, or other stamp tax or taxes of any kind which may be payable in connection with or related to the execution or delivery of this Agreement, the other Financing Agreements, the borrowing hereunder, the issuance of the Term Note or of any other instruments, agreements, certificates or documents provided for herein or delivered or to be delivered hereunder or in connection herewith, provided that Borrower shall not be liable for Lender’s income tax liabilities.
(f)    All of Borrower’s obligations provided for in this Section 12.2 shall be Liabilities secured by the Collateral and shall survive repayment of the Term Loan or any termination of this Agreement or any Financing Agreements.
12.3    Expenditures by Lender. In the event Borrower shall fail to pay taxes, insurance, audit fees and expenses, consulting fees, filing, recording and search fees, assessments, fees, costs or expenses which Borrower is, under any of the terms hereof or of any of the other Financing Agreements, required to pay, or fails to keep the Collateral free from other Liens, except as permitted herein, Lender may, in its sole discretion, pay or make expenditures for any or all of such purposes, and the amounts so expended, together with interest thereon at the Default Rate (from the date the obligation or liability of Borrower is charged or incurred until actually paid in full to Lender) and shall be part of the Liabilities of Borrower, payable on demand and secured by the Collateral.
12.4    Custody and Preservation of Collateral. Lender shall be deemed to have exercised reasonable care in the custody and preservation of any of the Collateral in its possession if it takes such action for that purpose as Borrower shall request in writing, but failure by Lender to comply with any such request shall not of itself be deemed a failure to exercise reasonable care, and no failure by Lender to preserve or protect any right with respect to such Collateral against prior parties, or to do any act with respect to the preservation of such Collateral not so requested by Borrower, shall of itself be deemed a failure to exercise reasonable care in the custody or preservation of such Collateral.
12.5    Reliance by Lender. Borrower acknowledges that Lender, in entering into this Agreement and agreeing to make the Term Loan to Borrower hereunder, has relied upon the accuracy of the covenants, agreements, representations and warranties made herein by Borrower and the information delivered by Borrower to Lender in connection herewith (including, without limitation, all financial information and data).
12.6    Assignability; Parties. This Agreement (including, without limitation, any and all of Borrower’s rights, obligations and liabilities hereunder) may not be assigned by Borrower without the prior written consent of Lender. Whenever in this Agreement there is reference made to any of the parties hereto, such reference shall be deemed to include, wherever applicable, a reference to the successors and permitted assigns of Borrower and the successors and assigns of Lender. Notwithstanding the foregoing in this Section 12.6, Lender may at any time, without prior or subsequent notice to Borrower, pledge or assign a security interest in all or any portion of its rights under this Agreement to secure obligations of Lender, including any pledge or assignment to secure obligations to a Federal Reserve Bank, and this Section shall not apply to any such pledge or assignment of a security interest; provided, that no such pledge or assignment of a security interest shall release Lender from any of its obligations under this Agreement or substitute any such pledgee or assignee for Lender as a party hereto.
12.7    Severability; Construction. Whenever possible, each provision of this Agreement shall be interpreted in such manner as to be effective and valid under applicable law, but if any provision of this Agreement shall be prohibited by or invalid under applicable law, such provision shall be ineffective only to the extent of such prohibition or invalidity, without invalidating the remainder of such provisions or the remaining provisions of this Agreement. The parties hereto have participated jointly in the negotiation and drafting of this Agreement. In the event an ambiguity or question of intent or interpretation arises, this Agreement shall be construed as if drafted jointly by the parties hereto, and no presumption or burden of proof shall arise favoring or disfavoring any party by virtue of the authorship of any of the provisions of this Agreement.
12.8    Application of Payments. Notwithstanding any contrary provision contained in this Agreement or in any of the other Financing Agreements, after the occurrence of a Default or an Event of Default Borrower irrevocably waives the right to direct the application of any and all payments at any time or times hereafter received by Lender from Borrower or with respect to any of the Collateral, and Borrower and Lender does hereby irrevocably agree that any and all payments or proceeds so received shall be applied in the following manner:
First, to the payment of all fees, costs, expenses and indemnities of Lender (in its capacity as such), including reasonable attorneys’ fees and costs of Lender, and any other Liabilities owing to Lender in respect of sums advanced by Lender to preserve the Collateral or to preserve its security interest in the Collateral (or any other collateral provided pursuant to any other Financing Agreement);
Second, to payment of that portion of the Liabilities constituting fees, costs, expenses and indemnities of Lender;
Third, to payment of that portion of the Liabilities constituting fees, costs, expenses and indemnities of Lender as provided herein;
Fourth, to the payment of all of the Liabilities consisting of accrued and unpaid interest owing to Lender;
Fifth, to the payment of all Liabilities consisting of principal owing to Lender;
Sixth, to the payment of all Bank Product Obligations (including with respect to any Hedging Agreement) owing to Lender or its Affiliates;
Seventh, to the payment of all other Liabilities owing to Lender; and
Last, the payment of any remaining proceeds, if any, to whomever may be lawfully entitled to receive such amounts, including, if applicable, Borrower.
All amounts owing under this Agreement in respect of Liabilities including fees, interest, default interest, interest on interest, expense reimbursements and indemnities, shall be payable in accordance with the foregoing waterfall provisions irrespective of whether a claim in respect of such amounts is allowed or allowable in any insolvency proceeding.
12.9    Payments Set Aside. To the extent that Borrower makes a payment or payments to Lender or Lender enforces its Liens or exercises its rights of setoff, and such payment or payments or the proceeds of such enforcement or setoff or any part thereof are subsequently invalidated, declared to be fraudulent or preferential, set aside and/or required to be repaid to a trustee, receiver or any other party or Person under any bankruptcy law, state or federal law, common law or equitable cause or otherwise (including, without limitation, provisions of the federal bankruptcy code relating to fraudulent conveyances, preferences, or other voidable or recoverable payments of money or transfers of property), then to the extent of such recovery, the obligation or part thereof originally intended to be satisfied shall be automatically revived, reinstated, restored and continued in full force and effect as if such payment had not been made or such enforcement or setoff had not occurred. The provisions of and undertakings set out in this Section 12.9 shall survive the satisfaction and payment of the Liabilities of Borrower and the termination of this Agreement.
12.10    Sections and Titles; UCC Termination Statements. The sections and titles contained in this Agreement shall be without substantive meaning or content of any kind whatsoever and are not a part of the agreement between the parties hereto. Upon Payment in Full, Lender will, upon Borrower’s written request and at Borrower’s cost and expense, timely file all Uniform Commercial Code termination statements reasonably required by Borrower to evidence the termination of the Liens in the Collateral in favor of Lender.
12.11    Continuing Effect; No Joint Venture. This Agreement, Lender’s Liens in the Collateral, and all of the other Financing Agreements shall continue in full force and effect so long as any Liabilities shall be owed to Lenders, and (even if there shall be no such Liabilities outstanding) so long as this Agreement has not been terminated as provided in Section 2.9 hereof. The relationship between Lender on the one hand and Borrower on the other hand shall be that of creditor-debtor only. No term in this Agreement or in any other Financing Agreement and no course of dealing between the parties shall be deemed to create any relationship or agency, partnership or joint venture or any fiduciary duty by Lender to Borrower or any other party. In exercising its rights hereunder and under any other Financing Agreements or taking any actions herein or therein, Lender may act through its employees, agents or independent contractors as authorized by Lender.
12.12    Notices. Any notice or other communication required or permitted under this Agreement shall be in writing and personally delivered, mailed by registered or certified U.S. mail (return receipt requested and postage prepaid), sent by telecopier (with a confirming copy sent by regular mail), or sent by prepaid nationally recognized overnight courier service, and addressed to the relevant party at its address set forth below, or at such other address as such party may, by written notice, designate as its address for purposes of notice under this Agreement:
(a)    If to Lender, at:
The PrivateBank and Trust Company
120 South LaSalle Street
Chicago, Illinois 60603
Attention: Adam D. Panos, Managing Director
Telephone No.: 312-564-1278
Facsimile No.: 312-564-6889
With a copy to:

Duane Morris LLP
190 South LaSalle Street
Suite 3700
Chicago, Illinois 60603
Attention: Daniel Kohn, Esq.
Telephone No: 312-499-6712
Facsimile No: 312-499-6701

(b)    If to Borrower, at:
Diversicare Glasgow Property, LLC
c/o Diversicare Healthcare Services, Inc.
1621 Galleria Boulevard
Brentwood, Tennessee 37027
Attention: James R. McKnight, Jr.
Telephone No.: 615-771-7575
Facsimile No.: 615-771-7409
With a copy to:

Harwell Howard Hyne Gabbert & Manner
315 Deaderick Street
Suite 1800
Nashville, Tennessee 37238
Attention: John N. Popham IV, Esq.
Telephone No.: 615-251-1093
Facsimile No.: 615-251-1059

If mailed, notice shall be deemed to be given three (3) days after being sent, and if sent by personal delivery, telecopier or prepaid courier, notice shall be deemed to be given when delivered. If any notice is tendered to an addressee and delivery thereof is refused by such addressee, such notice shall be effective upon such tender unless expressly set forth in such notice.
12.13    Equitable Relief. Borrower recognizes that, in the event Borrower fails to perform, observe or discharge any of its obligations or liabilities under this Agreement, any remedy at law may prove to be inadequate relief to Lender; therefore, Borrower agrees that Lender shall be entitled to temporary and permanent injunctive relief in any such case without the necessity of proving actual damages.
12.14    Entire Agreement. This Agreement, together with the Financing Agreements executed in connection herewith, constitutes the entire agreement among the parties with respect to the subject matter hereof, and supersedes all prior written or oral understandings, discussions and agreements with respect thereto (including, without limitation, any term sheet, proposal letter or commitment letter).
12.15    Participations and Assignments.
(a)    This Agreement, the Term Note, and the other Financial Agreement shall be binding upon and inure to the benefit of Borrower and Lender and their respective successors and assigns and shall bind all Persons who become bound as a debtor to this Agreement. Notwithstanding the foregoing, Borrower may not assign any of their rights or delegate any of their obligations under this Agreement without the prior written consent of Lender, which may be withheld in Lender’s discretion.
(b)    Lender may at any time, assign to one or more Persons (any such Person, an “Assignee”) all or any portion of the Term Loan with the prior consent of Borrower.
(c)    Lender may at any time, sell to one or more Persons participating interests in its portion of the Term Loan, commitments or other interests hereunder (any such Person, a “Participant”). In the event of a sale by Lender of a participating interest to a Participant, (a) Lender’s obligations hereunder shall remain unchanged for all purposes, (b) Borrower and Lender shall continue to deal solely and directly with Lender in connection with Lender’s rights and obligations hereunder and (c) all amounts payable by Borrower shall be determined as if Lender had not sold such participation and shall be paid directly to Lender. No Participant shall have any direct or indirect voting rights hereunder. Lender agrees to incorporate the requirements of the preceding sentence into each participation agreement which Lender enters into with any Participant. Borrower agrees that if amounts outstanding under this Agreement are due and payable (as a result of acceleration or otherwise), each Participant shall be deemed to have the right of set-off in respect of its participating interest in amounts owing under this Agreement to the same extent as if the amount of its participating interest were owing directly to it as Lender under this Agreement; provided that such right of set-off shall be subject to the obligation of each Participant to share with Lender.
12.16    INDEMNIFICATION BY BORROWER. IN CONSIDERATION OF THE EXECUTION AND DELIVERY OF THIS AGREEMENT BY LENDER AND THE AGREEMENT TO EXTEND THE TERM LOAN COMMITMENT PROVIDED HEREUNDER, BORROWER HEREBY AGREES TO AND SHALL INDEMNIFY, DEFEND, PROTECT, EXONERATE AND HOLD LENDER, AND EACH OF THE OFFICERS, DIRECTORS, EMPLOYEES, PARENT ENTITIES, AFFILIATES, ATTORNEYS AND AGENTS OF LENDER (EACH A “INDEMNIFIED PARTY”) FREE AND HARMLESS FROM AND AGAINST ANY AND ALL ACTIONS, CAUSES OF ACTION, SUITS, JUDGMENTS, CLAIMS, LOSSES, LIABILITIES, DAMAGES, PENALTIES, COSTS, AND EXPENSES, INCLUDING, WITHOUT LIMITATION, ATTORNEYS’ FEES AND COSTS (COLLECTIVELY, THE “INDEMNIFIED LIABILITIES”), INCURRED BY THE INDEMNIFIED PARTIES OR ANY OF THEM AS A RESULT OF, OR ARISING OUT OF, OR RELATING TO (a) ANY REFINANCING, TENDER OFFER, MERGER, PURCHASE OF STOCK, PURCHASE OF ASSETS OR OTHER SIMILAR TRANSACTION FINANCED OR PROPOSED TO BE FINANCED IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, WITH THE PROCEEDS OF THE TERM LOAN, (b) THE USE, HANDLING, RELEASE, EMISSION, DISCHARGE, TRANSPORTATION, STORAGE, TREATMENT OR DISPOSAL OF ANY HAZARDOUS SUBSTANCE AT ANY PROPERTY OWNED OR LEASED BY BORROWER, (c) ANY VIOLATION OF ANY ENVIRONMENTAL LAWS WITH RESPECT TO CONDITIONS AT ANY PROPERTY OWNED OR LEASED BY BORROWER OR THE OPERATIONS CONDUCTED THEREON, (d) THE INVESTIGATION, CLEANUP OR REMEDIATION OF OFFSITE LOCATIONS AT WHICH BORROWER OR ITS PREDECESSORS ARE ALLEGED TO HAVE DIRECTLY OR INDIRECTLY DISPOSED OF HAZARDOUS SUBSTANCES, (e) THE USE, MAINTENANCE OR OPERATION OF THE FACILITIES, OR (f) THE EXECUTION, DELIVERY, PERFORMANCE OR ENFORCEMENT OF THIS AGREEMENT OR ANY OTHER FINANCING AGREEMENT BY ANY OF THE INDEMNIFIED PARTIES, EXCEPT FOR ANY SUCH INDEMNIFIED LIABILITIES (A) ARISING ON ACCOUNT OF THE APPLICABLE INDEMNIFIED PARTY’S GROSS NEGLIGENCE, WILLFUL MISCONDUCT OR ILLEGAL ACTIVITY AS DETERMINED BY A FINAL, NON-APPEALABLE JUDGMENT BY A COURT OF COMPETENT JURISDICTION, OR (B) AS ARE IN RESPECT OF ANY PROPERTY FOR ANY OCCURRENCE ARISING DIRECTLY FROM THE ACTS OR OMISSIONS OF LENDER DURING THE PERIOD AFTER WHICH SUCH PERSON, ITS SUCCESSORS OR ASSIGNS HAVE OBTAINED TITLE AND POSSESSION OF SUCH PROPERTY BY FORECLOSURE OR DEED IN LIEU OF FORECLOSURE. IF AND TO THE EXTENT THAT THE FOREGOING UNDERTAKING MAY BE UNENFORCEABLE FOR ANY REASON, BORROWER HEREBY AGREES TO MAKE THE MAXIMUM CONTRIBUTION TO THE PAYMENT AND SATISFACTION OF EACH OF THE INDEMNIFIED LIABILITIES THAT IS PERMISSIBLE UNDER APPLICABLE LAW. ALL OBLIGATIONS PROVIDED FOR IN THIS SECTION 12.16 SHALL SURVIVE REPAYMENT OF THE TERM LOAN, CANCELLATION OF THE TERM NOTE, ANY FORECLOSURE UNDER, OR ANY MODIFICATION, RELEASE OR DISCHARGE OF, ANY OR ALL OF THE OTHER FINANCING AGREEMENTS AND TERMINATION OF THIS AGREEMENT. Any liability, obligation, loss, damage, penalty, cost or expense incurred by the Indemnified Parties shall be paid to the Indemnified Parties on demand, together with interest thereon at the Default Rate from the date incurred by the Indemnified Parties until paid by Borrower, be added to the Liabilities, and be secured by the Collateral. The provisions of and undertakings and indemnifications set out in this Section 12.16 shall survive the satisfaction and payment of the Liabilities of Borrower and the termination of this Agreement. Borrower agrees that Lender shall have no liability to Borrower (whether sounding in tort, contract or otherwise) for losses suffered by Borrower in connection with, arising out of, or in any way related to the transactions contemplated and the relationship established by this Agreement and the other Financing Agreements, or any act, omission or event occurring in connection herewith or therewith, unless it is determined in a final non-appealable judgment by a court of competent jurisdiction that such losses resulted from the gross negligence, willful misconduct or illegal activity of the party from which recovery is sought. NO INDEMNIFIED PARTY SHALL BE LIABLE FOR ANY DAMAGES ARISING FROM THE USE BY OTHERS OF ANY INFORMATION OR OTHER MATERIALS OBTAINED THROUGH INTRALINKS, DEBTX, OR OTHER SIMILAR INFORMATION TRANSMISSION SYSTEMS IN CONNECTION WITH THIS AGREEMENT, NOR SHALL ANY INDEMNIFIED PARTY HAVE ANY LIABILITY WITH RESPECT TO, AND BORROWER HEREBY WAIVES, RELEASES AND AGREES NOT TO SUE FOR ANY SPECIAL, PUNITIVE, EXEMPLARY, INDIRECT OR CONSEQUENTIAL DAMAGES RELATING TO THIS AGREEMENT OR ANY OTHER FINANCING AGREEMENT OR ARISING OUT OF ITS ACTIVITIES IN CONNECTION HEREWITH OR THEREWITH (WHETHER BEFORE OR AFTER THE CLOSING DATE). Borrower acknowledges that it has been advised by counsel in the negotiation, execution and delivery of this Agreement and the other Financing Agreements to which it is a party.
12.17    Representations and Warranties. Notwithstanding anything to the contrary contained herein, each representation or warranty contained in this Agreement or any of the other Financing Agreements shall survive the execution and delivery of this Agreement and the other Financing Agreements and the making of the Term Loan and the repayment of the Liabilities hereunder.
12.18    Counterparts. This Agreement and any amendment or supplement hereto or any waiver granted in connection herewith may be executed in any number of counterparts and by the different parties on separate counterparts and each such counterpart shall be deemed to be an original, but all such counterparts shall together constitute but one and the same Agreement.
12.19    Limitation of Liability of Lender. It is hereby expressly agreed that:
(a)    Lender may conclusively rely and shall be protected in acting or refraining from acting upon any document, instrument, certificate, instruction or signature believed to be genuine and may assume and shall be protected in assuming that any Person purporting to give any notice or instructions in connection with any transaction to which this Agreement relates has been duly authorized to do so. Lender shall not be obligated to make any inquiry as to the authority, capacity, existence or identity of any Person purporting to have executed any such document or instrument or have made any such signature or purporting to give any such notice or instructions;
(b)    Lender shall not be liable for any acts, omissions, errors of judgment or mistakes of fact or law, including, without limitation, acts, omissions, errors or mistakes with respect to the Collateral, except for those arising out of or in connection with Lender’s and Lender’s gross negligence, willful misconduct or illegal activity. Without limiting the generality of the foregoing, Lender shall be under no obligation to take any steps necessary to preserve rights in the Collateral against any other parties, but may do so at its option, and all expenses incurred in connection therewith shall be payable by Borrower; and
(c)    Lender shall not be liable for any action taken in good faith and believed to be authorized or within the rights or powers conferred by this Agreement and the other Financing Agreements.
12.20    Borrower Authorizing Accounting Firm. Borrower shall authorize its accounting firm and/or service bureaus to provide Lender with such information as is requested by Lender in accordance with this Agreement. Borrower authorizes Lender to contact directly any such accounting firm and/or service bureaus to obtain such information.
12.21    Confidentiality; Press Releases. Borrower shall not disclose the contents of this Agreement and the other Financing Agreements to any third party (including, without limitation, any financial institution or intermediary), unless required by applicable Laws or by any subpoena, judicial order or similar legal process, without Lender’s prior written consent, other than to Borrower’s officers, lawyers and other professional advisors on a need-to-know basis, and in connection with any filings required to be made under any applicable federal or state securities laws or regulations (“Securities Laws”). Borrower agrees to inform all such Persons who receive information concerning this Agreement that such information is confidential and may not be disclosed to any other Person, except as required by applicable Laws, including Securities Laws, or by any subpoena, judicial order or similar legal process. No party hereto shall, and no party hereto shall permit its Affiliates to, at any time issue any press release or other public disclosure using the name of Borrower, Lender, or any of their respective Affiliates or referring to this Agreement or the other Financing Agreements without at least two (2) Business Days prior written notice to Borrower, Lender and the applicable Lender and, except for press releases or other public disclosures required under applicable Securities Laws, without the prior written consent of Borrower, Lender and the applicable Lender, which consent shall not unreasonably be withheld, conditioned or delayed. Upon Borrower’s prior written consent, which consent shall not unreasonably be withheld, conditioned or delayed, Lender may publish or disseminate a tombstone or similar advertising material relating to the financing transactions contemplated by this Agreement. Nothing contained in this Agreement is intended to permit or authorize Borrower to make any contract on behalf of Lender. Lender agrees to maintain the confidentiality of the Information (as defined below), except that Information may be disclosed (a) to each of its Affiliates’ respective directors, officers, managers, employees and agents, including, without limitation, accountants, legal counsel and other professional advisors (it being understood that the Persons to whom such disclosure is made will be informed of the confidential nature of such information and instructed to keep such Information confidential), (b) to the extent requested by any regulatory authority, (c) to the extent required by applicable Laws or regulations or by any subpoena, judicial order or similar legal process or bank regulatory process, (d) to any other party to this Agreement or any other Financing Agreement, (e) in connection with the exercise of any remedies hereunder or under any Financing Agreement or any suit, action or proceedings relating to this Agreement or any Financing Agreement or the enforcement of rights hereunder or thereunder, or (f) subject to an agreement containing provisions substantially the same as those of this Section 12.21, to any assignee of or Participant in, or any prospective assignee of or Participant in, any of its rights or obligations under this Agreement.
For the purpose of this Section 12.21, “Information” means all information received from Borrower or any other Credit Party relating to Borrower or any other Credit Party and their businesses, other than any information (i) that is available to Lender on a non-confidential basis prior to disclosure by Borrower or any Credit Party, (ii) that is publicly disclosed by Borrower or any Credit Party in connection with public filings with the Securities and Exchange Commission, (iii) without limitation of subsection (i) immediately above, that was in the possession of Lender or Lender prior to its disclosure by Borrower or any Credit Party pursuant hereto provided that the source of such information was not known by Lender or Lender to be bound by a confidentiality agreement with or other contractual, legal or fiduciary obligation of confidentiality to Borrower or any Credit Party with respect to such information, (iv) is or becomes generally available to the public by acts other than those of Lender or its Affiliates, officers, directors, managers, employees or agents in breach of the terms hereof, (v) that has been or is received by Lender from a third party who is not known by Lender, as applicable, to be bound by a confidentiality agreement with or other contractual, legal or fiduciary obligation of confidentiality to Borrower or any Credit Party with respect to such information, or (vi) has been or is developed independently without use of or reference to Confidential Information. Any Person required to maintain the confidentiality of Information as provided in this Section 12.21 shall be considered to have complied with its obligation to do so if such Person has exercised the same degree of care to maintain the confidentiality of such Information as such Person would accord to its own confidential information. Without limiting anything to the contrary contained in this Agreement, each of the obligations contained in this Section 12.21 are several (and not joint and several) and Lender shall not be liable or responsible in any way for any breach of this Section 12.21 by Lender or any other Person.
12.22    Fax Signatures. A signature hereto sent or delivered by facsimile or other electronic transmission shall be as legally binding and enforceable as a signed original for all purposes.
12.23    Release. For and in consideration of the Term Loan hereunder, Borrower, voluntarily, knowingly, unconditionally, and irrevocably, with specific and express intent, for and on behalf of itself and its agents, attorneys, heirs, successors, and assigns (collectively the “Releasing Parties”) does hereby fully and completely release, acquit and forever discharge Lender, and each of its successors, assigns, heirs, affiliates, subsidiaries, parent companies, principals, directors, officers, employees, shareholders and agents (hereinafter called the “Lender Parties”), and any other person, firm, business, corporation, insurer, or association which may be responsible or liable for the acts or omissions of Lender Parties, or who may be liable for the injury or damage resulting therefrom (collectively the “Released Parties”), of and from any and all actions, causes of action, suits, debts, disputes, damages, claims, obligations, liabilities, costs, expenses, fees (including, without limitation, reasonable attorneys’ fees) and demands of any kind whatsoever, at law or in equity, whether matured or unmatured, liquidated or unliquidated, vested or contingent, choate or inchoate, known or unknown that the Releasing Parties (or any of them) have or may have, against the Released Parties or any of them (whether directly or indirectly) relating to events occurring on or before the date of this Agreement, other than any claim as to which a final determination is made in a judicial proceeding (in which Lender or any of the Released Parties have had an opportunity to be heard) which determination includes a specific finding that one of the Released Parties acted in a grossly negligent manner or with actual willful misconduct or illegal activity. Borrower acknowledges that the foregoing release is a material inducement to Lender’s and Lender’s decision to extend to Borrower the financial accommodations hereunder and has been relied upon by Lender in agreeing to make the Term Loan hereunder. Borrower understands, acknowledges and agrees that the release set forth above may be pleaded as a full and complete defense and may be used as a basis for an injunction against any action, suit or other proceeding which may be instituted, prosecuted or attempted in breach of the provisions of such release. To the furthest extent permitted by law, Borrower hereby knowingly, voluntarily, intentionally and expressly waives and relinquishes any and all rights and benefits that it respectively may have as against any of Lender Parties or any other Released Parties under any law, rule or regulation of any jurisdiction that would or could have the effect of limiting the extent to which a general release extends to claims which any of the Releasing Parties does not know or suspect to exist as of the date hereof.
12.24    Time; Inconsistency. Time is of the essence in Borrower’s performance under this Agreement and all other Financing Agreements. Notwithstanding anything to the contrary contained in any Financing Agreement, if and to the extent any terms or provisions contained in any Financing Agreement are inconsistent or conflict with the terms and provisions of this Agreement, the terms and provisions of this Agreement shall control and govern.
12.25    Relationship. The relationship between, on the one hand, Lender, and Borrower, on the other hand, shall be that of creditor-debtor only. No term in this Agreement or in the other Financing Agreements and no course of dealing between the parties shall be deemed to create any relationship of agency, partnership or joint venture or any fiduciary duty by Lender to Borrower or any other party.
12.26    Intentionally Omitted.
12.27    Acting Through Agents. In exercising any rights under the Financing Agreements or taking any actions provided for therein, Lender may act through its employees, agents or independent contractors as authorized by Lender. Borrower shall authorize its accounting firm and/or service bureaus to provide Lender with such information as is requested by Lender in accordance with this Agreement. Borrower authorizes Lender to contact directly any such accounting firm and/or service bureaus to obtain such information.
12.28    Additional Waivers. Borrower authorizes Lender to exercise, in its sole discretion, any right, remedy or combination thereof which may then be available to Lender, since it is Borrower’s intent that the Liabilities be absolute, independent and unconditional obligations of Borrower under all circumstances. Notwithstanding any foreclosure of any Lien with respect to any or all of any property securing the Liabilities, whether by the exercise of the power of sale contained therein, by an action for judicial foreclosure or by an acceptance of a deed in lieu of foreclosure, Borrower shall remain bound under Borrower’s Liabilities.
12.29    Nonliability of Lender . The relationship between Borrower on the one hand and Lender on the other hand shall be solely that of borrower and lender. Lender does not have any fiduciary relationship with or duty to any Credit Party arising out of or in connection with this Agreement or any of the other Financing Agreements, and the relationship between the Credit Parties, on the one hand, and Lender, on the other hand, in connection herewith or therewith is solely that of debtor and creditor. Lender does not undertake any responsibility to any Credit Party to review or inform any Credit Party of any matter in connection with any phase of any Credit Party’s business or operations. Borrower agrees that Lender shall have no liability to any Credit Party (whether sounding in tort, contract or otherwise) for losses suffered by any Credit Party in connection with, arising out of, or in any way related to the transactions contemplated and the relationship established by the Financing Agreements, or any act, omission or event occurring in connection therewith, unless it is determined in a final non-appealable judgment by a court of competent jurisdiction that such losses resulted from the gross negligence, willful misconduct or illegal activity of the party from which recovery is sought. NO LENDER OR LENDER SHALL BE LIABLE FOR ANY DAMAGES ARISING FROM THE USE BY OTHERS OF ANY INFORMATION OR OTHER MATERIALS OBTAINED THROUGH INTRALINKS, DEBTX OR OTHER SIMILAR INFORMATION TRANSMISSION SYSTEMS IN CONNECTION WITH THIS AGREEMENT, NOR SHALL LENDER HAVE ANY LIABILITY WITH RESPECT TO, AND BORROWER ON BEHALF OF ITSELF AND EACH OTHER CREDIT PARTY, HEREBY WAIVES, RELEASES AND AGREES NOT TO SUE FOR ANY SPECIAL, PUNITIVE, EXEMPLARY, INDIRECT OR CONSEQUENTIAL DAMAGES RELATING TO THIS AGREEMENT OR ANY OTHER FINANCING AGREEMENT OR ARISING OUT OF ITS ACTIVITIES IN CONNECTION HEREWITH OR THEREWITH (WHETHER BEFORE OR AFTER THE CLOSING DATE). Borrower acknowledges that it has been advised by counsel in the negotiation, execution and delivery of this Agreement and the other Financing Agreements to which it is a party. No joint venture is created hereby or by the other Financing Agreements or otherwise exists by virtue of the transactions contemplated hereby by Lender or among the Credit Parties and Lender.
13.    JURISDICTION; JURY TRIAL WAIVER.
13.1    SUBMISSION TO JURISDICTION; WAIVER OF VENUE. BORROWER HEREBY IRREVOCABLY AND UNCONDITIONALLY:
(g)    SUBMITS FOR ITSELF AND ITS PROPERTY IN ANY LEGAL ACTION OR PROCEEDING RELATING TO THIS AGREEMENT AND THE OTHER FINANCING AGREEMENTS TO WHICH IT IS A PARTY, OR FOR RECOGNITION AND ENFORCEMENT OF ANY JUDGMENT IN RESPECT THEREOF, TO THE EXCLUSIVE GENERAL JURISDICTION OF THE COURTS OF THE STATE OF ILLINOIS, THE COURTS OF THE UNITED STATES OF AMERICA FOR THE NORTHERN DISTRICT OF ILLINOIS AND APPELLATE COURTS FROM ANY THEREOF, LOCATED IN COOK COUNTY;
(h)    CONSENTS THAT ANY SUCH ACTION OR PROCEEDING MAY BE BROUGHT IN SUCH COURTS AND WAIVES TO THE FULLEST EXTENT PERMITTED BY LAW IN CONNECTION WITH ANY SUCH ACTION OR PROCEEDING (i) ANY OBJECTION THAT IT MAY NOW OR HEREAFTER HAVE TO THE VENUE OF ANY SUCH ACTION OR PROCEEDING IN ANY SUCH COURT OR THAT SUCH ACTION OR PROCEEDING WAS BROUGHT IN AN INCONVENIENT COURT AND AGREES NOT TO PLEAD OR CLAIM THE SAME, (ii) THE RIGHT TO ASSERT OR IMPOSE ANY CLAIM, NONCOMPULSORY SET-OFF, COUNTERCLAIM OR CROSS-CLAIM IN RESPECT THEREOF IN SUCH PROCEEDING; PROVIDED, HOWEVER, THIS WAIVER DOES NOT PRECLUDE THE RIGHT TO ASSERT A DEFENSE IN SUCH ACTION OR PROCEEDING OR TO ASSERT OR IMPOSE ANY CLAIM, COUNTERCLAIM OR CROSS-CLAIM WHICH BORROWER WISHES TO PURSUE IN A SEPARATE PROCEEDING AT ITS SOLE COST AND EXPENSE, AND (iii) ALL STATUTES OF LIMITATIONS WHICH MAY BE RELEVANT THERETO; AND
(i)    AGREES THAT SERVICE OF PROCESS IN ANY SUCH ACTION OR PROCEEDING MAY BE EFFECTED BY MAILING A COPY THEREOF BY CERTIFIED MAIL (OR ANY SUBSTANTIALLY SIMILAR FORM OF MAIL), POSTAGE PREPAID, RETURN RECEIPT REQUESTED, TO BORROWER AT ITS ADDRESS SET FORTH ABOVE OR AT SUCH OTHER ADDRESS OF WHICH LENDER SHALL HAVE BEEN NOTIFIED PURSUANT THERETO. BORROWER AGREES THAT SUCH SERVICE, TO THE FULLEST EXTENT PERMITTED BY LAW (i) SHALL BE DEEMED IN EVERY RESPECT EFFECTIVE SERVICE OF PROCESS UPON BORROWER IN ANY SUIT, ACTION OR PROCEEDING, AND (ii) SHALL BE TAKEN AND HELD TO BE VALID PERSONAL SERVICE UPON AND PERSONAL DELIVERY TO BORROWER. SOLELY TO THE EXTENT PROVIDED BY APPLICABLE LAW, SHOULD BORROWER, AFTER BEING SERVED, FAIL TO APPEAR OR ANSWER TO ANY SUMMONS, COMPLAINT, PROCESS OR PAPERS SO SERVED WITHIN THE NUMBER OF DAYS PRESCRIBED BY LAW AFTER THE DELIVERY OR MAILING THEREOF, BORROWER SHALL BE DEEMED IN DEFAULT AND AN ORDER AND/OR JUDGMENT MAY BE ENTERED BY THE COURT AGAINST BORROWER AS DEMANDED OR PRAYED FOR IN SUCH SUMMONS, COMPLAINT, PROCESS OR PAPERS.
(j)    NOTHING HEREIN SHALL AFFECT LENDER’S RIGHT TO SERVE PROCESS IN ANY OTHER MANNER PERMITTED BY LAW, OR LIMIT LENDER’S RIGHT TO BRING PROCEEDINGS AGAINST BORROWER OR ITS PROPERTY IN ANY COURT OR ANY OTHER JURISDICTION.
13.2    GOVERNING LAW. THIS AGREEMENT SHALL BE CONSTRUED IN ALL RESPECTS IN ACCORDANCE WITH, AND ENFORCED AND GOVERNED BY THE INTERNAL LAWS OF THE STATE OF ILLINOIS, WITHOUT REGARD TO CONFLICTS OF LAW PRINCIPLES.
13.3    JURY TRIAL. BORROWER AND LENDER HEREBY IRREVOCABLY AND KNOWINGLY WAIVE (TO THE FULLEST EXTENT PERMITTED BY LAW) ANY RIGHT TO A TRIAL BY JURY IN ANY ACTION OR PROCEEDING (INCLUDING, WITHOUT LIMITATION, ANY COUNTERCLAIM) ARISING OUT OF THIS AGREEMENT, THE FINANCING AGREEMENTS OR ANY OTHER AGREEMENTS OR TRANSACTIONS RELATED HERETO OR THERETO, INCLUDING, WITHOUT LIMITATION, ANY ACTION OR PROCEEDING (A) TO ENFORCE OR DEFEND ANY RIGHTS UNDER OR IN CONNECTION WITH THIS AGREEMENT OR ANY INSTRUMENT, DOCUMENT OR AGREEMENT DELIVERED OR WHICH MAY IN THE FUTURE BE DELIVERED IN CONNECTION HEREWITH, OR (B) ARISING FROM ANY DISPUTE OR CONTROVERSY IN CONNECTION WITH OR RELATED TO THIS AGREEMENT AND THE FINANCING AGREEMENTS. LENDER AND BORROWER AGREE THAT ANY SUCH ACTION OR PROCEEDING SHALL BE TRIED BEFORE A COURT AND NOT A JURY.
[Signature Page Follows]

IN WITNESS WHEREOF, this Term Loan and Security Agreement has been duly executed as of the day and year first above written.
BORROWER:
DIVERSICARE GLASGOW PROPERTY, LLC, a Delaware limited liability company
By:
DIVERSICARE PROPERTY CO., LLC., a Delaware limited liability company, its sole member
 
By:
/s/ James R. McKnight, Jr.
 
Name: James R. McKnight, Jr.
 
Its: Chief Financial Officer


LENDER:
THE PRIVATEBANK AND TRUST COMPANY, in its capacity as Lender
By:
/s/ Jeffrey Groenewold
 
Name: Jeffrey Groenewold         
 
Its: Officer___________________________




LIST OF EXHIBITS AND SCHEDULES
EXHIBITS
Exhibit A
Legal Description
Exhibit B
Form of Term Note
 
 
SCHEDULES
Schedule 7.12
Litigation and Proceedings



EX-31.1 4 dvcr-ex311x33115certificat.htm EXHIBIT 31.1 DVCR-EX31.1 - 3.31.15 Certification of CEO


Exhibit 31.1
CERTIFICATIONS PURSUANT TO SECTION 302 OF
THE SARBANES-OXLEY ACT OF 2002
(i) CERTIFICATION
I, Kelly J. Gill, certify that:
1. I have reviewed this quarterly report on Form 10-Q of Diversicare Healthcare Services, Inc.;
2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4. The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and we have:
(a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
(b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
(c) Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
(d) Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent quarter (the registrant’s fourth quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and
5. The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):
(a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and
(b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.
Date: May 7, 2015
 
 
/s/ Kelly J. Gill
Kelly J. Gill
Chief Executive Officer



EX-31.2 5 dvcr-ex312x33115certificat.htm EXHIBIT 31.2 DVCR-EX31.2 - 3.31.15 Certification of CFO


Exhibit 31.2
CERTIFICATIONS PURSUANT TO SECTION 302 OF
THE SARBANES-OXLEY ACT OF 2002
(ii) CERTIFICATION
I, James Reed McKnight, Jr., certify that:
1. I have reviewed this quarterly report on Form 10-Q of Diversicare Healthcare Services, Inc.;
2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4. The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and we have:
(a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
(b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
(c) Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
(d) Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent quarter (the registrant’s fourth quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and
5. The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):
(a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and
(b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.
Date:  May 7, 2015
 
/s/ James Reed McKnight, Jr.
James Reed McKnight, Jr.
Executive Vice President and Chief Financial Officer



EX-32 6 dvcr-ex32x33115certificati.htm EXHIBIT 32 DVCR-EX32 - 3.31.15 Certification


Exhibit 32
CERTIFICATION OF QUARTERLY REPORT ON FORM 10-Q
OF DIVERSICARE HEALTHCARE SERVICES, INC.
FOR THE QUARTER ENDED MARCH 31, 2015
The undersigned hereby certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that, to the undersigned’s best knowledge and belief, the Quarterly Report on Form 10-Q for Diversicare Healthcare Services, Inc. (the “Company”) for the period ending March 31, 2015 as filed with the Securities and Exchange Commission on the date hereof (the “Report”):
(a)
fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and
(b)
the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.
This Certification is executed as of May 7, 2015.

 
 
/s/ Kelly J. Gill
Kelly J. Gill
Chief Executive Officer
 
/s/ James Reed McKnight, Jr.
James Reed McKnight, Jr.
Executive Vice President and Chief Financial Officer
A signed original of this written statement required by Section 906 of the Sarbanes-Oxley Act of 2002 has been provided to the Company and will be retained by the Company and furnished to the Securities and Exchange Commission or its staff upon request.



EX-101.INS 7 avca-20150331.xml XBRL INSTANCE DOCUMENT 0000919956 2015-01-01 2015-03-31 0000919956 2015-04-30 0000919956 2015-03-31 0000919956 2014-12-31 0000919956 2014-01-01 2014-03-31 0000919956 2014-03-31 0000919956 2013-12-31 0000919956 us-gaap:MaximumMember 2014-12-31 0000919956 us-gaap:MinimumMember 2014-12-31 0000919956 avca:CreditAgreementMember 2013-05-01 2013-05-01 0000919956 avca:CreditAgreementMember 2015-01-01 2015-03-31 0000919956 avca:GlasgowKentuckyMember 2015-02-01 0000919956 us-gaap:RevolvingCreditFacilityMember 2013-05-01 0000919956 us-gaap:InterestRateSwapMember 2015-03-31 0000919956 avca:GlasgowTermLoanMember avca:ThePrivateBankMember us-gaap:LoansPayableMember 2015-02-01 2015-02-01 0000919956 avca:RevolvingCreditFacilityInterestAtFourPointFivePercentAboveLiborMember us-gaap:RevolvingCreditFacilityMember 2014-12-31 0000919956 us-gaap:LoansPayableMember 2015-03-31 0000919956 avca:CreditAgreementMember 2013-05-01 0000919956 avca:LondonInterbankOfferedRateMember 2015-03-31 0000919956 avca:RevolvingCreditFacilityInterestAtFourPointFivePercentAboveLiborMember us-gaap:RevolvingCreditFacilityMember 2015-03-31 0000919956 us-gaap:RevolvingCreditFacilityMember 2014-03-30 0000919956 us-gaap:RevolvingCreditFacilityMember 2015-03-31 0000919956 avca:RevolvingCreditFacilityInterestAtFourPointFivePercentAboveLiborMember us-gaap:LetterOfCreditMember 2015-03-31 0000919956 avca:GlasgowTermLoanMember avca:ThePrivateBankMember us-gaap:LoansPayableMember 2015-02-01 0000919956 avca:TrialOrArbitrationScheduleTimeframeMember 2015-03-31 0000919956 avca:UnaffiliatedEntitiesMember us-gaap:ProfessionalMalpracticeLiabilityMember 2015-03-31 0000919956 avca:PrefundedDeductiblePolicyMember 2015-01-01 2015-03-31 0000919956 avca:SHCRiskCarriersIncMember us-gaap:ProfessionalMalpracticeLiabilityMember 2015-01-01 2015-03-31 0000919956 avca:UnaffiliatedEntitiesMember us-gaap:ProfessionalMalpracticeLiabilityMember 2015-01-01 2015-03-31 0000919956 us-gaap:ProfessionalMalpracticeLiabilityMember 2015-03-31 0000919956 us-gaap:RestrictedStockUnitsRSUMember 2015-03-31 0000919956 us-gaap:RestrictedStockUnitsRSUMember 2015-01-01 2015-03-31 0000919956 us-gaap:RestrictedStockUnitsRSUMember 2014-12-31 0000919956 us-gaap:RestrictedStockMember 2015-01-01 2015-03-31 0000919956 avca:TwoThousandAndFiveLongTermIncentivePlanMember 2015-03-31 0000919956 us-gaap:StockAppreciationRightsSARSMember avca:TwoThousandAndTenLongTermIncentivePlanMember 2015-03-31 0000919956 avca:TwoThousandAndEightStockPurchasePlanMember 2015-01-01 2015-03-31 0000919956 avca:TwoThousandAndFiveLongTermIncentivePlanMember 2015-01-01 2015-03-31 0000919956 us-gaap:RestrictedStockMember 2014-01-01 2014-03-31 0000919956 avca:TwoThousandAndEightStockPurchasePlanMember 2015-03-31 0000919956 avca:StockOptionsAndStockAppreciationRightsSarsMember 2015-01-01 2015-03-31 0000919956 avca:StockOptionsAndStockAppreciationRightsSarsMember 2015-03-31 0000919956 avca:StockOptionsAndStockAppreciationRightsSarsMember 2014-12-31 0000919956 avca:StockOptionsAndStockAppreciationRightsSarsMember avca:StockOptionsExercisePriceRangeOneMember 2015-03-31 0000919956 avca:StockOptionsAndStockAppreciationRightsSarsMember avca:StockOptionsExercisePriceRangeTwoMember 2015-03-31 0000919956 us-gaap:EmployeeStockMember 2015-03-31 0000919956 us-gaap:EmployeeStockMember 2015-01-01 2015-03-31 0000919956 us-gaap:EmployeeStockMember 2014-12-31 0000919956 avca:StockOptionsAndStockAppreciationRightsSarsMember avca:StockOptionsExercisePriceRangeTwoMember 2015-01-01 2015-03-31 0000919956 avca:StockOptionsAndStockAppreciationRightsSarsMember avca:StockOptionsExercisePriceRangeOneMember 2015-01-01 2015-03-31 0000919956 avca:OntarioCommonsMember stpr:OH 2014-08-01 0000919956 avca:HuntsvilleAlabamaMember 2014-03-01 2014-03-01 0000919956 stpr:MO 2014-07-01 0000919956 avca:BarrenCountyHealthCareCenterIncMember avca:GlasgowKentuckyMember 2015-02-01 0000919956 stpr:OH 2014-08-01 2014-08-01 0000919956 avca:HutchinsonKansasMember us-gaap:LandAndBuildingMember us-gaap:PropertySubjectToOperatingLeaseMember 2015-02-01 2015-02-01 0000919956 avca:HuntsvilleAlabamaMember 2014-03-01 0000919956 avca:GreenvilleKentuckyMember 2014-10-01 2014-10-01 0000919956 stpr:MO 2014-07-01 2014-07-01 0000919956 stpr:OH 2014-08-01 0000919956 avca:NicholasvilleKentuckyMember 2014-06-01 0000919956 avca:NicholasvilleKentuckyMember 2014-06-01 2014-06-01 0000919956 avca:GreenvilleKentuckyMember 2014-10-01 0000919956 avca:HutchinsonKansasMember 2015-02-01 2015-02-01 0000919956 avca:SkilledNursingCenterMember avca:BarrenCountyHealthCareCenterIncMember avca:GlasgowKentuckyMember 2015-02-01 2015-02-01 0000919956 avca:HutchinsonKansasMember 2015-02-01 0000919956 avca:AvonPlaceMember stpr:OH 2014-08-01 0000919956 avca:SkilledNursingCenterMember avca:BarrenCountyHealthCareCenterIncMember avca:GlasgowKentuckyMember 2015-02-01 0000919956 avca:CullodenWestVirginiaMember avca:RoseTerraceNursingCenterMember 2014-07-01 0000919956 stpr:WV avca:RoseTerraceNursingCenterMember 2014-01-01 2014-12-31 0000919956 stpr:WV avca:RoseTerraceNursingCenterMember 2014-07-01 0000919956 stpr:WV avca:RoseTerraceNursingCenterMember 2014-01-01 2014-03-31 0000919956 avca:DanvilleandIvydaleWestVirginiaMember avca:RoseTerraceNursingCenterMember 2014-07-01 0000919956 avca:LeasedSkilledNursingCentersMember stpr:AR 2014-01-01 2014-03-31 0000919956 avca:RoseTerraceNoteMember avca:RoseTerraceNursingCenterMember us-gaap:LoansPayableMember 2014-07-01 2014-07-01 0000919956 stpr:WV avca:RoseTerraceNursingCenterMember 2014-04-03 0000919956 avca:LeasedSkilledNursingCentersMember stpr:AR 2015-01-01 2015-03-31 0000919956 stpr:WV avca:RoseTerraceNursingCenterMember 2015-01-01 2015-03-31 0000919956 avca:RoseTerraceNursingCenterMember 2014-07-01 2014-07-01 iso4217:USD avca:State avca:Lawsuit avca:Facility avca:Option xbrli:pure avca:Center iso4217:USD xbrli:shares avca:Bed avca:Letter_Of_Credit xbrli:shares avca:Insurance_Policy 7844000 7748000 13 P5Y 0.00 0.00 175000 -494000 5000 -0.11 -0.04 -0.11 -0.04 -3000 108000 0.03 P5Y 45000000 3000000 1000000 3000000 1088000 840000 2 P25Y 553000 6004 135 73 142 42 90 339 62 85 94 94 54 7 2 2 2 2 3 40 14 45 4 7 11 496 320 50 4250000 6411000 4442000 0.10 0.1 144000 1644000 249000 6.66 9000 0 0.00 0 144000 1751000 271000 262000 6.67 6.62 11.10 5.50 5.35 5.45 9.57 8.93 0.85 0.33 8.19 0.00 P10Y 249000 52000 197000 262000 52000 210000 13.85 13.85 P2Y 1501000 false --12-31 Q1 2015 2015-03-31 10-Q 0000919956 6233738 Smaller Reporting Company Diversicare Healthcare Services, Inc. 21594000 8121000 8928000 41272000 43480000 -26000 0 55014000 56793000 -495000 -553000 -338000 19970000 20174000 6044000 6533000 288000 52000 129089000 135945000 55939000 57922000 73000 37000 7000000 5778000 550000 672000 7000000 3781000 3752000 3818000 3604000 -29000 -214000 2498000 0 54000 0 360000 -1579000 0.055 0.055 0.01 0.01 20000000 20000000 6388000 6466000 6156000 6234000 64000 65000 -999000 -200000 -1024000 -200000 62824000 77145000 77701000 94375000 5000000 0.0470 0.0475 P18M 11540000 1341000 1692000 1686000 -660000 -116000 7016000 6962000 12885000 13090000 1735000 1879000 891000 7522000 -612000 -263000 767000 168000 2793000 16500000 0 0 5564000 0 86000 0 -0.19 -0.04 -0.19 -0.04 14642000 15293000 0.50 463000 571000 8000000 5114000 6051000 77799000 95225000 -433000 5000 -797000 8000 -408000 5000 -0.08 0.00 -0.08 0.00 -612000 221000 -610000 -263000 -90000 -173000 -612000 -263000 -0.11 -0.04 -0.11 -0.04 -0.11 -0.04 -3000 108000 -364000 3000 2000 84000 559000 694000 100000 716000 254000 875000 7445000 3436000 -36000 -2490000 711000 930000 246000 85000 892000 950000 739000 857000 P5Y P5Y P5Y P10Y P15Y P10Y P15Y P14Y P10Y 129089000 135945000 47142000 49849000 70193000 74800000 482000 317000 1152000 20000000 27500000 65000000 4500000 8106000 7000000 42559000 47428000 5705000 8302000 0.0687 0.0687 0.045 0.045 5000000 500000 1000000 500000 24906000 2061000 2155000 5150000 6953000 2652000 6953000 -612000 -5930000 -666000 -5930000 -4567000 -1237000 -4927000 342000 -1020000 -258000 -25000 0 -1106000 -258000 -895000 -842000 9 98000 850000 1900000 5967000 7145000 29295000 27537000 140000 178000 119000 120000 21000 58000 6359000 4932000 13366000 12942000 160000 311000 0 9000 331000 335000 86000 0 83000 104000 148000 153000 0 7000000 702000 1411000 1410000 0 0.10 0.1 200000 200000 0 0 0 0 0 0 2339000 2702000 5050000 8767000 82000 79000 -1045000 -258000 98869000 107279000 43855000 50486000 1361000 1503000 862000 443000 422000 1301000 -5285000 -5890000 11833000 12077000 14268000 14430000 141000 155000 0 0 0.00 0.00 68000 36000 74000 74000 12.31 12.31 46000 130000 61000 148000 1000 1000 22000 57000 5.09 5.44 380000 150000 700000 10.40 2.37 11.59 6.21 11754000 11296000 0 0 5000 5000 0 0 0 0 232000 232000 2500000 2500000 5975000 6045000 5975000 6045000 449000 <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">LONG-TERM DEBT AND INTEREST RATE SWAP</font></div><div style="line-height:120%;padding-top:6px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company has agreements with a syndicate of banks for a mortgage term loan ("Original Mortgage Loan") and the Company&#8217;s revolving credit agreement ("Original Revolver"). On May 1, 2013, the Company executed an Amended and Restated Credit Agreement (the "Credit Agreement") which modified the terms of the Original Mortgage Loan and the Original Revolver Agreements dated February 28, 2011. The Credit Agreement increases the Company's borrowing capacity to </font><font style="font-family:inherit;font-size:10pt;">$65,000,000</font><font style="font-family:inherit;font-size:10pt;"> allocated between a </font><font style="font-family:inherit;font-size:10pt;">$45,000,000</font><font style="font-family:inherit;font-size:10pt;"> Mortgage Loan ("Amended Mortgage Loan") and a </font><font style="font-family:inherit;font-size:10pt;">$20,000,000</font><font style="font-family:inherit;font-size:10pt;"> Revolver ("Amended Revolver"). Loan acquisition costs associated with the Amended Mortgage Loan and the Amended Revolver were capitalized in the amount of </font><font style="font-family:inherit;font-size:10pt;">$1,341,000</font><font style="font-family:inherit;font-size:10pt;"> and are being amortized over the </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">five</font><font style="font-family:inherit;font-size:10pt;">-year term of the agreements.</font></div><div style="line-height:120%;padding-top:6px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Under the terms of the amended agreements, the syndicate of banks provided the Amended Mortgage Loan with an original balance of </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$45,000,000</font><font style="font-family:inherit;font-size:10pt;"> with a </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">five</font><font style="font-family:inherit;font-size:10pt;">-year maturity through April 30, 2018, and a </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$27,500,000</font><font style="font-family:inherit;font-size:10pt;"> Amended Revolver through April 30, 2018. The Amended Mortgage Loan has a term of </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">five</font><font style="font-family:inherit;font-size:10pt;"> years, with principal and interest payable monthly based on a </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">25</font><font style="font-family:inherit;font-size:10pt;">-year amortization. Interest is based on LIBOR plus </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">4.5%</font><font style="font-family:inherit;font-size:10pt;">. A portion of the Amended Mortgage Loan is effectively fixed at </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">6.87%</font><font style="font-family:inherit;font-size:10pt;"> pursuant to an interest rate swap with a notional amount of </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$21,594,000</font><font style="font-family:inherit;font-size:10pt;">. As of </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">March&#160;31, 2015</font><font style="font-family:inherit;font-size:10pt;">, the interest rate related to the Amended Mortgage Loan was </font><font style="font-family:inherit;font-size:10pt;">4.70%</font><font style="font-family:inherit;font-size:10pt;">. The Amended Mortgage Loan is secured by </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">thirteen</font><font style="font-family:inherit;font-size:10pt;"> owned nursing centers, related equipment and a lien on the accounts receivable of these centers. The Amended Mortgage Loan and the Amended Revolver are cross-collateralized. The Company&#8217;s Amended Revolver has an interest rate of LIBOR plus </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">4.5%</font><font style="font-family:inherit;font-size:10pt;"> and is secured by accounts receivable and is subject to limits on the maximum amount of loans that can be outstanding under the revolver based on borrowing base restrictions. </font></div><div style="line-height:120%;padding-top:6px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Effective March 31, 2014, the Company entered into the Second Amendment to the Amended and Restated Revolver ("Second Amendment"). The Second Amendment temporarily increased the Amended Revolver capacity from the </font><font style="font-family:inherit;font-size:10pt;">$20,000,000</font><font style="font-family:inherit;font-size:10pt;"> in the original Amended Revolver to </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$27,500,000</font><font style="font-family:inherit;font-size:10pt;"> through September 30, 2014, as a result of the increase in receivables related to new facilities that continue to progress through the change in ownership process. Effective July 1, 2014, the Company entered into the Third Amendment to the Amended and Restated Revolver ("Third Amendment"). The Third Amendment makes the previously temporary increase to the Amended Revolver capacity from the </font><font style="font-family:inherit;font-size:10pt;">$20,000,000</font><font style="font-family:inherit;font-size:10pt;"> in the original Amended Revolver to </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$27,500,000</font><font style="font-family:inherit;font-size:10pt;">, a permanent change to the borrowing capacity as a result of the increase in receivables related to new facilities that continue to progress through the change in ownership process. </font></div><div style="line-height:120%;padding-top:6px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As of </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">March&#160;31, 2015</font><font style="font-family:inherit;font-size:10pt;">, the Company had </font><font style="font-family:inherit;font-size:10pt;">$7,000,000</font><font style="font-family:inherit;font-size:10pt;"> borrowings outstanding under the revolving credit facility compared to </font><font style="font-family:inherit;font-size:10pt;">$4,500,000</font><font style="font-family:inherit;font-size:10pt;"> outstanding as of </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2014</font><font style="font-family:inherit;font-size:10pt;">. The outstanding borrowings on the revolver primarily reflect the Company's approach to accumulated Medicaid and Medicare receivables at recently acquired facilities as these facilities proceed through the change in ownership process with CMS. Annual fees for letters of credit issued under this Revolver are </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">3.00%</font><font style="font-family:inherit;font-size:10pt;"> of the amount outstanding. The Company has </font><font style="font-family:inherit;font-size:10pt;">eleven</font><font style="font-family:inherit;font-size:10pt;"> letters of credit with a total value of </font><font style="font-family:inherit;font-size:10pt;">$8,106,000</font><font style="font-family:inherit;font-size:10pt;"> outstanding as of </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">March&#160;31, 2015</font><font style="font-family:inherit;font-size:10pt;">. Considering the balance of eligible accounts receivable, the letters of credit, the amounts outstanding under the revolving credit facility and the maximum loan amount of </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$27,500,000</font><font style="font-family:inherit;font-size:10pt;">, the balance available for borrowing under the revolving credit center is </font><font style="font-family:inherit;font-size:10pt;">$11,540,000</font><font style="font-family:inherit;font-size:10pt;"> at </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">March&#160;31, 2015</font><font style="font-family:inherit;font-size:10pt;">.</font></div><div style="line-height:120%;padding-top:6px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company&#8217;s debt agreements contain various financial covenants, the most restrictive of which relate to minimum cash deposits, cash flow and debt service coverage ratios. The Company is in compliance with all such covenants at </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">March&#160;31, 2015</font><font style="font-family:inherit;font-size:10pt;">.</font></div><div style="line-height:120%;padding-top:12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Interest Rate Swap Transaction</font></div><div style="line-height:120%;padding-top:6px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As part of the debt agreements entered into in March 2011, the Company entered into an interest rate swap agreement with a member of the bank syndicate as the counterparty. The Company designated its interest rate swap as a cash flow hedge and the earnings component of the hedge, net of taxes, is reflected as a component of other comprehensive income. In conjunction with the amendment to the credit facility, the Company retained the previously agreed upon interest rate swap terms, and redesignated the interest rate swap as a cash flow hedge. The interest rate swap agreement requires the Company to make fixed rate payments to the bank calculated on the applicable notional amount of </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$21,594,000</font><font style="font-family:inherit;font-size:10pt;"> at an annual fixed rate of </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">6.87%</font><font style="font-family:inherit;font-size:10pt;"> while the bank is obligated to make payments to the Company based on LIBOR on the same notional amounts. </font></div><div style="line-height:120%;padding-top:12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company assesses the effectiveness of its interest rate swap on a quarterly basis, and at </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">March&#160;31, 2015</font><font style="font-family:inherit;font-size:10pt;">, the Company determined that the interest rate swap was effective. The interest rate swap valuation model indicated a net liability of </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$891,000</font><font style="font-family:inherit;font-size:10pt;"> at </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">March&#160;31, 2015</font><font style="font-family:inherit;font-size:10pt;">. The fair value of the interest rate swap is included in &#8220;other noncurrent liabilities&#8221; on the Company&#8217;s interim consolidated balance sheet. The balance of accumulated other comprehensive loss at </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">March&#160;31, 2015</font><font style="font-family:inherit;font-size:10pt;"> is </font><font style="font-family:inherit;font-size:10pt;">$553,000</font><font style="font-family:inherit;font-size:10pt;"> and reflects the liability related to the interest rate swap, net of the income tax benefit of </font><font style="font-family:inherit;font-size:10pt;">$338,000</font><font style="font-family:inherit;font-size:10pt;">. As the Company&#8217;s interest rate swap is not traded on a market exchange, the fair value is determined using a valuation based on a discounted cash flow analysis. This analysis reflects the contractual terms of the interest rate swap agreement and uses observable market-based inputs, including estimated future LIBOR interest rates. The interest rate swap valuation is classified in Level 2 of the fair value hierarchy, in accordance with the FASB guidance set forth in ASC 820, </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Fair Value Measurement</font><font style="font-family:inherit;font-size:10pt;">.</font></div><div style="line-height:120%;padding-top:6px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Glasgow Term Loan</font></div><div style="line-height:120%;padding-top:6px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On February 1, 2015, in conjunction with the acquisition of Diversicare of Glasgow, a </font><font style="font-family:inherit;font-size:10pt;">94</font><font style="font-family:inherit;font-size:10pt;">-bed skilled nursing facility in Glasgow, Kentucky, the Company entered into a </font><font style="font-family:inherit;font-size:10pt;">$5,000,000</font><font style="font-family:inherit;font-size:10pt;"> Term Loan and Security Agreement (the "Glasgow term loan") with The PrivateBank in order to finance the purchase of the assets. The Glasgow term loan is an interest-only loan that has an </font><font style="font-family:inherit;font-size:10pt;">18</font><font style="font-family:inherit;font-size:10pt;">-month maturity dated August 1, 2016, and a variable interest rate based on LIBOR, with a minimum base rate of </font><font style="font-family:inherit;font-size:10pt;">4.75%</font><font style="font-family:inherit;font-size:10pt;">. See Note 9 for further information regarding the acquisition of the Glasgow facility.</font></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">CONSOLIDATION AND BASIS OF PRESENTATION OF FINANCIAL STATEMENTS</font></div><div style="line-height:120%;padding-top:6px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The interim consolidated financial statements include the operations and accounts of Diversicare Healthcare Services and its subsidiaries, all wholly-owned. All significant intercompany accounts and transactions have been eliminated in consolidation. The investment in an unconsolidated affiliate (a </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">50 percent</font><font style="font-family:inherit;font-size:10pt;">-owned joint venture partnership) is accounted for using the equity method and is described in Note&#160;8.</font></div><div style="line-height:120%;padding-top:12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The interim consolidated financial statements for the three month periods ended </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">March&#160;31, 2015</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">2014</font><font style="font-family:inherit;font-size:10pt;">, included herein have been prepared by the Company, without audit, pursuant to the rules and regulations of the Securities and Exchange Commission. Certain information and footnote disclosures normally included in financial statements prepared in accordance with accounting principles generally accepted in the United States of America have been condensed or omitted pursuant to such rules and regulations. In the opinion of management of the Company, the accompanying interim consolidated financial statements reflect all normal, recurring adjustments necessary to present fairly the Company&#8217;s financial position at </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">March&#160;31, 2015</font><font style="font-family:inherit;font-size:10pt;">, and the results of operations for the three month periods ended </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">March&#160;31, 2015</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">2014</font><font style="font-family:inherit;font-size:10pt;">, and cash flows for the three month periods ended </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">March&#160;31, 2015</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">2014</font><font style="font-family:inherit;font-size:10pt;">. The Company&#8217;s balance sheet information at </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">December&#160;31, 2014</font><font style="font-family:inherit;font-size:10pt;">, was derived from its audited consolidated financial statements as of </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">December&#160;31, 2014</font><font style="font-family:inherit;font-size:10pt;">. </font></div><div style="line-height:120%;padding-top:12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The results of operations for the periods ended </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">March&#160;31, 2015</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">2014</font><font style="font-family:inherit;font-size:10pt;"> are not necessarily indicative of the operating results that may be expected for a full year. These interim consolidated financial statements should be read in connection with the audited consolidated financial statements and notes thereto included in the Company&#8217;s Annual Report on Form 10-K for the fiscal year ended </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">December&#160;31, 2014</font><font style="font-family:inherit;font-size:10pt;">.</font></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">STOCK-BASED COMPENSATION</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Overview of Plans</font></div><div style="line-height:120%;padding-top:12px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In December 2005, the Compensation Committee of the Board of Directors adopted the 2005 Long-Term Incentive Plan (&#8220;2005 Plan&#8221;). The 2005 Plan allows the Company to issue stock options and other share and cash based awards. Under the 2005 Plan, </font><font style="font-family:inherit;font-size:10pt;">700,000</font><font style="font-family:inherit;font-size:10pt;"> shares of the Company's common stock have been reserved for issuance upon exercise of equity awards granted thereunder. All grants under this plan expire </font><font style="font-family:inherit;font-size:10pt;">10</font><font style="font-family:inherit;font-size:10pt;"> years from the date the grants were authorized by the Board of Directors.</font></div><div style="line-height:120%;padding-top:12px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In June 2008, the Company adopted the Advocat Inc. 2008 Stock Purchase Plan for Key Personnel (&#8220;Stock Purchase Plan&#8221;). The Stock Purchase Plan provides for the granting of rights to purchase shares of the Company's common stock to directors and officers and </font><font style="font-family:inherit;font-size:10pt;">150,000</font><font style="font-family:inherit;font-size:10pt;"> shares of the Company's common stock has been reserved for issuance under the Stock Purchase Plan. The Stock Purchase Plan allows participants to elect to utilize a specified portion of base salary, annual cash bonus, or director compensation to purchase restricted shares or restricted share units (&#8220;RSU's&#8221;) at </font><font style="font-family:inherit;font-size:10pt;">85%</font><font style="font-family:inherit;font-size:10pt;"> of the quoted market price of a share of the Company's common stock on the date of purchase. The restriction period under the Stock Purchase Plan is generally </font><font style="font-family:inherit;font-size:10pt;">two</font><font style="font-family:inherit;font-size:10pt;"> years from the date of purchase and during which the shares will have the rights to receive dividends, however, the restricted share certificates will not be delivered to the shareholder and the shares cannot be sold, assigned or disposed of during the restriction period. No grants can be made under the Stock Purchase Plan after April 25, 2018. </font></div><div style="line-height:120%;padding-top:12px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In April 2010, the Compensation Committee of the Board of Directors adopted the 2010 Long-Term Incentive Plan (&#8220;2010 Plan&#8221;), followed by approval by the Company's shareholders in June 2010. The 2010 Plan allows the Company to issue stock appreciation rights, stock options and other share and cash based awards. Under the 2010 Plan, </font><font style="font-family:inherit;font-size:10pt;">380,000</font><font style="font-family:inherit;font-size:10pt;"> shares of the Company's common stock have been reserved for issuance upon exercise of equity awards granted.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Equity Grants and Valuations</font></div><div style="line-height:120%;padding-top:6px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">During </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">2015</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">2014</font><font style="font-family:inherit;font-size:10pt;">, the Compensation Committee of the Board of Directors approved grants totaling approximately </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">74,000</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">68,000</font><font style="font-family:inherit;font-size:10pt;"> shares of restricted common stock to certain employees and members of the Board of Directors, respectively. The fair value of restricted shares are determined as the quoted market price of the underlying common shares at the date of the grant. The restricted shares typically vest </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">33%</font><font style="font-family:inherit;font-size:10pt;"> on the first, second and third anniversaries of the grant date. Unvested shares may not be sold or transferred. During the vesting period, dividends accrue on the restricted shares, but are paid in additional shares of common stock upon vesting, subject to the vesting provisions of the underlying restricted shares. The restricted shares are entitled to the same voting rights as other common shares. Upon vesting, all restrictions are removed. </font></div><div style="line-height:120%;padding-top:6px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Summarized activity of the equity compensation plans is presented below: </font></div><div style="line-height:120%;padding-top:6px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:474px;border-collapse:collapse;text-align:left;"><tr><td colspan="7" rowspan="1"></td></tr><tr><td width="240px" rowspan="1" colspan="1"></td><td width="108px" rowspan="1" colspan="1"></td><td width="4px" rowspan="1" colspan="1"></td><td width="9px" rowspan="1" colspan="1"></td><td width="9px" rowspan="1" colspan="1"></td><td width="99px" rowspan="1" colspan="1"></td><td width="4px" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Weighted</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Options/</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Average</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">SOSARs</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Exercise Price</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Outstanding, December 31, 2014</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">271,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6.67</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Granted</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Exercised</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(9,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8.19</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Expired or cancelled</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Outstanding, March 31, 2015</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">262,000</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6.62</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Exercisable, March 31, 2015</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">249,000</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6.66</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:6px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:474px;border-collapse:collapse;text-align:left;"><tr><td colspan="7" rowspan="1"></td></tr><tr><td width="240px" rowspan="1" colspan="1"></td><td width="108px" rowspan="1" colspan="1"></td><td width="4px" rowspan="1" colspan="1"></td><td width="9px" rowspan="1" colspan="1"></td><td width="9px" rowspan="1" colspan="1"></td><td width="99px" rowspan="1" colspan="1"></td><td width="4px" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Weighted</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Average</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Restricted</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Grant Date</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Shares</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Fair Value</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Outstanding, December 31, 2014</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">130,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5.45</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Granted</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">74,000</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">12.31</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Dividend Equivalents</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">13.85</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Vested</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(57,000</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5.44</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Cancelled</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Outstanding March 31, 2015</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">148,000</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8.93</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Summarized activity of the Restricted Share Units for the Stock Purchase Plan is as follows:</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:69.7265625%;border-collapse:collapse;text-align:left;"><tr><td colspan="7" rowspan="1"></td></tr><tr><td width="50%" rowspan="1" colspan="1"></td><td width="23%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="2%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="22%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Weighted</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Average</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Restricted</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Grant Date</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Share Units</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Fair Value</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Outstanding, December 31, 2014</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">46,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5.35</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Granted</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">36,000</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">12.31</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Dividend Equivalents</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">13.85</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Vested</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(22,000</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5.09</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Cancelled</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Outstanding March 31, 2015</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">61,000</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">9.57</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:6px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Prior to </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">2014</font><font style="font-family:inherit;font-size:10pt;">, the Compensation Committee of the Board of Directors also approved grants of Stock Only Stock Appreciation Rights (&#8220;SOSARs&#8221;) and Stock Options at the market price of the Company's common stock on the grant date. The SOSARs and Options vest </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">33%</font><font style="font-family:inherit;font-size:10pt;"> on the first, second and third anniversaries of the grant date, and expire </font><font style="font-family:inherit;font-size:10pt;">10</font><font style="font-family:inherit;font-size:10pt;"> years from the grant date. The SOSARs and Options were valued and recorded in the same manner, and will be settled with issuance of new stock for the difference between the market price on the date of exercise and the exercise price. The Company estimated the total recognized and unrecognized compensation related to SOSARs and stock options using the Black-Scholes-Merton equity grant valuation model.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In computing the fair value estimates using the Black-Scholes-Merton valuation model, the Company took into consideration the exercise price of the equity grants and the market price of the Company's stock on the date of grant. The Company used an expected volatility that equals the historical volatility over the most recent period equal to the expected life of the equity grants. The risk free interest rate is based on the U.S. treasury yield curve in effect at the time of grant. The Company used the expected dividend yield at the date of grant, reflecting the level of annual cash dividends currently being paid on its common stock.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">While no SOSARs or Options were granted during </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">2015</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">2014</font><font style="font-family:inherit;font-size:10pt;">, previously granted SOSARs and Options remain outstanding as of </font><font style="font-family:inherit;font-size:10pt;">March&#160;31, 2015</font><font style="font-family:inherit;font-size:10pt;">. The following table summarizes information regarding stock options and SOSAR grants outstanding as of </font><font style="font-family:inherit;font-size:10pt;">March&#160;31, 2015</font><font style="font-family:inherit;font-size:10pt;">:</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:88.28125%;border-collapse:collapse;text-align:left;"><tr><td colspan="19" rowspan="1"></td></tr><tr><td width="19%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="13%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="14%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="14%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="14%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="13%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Weighted</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Average</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Intrinsic</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Intrinsic</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Range of</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Exercise</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Grants</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Value-Grants</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Grants</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Value-Grants</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Exercise Prices</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Prices</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Outstanding</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Outstanding</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Exercisable</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Exercisable</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$10.40 to $11.59</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">11.10</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">52,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">144,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">52,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">144,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$2.37 to $6.21</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5.50</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">210,000</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,751,000</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">197,000</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,644,000</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">262,000</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">249,000</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Stock-based compensation expense is non-cash and is included as a component of general and administrative expense or operating expense based upon the classification of cash compensation paid to the related employees. The Company recorded total stock-based compensation expense of </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$155,000</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$141,000</font><font style="font-family:inherit;font-size:10pt;"> in the </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">three</font><font style="font-family:inherit;font-size:10pt;"> month periods ended </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">March&#160;31, 2015</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">2014</font><font style="font-family:inherit;font-size:10pt;">, respectively.</font></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:6px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Summarized activity of the equity compensation plans is presented below: </font></div><div style="line-height:120%;padding-top:6px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:474px;border-collapse:collapse;text-align:left;"><tr><td colspan="7" rowspan="1"></td></tr><tr><td width="240px" rowspan="1" colspan="1"></td><td width="108px" rowspan="1" colspan="1"></td><td width="4px" rowspan="1" colspan="1"></td><td width="9px" rowspan="1" colspan="1"></td><td width="9px" rowspan="1" colspan="1"></td><td width="99px" rowspan="1" colspan="1"></td><td width="4px" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Weighted</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Options/</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Average</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">SOSARs</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Exercise Price</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Outstanding, December 31, 2014</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">271,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6.67</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Granted</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Exercised</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(9,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8.19</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Expired or cancelled</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Outstanding, March 31, 2015</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">262,000</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6.62</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Exercisable, March 31, 2015</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">249,000</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6.66</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">DISCONTINUED OPERATIONS</font></div><div style="line-height:120%;padding-top:12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">West Virginia Disposition</font></div><div style="line-height:120%;padding-bottom:8px;padding-top:6px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Effective April 3, 2014, the Company entered into an asset purchase agreement with Rose Terrace Acq., LLC (&#8220;Purchaser&#8221;) to sell its skilled nursing facility in Culloden, West Virginia. The original asset purchase agreement was subject to a number of conditions including an amendment to the Consolidated Amended and Restated Master Lease ("Master Lease") with Omega to terminate the lease only with respect to </font><font style="font-family:inherit;font-size:10pt;">two</font><font style="font-family:inherit;font-size:10pt;"> other skilled nursing facilities in West Virginia, state licensure and regulatory approval. </font></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Effective July 1, 2014, the Company completed the transaction with Rose Terrace Acq., LLC to sell Rose Terrace, a </font><font style="font-family:inherit;font-size:10pt;">90</font><font style="font-family:inherit;font-size:10pt;">-bed skilled nursing facility in Culloden, West Virginia for a sales price of </font><font style="font-family:inherit;font-size:10pt;">$16,500,000</font><font style="font-family:inherit;font-size:10pt;">. The Company also entered into the Fifteenth Amendment to the Master Lease with Omega to terminate the lease only with respect to </font><font style="font-family:inherit;font-size:10pt;">two</font><font style="font-family:inherit;font-size:10pt;"> other skilled nursing facilities in West Virginia, and concurrently entered into an operations transfer agreement with American Health Care Management, LLC, an affiliate of the purchaser with respect to </font><font style="font-family:inherit;font-size:10pt;">two</font><font style="font-family:inherit;font-size:10pt;"> other skilled nursing facilities located in Danville and Ivydale, West Virginia. The amendment effectively reduced the annual rent payments due under the Master Lease by </font><font style="font-family:inherit;font-size:10pt;">$1,900,000</font><font style="font-family:inherit;font-size:10pt;">. Upon completion of the transaction, Diversicare no longer operates any skilled nursing centers in the state of West Virginia. In conjunction with the closing of the sale, the Company paid the balance of the </font><font style="font-family:inherit;font-size:10pt;">$8,000,000</font><font style="font-family:inherit;font-size:10pt;"> mortgage loan outstanding on the Rose Terrace facility. </font></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The transaction resulted in a gain on the disposition of Rose Terrace which, along with the results of operations for these nursing facilities, is presented within Discontinued Operations on the Consolidated Statements of Operations. The pretax gain on the transaction was </font><font style="font-family:inherit;font-size:10pt;">$7,522,000</font><font style="font-family:inherit;font-size:10pt;">. The tax expense associated with the gain was </font><font style="font-family:inherit;font-size:10pt;">$2,793,000</font><font style="font-family:inherit;font-size:10pt;"> for which the Company plans to apply net operating loss carryforwards from our deferred tax assets to substantially offset and minimize the cash outlay for this transaction.</font></div><div style="line-height:120%;padding-bottom:8px;padding-top:6px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">These centers contributed revenues of </font><font style="font-family:inherit;font-size:10pt;">$0</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">$5,564,000</font><font style="font-family:inherit;font-size:10pt;"> and net income (loss) of </font><font style="font-family:inherit;font-size:10pt;">$(90,000)</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">$221,000</font><font style="font-family:inherit;font-size:10pt;"> during the periods ended </font><font style="font-family:inherit;font-size:10pt;">March&#160;31, 2015</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">2014</font><font style="font-family:inherit;font-size:10pt;">, respectively.&#160; The net income or loss for the nursing centers included in discontinued operations does not reflect any allocation of corporate general and administrative expense or any allocation of corporate interest expense. The Company considered these additional costs along with the centers' future prospects based upon operating history when determining the contribution of the skilled nursing centers to its operations. </font></div><div style="line-height:120%;padding-bottom:8px;padding-top:6px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Other Discontinued Operations</font></div><div style="line-height:120%;padding-bottom:8px;padding-top:6px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In addition to the ongoing impact of the West Virginia discontinued operations, the Company also experienced ongoing expense during the quarter as it relates to the exit from our Arkansas operations which occurred in September 2013. The activity within Arkansas primarily relates to the progress as it relates to outstanding professional liability claims and finalizing the collection and/or write-off of remaining accounts receivable. These centers contributed net loss of </font><font style="font-family:inherit;font-size:10pt;">$(173,000)</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">$(610,000)</font><font style="font-family:inherit;font-size:10pt;"> during the periods ended </font><font style="font-family:inherit;font-size:10pt;">March&#160;31, 2015</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">2014</font><font style="font-family:inherit;font-size:10pt;">, respectively.</font></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">EARNINGS (LOSS) PER COMMON SHARE</font></div><div style="line-height:120%;padding-top:6px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Information with respect to basic and diluted net loss per common share is presented below in thousands, except per share:</font></div><div style="line-height:120%;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:75.390625%;border-collapse:collapse;text-align:left;"><tr><td colspan="9" rowspan="1"></td></tr><tr><td width="66%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="14%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="14%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Three Months Ended<br clear="none"/>March 31,</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:17px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="overflow:hidden;height:17px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:17px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">2014</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Numerator: Loss amounts attributable to Diversicare Healthcare Services, Inc. common shareholders:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:middle;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="padding-bottom:4px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Income (loss) from continuing operations</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(433</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Less: income attributable to noncontrolling interests</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">25</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:middle;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Income (loss) from continuing operations attributable to Diversicare Healthcare Services, Inc.</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(408</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Preferred stock dividends</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(86</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:middle;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Income (loss) from continuing operations attributable to Diversicare Healthcare Services, Inc. common shareholders</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(494</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Loss from discontinued operations, net of income taxes</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(263</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(612</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:middle;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net loss attributable to Diversicare Healthcare Services, Inc. common shareholders</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(258</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1,106</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr></table></div></div><div style="line-height:120%;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:75.390625%;border-collapse:collapse;text-align:left;"><tr><td colspan="9" rowspan="1"></td></tr><tr><td width="66%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="14%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="14%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Three Months Ended<br clear="none"/>March 31,</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">2014</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net loss per common share:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Per common share &#8211; basic</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:84px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Loss from continuing operations</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(0.08</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:84px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="padding-bottom:4px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Income from discontinued operations</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:108px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Operating income (loss), net of taxes</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(0.04</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(0.11</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:108px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Gain on disposal, net of taxes</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:84px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Discontinued operations, net of taxes</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(0.04</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(0.11</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:84px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net loss per common share &#8211; basic</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(0.04</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(0.19</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Per common share &#8211; diluted</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:84px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Loss from continuing operations</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(0.08</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:84px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="padding-bottom:4px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Income from discontinued operations</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:108px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Operating income, net of taxes</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(0.04</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(0.11</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:108px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Gain on disposal, net of taxes</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:84px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Discontinued operations, net of taxes</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(0.04</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(0.11</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:84px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net loss per common share - diluted</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(0.04</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(0.19</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Denominator: Weighted Average Common Shares Outstanding:</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Basic</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,045</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,975</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Diluted</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,045</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,975</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The effects of </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">52,000</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">288,000</font><font style="font-family:inherit;font-size:10pt;"> SOSARs and options outstanding were excluded from the computation of diluted earnings per common share in </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">2015</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">2014</font><font style="font-family:inherit;font-size:10pt;">, respectively, because these securities would have been anti-dilutive due to the net loss. The weighted average common shares for basic and diluted earnings for common shares were the same due to the year-to-date loss in </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">2015</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">2014</font><font style="font-family:inherit;font-size:10pt;">.</font></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"></font><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">EQUITY METHOD INVESTMENT</font></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The investment in unconsolidated affiliate reflected on the interim consolidated balance sheet relates to a pharmacy joint venture partnership in which the Company owns </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">50%</font><font style="font-family:inherit;font-size:10pt;">. The joint venture was initially funded by the Company and its partner and began operations during 2012. This investment in unconsolidated affiliate is accounted for using the equity method as the Company exerts significant influence, but does not control or otherwise consolidate the entity. The investment in unconsolidated affiliate balance at </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">March&#160;31, 2015</font><font style="font-family:inherit;font-size:10pt;">, was </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$571,000</font><font style="font-family:inherit;font-size:10pt;"> as compared to </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$463,000</font><font style="font-family:inherit;font-size:10pt;"> at </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">December&#160;31, 2014</font><font style="font-family:inherit;font-size:10pt;">. Additionally, the Company's share of the net profits and losses of the unconsolidated affiliate are reported in equity in net earnings or losses of unconsolidated affiliate in our statement of operations. The Company's equity in the net income of unconsolidated affiliate for the period ended </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;text-decoration:none;">March&#160;31, 2015</font><font style="font-family:inherit;font-size:10pt;">, was </font><font style="font-family:inherit;font-size:10pt;">$108,000</font><font style="font-family:inherit;font-size:10pt;"> as compared to a net loss of </font><font style="font-family:inherit;font-size:10pt;">$3,000</font><font style="font-family:inherit;font-size:10pt;"> for the period ended </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">March&#160;31, 2014</font><font style="font-family:inherit;font-size:10pt;">.</font></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">INSURANCE MATTERS</font></div><div style="line-height:120%;padding-top:6px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Professional Liability and Other Liability Insurance</font></div><div style="line-height:120%;padding-top:6px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company has professional liability insurance coverage for its nursing centers that, based on historical claims experience, is likely to be substantially less than the claims that are expected to be incurred. Effective July 1, 2013, the Company established a wholly-owned, consolidated offshore limited purpose insurance subsidiary, SHC Risk Carriers, Inc. (&#8220;SHC&#8221;) which has issued a policy insuring claims made against all of the Company's nursing centers in Florida and Tennessee, as well as the Company&#8217;s formerly operated Arkansas and West Virginia facilities. Several of the Company&#8217;s nursing centers in Alabama, Kentucky, Ohio, and Texas</font><font style="font-family:inherit;font-size:10pt;color:#1f497d;"> </font><font style="font-family:inherit;font-size:10pt;">are also covered under this policy. The SHC policy provides coverage limits of either </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$500,000</font><font style="font-family:inherit;font-size:10pt;"> or </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$1,000,000</font><font style="font-family:inherit;font-size:10pt;"> per medical incident with a sublimit per center of </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$1,000,000</font><font style="font-family:inherit;font-size:10pt;"> and total annual aggregate policy limits of </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$5,000,000</font><font style="font-family:inherit;font-size:10pt;">. The remaining nursing centers are covered by one of </font><font style="font-family:inherit;font-size:10pt;">seven</font><font style="font-family:inherit;font-size:10pt;"> claims made professional liability insurance policies purchased from entities unaffiliated with the Company. These policies provide coverage limits of </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$1,000,000</font><font style="font-family:inherit;font-size:10pt;"> per claim and have sublimits of </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$3,000,000</font><font style="font-family:inherit;font-size:10pt;"> per center, with varying aggregate policy limits.&#160; </font></div><div style="line-height:120%;padding-top:12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Reserve for Estimated Self-Insured Professional Liability Claims</font></div><div style="line-height:120%;padding-top:6px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Because the Company&#8217;s actual liability for existing and anticipated professional liability and general liability claims will likely exceed the Company&#8217;s limited insurance coverage, the Company has recorded total liabilities for reported and estimated future claims of </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$24,906,000</font><font style="font-family:inherit;font-size:10pt;"> as of </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">March&#160;31, 2015</font><font style="font-family:inherit;font-size:10pt;">. This accrual includes estimates of liability for incurred but not reported claims, estimates of liability for reported but unresolved claims, actual liabilities related to settlements, including settlements to be paid over time, and estimates of legal costs related to these claims. All losses are projected on an undiscounted basis and are presented without regard to any potential insurance recoveries. Amounts are added to the accrual for estimates of anticipated liability for claims incurred during each period, and amounts are deducted from the accrual for settlements paid on existing claims during each period.</font></div><div style="line-height:120%;padding-top:6px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company evaluates the adequacy of this liability on a quarterly basis. Semi-annually, the Company retains a third-party actuarial firm to assist in the evaluation of the current portion of this reserve. Merlinos&#160;&amp; Associates, Inc. (&#8220;Merlinos&#8221;) assisted management in the preparation of an estimate of the appropriate accrual for the current claims period and for incurred, but not reported general and professional liability claims based on data furnished as of November 30, 2014.&#160; The Company used this estimate from Merlinos in the preparation of its estimate of liability for incurred, but unreported professional liability claims as of as of March 31, 2015.</font></div><div style="line-height:120%;padding-top:6px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On a quarterly basis, the Company obtains reports of asserted claims and lawsuits incurred. These reports, which are provided by the Company&#8217;s insurers and a third-party claims administrator, contain information relevant to the actual expense already incurred with each claim as well as the third-party administrator&#8217;s estimate of the anticipated total cost of the claim. This information is reviewed by the Company quarterly and provided to the actuary semi-annually. Based on the Company&#8217;s evaluation of the actual claim information obtained, the semi-annual estimates received from the third-party actuary, the amounts paid and committed for settlements of claims and on estimates regarding the number and cost of additional claims anticipated in the future, the reserve estimate for a particular period may be revised upward or downward on a quarterly basis. Any increase in the accrual decreases results of operations in the period and any reduction in the accrual increases results of operations during the period. </font></div><div style="line-height:120%;padding-top:6px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As of </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">March&#160;31, 2015</font><font style="font-family:inherit;font-size:10pt;">, the Company is engaged in </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">45</font><font style="font-family:inherit;font-size:10pt;"> professional liability lawsuits. </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">Four</font><font style="font-family:inherit;font-size:10pt;"> lawsuits are currently scheduled for trial or arbitration during the next twelve months, and it is expected that additional cases will be set for trial or hearing. The Company&#8217;s cash expenditures for self-insured professional liability costs from continuing operations were </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$840,000</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$1,088,000</font><font style="font-family:inherit;font-size:10pt;"> for the </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">three</font><font style="font-family:inherit;font-size:10pt;"> months ended </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">March&#160;31, 2015</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">2014</font><font style="font-family:inherit;font-size:10pt;">, respectively.</font></div><div style="line-height:120%;padding-top:6px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Although the Company adjusts its accrual for professional and general liability claims on a quarterly basis and retains a third-party actuarial firm semi-annually to assist management in estimating the appropriate accrual, professional and general liability claims are inherently uncertain, and the liability associated with anticipated claims is very difficult to estimate. Professional liability cases have a long cycle from the date of an incident to the date a case is resolved, and final determination of the Company&#8217;s actual liability for claims incurred in any given period is a process that takes years. As a result, the Company&#8217;s actual liabilities may vary significantly from the accrual, and the amount of the accrual has and may continue to fluctuate by a material amount in any given period. Each change in the amount of this accrual will directly affect the Company&#8217;s reported earnings and financial position for the period in which the change in accrual is made.</font></div><div style="line-height:120%;padding-top:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Other Insurance</font></div><div style="line-height:120%;padding-top:6px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">With respect to workers&#8217; compensation insurance, substantially all of the Company&#8217;s employees became covered under either an indemnity insurance plan or state-sponsored programs in May 1997. The Company is completely self-insured for workers&#8217; compensation exposures prior to May 1997. The Company has been and remains a non-subscriber to the Texas workers&#8217; compensation system and is, therefore, completely self-insured for employee injuries with respect to its Texas operations. From June&#160;30, 2003 until June&#160;30, 2007, the Company&#8217;s workers&#8217; compensation insurance programs provided coverage for claims incurred with premium adjustments depending on incurred losses. For the period from July&#160;1, 2008 through </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">March&#160;31, 2015</font><font style="font-family:inherit;font-size:10pt;">, the Company is covered by a prefunded deductible policy. Under this policy, the Company is self-insured for the first </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$500,000</font><font style="font-family:inherit;font-size:10pt;"> per claim, subject to an aggregate maximum of </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$3,000,000</font><font style="font-family:inherit;font-size:10pt;">. The Company funds a loss fund account with the insurer to pay for claims below the deductible. The Company accounts for premium expense under this policy based on its estimate of the level of claims subject to the policy deductibles expected to be incurred. The liability for workers&#8217; compensation claims is </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$449,000</font><font style="font-family:inherit;font-size:10pt;"> at </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">March&#160;31, 2015</font><font style="font-family:inherit;font-size:10pt;">. The Company has a non-current receivable for workers&#8217; compensation policies covering previous years of </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$1,501,000</font><font style="font-family:inherit;font-size:10pt;"> as of </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">March&#160;31, 2015</font><font style="font-family:inherit;font-size:10pt;">. The non-current receivable is a function of payments paid to the Company&#8217;s insurance carrier in excess of the estimated level of claims expected to be incurred.</font></div><div style="line-height:120%;padding-top:12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As of </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">March&#160;31, 2015</font><font style="font-family:inherit;font-size:10pt;">, the Company is self-insured for health insurance benefits for certain employees and dependents for amounts up to </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$175,000</font><font style="font-family:inherit;font-size:10pt;"> per individual annually. The Company provides reserves for the settlement of outstanding self-insured health claims at amounts believed to be adequate. The liability for reported claims and estimates for incurred but unreported claims is </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$1,152,000</font><font style="font-family:inherit;font-size:10pt;"> at </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">March&#160;31, 2015</font><font style="font-family:inherit;font-size:10pt;">. The differences between actual settlements and reserves are included in expense in the period finalized.</font></div><div style="line-height:120%;padding-top:6px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company follows current accounting guidance set forth in FASB ASU 2010-24, &#8220;Presentation of Insurance Claims and Related Insurance Recoveries,&#8221; that clarifies that a health care entity should not net insurance recoveries against a related claim, and that the amount of the claim liability should be determined without consideration of insurance recoveries. Accordingly, the Company has recorded assets and equal liabilities of </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$85,000</font><font style="font-family:inherit;font-size:10pt;"> at </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">March&#160;31, 2015</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$246,000</font><font style="font-family:inherit;font-size:10pt;"> at </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">December&#160;31, 2014</font><font style="font-family:inherit;font-size:10pt;">, respectively.</font></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">BUSINESS</font></div><div style="line-height:120%;padding-top:6px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Diversicare Healthcare Services, Inc. (together with its subsidiaries, &#8220;Diversicare Healthcare Services&#8221; or the &#8220;Company&#8221;) provides long-term care services to nursing center patients in </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">nine</font><font style="font-family:inherit;font-size:10pt;"> states, primarily in the Southeast, Midwest, and Southwest. The Company&#8217;s centers provide a range of health care services to their patients and residents that include nursing, personal care, and social services. Additionally, the Company&#8217;s nursing centers also offer a variety of comprehensive rehabilitation services, as well as nutritional support services. The Company's continuing operations include centers in Alabama, Florida, Indiana, Kansas, Kentucky, Missouri, Ohio, Tennessee, and Texas.</font></div><div style="line-height:120%;padding-top:6px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As of </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">March&#160;31, 2015</font><font style="font-family:inherit;font-size:10pt;">, the Company&#8217;s continuing operations consist of </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">54</font><font style="font-family:inherit;font-size:10pt;"> nursing centers with </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">6,004</font><font style="font-family:inherit;font-size:10pt;"> licensed nursing beds. The Company owns </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">14</font><font style="font-family:inherit;font-size:10pt;"> and leases </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">40</font><font style="font-family:inherit;font-size:10pt;"> of its nursing centers. Our nursing centers range in size from </font><font style="font-family:inherit;font-size:10pt;">50</font><font style="font-family:inherit;font-size:10pt;"> to </font><font style="font-family:inherit;font-size:10pt;">320</font><font style="font-family:inherit;font-size:10pt;"> licensed nursing beds. The licensed nursing bed count does not include </font><font style="font-family:inherit;font-size:10pt;">496</font><font style="font-family:inherit;font-size:10pt;"> licensed assisted living beds.</font></div></div><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">BUSINESS DEVELOPMENT</font></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Acquisitions</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On February 1, 2015, the Company entered into an Asset Purchase Agreement (the &#8220;Purchase Agreement&#8221;) with Barren County Health Care Center, Inc. to acquire certain land, improvements, furniture, fixtures and equipment, personal property and intangible property, together comprising a </font><font style="font-family:inherit;font-size:10pt;">94</font><font style="font-family:inherit;font-size:10pt;">-bed skilled nursing center in Glasgow, Kentucky, for an aggregate purchase price of </font><font style="font-family:inherit;font-size:10pt;">$7,000,000</font><font style="font-family:inherit;font-size:10pt;"> partially financed through a </font><font style="font-family:inherit;font-size:10pt;">$5,000,000</font><font style="font-family:inherit;font-size:10pt;"> mortgage loan with The PrivateBank with the balance paid in cash consideration. </font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As a result of the consummation of the Agreement, the Company allocated the purchase price of </font><font style="font-family:inherit;font-size:10pt;">$7,000,000</font><font style="font-family:inherit;font-size:10pt;"> between the assets associated with the transaction based on the fair value of the acquired net assets. The allocation of the purchase price was determined with the assistance of HealthTrust LLC, a third-party real estate valuation firm. The allocation for the net assets acquired is as follows:</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:52.34375%;border-collapse:collapse;text-align:left;"><tr><td colspan="4" rowspan="1"></td></tr><tr><td width="63%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="35%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">February 1, 2015</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Purchase Price</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7,000,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Land</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">672,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Buildings</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,778,000</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Furniture, Fixtures, and Equipment</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">550,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7,000,000</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Lease Agreements</font></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">During the the first quarter of 2015 and the year ended December 31, 2014, the Company has completed several transactions to assume the operations of additional nursing centers through the assumption of long-term operating leases. The transactions during these periods are as follows:</font></div><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On February 1, 2015, the Company assumed operations at Diversicare of Hutchinson, an </font><font style="font-family:inherit;font-size:10pt;">85</font><font style="font-family:inherit;font-size:10pt;">-bed skilled nursing center in Hutchinson, Kansas. The facility has an initial lease term of </font><font style="font-family:inherit;font-size:10pt;">10</font><font style="font-family:inherit;font-size:10pt;"> years and includes an option to purchase at a fixed price of </font><font style="font-family:inherit;font-size:10pt;">$4,250,000</font><font style="font-family:inherit;font-size:10pt;">, exercisable after the first year of the lease. The center was already operating and treating patients on the transition date. There was no purchase price paid to enter into the lease agreement for this skilled nursing center. </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On October 1, 2014, the Company assumed operations at Diversicare of Greenville, a </font><font style="font-family:inherit;font-size:10pt;">62</font><font style="font-family:inherit;font-size:10pt;">-bed skilled nursing facility in Greenville, Kentucky. This facility has an initial lease terms of </font><font style="font-family:inherit;font-size:10pt;">14</font><font style="font-family:inherit;font-size:10pt;"> years. The center was already operating and treating patients on the transition date. There was no purchase price paid to enter into the lease agreement for this skilled nursing center. </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On August 1, 2014, the Company assumed operations of </font><font style="font-family:inherit;font-size:10pt;">two</font><font style="font-family:inherit;font-size:10pt;"> centers in Ohio. The centers included in this transaction are a </font><font style="font-family:inherit;font-size:10pt;">142</font><font style="font-family:inherit;font-size:10pt;">-bed skilled nursing facility and a </font><font style="font-family:inherit;font-size:10pt;">42</font><font style="font-family:inherit;font-size:10pt;">-bed assisted living center. The lease provides for an initial lease term of </font><font style="font-family:inherit;font-size:10pt;">10</font><font style="font-family:inherit;font-size:10pt;"> years. The centers were already operating and treating patients on the transition date. There was no purchase price paid to enter into the lease agreement for these skilled nursing centers. </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On July 1, 2014, the Company completed a transaction to enter the state of Missouri through the assumption of operations of </font><font style="font-family:inherit;font-size:10pt;">three</font><font style="font-family:inherit;font-size:10pt;"> facilities totaling </font><font style="font-family:inherit;font-size:10pt;">339</font><font style="font-family:inherit;font-size:10pt;"> skilled nursing beds. The lease provides for an initial </font><font style="font-family:inherit;font-size:10pt;">15</font><font style="font-family:inherit;font-size:10pt;">-year lease term with a </font><font style="font-family:inherit;font-size:10pt;">5</font><font style="font-family:inherit;font-size:10pt;">-year renewal option. The centers were already operating and treating patients on the transition date. There was no purchase price paid to enter into the lease agreement for these skilled nursing centers. </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On June 1, 2014, the Company assumed operations at Diversicare of Nicholasville, an existing </font><font style="font-family:inherit;font-size:10pt;">73</font><font style="font-family:inherit;font-size:10pt;">-bed facility in Nicholasville, Kentucky. The lease provides for an initial </font><font style="font-family:inherit;font-size:10pt;">15</font><font style="font-family:inherit;font-size:10pt;">-year lease term with a </font><font style="font-family:inherit;font-size:10pt;">5</font><font style="font-family:inherit;font-size:10pt;">-year renewal option. The center was already operating and treating patients on the transition date. There was no purchase price paid to enter into the lease agreement for this skilled nursing center. </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On March 1, 2014, the Company assumed operations at Diversicare of Big Springs, an existing </font><font style="font-family:inherit;font-size:10pt;">135</font><font style="font-family:inherit;font-size:10pt;">-bed facility in Huntsville, Alabama. The nursing center is owned by an unrelated third-party and the lease provides for an initial </font><font style="font-family:inherit;font-size:10pt;">10</font><font style="font-family:inherit;font-size:10pt;">-year lease term with </font><font style="font-family:inherit;font-size:10pt;">two</font><font style="font-family:inherit;font-size:10pt;"> additional </font><font style="font-family:inherit;font-size:10pt;">5</font><font style="font-family:inherit;font-size:10pt;">-year renewal options. The additional skilled nursing center increases the Company's footprint in Alabama to </font><font style="font-family:inherit;font-size:10pt;">seven</font><font style="font-family:inherit;font-size:10pt;"> centers, and the third center in the Huntsville market. The center was already operating and treating patients on the transition date. There was no purchase price paid to enter into the lease agreement for this skilled nursing center.</font></div></td></tr></table></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">RECENT ACCOUNTING GUIDANCE</font></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In April 2014, the FASB issued ASU 2014-08,&#160;</font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Presentation of Financial Statements (Topic 205) and Property, Plant, and Equipment (Topic 360): Reporting Discontinued Operations and Disclosures of Disposals of Components of an Entity</font><font style="font-family:inherit;font-size:10pt;">&#160;changing the criteria for reporting discontinued operations. The ASU states that only those disposed components (or components held-for-sale) representing a strategic shift that have a significant effect on operations and financial results will be reported in discontinued operations. The ASU also required expanded disclosures about discontinued operations in the financial statement notes. The ASU is effective for disposals (or classifications as held-for-sale) that occur within annual periods beginning on or after December&#160;15, 2014 and interim periods within those annual periods. Early application is permitted, but only for those disposals that have not been reported in financial statements previously issued or available for issuance. We chose to early adopt this ASU and applied the new criteria in determining the accounting treatment for the nursing centers exited during 2014. The adoption of this guidance did not have a material impact on the Company's consolidated financial statements.</font></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In May 2014, the FASB issued ASU No.&#160;2014-09,&#160;</font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Revenue from Contracts with Customers (Topic 606)</font><font style="font-family:inherit;font-size:10pt;">, which requires an entity to recognize the amount of revenue to which it expects to be entitled for the transfer of promised goods or services to customers. The ASU will replace most existing revenue recognition guidance in U.S. GAAP when it becomes effective. The new standard is effective for the Company on January&#160;1, 2017. Early application is not permitted. The standard permits the use of either the retrospective or cumulative effect transition method. The Company is evaluating the effect that ASU 2014-09 will have on its consolidated financial statements and related disclosures. The Company has not yet selected a transition method nor has it determined the effect of the standard on its ongoing financial reporting.</font></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:6px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Information with respect to basic and diluted net loss per common share is presented below in thousands, except per share:</font></div><div style="line-height:120%;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:75.390625%;border-collapse:collapse;text-align:left;"><tr><td colspan="9" rowspan="1"></td></tr><tr><td width="66%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="14%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="14%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Three Months Ended<br clear="none"/>March 31,</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:17px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="overflow:hidden;height:17px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:17px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">2014</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Numerator: Loss amounts attributable to Diversicare Healthcare Services, Inc. common shareholders:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:middle;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="padding-bottom:4px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Income (loss) from continuing operations</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(433</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Less: income attributable to noncontrolling interests</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">25</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:middle;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Income (loss) from continuing operations attributable to Diversicare Healthcare Services, Inc.</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(408</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Preferred stock dividends</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(86</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:middle;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Income (loss) from continuing operations attributable to Diversicare Healthcare Services, Inc. common shareholders</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(494</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Loss from discontinued operations, net of income taxes</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(263</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(612</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:middle;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net loss attributable to Diversicare Healthcare Services, Inc. common shareholders</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(258</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1,106</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr></table></div></div><div style="line-height:120%;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:75.390625%;border-collapse:collapse;text-align:left;"><tr><td colspan="9" rowspan="1"></td></tr><tr><td width="66%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="14%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="14%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Three Months Ended<br clear="none"/>March 31,</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">2014</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net loss per common share:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Per common share &#8211; basic</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:84px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Loss from continuing operations</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(0.08</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:84px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="padding-bottom:4px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Income from discontinued operations</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:108px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Operating income (loss), net of taxes</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(0.04</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(0.11</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:108px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Gain on disposal, net of taxes</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:84px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Discontinued operations, net of taxes</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(0.04</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(0.11</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:84px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net loss per common share &#8211; basic</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(0.04</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(0.19</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Per common share &#8211; diluted</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:84px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Loss from continuing operations</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(0.08</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:84px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="padding-bottom:4px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Income from discontinued operations</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:108px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Operating income, net of taxes</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(0.04</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(0.11</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:108px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Gain on disposal, net of taxes</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:84px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Discontinued operations, net of taxes</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(0.04</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(0.11</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:84px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net loss per common share - diluted</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(0.04</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(0.19</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Denominator: Weighted Average Common Shares Outstanding:</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Basic</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,045</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,975</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Diluted</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,045</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,975</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr></table></div></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The allocation for the net assets acquired is as follows:</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:52.34375%;border-collapse:collapse;text-align:left;"><tr><td colspan="4" rowspan="1"></td></tr><tr><td width="63%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="35%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">February 1, 2015</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Purchase Price</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7,000,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Land</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">672,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Buildings</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,778,000</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Furniture, Fixtures, and Equipment</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">550,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7,000,000</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following table summarizes information regarding stock options and SOSAR grants outstanding as of </font><font style="font-family:inherit;font-size:10pt;">March&#160;31, 2015</font><font style="font-family:inherit;font-size:10pt;">:</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:88.28125%;border-collapse:collapse;text-align:left;"><tr><td colspan="19" rowspan="1"></td></tr><tr><td width="19%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="13%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="14%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="14%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="14%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="13%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Weighted</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Average</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Intrinsic</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Intrinsic</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Range of</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Exercise</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Grants</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Value-Grants</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Grants</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Value-Grants</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Exercise Prices</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Prices</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Outstanding</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Outstanding</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Exercisable</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Exercisable</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$10.40 to $11.59</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">11.10</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">52,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">144,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">52,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">144,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$2.37 to $6.21</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5.50</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">210,000</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,751,000</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">197,000</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,644,000</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">262,000</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">249,000</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr></table></div></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:6px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:474px;border-collapse:collapse;text-align:left;"><tr><td colspan="7" rowspan="1"></td></tr><tr><td width="240px" rowspan="1" colspan="1"></td><td width="108px" rowspan="1" colspan="1"></td><td width="4px" rowspan="1" colspan="1"></td><td width="9px" rowspan="1" colspan="1"></td><td width="9px" rowspan="1" colspan="1"></td><td width="99px" rowspan="1" colspan="1"></td><td width="4px" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Weighted</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Average</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Restricted</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Grant Date</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Shares</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Fair Value</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Outstanding, December 31, 2014</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">130,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5.45</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Granted</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">74,000</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">12.31</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Dividend Equivalents</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">13.85</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Vested</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(57,000</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5.44</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Cancelled</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Outstanding March 31, 2015</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">148,000</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8.93</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Summarized activity of the Restricted Share Units for the Stock Purchase Plan is as follows:</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:69.7265625%;border-collapse:collapse;text-align:left;"><tr><td colspan="7" rowspan="1"></td></tr><tr><td width="50%" rowspan="1" colspan="1"></td><td width="23%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="2%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="22%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Weighted</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Average</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Restricted</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Grant Date</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Share Units</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Fair Value</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Outstanding, December 31, 2014</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">46,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5.35</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Granted</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">36,000</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">12.31</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Dividend Equivalents</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">13.85</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Vested</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(22,000</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5.09</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Cancelled</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Outstanding March 31, 2015</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">61,000</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">9.57</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div> EX-101.SCH 8 avca-20150331.xsd XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT 2101100 - Disclosure - Business link:presentationLink link:calculationLink link:definitionLink 2401401 - Disclosure - Business (Details) link:presentationLink link:calculationLink link:definitionLink 2109100 - Disclosure - Business Development link:presentationLink link:calculationLink link:definitionLink 2409402 - Disclosure - Business Development (Details) link:presentationLink link:calculationLink link:definitionLink 2409403 - Disclosure - Business Development (Schedule of Assets Acquired) (Details) link:presentationLink link:calculationLink link:definitionLink 2309301 - Disclosure - Business Development (Tables) link:presentationLink link:calculationLink link:definitionLink 2102100 - Disclosure - Consolidation and Basis of Presentation of Financial Statements link:presentationLink link:calculationLink link:definitionLink 2402401 - Disclosure - Consolidation and Basis of Presentation of Financial Statements (Details) link:presentationLink link:calculationLink link:definitionLink 2110100 - Disclosure - Discontinued Operations link:presentationLink link:calculationLink link:definitionLink 2410401 - Disclosure - Discontinued Operations (Details) link:presentationLink link:calculationLink link:definitionLink 0001000 - Document - Document and Entity Information link:presentationLink link:calculationLink link:definitionLink 2107100 - Disclosure - Earnings (Loss) Per Common Share link:presentationLink link:calculationLink link:definitionLink 2407402 - Disclosure - Earnings (Loss) Per Common Share (Details) link:presentationLink link:calculationLink link:definitionLink 2407403 - Disclosure - Earnings (Loss) Per Common Share (Details Textual) link:presentationLink link:calculationLink link:definitionLink 2307301 - Disclosure - Earnings (Loss) Per Common Share (Tables) link:presentationLink link:calculationLink link:definitionLink 2108100 - Disclosure - Equity Method Investment link:presentationLink link:calculationLink link:definitionLink 2408401 - Disclosure - Equity Method Investment (Details) link:presentationLink link:calculationLink link:definitionLink 2105100 - Disclosure - Insurance Matters link:presentationLink link:calculationLink link:definitionLink 2405401 - Disclosure - Insurance Matters (Details) link:presentationLink link:calculationLink link:definitionLink 1001000 - Statement - Interim Consolidated Balance Sheets link:presentationLink link:calculationLink link:definitionLink 1001501 - Statement - Interim Consolidated Balance Sheets (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 1004000 - Statement - Interim Consolidated Statements of Cash Flows (Unaudited) link:presentationLink link:calculationLink link:definitionLink 1003000 - Statement - Interim Consolidated Statements of Comprehensive Income (Loss) (Unaudited) link:presentationLink link:calculationLink link:definitionLink 1002000 - Statement - Interim Consolidated Statements of Operations (Unaudited) link:presentationLink link:calculationLink link:definitionLink 1002501 - Statement - Interim Consolidated Statements of Operations (Unaudited) (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 2104100 - Disclosure - Long-Term Debt and Interest Rate Swap link:presentationLink link:calculationLink link:definitionLink 2404401 - Disclosure - Long-Term Debt and Interest Rate Swap (Details) link:presentationLink link:calculationLink link:definitionLink 2103100 - Disclosure - Recent Accounting Guidance link:presentationLink link:calculationLink link:definitionLink 2406403 - Disclosure - Share-Based Compensation (Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding and Exercisable) (Details) link:presentationLink link:calculationLink link:definitionLink 2106100 - Disclosure - Stock-Based Compensation link:presentationLink link:calculationLink link:definitionLink 2406402 - Disclosure - Stock-Based Compensation (Details) link:presentationLink link:calculationLink link:definitionLink 2406404 - Disclosure - Stock-Based Compensation (Restricted Stock and Restricted Stock Units Activity) (Details) link:presentationLink link:calculationLink link:definitionLink 2406405 - Disclosure - Stock-Based Compensation (Schedule of Stock Options Outstanding and Exercisable) (Details) link:presentationLink link:calculationLink link:definitionLink 2306301 - Disclosure - Stock-Based Compensation (Tables) link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 9 avca-20150331_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT EX-101.DEF 10 avca-20150331_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT EX-101.LAB 11 avca-20150331_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT Organization, Consolidation and Presentation of Financial Statements [Abstract] Entity Location [Table] Entity Location [Table] Geographical [Axis] Geographical [Axis] Geographical [Domain] Geographical [Domain] Glasgow, Kentucky Glasgow, Kentucky [Member] Glasgow, Kentucky [Member] Ohio OHIO Missouri MISSOURI Nicholasville, Kentucky Nicholasville, Kentucky [Member] Nicholasville, Kentucky [Member] Business Acquisition [Axis] Business Acquisition [Axis] Business Acquisition, Acquiree [Domain] Business Acquisition, Acquiree [Domain] Skilled Nursing Center Skilled Nursing Center [Member] Skilled Nursing Center [Member] Avon Place Avon Place [Member] Avon Place [Member] Ontario Commons Ontario Commons [Member] Ontario Commons [Member] Counterparty Name [Axis] Counterparty Name [Axis] Counterparty Name [Domain] Counterparty Name [Domain] Barren County Health Care Center Inc Barren County Health Care Center Inc [Member] Barren County Health Care Center Inc [Member] Entity by Location [Axis] Entity by Location [Axis] Location [Domain] Location [Domain] Hutchinson, Kansas Hutchinson, Kansas [Member] Hutchinson, Kansas [Member] Greenville, Kentucky Greenville, Kentucky [Member] Greenville, Kentucky [Member] Huntsville, Alabama Huntsville, Alabama [Member] Huntsville, Alabama [Member] Long-term Debt, Type [Axis] Long-term Debt, Type [Axis] Long-term Debt, Type [Domain] Long-term Debt, Type [Domain] Loans Payable Loans Payable [Member] Debt Instrument [Axis] Debt Instrument [Axis] Debt Instrument, Name [Domain] Debt Instrument, Name [Domain] Glasgow Term Loan Glasgow Term Loan [Member] Glasgow Term Loan [Member] Lender Name [Axis] Lender Name [Axis] Line of Credit Facility, Lender [Domain] Line of Credit Facility, Lender [Domain] The PrivateBank The PrivateBank [Member] The PrivateBank [Member] Property Subject to or Available for Operating Lease [Axis] Property Subject to or Available for Operating Lease [Axis] Property Subject to or Available for Operating Lease [Domain] Property Subject to or Available for Operating Lease [Domain] Property Subject to Operating Lease Property Subject to Operating Lease [Member] Major Property Class [Axis] Major Property Class [Axis] Major Property Class [Domain] Major Property Class [Domain] Skilled nursing center Land and Building [Member] Entity Location [Line Items] Entity Location [Line Items] Number of licensed nursing beds Number of Licensed Nursing Beds Number of licensed nursing beds. Purchase Price Business Combination, Consideration Transferred Amount of term loan Debt Instrument, Face Amount Lease agreement term Lessee Leasing Arrangements, Operating Leases, Term of Contract Option to purchase at fixed price Operating Lease, Option to Purchase, Purchase Price Operating Lease, Option to Purchase, Purchase Price Number of nursing centers Number Of Nursing Center Facilities Number Of Nursing Center Facilities Lease renewal period Lessee Leasing Arrangements, Operating Leases, Renewal Term Maximum number of capital lease renewal periods Maximum Number Of Lease Renewal Periods Maximum Number Of Lease Renewal Periods Equity Method Investments and Joint Ventures [Abstract] EQUITY METHOD INVESTMENT Equity Method Investments and Joint Ventures Disclosure [Text Block] Disclosure of Compensation Related Costs, Share-based Payments [Abstract] Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table] Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table] Plan Name [Axis] Plan Name [Axis] Plan Name [Domain] Plan Name [Domain] 2005 Long Term Incentive Plan Two Thousand And Five Long Term Incentive Plan [Member] Two Thousand And Five Long Term Incentive Plan [Member] 2008 Stock Purchase Plan Two Thousand And Eight Stock Purchase Plan [Member] Two Thousand And Eight Stock Purchase Plan [Member] 2010 Long Term Incentive Plan Two Thousand And Ten Long Term Incentive Plan [Member] Two Thousand And Ten Long Term Incentive Plan [Member] Award Type [Axis] Award Type [Axis] Award Type [Domain] Equity Award [Domain] Stock Only Stock Appreciation Rights (SOSARS) Stock Appreciation Rights (SARs) [Member] Restricted Stock Restricted Stock [Member] Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Number of shares reserved for future issuance Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized Expiration period Share Based Compensation Arrangements By Share Based Payment Award Option Expiration Period Share Based Compensation Arrangements By Share Based Payment Award Option Expiration Period Percentage of quoted market price offering rate Share Based Compensation Arrangement By Share Based Payment Award Market Price Offering Date Share Based Compensation Arrangement By Share Based Payment Award Market Price Offering Date Restriction period Stock Based Compensation Arrangement By Share Based Payment Award Restriction Period Stock Based Compensation Arrangement By Share Based Payment Award Restriction Period Grant of restricted common stock (shares) Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period Vest of restricted stock on each year (percentage) Share-based Compensation Arrangement by Share-based Payment Award, Vesting Percentage Share-based Compensation Arrangement by Share-based Payment Award, Vesting Percentage Stock-based compensation Share-based Compensation BUSINESS DEVELOPMENT Nature of Operations [Text Block] Statement of Financial Position [Abstract] CURRENT ASSETS: Assets, Current [Abstract] Cash and cash equivalents Cash and Cash Equivalents, at Carrying Value Receivables, less allowance for doubtful accounts of $6,533 and $6,044, respectively Accounts Receivable, Net, Current Other receivables Receivables, Net, Current Prepaid expenses and other current assets Prepaid Expense and Other Assets, Current Income tax refundable Income Taxes Receivable, Current Current assets of discontinued operations Disposal Group, Including Discontinued Operation, Assets, Current Deferred income taxes Deferred Tax Assets, Net of Valuation Allowance, Current Total current assets Assets, Current PROPERTY AND EQUIPMENT, at cost Property, Plant and Equipment, Gross Less accumulated depreciation and amortization Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment Discontinued operations, net Disposal Group, Including Discontinued Operation, Property, Plant and Equipment Property and equipment, net Property, Plant and Equipment, Net OTHER ASSETS: Other Assets, Noncurrent [Abstract] Deferred income taxes Deferred Tax Assets, Net of Valuation Allowance, Noncurrent Deferred financing and other costs, net Deferred Costs Investment in unconsolidated affiliate Equity Method Investments Other noncurrent assets Other Noncurrent Assets Other assets. Acquired leasehold interest, net Acquired Leasehold Interest, Net Noncurrent Acquired leasehold interest, net. Total other assets Other Assets, Noncurrent Total assets Assets CURRENT LIABILITIES: Liabilities, Current [Abstract] Current portion of long-term debt and capitalized lease obligations Long-term Debt and Capital Lease Obligations, Current Trade accounts payable Accounts Payable, Trade, Current Current liabilities of discontinued operations Disposal Group, Including Discontinued Operation, Liabilities, Current Accrued expenses: Accrued Liabilities, Current [Abstract] Payroll and employee benefits Employee-related Liabilities, Current Self-insurance reserves, current portion Self Insurance Reserve, Current Other current liabilities Other Liabilities, Current Total current liabilities Liabilities, Current NONCURRENT LIABILITIES: Liabilities, Noncurrent [Abstract] Long-term debt and capitalized lease obligations, less current portion Long-term Debt and Capital Lease Obligations Self-insurance reserves, noncurrent portion Self Insurance Reserve, Noncurrent Other noncurrent liabilities Other Liabilities, Noncurrent Total noncurrent liabilities Liabilities, Noncurrent COMMITMENTS AND CONTINGENCIES Commitments and Contingencies Series C redeemable preferred stock, $.10 par value, 5,000 shares authorized, none issued and outstanding Temporary Equity, Carrying Amount, Attributable to Parent SHAREHOLDERS’ EQUITY: Stockholders' Equity Attributable to Parent [Abstract] Series A preferred stock, authorized 200,000 shares, $.10 par value, none issued and outstanding Preferred Stock, Value, Issued Common stock, authorized 20,000,000 shares, $.01 par value, 6,466,000 and 6,388,000 shares issued, and 6,234,000 and 6,156,000 shares outstanding, respectively Common Stock, Value, Issued Treasury stock at cost, 232,000 shares of common stock Treasury Stock, Value Paid-in capital Additional Paid in Capital, Common Stock Accumulated deficit Retained Earnings (Accumulated Deficit) Accumulated other comprehensive loss Accumulated Other Comprehensive Income (Loss), Net of Tax Total shareholders’ equity Stockholders' Equity Attributable to Parent Total liabilities and shareholder's equity Liabilities and Equity Debt Disclosure [Abstract] LONG-TERM DEBT AND INTEREST RATE SWAP Long Term Debt And Derivative Instruments [Text Block] Long Term Debt And Derivative Instruments [Text Block] Earnings Per Share [Abstract] Earnings (Loss) Per Common Share (Textual) [Abstract] Earnings Loss Per Common Share (Textual) [Abstract] Earnings loss per common share. Antidilutive shares excluded from computation of diluted earnings per share Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount Schedule of Recognized Identified Assets Acquired and Liabilities Assumed Schedule of Recognized Identified Assets Acquired and Liabilities Assumed [Table Text Block] Accounting Changes and Error Corrections [Abstract] RECENT ACCOUNTING GUIDANCE New Accounting Pronouncements and Changes in Accounting Principles [Text Block] Percentage of owned joint venture Investment in nonconsolidated affiliate Equity Method Investment, Ownership Percentage Equity in net income (loss) of unconsolidated affiliate Income (Loss) from Equity Method Investments Stock Options and Stock Appreciation Rights (SARs) Stock Options and Stock Appreciation Rights (SARs) [Member] Stock Options and Stock Appreciation Rights (SARs) [Member] Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward] Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward] Outstanding, December 31, 2014 Share Based Compensation Arrangement By Share Based Payment Award Awards Outstanding Number Share Based Compensation Arrangement By Share Based Payment Award Awards Outstanding Number Granted Share-based Compensation Arrangement by Share-based Payment Award, Awards, Grants in Period, Gross Share-based Compensation Arrangement by Share-based Payment Award, Awards, Grants in Period, Gross Exercised Share-based Compensation Arrangement By Share Based Payment Award Awards Exercises In Period Share-based Compensation Arrangement By Share Based Payment Award Awards Exercises In Period Expired or cancelled Share Based Compensation Arrangement By Share Based Payment Award Awards Forfeitures And Expirations In Period Share Based Compensation Arrangement By Share Based Payment Award Awards Forfeitures And Expirations In Period Outstanding, March 31, 2015 Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract] Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract] Outstanding, December 31, 2014 Share Based Compensation Arrangement By Share Based Payment Award Awards Outstanding Weighted Average Exercise Price Share Based Compensation Arrangement By Share Based Payment Award Awards Outstanding Weighted Average Exercise Price Granted Share Based Compensation Arrangements By Share Based Payment Award Awards Grants In Period Weighted Average Exercise Price Share Based Compensation Arrangements By Share Based Payment Award Awards Grants In Period Weighted Average Exercise Price Exercised Share Based Compensation Arrangements By Share Based Payment Award Awards Exercises In Period Weighted Average Exercise Price Share Based Compensation Arrangements By Share Based Payment Award Awards Exercises In Period Weighted Average Exercise Price Expired or cancelled Share Based Compensation Arrangement By Share Based Payment Award Awards Forfeitures And Expirations In Period Weighted Average Exercise Price Share Based Compensation Arrangement By Share Based Payment Award Awards Forfeitures And Expirations In Period Weighted Average Exercise Price Outstanding, March 31, 2015 Exercisable, shares Share Based Compensation Arrangement By Share Based Payment Award Awards Exercisable Number Share Based Compensation Arrangement By Share Based Payment Award Awards Exercisable Number Exercisable, Weighted Average Exercise Price Share Based Compensation Arrangement By Share Based Payment Award Awards Exercisable Weighted Average Exercise Price Share Based Compensation Arrangement By Share Based Payment Award Awards Exercisable Weighted Average Exercise Price CONSOLIDATION AND BASIS OF PRESENTATION OF FINANCIAL STATEMENTS Business Description and Basis of Presentation [Text Block] STOCK-BASED COMPENSATION Disclosure of Compensation Related Costs, Share-based Payments [Text Block] Per common share – basic and diluted Earnings Per Share, Basic and Diluted [Abstract] Numerator: Loss amounts attributable to Diversicare Healthcare Services, Inc. common shareholders: Income Amounts Attributable to Parent, Disclosures [Abstract] Income (loss) from continuing operations Income (Loss) from Continuing Operations Attributable to Parent Less: (income) loss attributable to noncontrolling interests Net Income (Loss) Attributable to Noncontrolling Interest Income (loss) from continuing operations attributable to Diversicare Healthcare Services, Inc. Income (Loss) from Continuing Operations, Including Portion Attributable to Noncontrolling Interest PREFERRED STOCK DIVIDENDS Dividends, Preferred Stock Income (loss) from continuing operations attributable to Diversicare Healthcare Services, Inc. common shareholders Income (Loss) from Continuing Operations Attributable to parent Shareholders income loss from continuing operations attributable to parent shareholders. Loss from discontinued operations, net of income taxes Income (Loss) from Discontinued Operations, Net of Tax, Attributable to Parent NET LOSS FOR DIVERSICARE HEALTHCARE SERVICES, INC. COMMON SHAREHOLDERS Net Income (Loss) Available to Common Stockholders, Basic Per common share – basic Earnings Per Share, Basic [Abstract] Loss from continuing operations Income (Loss) from Continuing Operations, Per Basic and Diluted Share Income from discontinued operations Operating income (loss), net of taxes (in dollars per share) Income Loss from Discontinued Operations Operating Income Loss Net of Taxes Basic Income (loss) from discontinued operations Operating income (loss), net of taxes, basic. Gain on disposal, net of taxes (in dollars per share) Discontinued Operation, Gain (Loss) on Disposal of Discontinued Operation, Net of Tax, Per Share Discontinued Operation, Gain (Loss) on Disposal of Discontinued Operation, Net of Tax, Per Share Discontinued operations, net of taxes (in dollars per share) Income (Loss) from Discontinued Operations and Disposal of Discontinued Operations, Net of Tax, Per Basic Share Net loss (in dollars per share) Earnings Per Share, Basic Per common share – diluted Earnings Per Share, Diluted [Abstract] Income (loss) from continuing operations (in dollars per share) Income (Loss) from Continuing Operations, Per Diluted Share Income (loss) from discontinued operations Operating income (loss), net of taxes (in dollars per share) Income Loss from Discontinued Operations Operating Income Loss Net of Taxes Diluted Income (loss) from discontinued operations Operating income (loss), net of taxes, diluted. Discontinued operations, net of taxes (in dollars per share) Income (Loss) from Discontinued Operations and Disposal of Discontinued Operations, Net of Tax, Per Diluted Share Net income (loss) (in dollars per share) Earnings Per Share, Diluted Denominator: Weighted Average Common Shares Outstanding: Weighted Average Number of Shares Outstanding, Diluted [Abstract] Basic (shares) Weighted Average Number of Shares Outstanding, Basic and Diluted Diluted (shares) Weighted Average Number of Shares Outstanding, Diluted Accounting Policies [Table] Accounting Policies [Table] Accounting Policies [Table] Range [Axis] Range [Axis] Range [Domain] Range [Domain] Minimum Minimum [Member] Maximum Maximum [Member] Accounting Policies [Line Items] Accounting Policies [Line Items] [Line Items] for Accounting Policies [Table] Number of states in which entity operates Number of States in which Entity Operates Number of nursing center facilities owned Number Of Nursing Center Facilities Owned Number Of Nursing Center Facilities Owned Number of nursing center facilities leased Number Of Nursing Center Facilities Leased Number Of Nursing Center Facilities Leased Number of licensed nursing beds per center Number of Licensed Nursing Beds per Nursing Center Number of Licensed Nursing Beds per Nursing Center Number of licensed assisted living beds Number of Licensed Assisted Living Beds Number of Licensed Assisted Living Beds BUSINESS Document and Entity Information [Abstract] Document and entity information. Entity Registrant Name Entity Registrant Name Entity Central Index Key Entity Central Index Key Document Type Document Type Document Period End Date Document Period End Date Amendment Flag Amendment Flag Document Fiscal Year Focus Document Fiscal Year Focus Document Fiscal Period Focus Document Fiscal Period Focus Current Fiscal Year End Date Current Fiscal Year End Date Entity Filer Category Entity Filer Category Entity Common Stock, Shares Outstanding Entity Common Stock, Shares Outstanding EARNINGS (LOSS) PER COMMON SHARE Earnings Per Share [Text Block] Insurance [Abstract] Schedule of Malpractice Insurance [Table] Schedule of Malpractice Insurance [Table] SHC Risk Carriers, Inc SHC Risk Carriers, Inc [Member] SHC Risk Carriers, Inc [Member] Unaffiliated Entities Unaffiliated Entities [Member] Unaffiliated Entities [Member] Insurance Type and Tier Identifier [Axis] Insurance Type and Tier Identifier [Axis] Type and Tier Identifier [Domain] Type and Tier Identifier [Domain] Professional malpractice liability insurance Professional Malpractice Liability Insurance [Member] Prefunded deductible policy Prefunded Deductible Policy [Member] Prefunded deductible policy. Trial or Arbitration Schedule Timeframe [Axis] Trial Or Arbitration Schedule Timeframe [Axis] Trial Or Arbitration Schedule Timeframe [Axis] Trial or Arbitration Schedule Timeframe [Domain] Scheduled For Trial Or Arbitration Over Next Twelve Months [Domain] Scheduled For Trial Or Arbitration Over Next Twelve Months Scheduled for trial or arbitration over next 12 months Trial Or Arbitration Schedule Timeframe [Member] Trial Or Arbitration Schedule Timeframe [Member] Malpractice Insurance [Line Items] Malpractice Insurance [Line Items] Insurance policy coverage limits per claim Malpractice Insurance, Maximum Coverage Per Incident Annual sublimit per center Malpractice Insurance Annual Sublimit Per Center Malpractice Insurance Annual Sublimit Per Center Maximum annual coverage Malpractice Insurance, Annual Coverage Limit Number of types of professional liability insurance policies Number Of Types Of Professional Liability Insurance Policies Number Of Types Of Professional Liability Insurance Policies Liability for reported and estimated future claims Malpractice Loss Contingency, Accrual, Undiscounted Number of professional liability lawsuits Number Of Professional Liability Lawsuits Number Of Professional Liability Lawsuits Cash expenditures for self-insured professional liability costs Malpractice Insurance Self Insured Costs Paid During Period Malpractice Insurance Self Insured Costs Paid During Period Non-current receivables for workers' compensation policy Insurance Receivable for Malpractice Other Insurance Industry Disclosures [Abstract] Other Insurance Industry Disclosures [Abstract] Professional liability insurance, annual coverage limit per facility Malpractice Insurance Annual Coverage Limit Per Facility Malpractice Insurance Annual Coverage Limit Per Facility Liability for workers compensation claims Workers' Compensation Liability Workers compensation insurance, non current receivable for excess premiums paid Workers Compensation Receivable For Excess Premiums Paid Workers Compensation Receivable For Excess Premiums Paid Health insurance, maximum self-insured annual amount per individual Employee Health Insurance Maximum Payable Per Individual Annually Employee Health Insurance Maximum Payable Per Individual Annually Liability for reported claims and estimates for incurred but unreported claims Liability for Future Policy Benefits Schedule of Business Acquisitions, by Acquisition [Table] Schedule of Business Acquisitions, by Acquisition [Table] Business Acquisition [Line Items] Business Acquisition [Line Items] Land Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Land Buildings Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Buildings Furniture, Fixtures, and Equipment Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Equipment Total purchase price Business Combination, Recognized Identifiable Assets Acquired, Goodwill, and Liabilities Assumed, Net Allowance for doubtful accounts receivable Allowance for Doubtful Accounts Receivable, Current Redeemable preferred stock, par value (dollars per share) Redeemable Preferred Stock Par or Stated Value Per Share Redeemable preferred stock, par value. Redeemable preferred stock, shares authorized (shares) Temporary Equity, Shares Authorized Redeemable preferred stock, shares issued (shares) Temporary Equity, Shares Issued Redeemable preferred stock, shares outstanding (shares) Temporary Equity, Shares Outstanding Preferred stock, par value (dollars per share) Preferred Stock, Par or Stated Value Per Share Preferred stock, shares authorized (shares) Preferred Stock, Shares Authorized Preferred stock, shares issued (shares) Preferred Stock, Shares Issued Preferred stock, shares outstanding (shares) Preferred Stock, Shares Outstanding Common stock, par value (dollars per share) Common Stock, Par or Stated Value Per Share Common stock, shares authorized (shares) Common Stock, Shares Authorized Common stock, shares issued (shares) Common Stock, Shares, Issued Common stock, shares outstanding (shares) Common Stock, Shares, Outstanding Treasury stock, shares (shares) Treasury Stock, Shares Exercise Price Range [Axis] Exercise Price Range [Axis] Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Domain] Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Domain] $10.40 to $11.59 Stock Options Exercise Price Range One [Member] Stock Options Exercise Price Range One [Member] $2.37 to $6.21 Stock Options Exercise Price Range Two [Member] Stock Options Exercise Price Range Two [Member] Range of Exercise Prices, Maximum Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Lower Range Limit Range of Exercise Prices, Maximum Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Upper Range Limit Weighted Average Exercise Prices Grants Outstanding Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Number of Outstanding Awards Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Number of Outstanding Awards Intrinsic Value-Grants Outstanding Share-based Compensation Arrangement by Share-based Payment Award, Awards, Outstanding, Intrinsic Value Share-based Compensation Arrangement by Share-based Payment Award, Awards, Outstanding, Intrinsic Value Grants Exercisable Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Number of Exercisable Awards Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Number of Exercisable Awards Intrinsic Value- Grants Exercisable Share-based Compensation Arrangement by Share-based Payment Award, Awards, Exercisable, Intrinsic Value Share-based Compensation Arrangement by Share-based Payment Award, Awards, Exercisable, Intrinsic Value Statement of Comprehensive Income [Abstract] NET LOSS Net Income (Loss), Including Portion Attributable to Noncontrolling Interest OTHER COMPREHENSIVE INCOME: Other Comprehensive Income (Loss), Net of Tax [Abstract] Change in fair value of cash flow hedge, net of tax Other Comprehensive Income (Loss), Derivatives Qualifying as Hedges, before Tax Less: reclassification adjustment for amounts recognized in net income Other Comprehensive Income (Loss), Derivatives Qualifying as Hedges, Tax Total other comprehensive income Other Comprehensive Income (Loss), Net of Tax COMPREHENSIVE LOSS Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest Less: comprehensive income attributable to noncontrolling interest COMPREHENSIVE LOSS ATTRIBUTABLE TO DIVERSICARE HEALTHCARE SERVICES, INC. Comprehensive Income (Loss), Net of Tax, Attributable to Parent Statement of Cash Flows [Abstract] CASH FLOWS FROM OPERATING ACTIVITIES: Net Cash Provided by (Used in) Operating Activities [Abstract] Net loss Discontinued operations Income (Loss) from continuing operations Adjustments to reconcile income (loss) from continuing operations to net cash provided by (used in) operating activities: Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract] Depreciation and amortization Depreciation, Depletion and Amortization, Nonproduction Provision for doubtful accounts Provision for Doubtful Accounts Deferred income tax benefit Deferred Income Tax Expense (Benefit) Provision for self-insured professional liability, net of cash payments Increase (Decrease) in Self Insurance Reserve Equity in net (income) losses of unconsolidated affiliate, net of investment Income (Loss) from Equity Method Investments, Net of Contributions Paid Income (Loss) from Equity Method Investments, Net of Contributions Paid Non-cash interest accretion Accretion Expense Other Other Noncash Income (Expense) Changes in assets and liabilities affecting operating activities: Increase (Decrease) in Operating Capital [Abstract] Receivables, net Increase (Decrease) in Receivables Prepaid expenses and other assets Increase (Decrease) in Prepaid Expense and Other Assets Trade accounts payable and accrued expenses Increase (Decrease) in Accounts Payable and Accrued Liabilities Net cash provided by (used in) continuing operations Net Cash Provided by (Used in) Operating Activities, Continuing Operations Discontinued operations Cash Provided by (Used in) Operating Activities, Discontinued Operations Net cash used in operating activities Net Cash Provided by (Used in) Operating Activities CASH FLOWS FROM INVESTING ACTIVITIES: Net Cash Provided by (Used in) Investing Activities [Abstract] Purchases of property and equipment Payments to Acquire Property, Plant, and Equipment Acquisition of property and equipment through business combination Payments to Acquire Businesses, Net of Cash Acquired Change in restricted cash Increase (Decrease) in Restricted Cash Deposits and other deferred balances Payments for (Proceeds from) Other Investing Activities Net cash used in continuing operations Net Cash Provided by (Used in) Investing Activities, Continuing Operations Discontinued operations Cash Provided by (Used in) Investing Activities, Discontinued Operations Net cash used in investing activities Net Cash Provided by (Used in) Investing Activities CASH FLOWS FROM FINANCING ACTIVITIES: Net Cash Provided by (Used in) Financing Activities [Abstract] Repayment of debt obligations Repayments of Long-term Debt, Long-term Capital Lease Obligations, and Capital Securities Proceeds from issuance of debt Proceeds from Issuance of Long-term Debt and Capital Securities, Net Financing costs Payments of Financing Costs Issuance and redemption of employee equity awards Proceeds from Issuance of Shares under Incentive and Share-based Compensation Plans, Including Stock Options Payment of common stock dividends Payments of Ordinary Dividends, Common Stock Payment of preferred stock dividends Payments of Ordinary Dividends, Preferred Stock and Preference Stock Distributions to noncontrolling interest Payments to Noncontrolling Interests Payment for preferred stock restructuring Payments of Stock Issuance Costs Net cash provided by financing activities Net Cash Provided by (Used in) Financing Activities, Continuing Operations Discontinued operations Cash Provided by (Used in) Financing Activities, Discontinued Operations Net cash provided by financing activities Net Cash Provided by (Used in) Financing Activities NET DECREASE IN CASH AND CASH EQUIVALENTS Cash and Cash Equivalents, Period Increase (Decrease) CASH AND CASH EQUIVALENTS, beginning of period CASH AND CASH EQUIVALENTS, end of period SUPPLEMENTAL INFORMATION: Supplemental Cash Flow Information [Abstract] Cash payments of interest, net of amounts capitalized Interest Paid, Net Cash payments of income taxes Income Taxes Paid, Net Basic and diluted net income (loss) per common share Schedule of Earnings Per Share, Basic and Diluted [Table Text Block] INSURANCE MATTERS Insurance Disclosure [Text Block] Discontinued Operations and Disposal Groups [Abstract] Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Table] Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Table] Disposal Group Name [Axis] Disposal Group Name [Axis] Disposal Groups, Including Discontinued Operations, Name [Domain] Disposal Groups, Including Discontinued Operations, Name [Domain] Rose Terrace Nursing Center Rose Terrace Nursing Center [Member] Rose Terrace Nursing Center [Member] Leased Skilled Nursing Centers Leased Skilled Nursing Centers [Member] Leased Skilled Nursing Centers [Member] West Virginia WEST VIRGINIA Culloden West Virginia Culloden West Virginia [Member] Culloden West Virginia [Member] Danville and Ivydale, West Virginia Danville and Ivydale, West Virginia [Member] Danville and Ivydale, West Virginia [Member] Rose Terrace Note Rose Terrace Note [Member] Rose Terrace Note [Member] Arkansas ARKANSAS Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items] Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items] Sales price of Rose Terrace Disposal Group, Including Discontinued Operation, Consideration Reduction in annual rent payments Operating Leases, Rent Expense, Minimum Rentals Amount of mortgage loan paid Extinguishment of Debt, Amount Pretax gain on disposition Discontinued Operation, Gain (Loss) from Disposal of Discontinued Operation, before Income Tax Tax expense associated with the gain Discontinued Operation, Tax Effect of Income (Loss) from Disposal of Discontinued Operation Revenue Disposal Group, Including Discontinued Operation, Revenue Income (loss) from discontinued operations Income (Loss) from Discontinued Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest Restricted Stock Units (RSUs) Restricted Stock Units (RSUs) [Member] Employee Stock Employee Stock [Member] Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward] Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward] Outstanding, December 31, 2014 Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number Granted Dividend Equivalents Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Period Increase (Decrease) Vested Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period Cancelled Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period Outstanding March 31, 2015 Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract] Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract] Outstanding, December 31, 2014 Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Outstanding, Weighted-Average Grant Date Fair Value Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Outstanding, Weighted-Average Grant Date Fair Value Granted Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value Dividend Equivalents Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Dividend Equivalents, Weighted Average Grant Date Fair Value Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Dividend Equivalents, Weighted Average Grant Date Fair Value Vested Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value Cancelled Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value Outstanding March 31, 2015 Income Statement [Abstract] Tax effect on operating income Discontinued Operation, Tax Effect of Discontinued Operation Disclosure of Share-based Compensation Arrangements by Share-based Payment Award Disclosure of Share-based Compensation Arrangements by Share-based Payment Award [Table Text Block] Schedule of Share-based Compensation, Restricted Stock and Restricted Stock Units Activity Schedule of Share-based Compensation, Restricted Stock and Restricted Stock Units Activity [Table Text Block] Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block] Line of Credit Facility [Table] Line of Credit Facility [Table] Revolving credit facility Revolving Credit Facility [Member] Letter of Credit Letter of Credit [Member] Credit Agreement Credit Agreement [Member] Credit Agreement [Member] Revolving Credit Facility Interest at 4.5% Percent Above LIBOR Revolving Credit Facility Interest At Four Point Five Percent Above LIBOR [Member] Revolving Credit Facility Interest At Four Point Five Percent Above LIBOR [Member] Credit Facility [Axis] Credit Facility [Axis] Credit Facility [Domain] Credit Facility [Domain] Interest rate swap Interest Rate Swap [Member] LIBOR London Interbank Offered Rate [Member] London interbank offered rate. Derivative Instrument Risk [Axis] Derivative Instrument [Axis] Derivative Contract Type [Domain] Derivative Contract [Domain] Line of Credit Facility [Line Items] Line of Credit Facility [Line Items] Long-Term Debt and Interest Rate Swap (Textual) [Abstract] Long-Term Debt and Interest Rate Swap (Textual) [Abstract] Long-term debt and interest rate swap. Revolving credit facility and the maximum loan Line of Credit Facility, Maximum Borrowing Capacity Long-term debt for syndicate of banks mortgage debt Long-Term Debt for Syndicate of Banks Mortgage Debt Long-term debt for syndicate of banks mortgage debt . Long-term debt revolving credit facility Long-term Line of Credit Loan acquisition costs Debt Issuance Cost Term of debt agreement Debt Instrument, Term of Debt Agreement Debt Instrument, Term of Debt Agreement Long-term debt five year maturity Long Term Debt Five Year Maturity Long-term debt five year maturity. Mortgage loan with principal and interest payable monthly based Mortgage Loan With Principal and Interest Payable Monthly Based Mortgage loan with principal and interest payable monthly based. Long-term debt interest based on LIBOR Long-term Debt, Percentage Bearing Variable Interest, Percentage Rate Long-term debt fixed based on the interest rate swap Long-term Debt, Percentage Bearing Fixed Interest, Percentage Rate Notional Amount of interest rate derivatives Derivative, Notional Amount Debt interest rate at period end Debt Instrument, Interest Rate, Effective Percentage Number of owned nursing centers secured Debt Instrument Collateral Number Of Owned Nursing Centers Debt Instrument Collateral Number Of Owned Nursing Centers Borrowings outstanding Long-term Debt Letters of credit issued under Revolver outstanding Letters of Credit Issued Under Revolver Outstanding Letters of credit issued under this revolver outstanding. Number of letters of credit Number of Letters of Credit Number of Letters of Credit Borrowing under the revolving credit facility Debt Instrument, Unused Borrowing Capacity, Amount Liability at fair value Derivative Liability, Fair Value, Gross Liability Net of the income tax benefit, interest rate swap Net Income Tax Benefit Net income tax benefit. Accumulated other comprehensive loss Term loan maturity period Debt Instrument, Term Minimum base rate percentage Debt Instrument, Interest Rate, Stated Percentage Rate Range, Minimum Consolidation and Basis of Presentation of Financial Statements (Textual) [Abstract] Consolidation and Basis of Presentation of Financial Statements (Textual) [Abstract] Consolidation and basis of presentation of financial statements. DISCONTINUED OPERATIONS Disposal Groups, Including Discontinued Operations, Disclosure [Text Block] PATIENT REVENUES, net Health Care Organization, Revenue Net of Patient Service Revenue Provisions EXPENSES: Costs and Expenses [Abstract] Operating Cost of Services Lease and rent expense Operating Leases, Rent Expense, Net Professional liability Malpractice Loss Contingency, Premium Costs General and administrative General and Administrative Expense Total expenses Costs and Expenses OPERATING INCOME Operating Income (Loss) OTHER EXPENSE: Nonoperating Income (Expense) [Abstract] Interest expense, net Interest Expense Total other expense Nonoperating Income (Expense) INCOME (LOSS) FROM CONTINUING OPERATIONS BEFORE INCOME TAXES Income (Loss) from Continuing Operations before Equity Method Investments, Income Taxes, Extraordinary Items, Noncontrolling Interest BENEFIT (PROVISION) FOR INCOME TAXES Income Tax Expense (Benefit) INCOME (LOSS) FROM CONTINUING OPERATIONS INCOME (LOSS) FROM DISCONTINUED OPERATIONS: Income (Loss) from Discontinued Operations, Net of Tax, Attributable to Parent [Abstract] Operating loss, net of tax benefit of $168 and $767, respectively Discontinued Operation, Income (Loss) from Discontinued Operation During Phase-out Period, Net of Tax Loss from discontinued operations NET LOSS NET LOSS ATTRIBUTABLE TO DIVERSICARE HEALTHCARE SERVICES, INC. Net Income (Loss) Attributable to Parent Continuing operations (in dollars per share) Discontinued operations (in dollars per share) Income (Loss) from Discontinued Operations and Disposal of Discontinued Operations, Net of Tax, Per Basic and Diluted Share Net loss (in dollars per share) COMMON STOCK DIVIDENDS DECLARED PER SHARE OF COMMON STOCK Common Stock, Dividends, Per Share, Declared WEIGHTED AVERAGE COMMON SHARES OUTSTANDING: Basic and diluted EX-101.PRE 12 avca-20150331_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT EXCEL 13 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx M4$L#!!0`!@`(````(0!49HK8EFU8^_8[2:%"J&M5K1+GIE$;^_Q?K>B3\D]N MEITM7B&FUKN:B7+,"G#:F];-:_;\=#^Z9$7*RAEEO8.:K2"QF^G)M\G3*D`J M<+=+-6MR#M><)]U`IU+I`SB\,_.Q4QF_QCD/2B_4'+@ MOW1X`F4*$91)#4#N;#E M/3SP4QT*?0%LP&S)YD/A//T+``#__P,`4$L#!!0`!@`(````(0"U53`C]0`` M`$P"```+``@"7W)E;',O+G)E;',@H@0"**```@`````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` MC)+/3L,P#,;O2+Q#Y/OJ;D@(H:6[3$B[(50>P"3N'[6-HR1`]_:$`X)*8]O1 M]N?//UO>[N9I5!\<8B].P[HH0;$S8GO7:GBMGU8/H&(B9VD4QQJ.'&%7W=YL M7WBDE)MBU_NHLHN+&KJ4_"-B-!U/%`OQ['*ED3!1RF%HT9,9J&7 M4"T\U<%J"`=[!ZH^^CSYLK$SO+=N5#9@NIS]NHFD++ M28,5\YS3$$X4UD^&'!Q0]47P```/__`P!02P,$%``&``@````A`,&G.;+N`0``HA4` M`!H`"`%X;"]?9!%3%97]NN]ZY4!Q?5T^KZ:OG==3;EAV+3 M#K'(J_A8JB:EX8O6L6K;S9MY;[VU=O>^?3!._2O/NQBXUS*B]JP=:E4 MXU34QSMD9EFSTI_(R7[(RGE`0*=(%C.M7 M.H@)!W'FN"BF>`ZWZE%:SB.2(TTI""GIPH%U0^+60&]8&N`,`6ZD(\?`S#&3 M,C,V-KCZ-87\ZQ_/47PQC3XJ:6)"8)*T&H)R6)K?#/G-D_)[;*#.13-.G7HJ MADV,F30"8SITN4D=_R7^CE'EDC0L"<*2I&%)$)9&&@D&(D&:"!`(TCL%-XJD MK2'H#4O#DB$L>5)8C@%WSIEQZCWS8(-II#/'P,PQD_(RY>,_=W;F.-3'*_RT MI:F$H93U2QX[CL#6%R>KJS\```#__P,`4$L#!!0`!@`(````(0`H;*Y,8@,` M`!8+```/````>&PO=V]R:V)O;VLN>&ULE)9;<]HP$(7?.]/_X/%[8WPAMPED M2D);9I(V$VCRZ!&VP)K8DBO)(?GW7+KZ[?BMQYI5(Q MP0>N?])S'<#MQWJMSKX>=/5RLA7^9"O#@@ MP-7`S;0N+SU/)1DMB#H1)>5P92%D030IPR3=.!VX>C6-&M#V15CBJ6P]6+L!>ZWK`M\D$Z*5V0*M,*;])F`%M:I3Z`RWW7D)8,WP&%]7_F$R`W.":#!O'UQ0BF3-4U%G7S:A2C%.ET/=# M?,-Y]X9-2V%2#"4CHIB*Q2)^D!3+P,"WK;WHRCS2!**/OR:)J(`ROHR_5\`) M\($E+I"$W^MJW`F^G%%9Q+=TKHT5PQW,8OQ(MMH*$]-:\7?0JBIIT+PG&L#% M841;G%N$3K5(7B``P/M&%+"JE-D@J(8(.KKY;0O-,9$C:'V M+1QOF4I$W<@*HOA54MEL4AP$QMFW0-R39#PC\QS^*C:C'F$\?8O/PX'B*8TP MH+Y%Z*X\=KC!B,)F[BQ")*()RW$=?0QE8$%Y>,YP'0$F#`X="X>G!`OU,>N! MA>J$=\8$2+&*VO)B4;JOR8T0:G*`:8-#IR8S'/;8-4,SQSH8NN8/%B_1?7X> M87HDPSH8NN!H>*=)1M,*ZV#F@@_""]D:\_7?;[#%G07OX2F`5=(*A1A#.'22 MWK=7FMYC'0Q/:.&,!J'=+KOXP5LNM%C>J=*$G-,8N]G2L5#>LZW^&4(Z?;PS M0\.S9Z*#QZ:$Y`D\S]4OYH$HZI\V8^RM'VF'?P$``/__`P!02P,$%``&``@` M```A`"`TM%U[!0``7!0``!@```!X;"]W;W)K.;,>'SL>/OEK;TXKW4_-+S;N6SMNT[=5?S0=*>=^\_?CZO4=8:Q M[`[EA7?USOU1#^Z7_<\_;6^\?Q[.=3TZX*$;=NYY'*\/GC=4Y[HMAS6_UAU8 MCKQORQ&^]B=ON/9U>9@FM1VKH;T4E? M7\H1^`_GYCKNTU8/WT\=[\NG"^3] MQC9E=?<]?;'FJZ':L$YB!9XX?Q;0[P@!2+U\F_[>FL-XWKEAO(X2 M/V1!Y#I/]3`^-F*NZU0OP\C;_Q#$I"MT$D@G(="4]N"S3CPD-"7RK1S+_;;G M-P>Z`T(.UU+T&GL`QS(#26/."4I;"?17`9\F`=L!1E_W:;3U7J%&E83D"$E< M9X8PBBCN"%%:H#%S@01-+J$_AQ96(W1,'>^P@ MA&#T@$5F\L3LQZIV)/=L,;H8-:*KVF%TA&#TV(^4>^QFW1PQIF:3Z`RT="'Y M:=B(;Z272PP28&FBNA<)4'L2JOF4`56V>_D9BH^^OS)31B0&&62;,%$A)`5T M@@#88;XJ$N4@Y,9N`88J1#BH'L)5D)B-U%AC"Q;$G"D)HN&%\BR$1T&"SUEB M-`\RO"9:,F=MA$:A.C8=(9IL,UO0-$&2T1"#R3)?I2-#Z^:5VBV4QK*M1BV]C'?")4S!,G6H]I4$.,JR53?4AY4_"P>M@HR7RVL+`F"9$D,:\%T M:QB_IT-4!BT>MAXR7[F2/!"$/%3=Y;KHQM4F5#1)/0*JAR:/R4Q/7>8;H7() MTLY=?82&H^)GA;-%D/FF"@8(DN4/8I499D[M,5-M1*DL:V!@:R#S53-AY27H M?0KH1-K?IR"DR];!`!5-EV%+>W()NE.(3&V2=CP*5M`\:M5H&3Y6R8; M)U\N0(7"]PAWJ\(VN>*!,H!Y;*L MEL&"6C)UOLK&T-50^9>-J1M7J>IK&GY!*?52+"BEUN*2!H+P)KX*[.8@=J;O M,<#FS%C.^82I*O#72&MWUD?BV*P((K:/4^FCB!,W5H!-&;3 MY67EK[43G>0-UP1]8YHR-9GI;9$QM;^0B`2I6(9\%R9`:R9*AFKF_<(8+F@E M4STE22#H`Q(&@*F]34E0M;0JLJ":S%3-$$%()EI'OZR4-$]TBX\0E`Y53HL. M*BAM3$,A\Q!!6F/J(S0<%S$N@[+G'5[E&EW>J2`CSSX M-M+6_:DNZLME<"K^TL&N8]#*\R@^+N7PN#0]T'BS`9Y\KN6I_J/L3TTW.)?Z M"%/]=0**V./K$'X9^75ZR7CB(SSV3/^>X16OAA<6?PW@(^?C_8O8O/.[X/Y_ M````__\#`%!+`P04``8`"````"$`.UMDU6$"``!4!0``&0```'AL+W=O<.`8.R%>Z=&U>$6-9S M2>U,CUQ!I-5&4@>OIB-V-)PV(4D.)$N2:R*I4#@RK,Q'.'3;"L;O-=M)KEPD M,7R@#O3;7HSVR";91^@D-<^[\8II.0+%5@S"O052C"1;/79*&[H=H._7-*?L MR!U>+NBE8$9;W;H9T)$H]++G&W)#@*DN&P$=^+$CP]L*WZ6K38Y)78;Y_!9\ M;T^>D>WU_HL1S3>A.`P;UN07L-7ZV4,?&W\$R>0B^R$LX+M!#6_I;G`_]/XK M%UWO8-L+G\+T`)7@%TGA+0"=T]?POQ>-ZRL\OYXMBF2>9@N,MMRZ!^%S,6([ MZ[3\$T'I@2J29`>2.<@\Q+./DI`H*#1R3QVM2Z/W",P!)>U(O=72%1`?.CC( MF'J"R3*/OO/PD`1J+9R^U'F1E>0%AL0.F'7$%!A-F/0E(B8/&UF\6PC<`$\0@]ER.:5&#='= MT122FXYO^#!8Q/1.!4O6Y70:+]4:+E5P)ID"X/61=OR)FDXHBP;>0FHR*\#< M)EZ+^.+T&#:XU0Y<'AY[^'IQL%8R`W"KM3N^>'-,W\/Z+P```/__`P!02P,$ M%``&``@````A`+T_\--Y!```?0\``!D```!X;"]W;W)K&ULC%?;CJ,X$'U?:?\!\9Z`"2$A2C*:,.K=D7:DU6HOSX0X"6K`$9!. MS]]OV>7X!K3ZI3NXCJM.E;@IW*YK+S__G[ M9;;VO:[/FU->L8;N_)^T\[_L?_UE^V#M:W>EM/?`0]/M_&O?WS9!T!576N?= MG-UH`Y8S:^N\A\?V$G2WEN8GL:FN@B@,DZ#.R\9'#YOV,S[8^5P6]!LK[C5M M>G32TBKO@7]W+6_=TUM=?,9=G;>O]]NL8/4-7!S+JNQ_"J>^5Q>;[Y>&M?FQ M@KS?29P73]_B8>"^+HN6=>SP'^ZTHT+\E?73&;Z^[LL=O;7GZHVPH5!O.B9_`D;%7#OU^XDNP.1CL?A$G M\&?KG>@YOU?]7^SQ.RTOUQZ.>\FW%*R"2/#7JTO>`Y!Z_B[^/\I3?]WYBV2^ M7(4+$BU][TB[_J7D>WVON'<]J_]#$)&NT$DDG2R`IK1'GW42("&1R+>\S_?; MECT\Z`X(V=URWFMD`XYE!I*&R@E*6W#T5PX7FX!M!ZMO^S@AV^`-BE1(S`$Q M*]]3&`>1/1&\ML!#D8$,73*+4,7F5COV.G%"#R&1C!C*R)M;=SX05_6,4B>M`V+6XD26*A^, M:MIF\6*AS!8'Z$,W78,#M]H<2)@J1R+.`3&QX!#:MLRT19J@Q2`9,C`*SJTV M@RC5CI`!8I"!8\M,VRP.UXJ@Q0&ZUJC"L^OYJAV;$/>P$3.>O6F;&4UKA>8O M!>#S]=,C!:`)NM3DL0K<,B$$.LRC1S8:] M:)D3HMO8*@4!)79K8;2",-M$B.$*>T&"\$K,HJ4^<&1BVPD)M9;87&R%?+8$ M00TS!2!.=#J2`X(,!9#;Q(H=A@N3/GX5!O7*O/R+P<4C",)4W9LGC:FXEK-P M/M7YA(N3)B#>!&;-4;M,(K%[N@?A8^?K6+K-9-'1BP(8M\BNQL>*2(:2&"=. MK(,$353%%$5=,IO$QY((+WKW.L2)HSH'"5()AP[+S`5,5L161]4?0UDD1'>R M;$,$?4#"`1"M+'9%QN61H+[9=V%`XBF"_.N(?TMD%&"J'2.N>XYDF15!633;KARW\PP"'&]FJ9@VDRF;SJOH&;:&\Q5(:8OC$S[T[":^](^LAVE(_+S" MF$M!-L(Y@,^,]<\'/D2HP7G_/P```/__`P!02P,$%``&``@````A`%,S1"0% M!```*0X``!D```!X;"]W;W)K&ULE%=;CYLX%'ZO MM/\!^;V`"9"+0JJ&:G8KM5)5[>69$"=!`QAASV3Z[_?X`L'&V.S/`>MZ4ASE MHJ8.HC!,@Z:H6J0B;/KWQ*"G4U62+[1\:4C+59">U`6'_;-+U;$A6E.^)UQ3 M],\OW<>2-AV$.%1UQ7_)H,AKRLW7,GK@/ MX0*UT7G.ZV`=0*3=]EA!!J+L7D].&?J,-WD4HV"WE07ZNR)7-OGML0N]_MY7 MQV]52Z#:T"?1@0.ESP+Z]2A,L#B8K7Z2'?C1>T=R*EYJ_I->_R#5^<*AW8E8 M4M(:F.#3:RHQ`Y!Z\2:_K]617S*T2/UD&2YPE"#O0!A_JL1:Y)4OC-/F'P7" M.I0*$ND@\*V#X,2/HV2Y^C]1%CH*?`]1(C]:)3A)'^\E4'G)>GPI>+';]O3J MP9#!SEE7B)'%&X@L"K%,H"&E<'X67HD!,P/KZRY.XFWP"J4M-68_QV`3D0\( MT1&@';FA'C;W(ARYA=?D7J5FX/T<$IF(W(&X[<[8#"1O;R:^%4)XH??(NQ5B M$9I<>X614RNKET\,!E5L4`VU%M8,P89O%$EB42C,6G8B]5,[6\N]'%<;]#"X MDTP'>F&UZ>UZ*TPLZ:,9^^"UVYPZ^835YKMM6!9PKS":+UZ/Z:CR#EZ;;^GD M$U:3+UI9]=LKS*2#$X-10O$>L$[-9%B$]]&P*,R$:F(PJ-8&U=`M836SB9.5 M69^]PJAAP:%OG=M4.#$(,:CI);F"4YD>4&J0YL9_8/=,`!ZLI1".KTH[_ M/A58@4;6VPE7@Z+]#E(A#[<^CJ1*-4Q2^RQ@!5+#F5B3E(]>>SBQ$`4'I=(* MD](JWEZNS=!*GC\:;L'!+L6QCZ`&W4M3A7!0ND4&WK&SN4UM'=4@ M1>E(\Y[.8+?02+,YN-%J89T5#9*)Z*&Y)R_8U!?YRIP7?75`Z>=O%\>*(>; MN_QY@;]D!"Z^H0_@$Z5\>!"IC7_R=O\"``#__P,`4$L#!!0`!@`(````(0"& M260T+`0``!X/```9````>&PO=V]R:W-H965T+L+292$`6M+?JS:\R[\]Y^GAU48#&/1'HN:MVP7 M_F!#^''_QX?ME??/PX6Q,0"&=MB%EW'L-G$\E!?6%$/$.];"G1/OFV*$R_X< M#UW/BJ-\J*ECFB2+N"FJ-D2&3?\>#GXZ527[S,N7AK4CDO2L+D:(?[A4W3"Q M->5[Z)JB?W[I'DK>=$!QJ.IJ_"%)PZ`I-U_.+>^+0PUYOY&L*"=N>>'0-U79 M\X&?Q@CH8@S4S7D=KV-@VF^/%60@RA[T[+0+/Y'-8TK#>+^5!?JO8M?AYO]@ MN/#KGWUU_%JU#*H-?1(=.'#^+*!?CL($#\?.TT^R`]_[X,A.Q4L]_LVO?['J M?!FAW;EXI.0U>(*_05.)&8#4BS?Y>ZV.XV47IHLH7R8IH7D8'-@P/E7BV3`H M7X:1-_\CB"@J)*&*!'X5"PONZS;+V-7Z$HI<(\NA@R(V+P,KL">MM5FLRN MQ%W3U6HQ\\AH'ET(G1&&I]3P-"4CK+L02'0R>3(3H`O$9++MM[%G!J,LTU*7 M2=R%GAK,N@C(C!B7&0;@IBI3K,)JQDJ=PB,FDVTAJ<[$*,7"2R^L%KU3"L0@ M_3*;ZV2P+[WLPFJQ+W2GL!R(4<'[R<6:U*,Y5498;?)T)D!RQ"#Y0[Z<[QJQ MK[WTPFK3YS,!TB,&Z>^4G<`R\00OS3:]/>8*I&J3K6;O1OC$H]RUEI.\;<^D MW00%2F%J=:B_-5OC.6"K06LXE;"A=/3-^OTB)JU+JC*8"H0M"HU2+S?1A MRG9.`[5XNPFH,Z`$0$7,+P'W$&RYU2!YE+=41GQBUB:K6XL=)0X MJPJTDMVX-ZQ^&1.?CIUA11"FL(K6.D6S$WXQ$U?-6:XI5`J3G,6[^'8I$U/" M]E:6MVT)Z$E1Y).8;7+J5[`T6T5W)*!`J.!,E\R(GIH"GH93FBT'C@`4"!VD M]QSX14R%V7+@3+\"J1WDWT#4KV!IMOGMGBH0\C]0O9C,$OGU2WWZM0=?@=## MG<$77U^>+2W-=@:ZR#@X"H3\"SU69@*F93JZIGQ^V5+7=FZ2UJ!?KNDJ:GB60;C.>L.:;H]Z_[JS7RI")-3BK>T!2]4HFN]Y\_ M[4YG]JKC-_/5GRTQ?!\F^LH9!MJ).NP('S M1RU]R/42'`YFI^]-!7X(+Z<%>:K43W[Z2MFQ5%#N1!_)>`66X-.KF>X!")V\ MF.\3RU69HL723U;A`D<)\@Y4JGNFSR(O>Y**UW^M"'Z.WC0C9VKL&](@`SO2W@3VTMPMZ4WG5-K9<]QWAS.Y=$O<*QM'C7DMY- M$#,A M6DULRA.MWDC^\B)>KT[P23C!6XW%#WM.OE<7X7IU"A\*9O-L-19^-03FT/7[ M_Y\1J-D2+'M'7,V13:$M8_?:!_LSFQOP@ZB&\*T@&UL MC%?;;N,V$'TOT'\0]+Z6:,F7&+87:RW2+M`"1='=/M,R;1.11$&DX^S?=WB1 M/*14)"])/#R<,]=C9OOYK:ZB5]9)+II=3&9I'+&F%"?>7';Q]W^>/ZWC2"K: MG&@E&K:+?S(9?][_^LOV+KH7>65,1>"AD;OXJE2[21)97EE-Y4RTK(&3L^AJ MJN!C=TEDVS%Z,I?J*IFGZ3*I*6]BZV'3?<2'.)]YR;Z*\E:S1EDG':NH@OCE ME;>R]U:7'W%7T^[EUGXJ1=V"BR.ON/IIG,9176Z^71K1T6,%>;^1G):];_-A MY+[F92>D.*L9N$MLH..BR1QT[[^(O9%/,TSC9;TV!?G!V ME^CO2%[%_;>.G_[@#8-J0Y]T!XY"O&CHMY,VP>5D=/O9=."O+CJQ,[U5ZF]Q M_YWQRU5!NQ?Z2BDJ8(*?4"B'-EGR,51HA/1I MF%4P(0>+69J2KO(T#4I>X//E&I][@6B-#Q8+!:)/PT`ROWL'BR&I'KK7?3K+ M`D!A`:8H'O631]UW5%M#RCR@M!A49F3P*`AH99@>:JDY?J^G#H38L,6GFY`I M5$UB!06O2IX%RW!P(-=8Z-NHLPXQ+BC1JO%H9E]18PY+N@Q*ZD"PBL,:Y]E# MQ]C1JF:4*<1GI/+,B;)B3LKLT]:#1-$Z*$MW9"E?)0'@E2'4>' M+/Y4^4(TFBHK+N],%5(@1XVE=5S;H+*UA5R:@4MP;6A8!Z#U;[+#W`L]0\[9+A`!Z++;VP/VEW MX8V,*G:&J^EL!2/E_:!$:YY`1Z'@F6C^O,+[G\'K(IT!^"R$ZC_H[@__ M4>S_`P``__\#`%!+`P04``8`"````"$`+E0!>X$%``!=%0``&0```'AL+W=O MQB+0+ M=(&BZ.59D6E;B"49DA+O_GV''%H:#E5MFHAOS\6UO4WZ*:_+ M*X1X*2Y%]UT'];TR7W\Y5763O5S@N;]%29;?8^L/3OBRR)NZK8_=#,(%*-1] MYL?@,8!(N\VA@"=09?<:>=SZ3]%:S.=^L-OH`OU=R%M+_O?:*GK5T7]C.6W^^G"T>PGD4+WSO1;;=`^'M M-5,=&ZTALJF#>9B^,K!`N6(_*?K6?_`]>.86T/==$CYL@GY<3V8ST MSE#E5F$%`KIH`0CKU4'AB+J["(4J$??I>P0@2*\J9AGO4P;&BLD6+B4>=%NJ M8!E'5"G44H4`596$*Z:+3Q($L'+"VHSD5"AT)'GP)'RT4^R1D_352CD@"&#E MA`8G.75OS,.^%=3HUH>J]45/HI#E1DZ"C;*P!]/[X'T9!0$L'^>EB*U% MV=Z$%G1%>Q7X!A01Z\0WUT$$16P!RNP&`?TJH`?^8!6X+87O@!$Q1Y.8 M(X)RK,2Q;:#WQ!IF6XAS_#`D\BHXB*"(G7C:)^,1GXSY]FI(N`C*)1U7,HQ! MHJ"(+0BJ3):`=T6LAEE%G$W5D(9TJ8,(BM@"IFTQ'K'%F._JAH05F>N*L,Y- M#670*"AB*[)]TBD)VIS=G7ROCXD78GG+4)]2IKJ3VZO82\`..(:$0=;J!'[9O M&,I0+$$16XGR,->J8K0V6PD_V!@2+8FCA%@DFJ:9-%(3VS2=]APS3WZRB;E5 MI@XB*&*5`@XM8Z70,+,*QSP-::AXZB""(G;B:?.\_XT)/P.-VY:AD*58&2W*^!NB2KA7:&'N2)^NC0D/&.QEDG[ MP?Z,11&L"MY.X75,*9N33.7ETGIY_5;!=VH5MT?[6[$G?2G&\'VT3O7E")V.\44,MVOJ0B#H)\"=US4[R:]9C^&'KK[J2Z.7 MNH/;+OWO&:XQ)=SBA#,@'^NZNW]0"?J+T=V_````__\#`%!+`P04``8`"``` M`"$`*#KU6LL"```'!P``&0```'AL+W=O\Z<.7.Q6=^_5B4Z,:FXJ#'#?[Q_?%N@9'2I,Y(*6JV MP6],X?ODXX?U6<@753"F$3#4:H,+K9N5YRE:L(JHB6A8#99IOSTEMZP)2L,PX9F+(CR?(-?@A6:8R]9&WK\Y.SL^I](U6(\R?)LR^\9E!L M:)-IP%Z(%P-]RLP6.'LWWH^V`5\EREA.CJ7^)LZ?&3\4&KH=&1%_D\Q:$GA?2<)%%$3QOZ5X+BU;CI1HDJRE.",8,1"N&F(&-E@!0\)K10"\T^"]ZC17FIU>8 M:3B*M768F1T?4YK=>"/M;0QB0_?&L6=15RMCW6#(I&O*-!['=IC`-UZGQ)^, M&KMS]JNVM+&PO=V]R:W-H965T8_V#X_<26)<6)D>2@%F\'.`,,!G-Y=ATE,6I;@>TV M/?]^2)&B-O=BF[0/=?)I<9M+O"Q)L>]^_W[83[ZUI_.N.]Y/BZOY=-(>M]WC M[OA\/_W/O]5O-]/)^;(Y/F[VW;&]G_[5GJ>_/_S];W=OW>G+^:5M+Q-;X7B^ MG[Y<+J^KV>R\?6D/F_-5]]H>[9&G[G387.ROI^?9^?74;A[[1H?];#&?7\\. MF]UQZBNL3A^IT3T][;:MZ+9?#^WQXHNXLP[<:9^K;Z>SAKC]!_]VU;V?R M\^3\TKWIT^[QS]VQM6?;CI,;@<]=]\5)_WATR#:>06O5C\`_3Y/']FGS=7_Y M5_=FVMWSR\4.=^V:;+N]?2?[_^2P7U5+^=EL:BG MD\_M^:)VKNUTLOUZOG2'_WE1$4KY(HM0Q+Z&(L7B:G%3%_7U+U0I0Q7[&JM\ MN`M5:&Q?8^-?]F$=]R?#OHY%JD6]O/F5LW$=JMC7H4IQ]C9F?(?W,$IO+YN'NU+U-['*U<^#\NG&+OUC9PF%*A7D1 M)YF=ZUNG_N3D]U/;?3M]SI9^>ZB6UW>S;W;6;H-FC9KR^C;5-(/&S5U76'`@ M.5`<:`Z,!_TLGEE[T:,]Q<3C8,519V7HPGH`H[=R6;!^HZ9:+E.-\!K;&7*. M;E*-S-2YF:<:E=.P_NB<9I'6,=B?49&<)[M&,^?)T>0\<=!P(#Q(SP";`9(W M4AQH#@R6+>LRFDVLV!TC8\71Q`H'#0?"`VJ%OF<_=R5OI#C0')A:6Z;>C]U.[E.*B+FNVJ-=>0_K-@>!`"`\F!XD!S8`;@(J3^ M@8?;Q$.?3>4\1I$[FGJIYFQ[7'L-\<*!X$!RH#C0'!@"DIE4V"N\S"#T^+TU M$$2DZT`$$`E$`=%`#"6I`;M9Y`PXS$\]VTG6A1?Y>5K/^W]QJO;KO`F2T:,` M(H$H(!J(H21UY,(0UT7A,Y(N[^IFG)5^6PJBL;L-$`%$`E%`-!!#26K`A6#& M@,_&G^^KA1=1`YP(T$@@"H@&8BA)#;CHRQCPB4A'`#?8PHNJ?N^[J?ET&HX. M5W0BZ@JX[18^-U-O<`M`PC6L=4Y$*#3.1@E$`=%`#"6I M$9>4HY$A`PL?H.\L%1Z[36@V=E<`D4`4$`W$4)(:<"&9,>"S,QT!-G'6A1?Y M[=?>I[K]EZ^7(8/'N<6)#&5&UPJ(!F(H21VYJ,PX\@F:.N)75P6)V3"G.!&@ MD4`4$`W$4)(86.0CO>R`2*`2"`*B`9B*$D-Y"-]@9&.VV\040.^ MF=^0K]DE@`"]!**`:""&DM2,G3&9Z;1PF%V?P/8;1-2,;Y9LR#?LME5`,PE$ M`=%`#"6I)Q?)N$06/JF3)7++5O0ZB*@G"'C02"`*B`9B*$D-N!C.&/#I_/-M M=^%%U``G`C02B`*B@1A*4@/Y4'/$"LAXIQF30EWCD%$O``10"00!40#,92D!O+) M7_H(__F^'$34P)#\P]D5H)%`%!`-Q%"2&G#YC"NE=)B-`#R:"R)_H7++[NR; M>'0TXXN.AB5H%!`-Q%"2FG'!/)KA2Z3TN9TN?_Z<-(C&3C9`!!`)1`'10`PE MJ9%\W)U@(T$H@"HH$82E(C^8@O?=2^LUOQ/&Y" ML]&2`"*!*"`:B*$D-9#/]1)SO;AAT;4.(G_SOLP^.PT2ZH@GM@2-`J*!&$I2 M1VFJ#U>292[-^95D$(W=;8`((!*(`J*!&$H2`U4^PGO\WLU[$!$#0`00"40! MT4`,):F!?(17/HN3L(#[W2"B!B#"02,C&:\>X2&EBJ)A5]-`#"6I)Y>T8Q`. MLZKR`4P]X;5\$%%/OME(!&AD))FK1A4/CEYX24,UJ9-\RJ4XNTU=5SRS&R`"B`2B@&@@ MAI+40#[%JX^D>!#1X>"Y+D`C@2@@&HBA)#603_$*4QR?!041-<`C6H!&1N+F M$TXG7D%'_3#!#"6IF7R`5[D`YT_?@XB:\!"-W6V`""`2B`*B@1A*4@/Y`*\QP'$Z!1$U``$.&@E$1>(F6%FR!]PZ'H[S MB9+4C4M&C.[:!Z;]?_S#)ER.!!%UPW-6@$8"49&0-[L%3[RTBHI'_`U!KS]DV=ZZM9!1#WQ+!:@D4`4$`W$4)(: MR&=Z[>/:#B59-/R!3Q!1`SSE!6@D$`5$`S&4I`;RF5[[<*:S*K.'\01O0K/1 MD@`B@2@@.A*W9I;LQ)EX%)9[/M]KS'?\`$<0C5UO@`@@$H@"HB,ADX%O:B:* MP%,^YNTW$_@U,/Y%(8BH)XAYT$@@"HB.9/0$&X'[]H3K8__V?M+Y+T/XCZP? MVM-SV[3[_7FR[;X>[4)9VH^E1!J_A/&I_TX$X^MB93\Q;L\5YXO5.J=O%JLF MQ^5B)7-<+5;VP[)87R]6]C.S;HSB&]NO:KQNGMM_;$[/N^-YLF^?K)7YU=)N M1B?_K0[_RZ5[[3^@_[F[V"]I]#^^V&_?M/;S\O,K*W[JNLOPBWN#^'V>A_\# M``#__P,`4$L#!!0`!@`(````(0`VBN>)NP(``)P'```9````>&PO=V]R:W-H M965TBQ\-I(!,@WC/9;PRK>!&#G!M5[4=T$J74\& M:4@XZ;"$^D5+1S&Q]=5[Z'K,'W?C5<7Z$2@VM*/R19,BKZ\6#]N!<;SIH._G M*,75Q*U?SNA[6G$F6"-]H`M,H><]SX-Y`$RK94VA`V6[QTE3HIMHL9ZC8+74 M_ORB9"]._GNB9?M/G-9?Z$#`;!B3&L"&L4<%?:A5"!8'9ZOO]0"^<:\F#=YU M\CO;?R9TVTJ8=J:65*P#)?CU>JJV`'2.G_5S3VO9EBC)_:P(DRC.D+)9%6?[O6@+3 ME_;C#DN\6G*V]V"/0>5BQ&K'1@M@5D84&A$=UE;75X]`FOCV')(53X/KO&*L><,"M M)WUU0V5+!'0G;L1.00:3ZODK"]>!&&CNMKD]856(+YFX(JZ@JF3D\&DVK!O'#*65_* M6N+%F^(JZHIGCKC!Y&9_%\7,3J\OIBUY]65X/4B3V2KJRN!:ZQAO,Q4E?3!MY<\&:"V7$6_(5\RT=A->1!LY(Z,-5XG%S MO9H7R49]HC=,PFVI_[;P%21P4D(?P`UCY7$TC/5E7Y^Z2[.-OS9#_,/3]]\]OG7]I^'8-&.D/5R&;7PA\VO`D23?GNKW$X.&A_Q8?W>'0 M[IH/W>[UW%Q&<-(WIWK4_(=C>QUF;^?=M[@[U_VGU^O=KCM?M8OG]M2.7XW3 M.#KO'GYYN71]_7S2>7]ALM[-OLV/P/VYW?7=T!W&>^UN`T3#G(M-L=&>GA[W MK;YX>38'^;INWP?M_-!R[MY_Z=O]K>VETM76?I@X\ M=]VG"?K+?EK2%V^"JS^:#OS>1_OF4+^>QC^ZMY^;]N4XZG:KZ9)==]*1]+_1 MN9UF0*=>?S%_W]K]>-S&(KU762(85W'TW`SCQW:Z-HYVK\/8G?\!$+.NP`FW M3O1?ZX3Q_^U$6"?ZKW/"<\54^M]4-I"6*<>'>JR?'OON+=(SIHD/UWJ:6/:@ M/4]U$(GNQVXR_CA9#48O#WKU\Q,K'C>?=6%W%E(")(NC!<(QHEI!L`6RT3P6 M,KH^[Y"9K)@,3Q8_AF\)D,P4?TJ@\A90))VJ%VE.=UK5^?NYD&1*@$@7P5M` M$>1JA&EU&VM6KEJ"Y`"0W%1;I(G$Y@J9WHBM9Y+6 MP!OMR4HXI(0#0*`&/$M<&$.Q0F8AW,9`%9CN&&Z#S1685DGTC$0'"%0@+4A_ M*M^JU(W8!8I--_=D)1S<-$$7``(9NQ*. M@C5PR71%_-S4V"B^O#&1%$&E$8#GN>.).:PK(`LE4)!BEA9CAS\-BPT^9GOA MYA4SP#JX5"$40*IQ)?-%3F5D=U;(+%,WJ2@^7Q=!LTRV/Q5@BX$,I90N0^@\ MLJ>2.8*8P;H(\A41I'-@,<`@RR1A6&%[+MV.P0S6)9"#O/FJ(\F@E18##'BF M:),J#"AX<6,2.5;`>0[,,NZ#='6$W6`Q=M*$*J2+83OA*Q_C19*[2N)*K"L? M!^7S=S[M=FDQWNG37\%1L,91M9^>&,C-GQZR2HN!G',1G'^073\2N8I@)NM* MQT'%4.?=[-BJ`\8R*'@P>\C.N.L:9H!5,*A%J(:TNR4'C#T),7H40F:9NUV* M>:PK(0<50YVG2F@Q?N?AJE#S^;K:F64RY22-TF+LE"L>W-XQ0*;>A*),]3G[ MO;.&,1,NI+>EQ5@N/,D(V0H#6.Z=$S"7=>T3H?9)MV-A_BP&.,A"N+["GD?V M5*O"P)K&UTIQDS[KLB-2TMQF:NBG&$["N@2+40$4UT&)L"%YX#;9#Z(L@$R)UVH$Y8!6<[WXB5#_O MS&KK`!C@H(\`"1G3RCJQ@(1YPH$YK"N@`"WS[P7*96$YS'KG3L8JD(1W,9@) M5DDSJ=X;$A&>#97KK67DGPV#BJP;$0>)57+NB%G&KZ$\98'8%N/M27\%1\'Z M1S.5H0ZF))G28M:?N&X8,0>L@(9#YMY'R5`)4ZI"%@,<4G?6,/6HL-7M(E06@P,^AU7P4YX!X"Y8*5<>@^G0,2!JI($#'#@";ZB3E@A5PXA&?#E(0H]5:9SH^V#BH/G@X)0+^G7K\W2JR,04]"A:2] M+XV+;0R3<:<4J5>%[?+6TX%SC.\3GL+:W>CK(].'?R)>E74"Y6(L\U0> M=P3K8U"-4"=3HH&E_FHR=0;>'[.U)Q6,6'M2@<\F\)W@W/0O3=6<3D.TZUXO M^K4$UR]EEU7X7%.RAY)/[\3)>J4_XYCUS6+0'U>N]4OS6]V_M)N&^>Y0OJ`,``&<,```8````>&PO=V]R:W-H M965T&ULE%=1CYLX$'ZO=/\!\=Z`(2$D2K+:4.VU4BN=3G?M MLT.^Q M*A='7IVW_K__/'U,?4\J6AUI(2JV]7\RZ3_L_OBPN8GF65X84QXP5'+K7Y2J MUT$@\PLKJ9R)FE40.8FFI`INFW,@ZX;1HWFH+((H#).@I+SRD6'=_`Z'.)UX MSCZ)_%JR2B%)PPJJ0+^\\%J^L97Y[]"5M'F^UA]S4=9`<>`%5S\-J>^5^?K+ MN1(-/12P[U\"E8!,.TV1PX[T&7W&G;: M^H]DG9&E'^PVID#?.;O)WF]/7L3MSX8?O_**0;7AG/0)'(1XUM`O1[T$#P># MIY_,"?S5>$=VHM="_2UNGQD_7Q0<]T(_DHL",L%?K^2Z!V#K]-5<;_RH+EL_ M3F:+91B3:.%[!R;5$]?/^EY^E4J4/Q!$6BHDB5H2N+8D)/K?)'%+`M=WDBA= MD$7RWU("W)8IQR>JZ&[3B)L'/0;"94UUQY(U,.LZQ"&<1ZZ#CSIJ,+`L8?5E MEZ2;X`4*F[>0/4*6OM=!(AN1W4&0#A*`CDX,U&="C(XZ8E8=C]&[1XCI&[.0 M]1:L3+#5B4PZ"G7H[6D9.ID0,C?'K$N5]1:L3//)3#JZ]4%E5[WE>VUP3PA) ML?J+.+:%9%8XG,^[L*4">G5BOSKJJ'`.<8^0E5$1SAR-V5C4TI!,:M!11X.S MU3U"$J-A$8;.D62C84L%=.I$)7344?%>43P/A,RQ$EVUL=WNQZS\^@LR_L+I MJ)-_8>?8(^1^_OLQ*_]J,K^..OD3)S]"QCIA+&II(.#7$T4P84?%TE'18K`9 MX.,Y;(53)LE&;IEZF3:MYA^7PR,8AIC M*[*-L^N-H6.FKF/".*'?)522S)/D3HM:D#A-^Q!;Q[1YDJ%[IJY[MIA63Q3/ M^\G0OFP(#!9]B*W'MM&N+D/_3%W_A+'NO2Y1K-]=^]W6@]\H`E7@7(>#3,F: M,\M844@O%]<*/J01>'.WBO/DGJQA.(#QSEG/8,XTZT$7@.FOIF?VC39G7DFO M8">@#&=+.*L&!T6\4:(VT\A!*)C[S,\+#/0,AH%P!N"3$.KM1H^BW;\(NU\` M``#__P,`4$L#!!0`!@`(````(0`QO5+5'DT``!(T`0`4````>&PO:Y^]'FG?82F5/IR7`D$F>/"Y:)`1IRB301*3= MK=%<;"(V$.4@@HI#INFK4FL>86Y:ZI&LOIZG\+R)GV1^_^];:Y]B!P25"55V MEU4JD;'W7H?O?%K?^OH??KP<)!^R\:0_&O[NT<;:^J,D&W9'O?[P_'>/WG?V M5E\]2B;3=-A+!Z-A]KM'U]GDT3]L_=?_\O5D,DWX=CCYW:.+Z?3JJR^_G'0O MLLMTLC:ZRH8\.1N-+],I_QR??SFY&F=I;W*19=/+P9=/U]=??'F9]H>/DNYH M-IPR[\:SS4?);-C_XRS;\9^>/WWZ:.OK27_KZ^G6[J@[N\R&TX1U)*WAM#^] M3O:'/@'K_OK+Z=;77^I5?_U9\FXTG%Y,>+67]>I/WZ7CM>39QDKR='WC>?WA M]I4>KC<_O&49R?_8/IU,QVEW^C_KPX8UGV3G?;W!3@[3RZS^UF[?$-%-QUGR M398.IA?V9SL;?^AWL\D*>^ZNU3\*0^\`GG$ZX)5>]F/R;79=?R]??.?Z:F[F MC?75?USXP7$V[H\$]UZRFT[GOMT&,SW#SMX@/5\XREY_TF5]_YREXV0/?$YN M>S-,V_CN/V[4O]Z9C<>`("E/LVC%`61[_4$V3G;8TOEH/`>O]F4ZT/.3[&HT MGL(.R<[H\BH=SKT8$3"ZO!P-D_9TU/UA)6E?@,1)7W!^\,I<+UD MU.%D-.CW6$8O>9,.TF$WXW,X99(\>=_>31Y_,?]ITKD8S29P`T0Q&PZRR209 M32^R\MPTZRW6ZW.NVOYAZGDPMC MOZ[^R/XXZW](!P!\#HTG63?CV2F+6DEL9C[.KM-]+LA^1 M11,0(<%A$$JZ@5#2R000US^$PT:763)-?V3XLQEBCXW47XJTYD-H_3V(&Y'3 M'\Y`(O)OG$Z12W.C[V9G&63:2_KY--G<2YW1%#ZY>9G')T?'K9/./R?;A[M) MZQ_?[Q^_`W\2S`"XJN9)D:'SUJ/--ZV01N>60.NL/(1VQ7PF%;!'B M:IA^?_@AFTQ-&/6'<`9(*9@K/3OK#]CS'#Z=G(:CX9GD1\/]K??[!_L=_9;#4P9:-DD%,('2D1+GZ^R MJ,NDEYVZPNRF5WU(JO\O<>G)Z'30/V\FTCT<#1(2(Z/)J,+K.LN0T&V9G_7F6;6>#L]7^<#)# MKR(Z00?Z4L(G8C-`IT[6CO7X4FDG]1>K#'G#BX='A\M@[>".*`IB-*YTP786 M@J%$UPL^G:/_&_;HP"B-><.[.T?OWNUW))G:)JAVC@X[^X=O6X<[$',=RC__ M]/-/]=^P?$19.R"UEV%;(HL3!%<0HA-7M8_7-M:3*ZP*%-(L6TF>KZROKR<3 M5\#I;'HQ&HOT85$,V*0_F8CT3)@L5L[M;[9/6M\<'>RV3MK_[S]^^=?_^\O_ M^@^3LYU_GB/6L,CM^945DV-KKI>6M9+4%WV'M6&&R-`(NZ_,H2EJTZQOE&'S M8F7S!?H5^`@`+U:>O7I5>C\`!S5B#Y\^VRR]NO'H4_.RY*L8X.1Y-D/D0 MX6*/9_L6HZ\PWNJX/+F!UW,V3Y[T4!#I>))@;CBSSYG)-PTT)QZ2)_[3GS-* MD"F?,$*)FQ8NY+@N^.X$C+FOEX?`HD]OV?:BSY;9:U7&W6FCU4^7WV7C=[=L ML?&;9?97%8HK45LMHJ!&X9#SIIE>1[G3@5@8IK->'W_R;B+B&$YJ2VW>64R4 M0RISCF5PJ?+EWB`TCK:>FRL5`#-GH+1,5>&KR&.*KN<3Z;LO9+0O MZR49$>+K1+.]$3F^#]>O"^#L6TB>'!RUVU\D>R='[Q(W#-]K@V&K1X?MY$UK M[^BD%;:<=+;_:=YH?-,Z;.WM=Y(G.,3?[;?WCPX9\>CDQF^6G;\.Y(;O=O?; M8>FMW=+*YS"04Z99&08X05Y1AN#5Z)^/-UZ\,KIZ_/+%RYN-J@.0EYR-1WAY MS? M=\Y:BG,DVYW.R?Z;]YWM-P>MI'.4[.Y_AQV]OX--G7S3VC[H?&-_MELGW^WO MB,L![5Q<\_BDM=G*:3?M?PU.L/9DC9^J=$]!0)$JP4#'$_6S`F]G6; MS;(@UK+DUX?PM_AZR=@:C=!ZCB,DJ.]'&9ZN;[C[UO[;[_I M\,4VB-Y^V\I?EAO53H[>=]H=(E7P]QQKO+D-FI^@^Y8SESMP879V1JPQ40C% M,69T#O[GI/H2R\$JN"K\BJ#^GHAEI8]OU$$6S@%^YR(=GN,/#Y.SM!^<9TDAB^^>$;%-+K+>.?ZTE(8+JSK:77A@R0\( M81%Q[H9X8N\/LQ"$4\"7T.*,.''">Z/SH46A*JJH/FI9A8"!$BA=2M7?K^YV ML9!K&FM967?[G)]'Z"U#78J_[X$?I0=N)::=[?8WR=[!T?=MU[2%);&]TT&B M-H85HQBI[WJ!<*J_5J5XTU(A.%X5B?7OMG.ZF22H'=$+D5]"/H[W))@LBP?4 M5Z)6(^&K\>A#G_1?FTBF)B')$Y(8W& M2'[5$JQH?0_@+K(%\V7T\P![?6N'H^&J+3+:!PHBCPE5S.=G+=Y8_][ET40" M*>159&)'.UQA0.+W2@@5:I6_;L#B29$>LN77)SQ>G"-JCL@WA\;=$ZA%M.MS MB:-NH,JEV",?(Q!S(RW7)Z[S__[A=ZVV>1(W\/_Q;-R]@)C,L80NX9EZ1J<^ MC^5&0E`(9='\43*]&(]FYQ?)Z6S2'RHG!;&>$E5J(I)"/RG!,NYWE1\5#.M3 MXVW,#D+N)`4.PFP=T<50DCLE8UQ=4^@!=7X[M+_X&3>0^ M"M+%E,4"'V717)+K]=JI92;S)7)W('8I9:4)DI51.(?TM(CY61G!((%L_L/$BC)U;VI,;8E)O MWK?W#UMUSWE,69+*G[Z:7*5=RJ(@)DL[/MK:7::()WDR'9UG5L7PL3^]2"2^ M)K/32;_73Y7R6DE^^=._WS+2+W_Z/PEDS"!Z>0>U3W$*/WXAZ2L:G>`+QF2P M%1)IA2HD,CMI1LF7A`"@P=6]`CRR+*1^'<#L4/\[YO\F_Z+<&E5:ZX^^W/JZ M.QHP[?C\]'>/]O9()?&??A[OX?;Z>_M#RC/Z4_WZI0TPW8):@RMUR[ALYQ)X M;MPZ9#/T5:LV%?RNJ*T!E(-K[4@P:A.7O2`02*[^7;_WT9+V(@_[7?],S042,1'D6^HAH:1FL3($SE4/3A2AH-=A. M+ZC/P$@"[T2RG-]8IM)\M-!Y,1BT24LN0/(BC4-XN&MZ#3F/#B+T_>.V?$7;""2?(Q4_9=(R-F M?6+H\TKYX]*J2O`BK]6H0O/M1EB"C>U!>II>DH?"BQE3^*2Z-NA^R!_?IEBN M8.];X#7K_L!>WZ'/1HCDE>3HHC]:23K94)9#%B#5R7ZDXC"GV+P($"I;P)_; M)JWR+SXCC1,%[U[\_%.UM/!^R7V>%IJQP*\35*:(X#YV_CP$_>]WLW-T;J+S M/O:C3/?#;&F`/*9`K9?O[11#KB*)DM%'3)S[V.7&PVQ1,M`JINYG%YOK2\$& MP?Q)>@7.D9*NB=HU*CS']1^#ED#238AV>9C^^;J4[K.GZWBT"S'>]`BQ.D.O M]D:H[>&H4!^;KU\40RG\-I%_-,#(1JD;$>5@R87B="L:,YBDW[4.CJQJT-\K MJJ=+KES=5F_6N4?#9"\['<]2BCPVO'*Z(I5G`(PP"!%`:CT,HE>9K)] M/J:XAY>PBMR8F7]D=HWQ^YM4A;[H:)%#^_8/-(FE+EJ)J_70RV. MIRG8H+26*J`^.G#TP>9#T9S-QL,^)C_JY*S_H_YP/U(N3BA=S/4SW_%W\(39 M"[9`WRN2_'FN$66>O"5^>C[Z6%9[ M%CC%?CT'-E3J4?84?'(9-E2Y08Z/7ZI^QFIH2)!/,1@P=MPE89;H:J?)8RN( MLO=4Y'F>8L$,1J#!P"D=?CRF8'>:O4F'/_B/0D-PG;%EJ*-ED1:^,#U"'8R9 M#&M!*I5(!^`E@'`V\)`QP^B+V24'`8+UK:%SA%?)1'7"A)!M\;=L^#2;?LR@ M`HT6HT78":IHY7/;F!ZIU'XBUQS+WZ-C_*$'U9"WC1*+.X>0I@_I8CBLJK3\ M&BH^8B?U,BB<9'!Y7<*D0:6G&QT$CIX`D$$`<@S41\>,YGR]D*A'?G,AN/ZX+@`'ZI M__9FUA_T(.NZ9-C:*QAI+S"2V[**.1HGU8?RK'Q."W,C[IHC;ELUE/7'@.Z/ M2!GY*]"_CF^8@Z>GUSI6@&<+`JARSRY/>2<88IM5*B.P98;P`)3!E-D'2^>7 M*,7<(Y`WDR/*T"%DK$`#LZ:Y)3XG]B/+Z2/[/H^<%'Y8&`RYX"K1L5N9O9?O MFZ(%]]+!*O+M!LS^\J?_J('WSQ35OF\"!$QL-,C4TZ3LB0*#;V;3[@45MZ.A M4)R\>GZ+?"N_[Q:^;_LL);ROLSS""0-13"$QYJ!)Q%&".-6=PJ[>D"`R[\E> M'SE\D?0Y1[+65((WT3(14D):1$//I%T.. M+S*(:7%Y.M`I)EPI!XZ$.TN:\J-%I7.O+P@9PZIY3RJHR6PXT*B1AJ4U^T)- MS+(5TV%LDS_SA:`&HH9TYH?-F[7)G$A>2`9'W>E(3.(*N\8C2U'!6]8T_""= M)F'VXFDC$>0HEIHK?1`=/`&%W>2O+:0$8[Z-32>%WS1FMF?G4A++(D84^W&4 M^_[`68YR&4(*ZAC7F!Y'ZR#A2HK11$NRL7D+`D7J:1+>@D`J!JW7X_PSAK1*E,1==%6`0EM.2R0&+` M#0-0'<,A"`=/I>AI5=F41+=),[@N\I>R:%,=+Y)A^NS9Z[E]%=[GS5C<>+YJ MXM+?,DEM1E>:A`>8Z-E'1+G+Z/\$Z.5H02-ZEQ*EA_TN]>7I)$K3(8H*_A*6 M7CXSN9H+2/B[]G99E`;-M9#[/@%OIK=^A1IPZVB86&3N$_#SIG^>M-'3V+UF M\>38V7CFMD\9/=_@F$9,AE"GTW\U=B!;G=`.E@H%"@C(V7"<#8+W4_@%9F!$ M@V0Q6M>;V5&*H62P-O(F0JPC&5+8MW2POVOIN$09Q#?;[7V*Z_82BKW:RM@I4:=_ MAQ0S&3S*[CJ6S:NE%Q>'QT4+X)+\S:7Y[OG1Y)#L1*:;,K(Z%-&$)3.$Q)+> M,5NA=+RW[#^X(VR)DW;,1^G]^108GG?R$;DXN%XU1B$-PB^3/D5DJC4S@F.A M4J!DOG""+53F?D))DTYP+SC?=GBC]2/E2TK4,O@E^4->72,Z[%'@?M$WQ(:3^AI"O%9)3_&T MA8"'ZEVB>&J^$3;1*`'S_4AY'!?P&> M]UBIMNSA$'5B!?964.NG2$MVLI[F MI\!+?@`A;?3';P<@,;"']9UGSV_VF6X6VW^S4^]2+/A0_&Y9-6P_4JENAGBY M8,\.,N$R!I.H2/=$)%LAWV5ZC5-IIV&M-ETJFN33#*-'L5$3)H2.ES>;)O3T MHJ<08RK-Q(=B/)9FZ>L\IQV.=B_#E.@A6;86L.$DQH@ARWF`JGFU/1S.<.ZI M/%>1'^;A'K*.Y-OJM^8+2H.=>0LWB_S>G\=UWR)PJ\%'G6[IM`BVYW9ALK^= M49M(1R&7:J4BA^*5>&9%&K\U'D,`.R.J4PQC-]44G[1VB-=P`&#GZ+VUQ$G> MOB>R<[C3JDXFD;.%U4Y7POY`">^0I]O;;K\)S5IHH/7>GJRNOUJ)'71*08,^ M2K>I?A=\+E[D",$?%`T%/.G@571;R_`OSJHY#K3D&E0.F!UYEE5NGN"K9]$]8Q7\$S>`2E=QJ50V MS7U4O\R_B-JTK$>D`[,$C$\#Q,\_F5NIA8H;B'TH3`;+@W>\6C50XU&O^4"V MVQ9"EJE-\20FQ&AHCLX(.<%W;`@%*Y9$->JO,MLJ^LR\TIZ/& MO"K&)6//R8`NW23Z9SC.FL`<[[02-)L[ZQHA7&CV*.<^DMUU>:3=L39DTJW[ ML^KCL2)&WVC3*=!Q5&"R9*-!+!_Z=(UD5IT1XDWMYT/:IQR;0Y::1K]+Y*TE MWT/?-B=:`V6FE?;(Y3$QJQ05BR5M\8PC;)'N*SA"9!(JHB*W*)0PT[EXF$<% M$U;OYUO+:^%CLD#9+U%;J(21W'.R]6+QH#-H&K04E$:?P.Q;]8%A^.UG[^28]7UU_?CT`^46)E!L;4 M_V%'G1G8(C7[.DBR0^D`)VBHE@DB]L7ZB]#2Z+/)06)U%R0LD3_&XQ+/*EM1 M(0_4@OKS8]X&<3\$)*D,]=FJ><4_[WLG$2V=WV1):0Q52$:RL""^3C'P.<67 MA/)X>#X:]1#S-'V*V0.^IIVL;[N0#2:[8(H!YW.(%E-1D6?MXE+"4LV^RBD) MVGV_UEY+WFYO'[-2D@8L])1-76)(Y=+&YQ'1PV%T"26E-2>,Q!:!XD2`OT\Q ML,;7/__D>>*7"T2`&#H7`SY-/H7_;O8"B/*ZU9D#=\".W\`3<0#<6GH6I1H,/`BUI8DXKE8K62B,ANW@K&S_Z@M)Y)>9C M5$>ZQ==(0M"*N?$:V1[R8Y/DI>/>NWXH_K/+-:ES24MS=43 MV8A"FS1349MHWJ7-5GD7B/O5F$$_Q6D8 M?330I:BK($@?OR@*MXFDA]+H6/E,7?=F\;R"H.3)HPBRRN\!<7SYU,LA*1\' MH(Z0TD?Q)^%(""<-@*`/A[OMT+`JCN:*K1OGS,$8G\;!.6)&_K%T-C2:?87& M>+RQ\FQSPPK7S=K@_5.226001*W62(1"?B_A=!:Y1<7=,?5WAN!<:ES(9$E? MRLLTC,>"?,I+.^]VBNT]'.$[K]!R&EDEYWQGJP:^URD(ZX\A(H_8J="+6Q3@ MGU-Z+@=B.)2U+P68.P*\1-%+#;\TW)O%9=C?O6SE\]-.\QZ7+[7J M.Q+R0V'?JZ$]=QY3S*AK8=M\490E)1[6P=L+)O#C\G,P]U._\O3Y4@#]1-9U ML@]ZP+QG9;<1A=HQ5FR^R8/]-W2%NQK,[NGPX=KSOWN(_5+ZE%Q)Z6'%!L71 M3-ME)P1D^U&(>\I5O5A[]?)!=E\I<$`?Y;2M@%]NDNYPP$2U)MCE%-;>!\A4P3JEFG"IL3\1]:%$N%HZ/%$YSA`Z\MG9R$R2E1LK(R%5N*LN=4,-D ME5X@6L?8;Y?PP6MCL#V=E:O.H67..MJ!OC<4%B]RK MS^GDR:/Z=_)&.\"F_CN&'/F2<>SUXA[V`L+%W73WVD*G@G39%;90/8"-WLX< M\;+R'&!R-3]3;YR'-J&CQ=Q6\:&?E/4+S\@N(F'K)[ACU$(..A'3>+E3+H*` MBN*@X0B$'3%2M!"L$^TG3,US?$T<4OJ]Q:D%^E"CR:BJ[K8:9+VH3#RAT9S8 M%I^OY& M?-FC+2C,HMNILK61!`+$"DF5@^JOA1QSME]"3OX&;;68'[B@+*74=B)'&(JK MN`Z&DTR]/"-1BPGGYZ2ZJBN6G@#WCS=C!*$R#+C',"A2K?$XOZN!\H3E=;@" MS=4@A1.7KAIB4;)X,^R'/"`IS/$H)9G%.M#4^24R[PAA=]7Y0NK)_X'14Q9_ MB#C]S4[[]HX`)Z6/LL004J/ M<6(4/6L00N,IW!YRNA'XF,&Y,I6]EE/P9U1OUE.6R),CC5RL;ZWZS49FDG/CN`VA_`8>+PP]8>P1[ MK?Y>#%`*Y'(DRMO8-!BJ'CR>`Z7_[,BX.^M'MR(:N=:+)F+VOOSU!PU2.GPB MC*LE%KFLNDE,NG.F0-;C#2(-F][EYY["./=*D$W%=DLE,"VG:)UOBPR)V93J MY*2>AE2RE)*X73)!E`OI6DC1M^7[YND9-EI?I<7* M!\+N?%)@0QF%4!UMD\I[:3W$8$'"G))BN/#2W9^@790/+V7(78&#T9FVJ25> M5S'.^4?.HEH81KY[-:#E$\J;*@C*+E0PBT(+IZQ*/7R]&Y$5_$40S%V\H(:F MT%&U4K=NX+;^P/-'>OE1(K6UCVE((I$:VT*H`I M+X'WS'KAX&CA`AE4>\GL2A46D2**R"RPNV3Y8B8,E0)D`D'#Z[ZSG`<-%`[V MII=CFI.A0RU2F23$Y#AM(0IN2\H[%O-,KQK.N4RO&R[�&84):GNKCA;S*D M+"D$DX2B1$\3&(`@I?N03@^7*T#,@[4C@S$ M,$GI!%8C`X1_#J8E?,).25!1.Z$&ME[%Y<5*%!I8.WR`OT"2L)0T-C_S)%X_ M,-6O49TTY[*KXJ92U<4FA=$&$:"<0`[$A8*B:*E''5!&66@H@T*26A^]>,V$ MM4G.$?L97:7'KUY;)I)FN'XJ[0PFK?B")WOUMA`"&9_%<=;:(GN M*E$W`X1KLB.6B5%:\_1*4;`9G#9NO?-%-.3M$*"O*/X$PY:C!DU*F)IWE/6O MT.9KQH@Y)<^?/\O+LH)1XN(L0E@-+0=F&04].X^P_)X`9VQ9*G,7XCU[9M<3 M6_Y3KP4Y7:!*QF=A:D`"B&EUT5*YH(E,@C^TDZ'TU\,L+F)*],0G)4'C#2_4 M,SUVX,PU0NK'%60+ED[WHD#3P35=7406C!7_R?;M"+Q#1:%PU6CK?)690]'0 MFX=*J6I2%A-%OM)?*<78V%T'Q!3X0!27'<)@!=]7"+ZGM.JG?<40RAW0!#2[+!2 M7EZMSK\$L'3GP9"*XIWD%<6(A2Z-(O?3CRWMZ5:S[RS,\XZV122$9>E^7OG; M[!:%=KY)1Z6T*J#T2:,G-%5'JOF&R8"CV4@O%5\B;LJM=/AGWCIX89OA:,P+ MWOG;L6=85>567:ARX^!\*U`X#2J\W<9U40D;JF_CSD7D5D2L\EL=2^A`!\>E M+L.L!3I1E'@4G'@WV?)&GFQ-M"-;:1HH=FYPB:*T\#E6[;2,19/"\1A[O/%J MU7O%Y$5R7K1;:;/XPAT4ORW!.*W",[5ZHE!PE>8A!,^LPGAB$"H4GE.AT,XR M:XJ3O+:`+8VFV1!';$IGR-7:>=P3X]I>JXC63W'+$8>A0KV@I'V:*^-Q$VUX MQZV=!(3KI%:\L/C2P/W#]OL3'3Y,WG%S)S=UU@D,*=I57 M4OR6SU<=0][_5H<=14M;=0!$PQMN/`-"<4]YO$41;QG&M3((P)9RM#"7T4C@ M*=E;W#F)KSXEWKJ"ENLO`)`YT(/^#QG6,T1'`EWWK7!V(S3.IC.+A#7T),"' MSXV.%#W7.'84P3_%L99)T5N0IWQ68RNF.1WT,1]D;I8[6A%M(C";M]CBR@[. M`#.=50/P-NR@,X$ED.27Q"!OV]_L)"?]R0_J?LXFQZB"?;4^?X+MPS-OF6XG M=03MD!\@_<9\7>4K`;-H+^SU$J6)]L'%1Z>J$S\I M^%9?EID"#0O+[Q@I))W?'R*BM4M#G$"E;V[/Y&_L;;Y^N?OG7DFSU$S`Z5-L M?A&I';PTG@&JI3R0(]P-5]%,(`#8SV\)RMDL%J%PU9>?*EIJY7:Y=NTTHAC`1"(8V>RGD#>#KV7[>;':Y8:_1.1[.R)D8H`EE2NRS0Q>.1MZAJ) M%TM`AQZ;KNQ,@M^J5(W[5:43;2V^E0##7FI?HZ\E?NA;5UQ:T8A.FF!';ECY.N@C*:M#,;F`,2;K)OJ M[&O=L`C^=1&!D-&8'_F5,)&M1P\^\X\7L(E>"_WY,,*BH1LL)#OS&DQ(`@I< MN3FWB&BXS=NP59-0!AG5(_*!HI"+TXDUM?3\/+_6-.?8AR7=EZ1_NKGRVJLB MEJ+P3Y1]2F?=TT[N.;D=HCZZ_1?3%-VL;KBX'8'^;5L1L9S&D!L37`?K[S`D M6I7CV5'*'16+/\[?57,(-8S&=U#'KOAIC0=$2J4X'*XTQ^L5!<%3\+6*STL_ M!\_([J+PHY7]2]WN4*)`WQ*.*SZ6[H\M3P`9P)B^&&)V^!`*?K((*2\X3L7. MK%:!.?6[MOX?,PNHX<*9,P^3VJN,8[\K>$!9#I/(4];RU.GWBJ9&YK>QB^@K MBIMP$,Q5V`XWSIM1W',6,U8E/&6(,M%0!G-9-%3Q%1@M1UOH29&I9DR^Y:@7 M0@>E.9EQYBVAI%@EJ,H3E^'MD"ZU>P_3S<_2>#B]4SA7\>`^T+8)>R1$4]P\ M^&JJR&2QJZ94DMRKR_ZJ&UJU*R8!OA*_8%$CY3<6&:U9CPW=4F2HL4LAP(FM M(#828#I;`X01PO"5@TPL#3*6YEBCSF[,S02CR<\__;?T\NJ_ZYXP/V4,O>Y' MSS:^9.XM\2&_AZ+4R#3,?P6SI,2&PY$I*"XR5ER/U?Y1(*BX31E!@E]<:\"' M8]H8HXAG%BB9,&8>MB`>I;YA5`-XB,!8[!!JKM1F2^^6\8T. ME/X!?OF^S(Z+\(EXJ,%!893\`Q!3T,7\QB1AA"PFNGDK+K_]_[T^(UZ"68]8 M->MT`J(-V4WA(<:+1J=.@[X@@Y!B@[:V`$]!?)!^G,P\A6H8)$(#S!!*X;O8 MNB0(I/PFY])4(;F`7%%]I0:MTGVNY-!I;',?NF*N&]RA%1+*(-S1! MD,Z*)='!-[_@)!UCU>87YRK/;BLLXMQ,P3*XO<\8K-1^.,I47X$Q!:,1`47/2<#6AH.D0Z.+YN&" M>A,Z?%.QFN)V\W_;EK:457I'U_)>3<5FN5=U"B3*A[J>T5)N]['%S0/>D2WZ=)/3(( M7N3:;"QD_DC'IWV2O\8E);(?9C^B%Q#O>,R6GL+$$5M9(7\IW:"35&51@CQ5 M,Q],ZU/)0LNE%I-=4%.(2>^QI'+4W6H03?%P5`#-YBXF#9;.5LV$9M6+-+P9 M^296E<;F1)=\AI)HL#XN2P'^COSX^)77/2\U]J4G6IR>ZX%0ZM9-E2`W_J+IPA$(9RW9::\8Y;^0N(>N/N^]B+6@TN M->[26-G2\?+81VYPW>AY;@_DF)]S;@IJBT:ZW^R`18G]$"T+461%M(C3HI-4 M.!_!1L*4F',$#')+^:`EV]"SO.X>8C'EMUQ@J`0C3F),BV_P`KE]I)R:OG'% M4@+]H:XYL9-@U%C[/2,NSC5!L4F64^F:58XZ!`!@`Q#%N*;8Z(P[CG2/,LY# M-#O7JA'48F#$.R(]]'K59;-)][JKGIXQ_J"2!]G^>,'89IY`"EZ)/;(J=39B MSKC%E'S]:N0WR"NDZA'2SYFMQ)X]TQ1W%@!>@5_#F7,6NT99E0DQC9<4'JX7U2J##!WN9J9LG&J'WA,Q874?!BE88/J\4B@J#CC9]/DO4G, M?8^<8EJ]1]/<.>7YZ0-19]%NT4RRRR*,F"$X#:_/S+UI` ML9PX-WA0]JCNK6]Y><=^C+*YG+G=2/]>-3]!A@AP'T=4X8TINOPW>5MR?YV4 M\O#=2JT:8[[^P';/2?_!Z%IG($_)`E`P&#-BGNT.66LC\EYVR6TZH"M<)$63B/0#1/+[HS:XG$RX]!2C"IW)U5?4>=LF6?2[D6?'"PCDGUQ.. MI)O(5($X'U")R#85H5B\@PA70/"'F6*HGETN85`BW6S(3=_ M>:^Q]6?$=:?T*J_\^'*>>1?!+*>(`BW@QT,->8I10*]+%PN>7`&\OOIFE*X8 MXF07AH09K2;\K'`G!*;9@?`"5`.;F*10QX'0I77]%4^]I=I2.O:OWPZIH,(I M&X4#&YA(`X!GXB4=?#/?7B=@8OW(^W"N&W;PG^;&FF,-@9;P,"&1^P#?@Y:2 M0"%.=":K8M\61$J1)XTG6E&T][+=!TT,5T6@J$(RR:K9]0\9>#H9YY)">'9' MTN04YVM,`04F//9FL=.O]M M96)A=D1HQ)9QNM>.%"LAZK*HNJ^CX?(T\$VR/HJC^VDS]WAS\_6#%03\=LXJ M5&G,K#I3JC&Y@ZD5^V+=A-N\UL4SC%C74*BUTO?^BS*L[X7?.?J]_H"GAGZ= MD=4MQ[*,I0:\(C.46PLG7T%4?O3/XO_!!PH.K-F8A07"';4JJY5=J'(/ZH/Y M7B(D^F/DFVJR9I$DR]>7&RL;SIW_3F`3L M=9;M=X_V%:'J3Y5%^=+:UDV#V%2<2;$KQ!O()B%!;"9$N]F,P(]GQLED)E)-P6K%X>)+7$ZWHK*C% MIB#:L2X1L(,B,`RW"9GLLLO,F4/QAG")VY#*KB'IF4*;8&R$`J7BE$42J[., M'6)82E$PP%"-3=D;)6.TN"RN='XQEDOI5(G:_>2;;EH&X34[K0<\ZQ4_E?)$ MU5D@:`4F20**NH)%+$#/QTTUID+34VM/M) MZN^>\#'?2.[S[F:9K$E[.NK^L.I%,9)R,1#J*XEQU>E6Z>H8&*S\9BZI=I27 MY0S8!=(XG`<^3J^MN/.&ZV;:G:.=;U??;+=;N\G.T;OCUF%[N[-_=%A?P!$Q M(94!B;^/B9LVG"M,(D"Y"VN=6]`DLBHKY1]65V.)!SU],[)"%9UA11AR4@^A MHDO%9&KP6,-P7'9XOMK1\=%]=!(BE?RX%F"'VNP-_4NU?VZ/Y#_IR)J415R& M4@T8,';JC9`O<"=IK2R\2S(_J3\1](QK+$'N%7FI:F@F:]S&[F&'L#+-NY*\ M]*L.$/-\F3L$VC<30$)6V(EBV-,XL".)%M?8[UFXI+"((H8:!*S=V!J\TSWI8AD=P"1]: MQCZ=D<`;VR4J1/[T=!X]]71`Q]T@XW7<>I5 MKKD74HYG'!XG?>58ELG_;7:='),MT-VG`S_,./]F00%-P^3&L<;+=VXQ8"XB MZY]?H,\@CG@"9CEL\H%G9XQPT880`KQCCG(/<(Q9MMVCICQF!>1".W:+DKM^&)',\5,B*^A-NEK1*N7#D MRMEB-)PA:@!EW+\E$Z+PJD"2#5'Z8L7/$1(ZRE#]$=*5?Z=SJB?M]W^O9AQ? MJ$7&J^=_)RX0POXXH\9;&3AKWT#^I.OY2T=5?&L!W\&`&B,F/2.:'7)Q,=IU M,%4C)]%<>I[2%",/^6HEE3^.&MF+9<=I3)Z$4I\BYQ:@4=R;IA46I.BA*-T" MJEP'L=:5Y&+T44=>G:7BJH&)C43_=A`'_>&9A8*@(28G_AKM;1":BNB# M;]$QO!%US$KP08"(TB-7DBL8P$%@%M17`K&E$8,\W%B/2BJ,&5DT[J-!26D2 MF-,M=ZN"&I6_'\N/QH;P5+!'+'J M="'3^(N+#Q!I2-K[@,S+![NRQ23M?6SAQ<,5$P:5A?R/0A^D=-YT[)68F:QQ5)7H>J<82&RU4O!#HHF)$<76`IZ9!IH8(=9X[+= M;,?6T/-H(.AO(\:JA51+`2E MD$)N%G"VB[^&LAXF!+H*]\9@8]"25R00%*!1R=6PL"%D.5#N/)R<9=X@)0AJ M@5@?BL_=ZEHI;!TO%L3`\[65J,WA[\>LA'Y+VA!G+)5$%U0:<6S*TMJ1AADK M&?O*2E1:,C&G$(K3DQ+)S"UC$75H81;]4_%W-+I4G?2!UJ'L-UAYT*M[G7&= M1HM`E$JD"!M,,$J[X\RV,(U.60NQ0PXSY1(ESR,M."7=GEUB.YM[1S@7HQ*W M,FPQ.)FLHK"CKG`@L5S4D\>BI6S$DO9?A1D+B^S[3.Y3UO.5%+\?N7/]9?WW M;:B)(PWUG]M'[>V3FK:?;K6B+WPL@[_^S5'1]GVEB#[$:P'J;YMY,;_.7_[T MO^MOQEGG]O2DE'0O=AJNTRY^:)GC;48S]F\W&T`']3DJ:[?RXWA_3K`URL-9 M0$!=J%9"M^-XFJX^ZDGN6-6?V.Z3751I_4G;R*[^:]$MK?YD-W@DBHV\PX>QVS?)#(#D^CH:H M5O]SN^S_G'BHQAI:F<#P2`$:*WP7(WJNS^O1`B%\ISDT%U1-6;-U1!XVB^G# M(-#^LVM\3THMC"TN`4`+-R(X9B@5&1I*A%G?BY`OM/;*E.AS!Y1/5CK>1+^" MT(,F#YI"-+IN:F):/L;WBC1FGL44\JL$48T*Y7'7&!/)?[B2\G%E'Z@G3VI[ M],3/TVH?YT-7L6Q+AZ7S'RK*-2;YX/P2??D&8DS:.X]JS6\&*3F"=I>(3399 MY33W%%H-.MNA+5AZ?,":&3?D5]6:WV)TA/PP0#1LR;B6&28GBQ#R)#YNG+4V M4>'O>=QB]`/I3;D`E6RC)JN"LF9XV";<[Y_'D5MA!=,&*%519R-4$33345@/ M@I-:X&\N'@)&`]D]EKL%@O1',U!02!C;!);>4G+6'H>[(Y1]B`%"^SB:=DIW MVQ2#_ID%)6W''M/PO05#4:WYSC@S)2@1D,-Q("%KARP\T1!DT/NU]AHVL_4H MO4ZN^]D`+VNF5CHPB+>V5G!4LX`WFW$1`!SV87DQE!B&K/D\-H2\,.M3&\D@ MKV3X_)J?5"9^@%4X@NJ(@Y+LBCCRLPJ5&B-Y.6=NOG$H@#LZ M%$YSAG`+RTC-6JQ.HH^BF"F2')FDJ')QM+XJ(B6G;0TQ<%0N;6J<-MART$OA M+NG2$D*'DWZW;LV=I$.N=AF=U7^/[D']][<6OZS_^IT4W6KSLS@2Q[C0,'-6 M=/.O)<^A/E<83\"L/WI,['ES72*+&X36GK^>>_YT[=E+>_QB[>E&]>EB=FU+ MZ89LI!5BZOX.X8M_4P&FIDA(9V2^*:7\KI-X#%!OID5'"^5\ MXX`(A'#@!#T6?W3Q:1Z^)!ZE,>0M+!QCP<^^QSL#O6#$.?< MQXXL!E%(Z*6F@-D^K;+GGJCL7C0@!IL,*831@B/0K7A_TY,#NIQ]H9H%>9LR M@BQFX""-80&"6_%]O>A1A<4]N5O;)X?[AV_;R9.#HW:;P5LG*MAY=W1(V^?M MDU9]\/V2`K6C<&'Y$O&(RW[7Q'&O/YC).%9EHIWD(12;&VZ*"S6$`&6%ZJSW M!"E-5EJ5\%=F&'MP?"Y>TE&;@.0=I:<7DZ0E^JVO-0]_U1\ZI=<663 M0&Q:`P?")86+&H\\&WYA*9CVSSWE+'&OAF9A42'5N3S\/6YMEB0CS9T8"!AW MO$X8:P:CJ>AR4>YTL'S_?OFW32H$OM5UIQ7IQIYM65-(6/B2E%8I0-$B:.D` MLVZH]8&98%)N>;"\\$WYMY>8!.:[#R9VK?V7#PZ^>5#^Z79WGU%JP&BY@\'R MH^7R;T9+E@UE'0<-O3!!4\A:CR()R+L:_M+6S@9+#UHH'SQ87"J_MAUYJR2! MF3`TTQF75EI8&Y#QOM#"1[V7DL];C""9E#(,F=/_<,%1GJ^!YFR27BV1ETWSOAXBQP&"_<6"XWWZO%S.APJ_@2%4+0]/)V^ MKO(S74QTTU'G9GJ1T0]K;;6ENG>B*DCVFZ`V_5C].[P+8.SJ*#^P?GP^HA&> M"^T8&ZI"T">[#L=58LFTZ.^)[JC6XEW?[+=.]N5YLK8)9H/Z:I]7*?^2126W MI2Q]P79$BH6^;O0\RY&GHP.;NIO,ZLK>/6Y*(807JUJ:LFBJ,^8Z&'Y+-J.W/W M:G37$D.D$_Z?M'JJQV[!Y.J,8RCHC`M_ZQ@3Y(CD<65T-'.\$N.JYSF/,_QA MA,)=?8='?P*E3JF/>/JG5QO[?ZFVGNZ_V%FO-K:_>[JWO_5T>S^_F:9?02?U M)D4]E!ZKT;#.0UCX16=`F]G2X%*PN__Q+BTF5"?FA- M`:4=;YCE%%J8Y&FZ[H\D4*'\>`!D_S^@C2MZG^N6J@T)@0;(>TG?,?]EI+FI MZ.3)4)\(1B5RFMA:"-Z=.0VS4XF>B`V%RMB4\J[-A0F=X@S'ATPBB><]'8T@ MV7-2K((!J10K2R1ZKZJ1A+IL7:@`AG$8S4B)<9@E$:*9\/>!Q6._@:>)-L^` M^38.,[?R\,LY-#F#="'\%Y97=BOG67Y@765F6ON3]9S;(;!8B%9[,X/)=X/J M_XFGH1;KB&:J1!R4&)K%QJD#&YLW#>U5O"YMAM(!:VJ@6(&D'NK MKK!'E`GAVHEQ4^"7X>[UT50H]+U/&;W-K^9FZ9Z3G.VBVD:W?K&WMK.]O[&]BM*7G=P MHUN]ZU[YL7SNH"]OS%T\V&T`/36O@VP8KU:Z;V%O^@^(>^J;WK)`B(DJ9P:M MP^KJDZJQ-_C-C3/-?[^KN8\4PC(WF%4/?[XW7VUNKEG-7"R9O+1L.!:CKP?# M9Z1%_$1G:"Z+.#PLS@V5YK(VH4"6TK+Y*CNK0-2J("\(8[)673@?D-$=VHF#5K:6:\*I^9:\2B+MH]F*1#*X**B M*ZW-K$PBVU*LM5%R$VC%3X2BJ0:+2=DUX=Y$(FHO6'EB1$$ADAQJ,AFRS)1& MK^1M[(-I)!$)(*48$NFJ1PMW#UCJ(VC"]%>J1$GV548X$##IM?B`?E16/I9= M%Z2LD]O)E8)5':A;9/_LY/45W41H[6.83ND@1:L?[8LA54B$7D-+$1"1[3NW M!6(=`_TZ,M;D/,"$9SWVI/&KFK\;>PP;HRJ3,3'VX!+!)):(TC.TZ)`Z$XV> MJH+:8$QF]_D[\;I1Y<:[ZR-PUD7.JH!SZF79/TD8$>RESH4P^6N?D!B2B`:'S1W22AD_T_"$JD<10`+Q(.9?&GA#"D]'Z M"4_.V3VNO'7Z\E]>:1P#^Q5A--4'T6)/.2[.JL7T*JZ,Q_LY.`"^1FPX'H>5 M)N[&!8_L6K-[1SO/UC=#'K*R]LY&/CJGKV7:1:/-&?_R*S*TN`F0=(S^2LL\ MM!(;Z+ML@V\BD]Q[48>TSS87N$N%"[7J_B4[5D(+9IC-/9Q?\=1Y?T7/Q]P> M+J"L1[8.:2"213>W-/_P4:-$M7T;7L>B^_7B`N:6GAS``BV80X](\>4U&I@U M>?"(K_3BHQCTU%[L$K3:>;7?;69$:SXS*TJ&:/C/F8KIM3]+-X(^3D/;2VM5 MF1RZ2(?L*=G9]^EI@>ZA:H\@0R?DXAV?3V`4:&)NP;X_MS*_\L"J&>V_.FC0 MT$,L6X\.'AF/4EO/CN>6ELQRC2X.;=PU]9AFDJN+*_:6_'Q%K5Z80Y5\,E@@ MD>QJHFMXN&D6!8GK:$38.5A"LK67(_C%^#IW+"H+(B]F=8V8AFTIM+,ECDU; M(0;@(]WE-QH[M/Y)+B%AHZ3>S*?>%6P83OH5K0;="7&A1] MW[%=%\8%&5BOA,IS1O$<`J3X,D8\JH`R4\I]I;>#3'T>`GTHU+%9UG7L6"U> MM+;Z)W]K,,Y-[A<8OWX-.[VG6=OQ7>2-6-ZS;/5PW2:7',70N=2.`H5&7DOE MAEC4A)X)@\6')CF#-"!U(0B'!.P?)0]*&O(D40*ZH%BV3]VL8;"O!)YQJWY. M=P_;E([-1BTS*N1;9J^O8@NA-TB1A*VH%Y*+)6]]5*U*K+C79JO+"<+/.^J70F3UG:&C';VFA"1 MW$O1F:/C!+UA&%=43*"_L+`^SF!=`S9/VXSQI/WU-5,/2LB81E;^4=W])KII MWU0OU?-:5N[WFWAGJ@U$X?BOY?-DWQV``>!ERK:IWJYA"62J'P9!V!\M1TWS M8M0V@S#J_X);U0`]OG%P?#3SNE'5UH$(9K6!U+>A]$7S%[1$1?-FO4.0ZB-& M::LC6';M=$O:X.3L`\\K]2O([?+-K2%],-H+KM4.%.D&NDG$5Z87ON1>`D^U MLO0,UPB37KB!$G6]E](^>6%F0S`9Y?3.E-CJ2\J:M4,KLG#$%:'+)KRK*]M3 M)CM"IR6PFGX^Z\<'KIYOQ(JK7?EP]MX/+ZKZ[-7@U=YZ-=>ZAA:F)JUN,CSY M^/*'G=<_K"$L3J[*33P[/KA7T:W;ZEW*']&L[U4^(2,.:VIDZHS;GP'"MA*[ M/$.G!!`23>-K?'/R&HBO#X;G/S'H)9JU>JC<:;F$?)K*BM"P&UKNM*^\%6^' M5:ZS%3]BMK.9JVA5$.2%G(P0;JV`TY#;\GH1^U=O4;E,82Z76^KY3+'=>E%; M1%;UYL:3G=URM>*MUR>_((GJ5Z1BU@N9N3&&?LHU&DEA(J@69$'T>=9+6S0Y M&1G',B(3.L(:'\L4 M>B0''/[44EAJ/ND_)STL3)%=K:<6Y<`Y0I]_A]@A2EY^/MZF&')0X_#D4B&; M2>M>W^;JY`@.=Q0`C&J,\-`&7)/*.61=/=F%"X>:A'.`:?1[MS:D[I(-@V!7 M`^T9WGLRNKP#C4]LYI=[2%`--]`+NXJW3(SEQP:`W!8AK%8>RR52M1K= ME.7OO?`Q3A3H!5;O=/%ZC#%YK/'?E?G2V&@W5KU5@ MF,I.8P?_U5H349H'C1\_08"62S1\8835!4%;33_44C0@LUQK\9LP#+3\(2@8 M)J2\BAAJ"+=I^:R+&.$BP/%S@[9IDKU%CKNK9L^E[O-IAUQ.]9L9/%MUL)*PN^_#A_+O6.+PEFO_L M$]GR1RF+G6!C*_$(Y:ONN]XX&TRE"+,P+GS6EO*I3EIZ=(B,)`M&"9-!/(0> MO,['U.%F[D$)J?RH=5Z$'\\$&7=$Z&L@8*!LJ&\\%_OD"K%=O%"N'LU%?#.\ MB\V/FL(_TNF]UB#`YO8N+O6PZ73E#GK.)UTI'HS-N7NQ M&Z>8`"'S[:@7^'Q% M6[#O6MY[L5;MJEL"D31-7!E;!1?B./O8!\)SU;>!!]^.Y"="#3H.4Z(;!3P8 M6^7&RY._.J^3-X\H;,,DE@'Z:9MLM$A:S,F MV%Y`=AUK[*89+H/FIFR9?-8]7-:`7_@;B#[PBDJA!K#E/AM<^7ZT7PW$<)$1 M.#.VJ2E??JH>86Z6\7`BOZ,T\URF-XHN[.=B?5>S*?KCWI?^GL9Z7>=W?FJVX_ MQ(>O5"+S1 M3[DE-;-';OA2"\[6#J.+/",[05:.3A%7ZX]Y,"$CIV[2Z%EA0!?UMGC\#/@( MU1=H"U>7U&8K\.(**RV5SAL&0AG&^H>'YJM&2-KGT5UOFV8^?(\M+/L-M(Y8 MK)[)2V$]7*:151A#[+B=G2JBDBD)G7-YRF4NAVY;RK2`D#-5BT^\HTTJ#LMS MAR<2ABJ?V`T==A"S=CSN6>Y[I:3T^+LQ_+U7CZ,DM-69MHGR#1)$KF-:-^E/W+TRI.K`5?7O?_[G[_]BNH'L]799*VJ&G%S3JI_AK1G*G:L! M;O(C9#+#TDV_-1'7ND6?APPCHO0=M1EY0/.-:_?#JJ3(.$+NQ M3<.,W^]8KB>#X;/B07[.$\=].,EL^.."H7]'GQ:\'GIZ]/T^,WFC`WL,IV3; MFU>(;TZ1F:LHUG6EIU_%N&/2TE^8XL:R7WNQM;^>VK]4/>N^3^L0;)*M?O-; M.X=7=:AGN=R,A7I"'*CUHX?\RU=6)V_ZUR-;>-J/Y_T_FHEZC6X>,JBFN=5> M3*X.20,9#V*FX>(\L('^\U;+8B84 MF=D>1BD_X/!39E+,I+7(@L5O""^U6T8_)W'7$V7[8R"+R]V6S8L)^HXEV/W>#PX9H=A%[T+YW5X_7!X<7+%\Q:"QHI,WV[!O17" M`:1/<).0.+:F\/YUEH6\AH[&982`*[?:M4X$^O:$;CH8AN'MC_O`SMN34?E1 M_8W]KK[#JL2D;N,G/+!#6!C8R<;C$FW!8`NKFE2ODW+YQ9ZHX/:)NJ<.(_+Z M@E_=W)\J:46*2*:A=P-O?B;DS,=`0T.5O=9@8(R/PA&P;^&]!&(-!4N$"2&> M:;)B?R3BK1FPD^\R;2%P.XB]6;;B6MU2(+BG=13E-0B\^UY>4YXD7.MUOH-P M@1^'V,+>VV.EYV"#-35[F8>==#*VG)84F0N2QA3BB[[33(/2[#I&>8PLZSM' M>^M1]_/"72B"77G\K1?2JJ)\;6BEC(;E.V$@5[E<$_NJDPHLS-45$L@7*R5. MED]:?@;'=II2CJX&IKJJLQ[OSY!)7JY.W%'9U:T_3P55K*;*$V'+-?;R"IH4 M!.6CZ6]8T85`GJ''SU^+\"````__\#`%!+ M`P04``8`"````"$`)`PUYJ\-``!+B```#0```'AL+W-T>6QE":8L>4%LORI)\E@^Q;+8!TO1P<=$"O:*@)_-LJFM1;/DKRPU\>ZZ_V)'^W?6O?W45Q2^N_?')MF,-1/C17'^* MX\UEKQW#)^L@]*P8WH:/O6@3VM8JPI,\MS?L]R]ZGN7X>BKA MTEN*"/&L\--V<[8,O(T5.P^.Z\0OB2Q=\Y:7[Q[](+0>7(#Z/#"L92X[>5,1 M[SG+,(B"=7P.XGK!>NTL[2K*66_6`TG75_[6,[TXTI;!UH_G^K`XI*6?O%O- M]0M=2TU>!"L`\;M_;X/XV]^D_[SYPYLW_7]]\^T_?K!7__SQ]]7/?OQ&[^5J MB$SP0;/,\WZC6/@XE=S+++B^6@<^,60*EN"1ZZOH%^VSY4(D#!#),G"#4(O! MH6!*$$UN MTQ1A,#:-\`BUR0.3+#S8;)/UTQZ;&%UCOJY#^&-T)58TVR5-5S4N*AP>HJOP M%=$3/C[,==.$S;&2.S(E4RYA8K/H-%8Y, MF51R%)IO)[/9D?;!_EG[(?`L'XFE@UKR;69,WE+_<,6_\Y_LT(E1+".E\+!4 M"<484`W*.B!,N'4&PV1C9RG[2,E,&IC&;'++AGV=2;F8&7Z]R?<\`=5.:"=X M>`(&A(H&W[2(P22((HA1QW6+%GMD8&<*1ZZOH-N/[=`WX8V6O;Y_V4!?ZL/$ M)(W"Y'N<;S^&ULM@F'1GO?2KG!.BP'56B.)QD73#F;6+BSMS<9?H)<@P%T10 MU`@US<7D"$+O;F8+^4@7LR0,>Q+-'YKP)QGIVS'^219JPO\6TCC-QB-#%LA" MGA8[.%'MGT]FL]ET<#&=3F?&:&`8"C@>SH0'_3RK>\1'(YG2LJ_8J0:#(JP2!(J\F$R@9 MI2_+%%@V4IRK!($BKQ($BKPZD5R!)\J]2A`H\BI!H,BK2;,K,5=A.59QKA($ MBKQ*$"CRJK3F,ZO`,^5>)0@4>94@.+57\VG5XN[.3!:!JIU9?7^<3+I@[O@0 MA"O8R\HW:`87,&]+CUU?N?8ZAEESZ#P^X;]QL('_/@1Q##L_UU9Z_.0L/X$R9DZ>XDU5'$M#48D,[/"-B=&?&./A13J) MDJ3:LU?.UJM:5^C>&RM`(W++-YQPZ!=*LG`HUP1[Z(7,?8)G)*Y./"UX`L1$ M'A*"9\BPL5P?%[61G"%F(SE!T$9RAJB-D#K[DBMGWWTZ5( M43W-`@GP/1&S'P0YI\HG]Y0]C'+/:6LKU)=*;MP,\2_I6/=8RCFC:B?GA#U6 MW:R3JFG8KX/@]A>QLDE2 M40V>029(!,\A^HT:_<"3,!^'Z(=UL+U.!%Z4ZH?@$M8O,Q[PXJLLJ,$%-*B; M\,A$`*L=.0)P@@H$>+%8Q@&$IPH$,(O,$4"`E@@`3D-4')('L!M9J(08*%6" M_F.IA!J36\FH/**5=>47]#=8:3+E]R":2;V%0"]IAC<-``Y265=B5948XG;( MM)(">--`@0FCKIPA;U!7\Y410HHN8"@9@3+0Q(B\J"0U%W26`)H9N9'8AY"@ MP%*D&@+`40*!.&*@:/P=4`R*1F`:#8J&8`J!&8-/F!/4$\P(J0@#X%&2%66? M,&!&C!/20""HJI`D&H:J2B3%H*I&EJX8JBJ1!(*J"DD]H:I$4@RJ:B1QA:H2 M22``(THJ)/6$JA)),:BJD:4K1JI*)(&@JD(23XR.7")[=-DT740EZZ>#_J33 M`JKVO.:NI,+6=+%\L.OK_/1T^I1.'<$9R62*S*4'`,[*%T^UIR!T?H%9)OYX M;PFKJ7:HX^\Z8V=)C_P<6IM[^QGFHNF>V_.Z?K$78.4+',T(:S&5^F'A6]?: M*)?.SP%8#B>":WDRJ^>NS!>!M6]BS8T0+@AW(8XR^X($ M%TY9/[&[M[F'V`IRDZWBYI_6]B+4?WE_U(:U8WN0XFN?>O7H<"&6I94ED`W_ M3G0*PB7M13W<3D'`VB`4`LGU3P+E30ATE6.1T&51=V)>U`H<)[*6I07U38%2 M2[*7=@T2:3A)(6EYCK(0U:3KLW(1)*U M-MXI7M%TK$')-@;=QL/75E2J5KR>1.85&>&R0F-`<#"LJ.!HC70@D7_J,AK!2.KY2=:+9-72K:(V%! MYL+C]<;JYQE@QD.R^)?]A.7@!N!`_A@\1\G95PF0VPK4S"1V)KN=>G+U0+@!K*BAGP'E5BQJR9T*4QI^V4>RL7P0V.KTO#\WJK$NM/N(*_J>$1CK=6_5?=;S'Q@A8B;<3Y,JKBJ<>?UE>"G^`*@X8-AB((DJ><-&ZK4*#* M62UPI[=);-H.HKB9F@IOFHI8IT2KN+\CT-=#,*R4\G:A7@G#+9&R%/.&M%?6 MWL'UH$VQ*]P.T`%89GMW#'Q=VCO(\7S6Q/J;D_RLNR67@G:UEJE9O#!5[G@. MKPKPL7Z'![\U9@[K^"\![H%IQ80GQ_N=\NC0>0'K?PY"UOV=\,IJ`8Y.;#W0 MUSZ2'ABR;$0,.%L;;$@(5X16$VWP]?I4BWOU;F_72[,LJLRKEN'*)-91!E2I M\:F2V?3A+O\'LZL:H$);2Y7\?U5;2W5K<)RPJ!VZ6M6E8^YK"4XW<-T]OYX' M7PJ5R?T>[,X)5HDC8!?W:C'1F5G>`I4+.?F1?=Y,[OH`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`#;\NS(WH1?C(D8^HY/I_````__\#`%!+`P04``8`"``` M`"$`^V*E;90&``"G&P``$P```'AL+W1H96UE+W1H96UE,2YX;6SL64]OVS84 MOP_8=R!T;VTGMAL'=8K8L9NM31O$;H<>:9F66%.B0-))?1O:XX`!P[IAEP&[ M[3!L*]`"NW2?)EN'K0/Z%?9(2K(8RTO2!AO6U8=$(G]\_]_C(W7UVH.(H4,B M).5QVZM=KGJ(Q#X?TSAH>W>&_4L;'I(*QV/,>$S:WIQ([]K6^^]=Q9LJ)!%! ML#Z6F[CMA4HEFY6*]&$8R\L\(3',3;B(L()7$53&`A\!W8A5UJK59B7"-/90 MC",@>WLRH3Y!0TW2V\J(]QB\QDKJ`9^)@29-G!4&.Y[6-$+.99<)=(A9VP,^ M8WXT)`^4AQB6"B;:7M7\O,K6U0K>3!`6#?!TVM+$6:]?Y&K9/1+(#LXS+M;K51K;OX M`OWU)9E;G4ZGT4IEL40-R#[6E_`;U69]>\W!&Y#%-Y;P]?O/R\1?E>%G$__K#)[_\_'DY$#)H(=&++Y_\]NS)BZ\^_?V[QR7P;8%' M1?B01D2B6^0('?`(=#.&<24G(W&^%<,04V<%#H%V">F>"AW@K3EF9;@.<8UW M5T#Q*`->G]UW9!V$8J9H"><;8>0`]SAG'2Y*#7!#\RI8>#B+@W+F8E;$'6!\ M6,:[BV/'M;U9`E4S"TK']MV0.&+N,QPK')"8**3G^)20$NWN4>K8=8_Z@DL^ M4>@>11U,2TTRI",GD!:+=FD$?IF7Z0RN=FRS=Q=U."O3>H<],9&R;,UM`?H6G'X# M0[TJ=?L>FT1.[P:3?$45*&'=`X+&(_D%,(48SVN2J#[W$W M0_0[^`''*]U]EQ+'W:<7@CLT<$1:!(B>F8D27UXGW(G?P9Q-,#%5!DJZ4ZDC M&O]=V684ZK;E\*YLM[UMV,3*DF?W1+%>A?L/EN@=/(OW"63%\A;UKD*_J]#> M6U^A5^7RQ=?E12F&*JT;$MMKF\X[6MEX3RAC`S5GY*8TO;>$#6C\S210*:D`XD2+N&\:(9+:6L\ M]/[*GC8;^AQB*X?$:H^/[?"Z'LZ.&SD9(U5@SK09HW5-X*S,UJ^D1$&WUV%6 MTT*=F5O-B&:*HL,M5UF;V)S+P>2Y:C"86Q,Z&P3]$%BY"<=^S1K..YB1L;:[ M]5'F%N.%BW21#/&8I#[2>B_[J&:+T5';:S76&A[R<=+V)G!4ALZ%8JNU'N_*J8E+\@58IA_#]31>\G<`6Q/M8>\.%V M6&"D,Z7M<:%"#E4H":G?%]`XF-H!T0)7O#`-005WU.:_((?ZO\TY2\.D-9PD MU0$-D*"P'ZE0$+(/994FRE)")J(*X,K%BC\@A84-=`YMZ;_=0 M"*%NJDE:!@SN9/RY[VD&C0+=Y!3SS:ED^=YK<^"?[GQL,H-2;ATV#4UF_US$ MO#U8[*IVO5F>[;U%1?3$HLVJ9UD!S`I;02M-^]<4X9Q;K:U82QJO-3+AP(O+ M&L-@WA`E<)&$]!_8_ZCPF?W@H3?4(3^`VHK@^X4F!F$#47W)-AY(%T@[.(+& MR0[:8-*DK&G3UDE;+=NL+[C3S?F>,+:6["S^/J>Q\^;,9>?DXD4:.[6P8VL[ MMM+4X-F3*0I#D^P@8QQCOI05/V;QT7UP]`Y\-I@Q)4TPP:&PO M=V]R:W-H965T"9!`+NKT:,#V M[DBSTFJUEV>:D`1-$B*@IV?^?LO8@*LJZIYYZ70.Q\6QJUS'[7[\\.UR]KZ6 M35O5UYT?S@+?*Z]%O:^NQYW_S]_J8>U[;9=?]_FYOI8[_WO9^A^>?OWE\;5N MOK2GLNP\B'!M=_ZIZV[;^;PM3N4E;V?UK;S"DT/=7/(.OC;'>7MKRGS?#[J< MYU$0)/-+7EU]$V';_$B,^G"HBE+4Q\P[TMZ?JU@[1+L6/A+OD MS9>7VT-17VX0XKDZ5]WW/JCO78KMI^.U;O+G,\S[6[C,BR%V_X6%OU1%4[?U MH9M!N+D1RN>\F6_F$.GI<5_!#/2R>TUYV/D?PZU:A/[\Z;%?H'^K\K5U?O?: M4_WZ6U/M/U?7$E8;\J0S\%S77S3UTUY#,'C.1JL^`W\VWKX\Y"_G[J_Z]?>R M.IXZ2'>LAQ3U&=X$/[U+I6L`IIY_ZS]?JWUWVOF+9!:O@D48Q;[W7+:=JO18 MWRM>VJZ^_&=(O?0Q2&2#+$"F?1[]=)"E#0*?0Y!XMHSBU?IGI(#H?C[P.41) M?CY*8J/`YQ`EFH7+('E_4>9F@?O$B+S+GQZ;^M6#:H/\*R2]L)R4P MBV2#!TG.B8,$<]3`T44($QQG":7@S'*8C$;U9`89J0%<&1%^038,F82N5Y@B M.&6Y)@L@.23PMJZ"`I(!R`*11GR!(FUM, M.=9/L=8X(.TG-9QUK_4A2A9!$)`E18PDA+,%80C#F"8D*:`<`.G?(/U#%6B4 MZ`[).U/#F=Z944!00%)`.0!2%<()@"ZKLW7ZQ^_M'4MR!#)$,$0R1+D(%JE- M8U?3=R*C4T MMN!N_#@DO3&UI$ECQA#!$,D0Y2)8I.[Y1*2;=V,);_?,T)!$B-#FEZ7,40P1#)$N0@6J8UG*NA>I-/6(N-+;[+F*T@-:_,#G/%#1S=IS:DV"7C*Q?!0K&3C1ONGH/1 M0[:^R,`.QA!A$5/381+WSHNK6K)1RD6PW#N>YARX(F-.J*M%9'522YI6,V.( M8(ADB'(1+!)[&JM08U+O5"AULBRBB&"(9(AR$2Q2N\RTC<;$&_-Q5Y`;;T0= M*F.(&!'LI+V-R/'AT&J5BV"=V+]83[KC8_1V)HVH:V4,$0R1#%$N@D1"";J+ M23/>/W[O3RM+Q39 M@<)2IJE*ANB;[;&YF&F8BVIS'WHIFV.9E>=SZQ7URQ7N56+X6W]$QPORC_T[ M")Z&VZR_?"9X%FVS>WP1;>'""DJ5\&6TA7LKP.?C`[@6O^7'\H^\.5;7UCN7 M!Y`6S%;0*1MS@VZ^=/6MO\U]KCNX$.]_/<%_.DJX7@UF0#[4=3=\T2\8_W?R M]#\```#__P,`4$L#!!0`!@`(````(0`#+\B)9@,``*P)```8````>&PO=V]R M:W-H965T&ULE%9=;YLP%'V?M/^`_)Z`@20E"JD:JFZ5-FG: MY[,#)E@%S&RGZ?[]KC%0,)'6O1"X/C[G?ODZN]N7JG2>J9",US'"2P\YM$YY MQNI3C'Y\?UC<($DY#6-T1\JT>W^_;O=A8LG65"J'&"H98P*I9JMZ\JT MH!612][0&E9R+BJBX%.<7-D(2K)V4U6ZON>MW8JP&AF&K7@+!\]SEM)[GIXK M6BM#(FA)%/@O"];(GJU*WT)7$?%T;A8IKQJ@.+*2J3\M*7*J=/MXJKD@QQ+B M?L$A27ON]F-&7[%4<,ESM00ZUS@ZCSER(Q>8]KN,000Z[8Z@>8SN\#;!`7+W MNS9!/QF]R-&[(PM^^2!8]HG5%+(-=5+D^(V6-%4T@\HA1U?DR/F3WOH()@]$ M9`O0(O)W+W/G:Q5WD!F_]Y(/;=F^"">C.3F7ZBN_?*3L5"A06NGM*2\!"T^G M8KIQ(%_DQ;C!,E7$*%@O5QLOP/X*.4Y&3GJ7BU2\#PAV5(?$[$OB] M="3!,O17FYO_80DZ%OCM6+"_Q*&W_K#@.>`P%-$TB-T14!L4(0<7%'4 M5JVH"Z!=.!C#6,"W!.:(8$!,%"%?(T5'ESK0+61BU:M@&$42#C3&%8,(!]^2 MD6$B%$Z$>@%MC1%X.Z1J90D8!#P'Q'J*2'J$G4QHP5%HO:*V3A4W4[Z#081M M:2,<12M;L`?8@NNK@MHZ%;RQ!`UB'&(T120]PE:$+KP2HK9.%;'=H@:R:F,, M?2^RRIJ8];:LDRKJ>V%^)+35$K0Z_F`@)L;CM5.3]`@[QNBJI+9:DM89.!B( MJ:/O8:NQDG[9UL,P9*_$V)HMQ=.53)@ M9KIZ9+SJVC,(KL=9J>T3U&%&8ZBSK-M66_M!L`E>-YF6-G>AF?@5%2>:T+*4 M3LK/-&PO=V]R:W-H965T7T^X*;R\O\_;M4N^>ND*GXSQ+DN7\M#NW[[LF],;5/%X.!ZN M?W253B>G_?:7EW-SV3T>H=T_TF*W[^ONWJCJ3X?]I6F;Y^L,JINC4=WFS7PS MAYH>[IX.T`+?[9-+_7P__9INW2*;SA_NN@[ZWZ'^:,G?D_:U^?CGY?#TZ^%< M0V_#./D1>&R:;U[ZRY-'4'BN2KMN!'Z_3)[JY]W[\?KOYN-?]>'E]0K#O?!% M]LT1/@E^3TX'/P>@Z;L?W>O'X>GZ>C_-E[/%*LG3;#&=/-;MU1U\V>ED_]Y> MF]/_492&JK"2+%0"KZ&2=/GIPGDH#*]]X626%LGR;Q@H0AU@N:\CFV7K1;KX M.[6`YZXOX#76\LF^F&._=N-A=M?=P]VE^9C`)(>>:]]V?LFD6Z@X#$3HS6%H M8(;LO?JKE]]/5],)='H+]/M#OES?S;_#6.^#ID0-_!XT*5=48[5LN,;T&C\G M_$?;OMH>.`+FT)JA23#,I$F]:=604-]R7JL!(X`Y@N6W(@O3YDO!,S7*A&^@H;Z MDO58"1P!S!>L->*K6W=Y,BPS?Q6V.C(W\Y7HIA(UQ3!XE01&`BN!(X"Y@P5^ MPYV_>C^%23NLG'Q5\,XJ4;/&E;-(NA\NJ5`2&V`DL!(X`IA??RZ(NUB_Y#V5 M/L4*+E$#LX>T92F,]IIAF4A@)7`$,*,;9E0.N[\J#:^XF1(UW+#8@:M>,QB6 MP$K@"&"&4\AVTK72<7=96A9;>1E$:;+`Z3`K-NQG;;_(O2D4(9-#$:N(HX2W M`E;VK5;XRZ(5:['\RQ1%?2N6L_62M6(UT@HL0ELAB0W51HVCA+?"YT2;28H)P\T**V40A=X5?5\-5V/O8J74J"2. MEN)&?;9$HVHZ8/10PTNY^\&9VT]\/.`L%CELTWR[J8(B.C2*6%9+L?&[/:_% MT3*\#3Z!8AN&SL9@HM[SA=CE2G^('\PODT1$4!6N4^LD[\*A4A)'2W&K/GQ& MK&(F,:MK8:5,27#AX4L1HXA5Q%'"S?G`B>;47,`\@H5"8DY-7A):P:0D)I7$ M*N(HX29]R$23PV!C]K`>U(--`BJ8D\2D/?'?2S9B#.QPM5]]CA)F-..AUQOM ML(P)N:2"*,ZZ2A&CB%7$4<+-^0B)O2B'.L.$N3W4041-RF`R2F,5<91PDS": MMTSZR[(GQ:919BCJ=_[/!&XH$MME%+&*.$IX*WRRW.AJ#!XV<=?B\%AF*,(M M-DL7FT)MCU704-M8*A*K-(X2;GL\P;*Q!)/'RR!"NU_6FW3$K8PH$PI1MU+C MJ(:[O1UC_C:+FBHR"H(HN!X-LB")'HTB5A%'"7?M@^/&U,!QY/L&PLP>09/HCB!U>*&$6L(HX2;LXGRXT.Q>"! M97$CP3*93I4B1A&KB*.$F_0)$TT.P8#!0T<[WZCMK$^G/G^J#$G8&F#X_0\_ M.9F@B?UN%7&\GA5^VQ[J80V`>PRT`3(\NLMB7]Z(8VP91&@[31=^0Q.VJZ") MMHTB5A%'";?-,Z_O]QQ#B_>[_`(11-%*I8A1Q"KB*.'FX//)I%!]ZB__U_QH4ALEU'$*N(H MX:T83[9\)-DV\G@;1-%*I8A1Q"KB*.'F;@=9CD%V>P<+(FH2BT5BE,8JXBCA M)GEN#2M)YU4N3]!ECJ(X_B.W/(*&VI4A9I7&4<+MCD=6/A)9\N9\&4312J6( M4<0JXBCAYFY'5OZ9R`HB:E*&F%$:JXBCA)ODD:46_EATR3-LKJ(K$,R`Y>C] M7:-*644<):%/M485LHHX2KC;\7PJQO)) MGEV#"+8PLO6*$:@&47]X,(I811PEW*\/%Y$&A;\[VWVU_EI@]K`TV,@T""+: MRU@L$J,T5A%'"3=Y.[(*3*/;^VD014N5(D81JXBCA)L<3Z1")Q(_[I,<+<3MW\XLF!/RRU>1R/-@$$6/E2)& M$:N(HX2;Y)DEM[`"`^8O)H),H2H4B[:-(E811PDW.9Y4A4ZJ(I%'U""*5BI% M3"`X648W7*L*.4JX6QY=P\+'[*$+OY#WV\M"!E2EB!E(W-0*>8/6#J)^4W.4 M<+\\Q0:_.KV*1-Z1*U1Z*6("(4>;T,6X*I-4_7/'JDH<)M MZ"[S4(/G2\1F$41DCBAB%+&*.$JX29YAK^&!#@]V>?Q*\2K>F>YA)\FQ;C>E- MMC5CW&9;>#8!UIFHQV7PH)?G\^$"/'[UMGNI?]M=7@[G=G*LG\%R,EM!%%SP M22U\NL>''ILK/'C5_?D*3]35\*Q.,@/Q<]-<^S?^`_P38MWS1P]_`@`` M__\#`%!+`P04``8`"````"$`^X0OSH0#```."P``&0```'AL+W=O6*U;+.5^;^D*XEX.M MHW"],@3]9/0B>_\#>>*7#X+M/[.*`MO0)]V!'>=/.O337IM@<3A8_6@Z\%4$ M>WH@YT)]XY>/E!U/"MJ=Z"4Y+P`)?H.2Z1F`TLF+>5[87ITR%*>39![%>)J@ M8$>E>F1Z+0KRLU2\_&6#<)/*)IDV2>#9),'3_TX2-TG@>4TRO4UPDOY]*Z$M MR]#Q0!19KP2_!#!CL'%9$SVQ>!E#'W)MO-?6#,U1`*5)L#ZOXP2OPF=@-&]B M-C8&?KN8J1NQ'8FX)@EA`]TN@)B176BKWH7NBM[6QAKZD''B@[X=XZ`"DR.H MVNJ@6H.+&GNEMC%ZYOJ%S48AM-6!L`878N9!M#$^!(SA2!7:"K/:ZTZ<)&[& MC8V9=?QN>P:GBM2!"/3'$D?=L&AOAH#W;A#B)/6@;,S,C-+"]6U;GU\8C-]( M8=KJH\W=C!L;8]$2G\?6Z<-I:1]^"=KJP]UZ<#8F-<6E4>0#6K>AV6%UX0#Z MK&JO#^PQM[$QMD[LP[9.OTX,8MDKU,Z4SNJ%,[VIIRD;LS9#?4R[ M;-A4K)5@!,8*Q-O?HUGKPMAE(S"NL`R8M&+A5N5IU@;;H'Y5K44SF5S;ZA(Y M+CAP>@Z;Y\WDI@GJ0_Y)<[`K.EV_K%K\AI)BIV9IL#;5N-:[*#(@&ULC)/;CML@$(;O*_4=$/=K[!R[D>W5 M1JNT*[525?5P33"V48S'`A)GW[X#)&G42*O<&,/,?,/\,^1/1]V1@S1605_0 M+$DID;V`2O5-07_]W#Q\HL0ZWE>\@UX6]$U:^E1^_)"/8':VE=(1)/2VH*US MPXHQ*UJIN4U@D#U::C":.]R:AMG!2%Z%(-VQ29HNF.:JIY&P,OG.9FMQ\>!.@!$5O5*?<6H)1HL7IM>C!\VV'= MQVS&Q9D=-C=XK80!"[5+$,?B16]K?F2/#$EE7BFLP,M.C*P+^IRMUE/*RCSH M\UO)T5[]$]O"^-FHZJOJ)8J-;?(-V`+LO.MKY8\PF-U$;T(#OAM2R9KO._<# MQB]2-:W#;L]]B(`.,^&7:.5'`"OGQ[".JG)M0:>+9+Y,I]ED3LE66K=1/I82 ML;<.])_HE)U0$3(Y07`]0;+)O1`6+Q0*>>&.E[F!D>!P8$H[<#]JV0K!OH+9 M'(44WOCLK<$'CRV>'LKI8IZS`VHB3C[K6Y_)Q8-AEDLJQ+^3REM1%DJN4BTN MH'"==?29A9YQBZ;07CMYKM)5Z1)]AZI[S%;DB0-JL&P$9^+(CP]L:;XO5S0*3S3K4YY?@!WORCVRO M#Y^-:+X*Q:'8T";?@)W6CUYZWW@3'"9GI^]"`[X9U/"6[@?W71^^<-'U#KH] M]T>8'L`3?)$4?@0@<_IA<_3^[R)AE->F3Q.>+,)#_EZS?(4NM\% MPTE89?X*BJZBI@J%.8VTFI"/Q?#6&E?0V)1IF<]2;!$91<7_1),$H%LG!0D) M5/DRNYRG)+PBN$S5B99B4IZ\2D%,^(MS?KDL,IB28TI>,>5'RQO^_`T_SG"< M'\E-QS_Q8;"(Z;V"TOCQ2=9T=;:E+_-;>[7:ABM%T@9,^D@[_D!-)Y1%`V\! MF?NB(!,O15PX/8:IW6D',QY^>WB[.(Q0GH&XU=H=%^"8I-=P\P<``/__`P!0 M2P,$%``&``@````A`/=K2R5]`@``S04``!@```!X;"]W;W)K2"H4C86'>P]!5)1A_T&PGN7(18GA+'=1O&]'9 M(TVR]^`D-=M==\.T[`"Q$:UPKP&*D62+IUII0S&5P5>)XO[#)/5,OCS6_"]'?PCV^C]9R/* MKT)Q,!O:Y!NPT7KK4Y]*'X+%Y&KU8VC`=X-*7M%=ZW[H_1&/`.R=+ M\@S[8X><^Y@#WU-.GT%`MM<&O8'V4<)'O80WP&O>Q\"0-WF;-SWCA;VDL[YT M/PN6#DZ=Y3_:S!4ZA\Z<=Y]D%.B8E_THZ,P;:.3`F M-B5->CT_'?1ZBV(D&7J4Y+=]!6?P^35\.LM&V#9Y'!(QR-(KK1V MQP$(D_XA7OT%``#__P,`4$L#!!0`!@`(````(0"K,*@V:@<``"<=```8```` M>&PO=V]R:W-H965T&ULE%E-;]M&$+T7Z'\@>(\EDI(E$98" MBV3:`"U0%&E[IB7*(BR)`DG'R;_OF_T@=W8WMI-#;+^=G7DSL_NX7-Y]_'8^ M!5^KMJN;RSJ,;J9A4%UVS;Z^/*[#?[Y\^K`,@ZXO+_ORU%RJ=?B]ZL*/FU]_ MN7MIVJ?N6%5]``^7;AT>^_Z:3B;=[EB=R^ZFN587C!R:]ESV^+-]G'37MBKW M8M+Y-(FGT]O)N:POH?20MN_QT1P.]:[*F]WSN;KTTDE;G_+MC?>VTM_/N M/>[.9?OT?/VP:\Y7N'BH3W7_73@-@_,N_?QX:=KRX82\OT6SN7CKC M]Z`[-B^_M?7^C_I2H=KH$W7@H6F>R/3SGB!,GCBS/XD._-4&^^I0/I_ZOYN7 MWZOZ\=BCW7.:LFM.B(3_@W--:P"IE]_$SY=ZWQ_787)[,U],DRB>A\%#U?6? M:IH;!KOGKF_._TDC07UP$BLG^*F=)*].P*B(BI]ZPKNC3F0&(O.\[,O-7=N\ M!%A.X-A=2UJ<40KN*F7%>R@">K$CZWLR7X>+,$!Z'="OFVB1W$V^HJH[9;/U MV'"+3%M092K98*2G MY0Y2F`AC>>NRG*,H/Z)(YIRB1"R*"XOB8#10=)#"1!A%;$:CD+K+A'(F"N$M M75I,!J.!B8,4)L*8T'-PU!+-A%#.1"'81T;;5A:3P6A@XB"%B3`F*\9$J-IM MC@:6#%";"6$;8@YZ""9AS45!B*(,+Y2Y4 M,(@')XD=NR5J]-K2CLC>8B4AOKB7D54B-1%60XUR#(%)5A_QBJSI5!;):](H;;Q=)7D]B>J)M6954T)]GBVR*CSR"6)C:6F MH/'I6&@KL8-YU4AB7R'UI;F:SSW:A@C'2$G(/*PI*P/*7:A@$"=%HCJ2&EHI MM98%5Q#VH-$W^X4#&U&P-HOD0`6SXGRXE(OUGBQ??7O#,G8*I2#L8H.K_4JB M)XI=)Z\+7*A@$..*G>&KG8!YXQ1DG(\R!G&W7+#5EJ>-(&]*:.=8"T-!"5=N M^\5'6Z$?8U56HSQQ%GY5QNIW@DN()6="W*VIM_A=7`O%BQOC.L.5WD1";Z6G MK'AZXTL#YV'JJE%;5S\3";'T3(B[-951IS24%4]N/&9R%B1+ M>E,;P:5:F9LZD1!+SH2X6U/`?,FYBD59D6:^L3"5%4]N?"1P%K#R)4>PM>LD MQ)(S(>[6%!Z='%^8KLY`=M^3GK)";&/?C8=.Q@/=\:4G8)Z>@LST&,3=FJ*B MTHNGLT%4P0#7CR:IG0MX9D1X7Y?OG#8OJ(8(^)A98_$"\07)TUG M9(D1<>"T1O`9X=[KB\+[>"&XUSY)!LGZ1;G1-<3#L)I[AW!81=9^^9LXSF\^7CAT)C2^+X1O#>ASB^D6T`.7Z^NY6/U9]D^UI$T):=`F(0*ZW?WV9WL&[#&F MUS>[#3/,_&<\_IF$AP_?+^?@6],/;7?=A^PN"H/F6G>']OJ\#__^Z_,F#X-A MK*Z'ZMQ=FWWXHQG"#X\___3PVO5?AU/3C(&,<)>J__IRV]3=Y29#/+7G=ORA@X;!I;[_\GSM M^NKI+.O^SD153['UAT7X2UOWW=`=QSL9;@M"ES7OMKNMC/3X<&AE!:KM0=\< M]^%'=E^*/-P^/N@&_=,VKX/U=S".JZK\KURT%= MDC=O%W=_UBOP1Q\Y M],BSV86(D=UX0XRRRE6TB^3Q'$@WJP`?H1=1=:^T+I!4@J2:>JVN[D,IV/21 M_F`-`B>`C,'_JR"N).66F M021]2M+K&;2675E=&:8.D`$^(,.QE;9M(ZP.$@UR7*T6:`VI&3UE=5<[=5H! M/M9J6Q=(*D5_L^6F;JNKM,R=4TD!+BELNSS;40$E,6?:"W3":6/,68&2VM/4T(%*\##/ MFC<&=*+[SNEU@4X@9<=-)MVJDI@SMM8+!:/E)#!@%!$@G`P%.H$`EIC%1@$0 M`\UB38`"DA&@IUXD,W`9\(H*,:%@*M!I6I3(6;22V,W,T!7Q`Y!Y""@,0S`_ M.$%^ITLE1@!C;.:%9O?C3Q[DBSTA3`&8G1".6RN-ZT#L;'4DWT8@`X;)Y3!' M@7!1C$X6@.PKM&)*NPE!#(A%U]N9K`*=``,;+KCI*I8,4=`A$VN'#O-S4%]V M2""<'`4ZX=#EF2.RI/8X,;VB?:`P=$\>YJ&B<*F(3B`E6S()8H"9169`B9"8 M4M$5HLUN3YR-5J`39.+N/BG1C,LB=K$IA$JA=)QF(_91T;05=@,Z80Z6+(XH M=$"-:[LA5O`R6)HE`-/H>+I@UO?NPTE"[)YB)7402;K6!P\;K5,B!C:2+9F8 MU<5^@).U)?$V?86VW8_`V(/`Q$4P.DTUBP6%T`':OLDBPU"J@8)P,84>("8F M%)8,3J@EBZR)!SRH+SSR40.TF(91(12'\P``!LD`)"Z18W`"`;'8F128'^S3 M",[/4%2`'Y"Q!Y`66[`#X(3-=N:SQ!!OE^\G8PP/>+1\AWP%.F'_D^6C"3J@ MO#0U:*4=H&BI M`VO?2C@%H;L;M-GY3I`8EJ`6H*8%`+QM"0"NZ+:$GK[LENRB'YVP9,8CAQ`E M.F#)(C:[EK:=,F]:=`X8HX/G#':!3J`ASRRLPKXC]B2R6$DE^#G(/1RTC@_L M-CAAE?+K[KRY40*QYX8<5,';%.0>"EI?=E")#;G%*8@A0&>^MA9^!G(/`U,3 M`M/;C-MPZZL@-L*QFW&AG?!3D'LHZ'[S+]`):G090(R;W.Q@FMZ/0>[!8.HL M=8%.*^DAPK1=!#/ZJ`#*P`4!/"Q,71YS&W<;YAY7I6,79FL3*8("T96BS0XE M+++#5*`3E)WN%E*(/4ZMHYU*H5R<("'>\X"(3OYE02/HDR?W6BLH*!>M4.;_ M;04XK;?"MB=L#5:"\G(AQ<--EXN%CC$]#VUBYDQRZ=@-=NFB4&PNE/CP:?J+ M\P%.T!2>,\=>"F+/\A5JR!\0[(-L(<7'3U,52@$GE)(N2*YS3$_Y/%L=53]# M!>!/KH[Y.IT9!J"$B9'JUWS]ZRW>MCRZ!>7DHF(/+S/3/$P'3G@FN`\2I4XQ M34G&3;_H%/B)*5^!++9$YIX9Z`0_)>>+*8008#6W0G9X/P*O%2Y-_]R4S?D\ M!'7WGBQ`A_&[J;?`3QUHWQ/HO\\R1=@C?QY/;J3SL>N&Z&PO=V]R:W-H965T M&ULC%;;CMHP$'VOU'^(_`ZY$*X"5DM6VZ[42E75R[-)'&)M M$D>V67;_OF,[-QM4\0+$:1.64;KTP[] M_O4\62%/2%QGN&0UV:$/(M##_O.G[87Q5U$0(CU@J,4.%5(V&]\7:4$J+*:L M(35$:OYV:2LJH!BB,MJ?S0I,BKTLW+J68<'TOP_1[&..VX M]<,5?453S@3+Y13H?"/TVO/:7_O`M-]F%!RHLGN2 MBQC]]D3!+E\XS;[1FD"UX9S4"1P9>U70ETPMP6;_:O>S/H$?W,M(CL^E_,DN M7PD]%1*.>ZZVI*R$3/#I553U`%C'[_K[0C-9[-!L,9TO@UD8S9%W)$(^4[47 M>>E92%;]-2`MO2>)6I(9R&SCT;TDOA&DC3QAB?=;SBX>=`>D%`U6O19N@+AU MT,KH/4%I4X5^5'"]"=0*6'W;AU&T]=^@2&F+.1C,$GD#QD8D'4+5%G3T8L"A M*V86]+E5U,X=!3;QX0;$1B37B-6RAUABH!K_$:.B<(ICD]&L)]+%.AA,K/M! M52\9+5BI8BM55VNUND,@>*ACL')2&,Q*G\0DFCOAQ`J'03SOMUOYH0='5KO\ M:M6U&/<$QJ+!C"R.%JP4"RN%[K/1T:JH8S4:M)I4!A.;IENZ3JUH//2%)0)Z M@AW[,B[>P0Z M["H9JFB*T(*,%%>'%1SUD*WBQJT7S_N+!D;&53UF3J)#"^I>O:N"V/'U>G!A MI)BA8N[BBO`324A9"B]EYUI/@OVV7S7#[*"&F1Y'?0!&3(-/Y#OF)UH+KR0Y M;`VF2W@)N9E&YD&R1E^<1R9AN.B?!?QK('`G!5,`YXS)[D'=R?W_D/T_```` M__\#`%!+`P04``8`"````"$`640MRE<"``!$!0``&````'AL+W=O(@;8`&*(H^SC1% M281%4B#I1_Z^2U)6_,C!%UMQEB[;<6*%5CM-1@A%73)="U3G^ M\_OE9HZ1=525M-6*Y_B=6_Q0?/V2[;19VX9SAX!!V1PWSG4+0BQKN*1VI#NN MX*;21E('1U,3VQE.RY`D6S).DBF15"@<&1;F&@Y=58+Q9\TVDBL720QOJ0/] MMA&=/;!)=@V=I&:]Z6Z8EAU0K$0KW'L@Q4BRQ6NMM*&K%OK>I[>4';C#X8)> M"F:TU94;`1V)0B][OB?W!)B*K!30@1\[,KS*\6.Z6-YB4F1A/G\%W]FC9V0; MO?MF1/E#*`[#AC7Y!:RT7GOH:^E#D$PNLE_"`GX:5/**;EKW2^^^*)..>9`(R^_OQM20D"@J-/%-'B\SH'0)S0$G;46^U=`'$?0>]C*$GF"SS MZ$0L]*7B/EL@)R(@6DT?-S>=#?IC14X0$VX7`\BAP4N'V MTPH^FF/0^3&^<7I6(F+F<0'3,P'@>,\0;V?3\_:BFZ,))#[FC-WZBIA;*HY16D)J,9F-G$UR`>G.["QE;:@:O# M8P-?*PY62D8`KK1VAX,WP_#]*_X#``#__P,`4$L#!!0`!@`(````(0!$>A-P M/P,``$\)```9````>&PO=V]R:W-H965TTT[;_?V4X`$[+U"R\/Y^?N MGKNS6=R]5B5Z85)Q4>>8!!%&K"[$AM>['/_Z^7ASBY'2M-[04M0LQV],X;OE MQP^+HY#/:L^81L!0JQSOM6[F8:B*/:NH"D3#:OBR%;*B&E[E+E2-9'1C%U5E M&$=1%E:4U]@QS.5[.,1VRPOV((I#Q6KM2"0KJ8;XU9XWZLQ6%>^AJZA\/C0W MA:@:H%CSDNLW2XI15\D$*)K0Z`+G2!7N8\ M"V,U)[8KKQFH#74R M%5@+\6Q,GS8&@L7AQ>I'6X'O$FW8EAY*_4,J*;+A11'!,T!+E5#3:N1>0P"%@9<&33'4XP@*`7HRS(F MLT7X`E(4)YM[9P/7UH:T%B&PMRX@WA$7!C4NC%;&Y[T#^GSQ.%\RRF?0',.U M#2>.HY;`N7`VJ2UI/\)TE-&@.4ZA*7J478Z.TAF1:T:>$%#JGA#(-$NSI.+W9$+LV=-+,TC9V\]DG=\@@]LDX^6R$G$R#3G=CX-,[A/CME(W3F^(/ M@T^2N%]8:^)[.$&##*977)AA&^A#)DDP[7(P1(,D3M#`Q>T5%_Z8VA(D4>:Y M<",*$]'VIZDN>!VXZ+8*KX>,G+TLSEUOX8$X;E+]WDFZS"P?!I3;)E>&%4ZJOC4UBZ.)R@NVJ MH?S)<(3=\>6V_8K)'?O$RE*A0AQJLP7!E+5H>VRN8E/D(9[.5^XX#=LO<,HU M=,>^4;GCM4(EVP)G9-H&27<@NAP?-^`(6>%5.E6 MW:VT*ZU6>[AVP`2K@)'M-.W;[PQ."":)U)L(AN&;\3\'LKI_JTKR*K21JDXH M&X64B#I5F:QW"?WS^^EN3HFQO,YXJ6J1T'=AZ/WZ\Z?50>D74PAA"1!JD]#" MVF89!"8M1,7-2#6BAB>YTA6W<*MW@6FTX%G[4E4&41A.@XK+FCK"4G^$H?)< MIN)1I?M*U-9!M"BYA?Q-(1MSHE7I1W`5UR_[YBY550.(K2RE?6^AE%3I\GE7 M*\VW)9S[C8UY>F*W-Q?X2J9:&97;$>`"E^CEF1?!(@#2>I5).`'*3K3($[IA MRPH%79\S-,'+P<7;3VT% M?FJ2B9SO2_M+';X)N2LLE'N"KZ2JA$CP2RJ)/0!'YV\)C2""S&R1T'@ZFLS" MF$432K;"V">)[U*2[HU5U3_GQ-KHCM7F\,@M7Z^T.A`H+'B;AF.;L&4$AT_1 MN$%K0F>4`,^`]74=A=-5\`K'2(\^#\X'?CL?UGD$0.]"0+Y70J`50^`Y,>:# M,_1YT75>?)6'5E"DETX4SCJ`"^%\VEIZ&8X](L$*1-,1J'K2`QT2.H;:=H>- MPOF`[IS8+2LF?6J@U^]2CB4'GG]N*C6]@<=X&FD1^RV!^ M@\2/ID'FDQLA_$EULD]F?=DQUV&(X^!Z?%OS0!PWK`-QSA/M M8Z],,%OT]EDWP-TTP4K'DPR4.<^TX[NM[39F)?1.?!%E:4BJ]C4N"6B9SMI] M+381+K6A?;S&PO=V]R:W-H965TC.!0Y_!BW M?3D^_>;"F=%P.*3$O/OK'T^/%[_O7H_[P_/[R^QJ<7FQ>[X_?-X_?WU_^>]_ MM7^YN[PXGK;/G[>/A^?=^\O_[8Z7?_WPYS^]^WYX_>WXL-N=+J#A^?C^\N%T M>BFOKX_W#[NG[?'J\+)[!N7+X?5I>\(_7[]>'U]>=]O/D]#3XW6^6-QT??WM MV\M?[@]/+U#Q:?^X/_UO4GIY\71?#E^?#Z_;3X_P^X]LN;UWNJ=_D/JG_?WK MX7CX)U]^7]Y<>L'%'PO7O=?_[;_GF':.,YF2?PZ7#XS;`.GPT$X6N2;J]\J(W!\>,1+^>_&T-SD`U[=_3+_?]Y]/#^\OBYNK M_&Z5K6[RU>7%I]WQU.Z-\.7%_;?CZ?#T7\N5B2ZK)1+(OL%)84H MP:\HN;V:=9P9?"ER^!6Y'/$Z(P"_)I_Q*P*KJ]MLL2YN@9R1NQ$Y_#HO5T&L MSDC>BB1^?\DU3,?)4OPZUXJ?,G4M@OC])1 MMA_>O1Z^7V!Z(V6.+UM3+++2Z)4_(\WOA6?#/)GFJ!R'276CMHZ!)@;:&.ABH(^!(0;&`+B&_W,0,"-^*0B& MWP3!F;]Q0!"5R&/'X43J&&ABH(V!+@;Z&!AB8`P`Y3&F;^BQ>[H&1G%13_=& M>[(1GO7L?45(34A#2$M(1TA/R$#(&"+*1Y2:E(\&?G^Y1*X'*7P;.2E,2)BW MF:J9:7ZHA#2$M(1TA/2$#(2,(:+\1GU,^6W@R6]G[<8BIO@'3M[I2%0SDQ.K M"6D(:0GI".D)&0@90T0YB?*>!"N8=6L]Z^J9R^,-4,-0RU#'4,]0P-#(T"X8<>OFD=?L5IVVHHIRUT8[HAJ%6(&OVU$%VGFMJ2A?94F=4[QFI9 M<&!H5+JTZZ;7"%R?_94>)$QT"TTE8MXAK'/]+"I4^*E2P-0Y*ME=H;EJX5J9 M"O/[ARA3&J':^3JYWC+4_=1(O1_)VY.O(WN&E*Y\%>79J(S0833=3"J,MLM1 M:6,AA-$E:X63`8F9@VJ!$"`'-0*IJ%C!`.I85\^Z!N8:E7KMG&EH4L[91DB.%;(ZI9 MU\"Z1J5+.VWZI=CIO#`E\NT#!=MC*<6Z6:2J0^VI+GB-0(6? M4ZU`:FK,:H.T6T>;X)[5#TZ]VC-R=;#J[8@Z>*8/"X(W%UGIV/S3W&064M7! M0D$IJ(4K@!J!`G];ACH6[!D:!%KZ:38J7E2SN=ZC5_4#=R[C<%BNI&M+6J MA.N-NN&I[I$V`H5U0Z!@'G5>T#_X8A%M:WK/Y=0/3OWYNJ%&U,$S_5ZB;N"9 M3>MG4#<$"NN&0$&1J!EJ!`K\;1GJ6+!G:!`HK!M*EW8NZCRG933'RP^L**DM M*-IE=RCZ\1Z"84I*:P%2[T"TZP\[K" M$:.>L_=<3G#XJ1%'-:*.J>D'@X298EH8^Q-[>A/H:$\OT`WZAR"@48FKA.LV M/&?E%M]QA:KE4_M?A)3Q-F?BCI=%VMNHP4]A"K$Y@30)K$UB7P/H$-B2P46,Z MZ4RW&7CONIO<=J%A^R<0VDR7\A5#-4,-0RU#'4,]0P-#HX*T=R46D8:AGJ&.H9&A@:!<)TQ8C*7[0_RM\?[=PF?AT'@<(X."X\V+EHYG3J MZ;GF.##4,M0QU#,T,#0*E(J#Z2R#I/YA'`Q_%`<+A0>`A85NWSP`]`P^!+., M@UKA"FN]%WSC`-`S.#4#0Z/2K!,CZE)="2NX$Q7H-GS:Q2+>PP@75FIG4,U0 MPU`K4-A-,%?/T,#0J'1I?]]H+`MN+`6ZQ62?L[M81-NE2KALKMGW_@PU#+4" MJ:=MC0AT]2PX,#0J7=K?J->J:I5PJ;T@=1^U<"W#V-$Y M5R-Y0 MSGS69/%.1+B"S*X9:AAJ!5*SQ!H1Z.I9<&!H5+JTYU$C9W=DRG-NZ0H+W:%2 M!IY'NZM*N-1,*+)H1U1[+I\&5KTYG)[54ZJV(JBJII@:SKV"WASQB(/3=7;$ MT7%-NSX=1=/@!8OK/#ELXZ>RQD)KE)S9N2)^;U85E@O[>,]%5:3V7#YV5C!( MD5:X`JCS@F?4]Y[+J1]8UZ@@'173+`91^6'+8?BCEL-"B)8SH3);6W"M_#OH MFJ'&0;X&M0*I.)"NW@EZ]8.#O*Y1Z5).XUFSTV>.."9^[;1`=^'6M,BB#6PE M7.LP9WEZ>2X7P,:I#S.0IY=PA=/+Z_)9P]/+<[D1AY\:<50CZIB:CC%.I',Q MM1TF%#H3-DL+1<4Z;N$<5QA37N(=%ZIQ,(6CPM8XKE!7(LS6KK#*IP3)B-YQ M:2.B'FUP7&>-&(7+&J$C'S7)-(6C4XXE-\\"W:$V!]&*FROA6OL3M9JAAJ%6 M()6GUHA`5\^"`T.CTJ7C\$;SC&//N&0)M%;^+LA?$0Q;3GK(M>@ZOPPTPA44 MMI:A3B#S,S\'&K$7+C4B-Y,I793;HW!9NW0X3<,=3&BW7BYM(ZXFKH403C>7 M*\?EZW$M4'#NW0BDHF)U!5#'NGK6-3#7J-1KYS#90N>XI5H:CJCF6RBJ^7$S M*8)!-UPSU##4"J1FB1TQT-6SX,#0J'1ISTU_&CS6A.>V@U4/V$)W85X6>;1] MJ9:6*\K+J.;6GLLE2R.0^1IF3GM*U=9Q^4\O.J_+"R96N]DN-^+@=)T=<71< M_*G6TG2Q013GR2'=;;BJ66B-IF]VCIO)22'2#\_EU`^L:U20SBW3V`91H94H^GK1?)`8SS$+(5K.A$JXPC>I##4"X7#- M";8"!:'I6+!G:&!=H]*EG3;]:>STN<;']K-J>EDH:GRHF;1<:_S,*9)H)F+7Q5H@7:SSN%@+USILXVG!K1T7^L#9'8I\X[A"7>1T*UQAE4\)DA&]X])& MQ,VDXSIKQ*B,4-ELBO?9;(Z:R8D_BKQME]?JY"&/3QY$<.4G>LU0PU`K4)BG MS-4S-#`T*ETZ#E%3[0H\MK1QR1(H6X0Q+_)HW:N$#9]DF,/RF\4R>N5:>P8W MCQH'^2ZJ9:ASD'RTN;Z--/>>P6D>'.0UCPK2P<`R24D1OD>-ZOK*\$=)82$3 M)&=#)6PK?W!0,]0X*/B&3*"PL#LNKZMG:'"0US4J7=KKJ`&FU2R>"MP8PS43 MB&RA)FT>5=!J9LO?S`VGR!]Y-"(5S*!6H+!YCG2O$MG!N@?6/2K=.E"I9OI< M>G!KO;*0"91/#XOAN-M!M;`%4.,@OREM!5)1(%V]$_3J!P=Y7:/2I;TV726M M^^94ECZ\M)]YQ.EBN]*P#\#-9Y,N,#Q89_)H-E>>R\=E%G10PUPM0QU#/4,# M0^:2MIB*$6U<[*5K>]7U:??Z=5?M'A^/%_>';\]8-3.\]?KP;L;GZ]X?IXR. M\`VN@4^9$.-YB?N5&#'&BQ*7$AG_N"P_PE(F;)8E;O,E\!7NGZ?PFQ+7QQ+\ M.0CX!B-!68&2'!N%%I24N9O5LMP@XU@;2D1ILI\I*`.EF01,034HS5Q@2@>* MR7^F8.*79AHP!?,?5JJ94BW798W>E"D=**;=94JURN!/*F4[4$SKD9!9WF"< M5.Y@7XMQ4I0-K-Z\8?4MM*7\P1:Q--LCM@`[Q=+LDIB"#2,L2%.*TIS(L`S. MI2"3H@R@F/,9EL'Y$YY"BE(M5[`ZE6\=*.;,(Z&MN$,=2#Z?Y0+1F7J/J'1T MH/1)2K5$CN*XD1'#%+R`*LW[&*;@-3AD M4D\.K[XADZ+@=3>>:8I2%3>P.C5+.E#,*U:V`"\\$8/IG#+.`U#Z)&4#"S9O M6+`LS6MS'@>?&&"<%`6?%<#J%`5?%R#6*0H^,BC-*W4>IRI0=_#]#%,Z4,S' M-DRI"N0U5F.F=*"8#U:8@@])().JL!THYJ,/EAESLUJG*/CTMS0?]K(,/M$M MS0>X3-GDJ-?X'C!%6>/YI.9VE:]+\R4:RU3%`E:G9/"9&O(M1=G`G\T;_F"= M2U+P)7MI/N5F"UI0S!?=3,%W[8A!BH(/U^%/BC)FJ'SVRXTHKS?Y`E8G\P"4 M.DEI0#%7$]@V7-R`U2D*[F_`ZA0%%S1@=8J"2QEXIBG*!OZ8.S=L`2XAE>:> M#5-PVZ@TUVV8@DM'I;EUPY0.%'/3ABFX7%2:"S=,P=5%R*1F(ZXK0B9%P15% M/)\499/=P--47N,Z'CQ-41I0S)4SM@W7[N!IBH+;=[`Z1<$M.UB=HN"R':Q. M47"K&!:D*@5N!4-;BE)EJ"$XXV>K.U#,]5BF;!"W33)NN-!:F@N:+(-+K(A; MBH(+K+`@1<$]5L0M1<%UUM)O^^?CQ>/N"_9=B^EK]U?[IZ[L/T[V MJ_>+3X<3_G"5^0#^X@%_DFR'V^(+LWW]:5UT,W:G#:R<65L7/7QM+T%W;VEQXIOJ6Q#.YZN@+JK&%Q[B]B,^V/E< ME31CY6M-FUXX:>FMZ(%_=ZWNG?)6EQ]Q5Q?MR^O]4\GJ.[@X5K>J_\Z=^EY= MQE\N#6N+XPW._4X61:E\\R^6^[HJ6]:QB]=;_P=[_$JKR[6'W6%/0!'+][YYZ,Z M]=>]'ZUFR_4\(N'2]XZTZY\KW.M[Y6O7L_IO842D*^$DE$[@4SF)/KP9+#D# M^)2;P8T=+!#$^8&SHB\.NY8]/.@BH-;="^Q)$@-E>5+I83@[E*!$ZR\03)+:9/8-L2T2)4%)A3=9E,@UX``F`YTX7#_ARZ:(UT5 M*%'`R#^<<%,6:DLV!7(-,+A!":;<%LLA<[@*[:%ECJP79NQ$VFP'OJF%9!:2 MZXA!:&$04B5$=.\O8"BT&FXG3(01-O%HM)R;1NE@-.3*0G(=,;$0C(+R77$"+MRAD74#"L0,K9.:B&9A>0Z8H2%B7&<%E$SK$"( M=EH+R2PDUQ$C+#Z0K.F>K2$[_;4J7Q+&Q4DE'ZU-.@(A0J]P4E.);/CL+\)Y MM#*;(AL,5`5S'3'8;0UVB@6B)@N!$/@8FI%LIG,KC."IH!M%$W+2*.3LUW/^ M8YKDTH17P&!+P+663$67PR9?"0%AE8/4AC()A6-R0(S@JG".X$#XC MN-1"F%8M.4NS_U*8?:Q?*"9LN5YO'-D9;-0QW'LE&10(S@JHB.X$$HC.P*:M,Y$75(BK43K+)2N?(3]Y__E4AX7DP%2<)&2TEK,)Q_C-E-4*YA")Q%=4O.005)29D=)2E'? MH?&C<)C-3$'CXS!7$)]@H\]1^G]$ZAN[XW47FD+<^\4UN*;MA:;T=NN\DKTV MD#)H_\-N@(<7CB?.:X(G\"+"74[Q$%Y0,-04CV*XKMGXTR)^$H^+Z89%#%T.RC.&.X\#)*DZ@L^P5&)T8V]!>@?&`4[A6$K(!;[QG)[R@S6*LF.TM@Q4L MG+V2PPK6SUY)">;1F4@2`@-7RN`I`G%<*_"D`&^NE80LP)LK;R"[X,VU`LH* MWEPK":2-M^$T-W#,C>.4R1:"\VF?;MA"+ET+V19(N1;R+7`2PC'X@O?2>W&A MOQ7MI6HZ[T;/T,QS+F6M>(457WHQ!]Z1]?!&RM\`K_"O!@JWN_D,Y/[,6*^^ M0*F"X9\7AW\```#__P,`4$L#!!0`!@`(````(0"HE[-\D!```.]*```9```` M>&PO=V]R:W-H965T3\V7W?+][/#[O;Z9_ M[<_3WV___K'_?XR@8;G\\WTX7)YR:^OSWKXLG\&Y?/Q M]+2[X)^G+]?GE]-^=S\(/3U>I[/9\OII=WB>&@WYZ3TZCI\_'^[VY?'NV]/^ M^6*4G/:/NPOL/S\<7LY6V]/=>]0][4Y?O[W\=G=\>H&*3X?'P^6O0>ET\G27 M=U^>CZ?=IT?X_6#Y^OEQ!W;4Q5/N\N=Y<0]/MA_L# M/*"P3T[[SS?3CTG>+Q;3Z]L/0X#^>]C_.'O_/SD_''\TI\/]/P[/>T0;\T0S M\.EX_$JLW3U!$+Y6TO4P`_\Z3>[WGW??'B__/OYH]XW?$1(^&_ MDZ<#Y0!AC]#4&H'@WQ)8LAE\62[*K=\BM6`Z_XW#OE_WN/BM'Z.Y+TCGFVFB>1'(7EH.PBM64(5"%0AT`3`FT( M="'0>\`U_!^#@%7Q2T$@?@J"-7]K`1>5-/#8Q[;&>78)0&;W;3=3B[S+,9O2\44BJD4DBMD$8AK4(ZA?0^(GQ$M?%] M'%([75R-I4,G-TG<3.=8!EYVK^1,;@T35:"1*5VO)5,Q,HWSK9!*(;5"&H6T M"ND4TON("`F,]D-BIYW@P6]K[=8@R2QSLZRA4D.5AFH--1IJ-=1IJ!>0<`VU M/N8:P=(U@R1N]18**152*:162*.05B&=0GH?$1ZAR,8\(EAZ9)!D[N9*(:5" M*H74"FD4TBJD4TCO(\(C:CN]AXU-/X*E1P99I[K]LC/$C&!RJQ2^<-XCO/ M/!C2.;^9!>IA?@5[P=^Z3Y#B>D]J3LH&%JY M:E1JJ-)0K:%&0ZV&.@WU#!F[Q(P#^C6G31^"YXR=JNV@XF:Z-+V[<9J[E?G0 M9:6S9!%,.,NLW+JO-%0SA!\[6..XJ'^#YKG4W#H&*]-IJ&<(/^"2`:&VPUOH MPQK(UE=(&+OF$].9B!@8:(F"Z*6Y:AT-5^J\+EF7!U4:JAE*EEX@E*Y6"W8: MZH4NZ3JU(Y[KH[^F31'^&F@H#+:93C=AXYBP('[&J"3K3,Y8R5P+JBO?;X-, MJ9AJUNO0<-<::MXU4NM&+J8K701YU@LC9!BIA8F%T;0V(HP&0AAM MLA9X%`Y%U:\7!D*`+%?%7"(JALN#&JVK9VS16(C\,%-208(8*-+L4L>4L5AU*1[7!JQC*W)JJ M&1)+8U3KI=TFV"^V6GUGU>,)Y^5KD-6]&%$&CYHO+WACD>4VS5#'D^5MKJ-&"K88ZAN9NF?5"EW2.FJN8<]R&^7R@+?"!&H]!=[S8%? M]IH,^76#(6^MEQJJ&/+K!D-^:+1@JZ&.H97;D?9"EW0ZUFO^I&ZDNM]D**@; MP7ZJ8*Y7ZH:CVBFM&/+K!D/>.FJ\OE9WXV"Y[SE>7R=45B;.PR^[9A-]#$!)41K>621@3/^\YRO6E$SUR1 MS2-6C@Y[LG`'*'\<7_P#E($_*.NFK17'E\SF8V4$JR)8'<&:"-9&L"Z"]1*3 M21A7D#2.6H8O14U.F<:25%_ M#81-E'-.066JH$I#M88:#;4:ZC34"T@Z1VUES#G3;@KG#.0?\:7,!8?&8I&N M@P=RZ;AL5"H-U1IJ--1JJ--0SQ`R%B-*?ZDQ\_S]V;8M)?Y@G1I(Q(&Y$`X7 M!W76:76MQ^RH-%1KJ-%0JZ%.0SU#D3B@!_RE.`S\,@X,^:=_#.%PC\_H@EI? M.H8Q%314,^37>L?URNF?8[":.PWU0K-(C(S:32\Q["H?\,!Q8L6;5'^VLUFX M@6%!/#*L0:6&*@W5#/G=A.9J-=1IJ!>ZI+^O=)69[BH96B')Q^S.9L%>J6`N MDVOF_;B&*@W5#(G9-D9XNEHMV&FH%[JDOT&C.CRH$;K:K6N3G/U0KUT+M;,#2_A1S=- MK^8_'K%]I*JP%GUF$NY$F,O+[%)#E89JAL0J,2-ZNEHMV&FH%[JDYT$C9[9C M2_\=2*9[.H;66+5NP23!]JJP@OY2R))@2U0Z+I<'9D0ZBQW5JURM65"43395 MCACL95H]8F=UO3EB;[F&;9\,(W5XL8>)Z?Q$VAAH@\0>G5'[6>V7<77IGAPPA M6M:$@J&%>^U>:JBRD"M"-4,B#F9$3U=K!9WZSD).5R]T2:>1?,IIZL=C^W': MIP?=)D-K?V.:)<'VM6"NC9^PD;5EU(/+1J^RZOWTBZPM(RC6UJC+I4RFWLDZ MN^R(W;M&[)G+C"@"BL43">A0HJ(Q'?AE`\=04*K#!LYR^3'5#WC+A5+CK=^@ MJE66R]>EP\QF3H=!. M_I:A->7_>+J4A*T55JIH4I#-4-^GFJN5D.=AGJA2\;AE=9YKEMGAC;" MWYGREP7]AE--BXP+BB%#"*?-J,)RN6)<,N0=>5<,B:@8]1[4:%VMUM5IKEZHE\Y1 MP^HY9QHJ^IYS=-.TM&*5&"BH^6$K.3=<7B]<:JC24,V06"5*5ZL%.PWU0I?T M'&5&>RY:R3FQ!*790&L_,;,TV+T4+"B6@G[<.2Z;+15#]`G'6']4KM:6RWUV MT3A=3E`_[AR7';&SNMX.RZCNMJQ>03"YJ:[VHJ$=1\+WBG/B# M3#,0HF5-*)C+?XNJH8HA'"59P9HA+S2-%FPUU&E=O=`EG8[USZ^UDG/=/#,4 MM#UA*\E<&S\_(FO+J`>7#4)EU?OI%UE;1E#T.*,NES*1M35RV1$[.Z)OJAJQ M9RXSH@PH];!A%J5OM)+$'V21@62I3H/55-!B@^#&;^+5X[:T7/XF3T6^LER^ M+N5TS5RBQK_'B-:JET:H5C*B2QG1"R-$Y!<_:^*#5G+@EY%G:",.'=+PT(&Y M%FZ5EQJJ-%0SY.>IYFHUU&FH%[ID'(*6VE9W>K(%F<90,O,G/DN#G4;!;/B< M@`[*E[-Y>`3O&.PZJBSD>JA:0XV%^&O-S2K0W#H&J[FSD-/<"T@&(^BK?U;4 ML4U703(0!Z):!HA[UK4`%SWQ,N`J4@2A0+CT,AM-@"Y4LZ4&5A=R6M&9(1$'I:JV@ M4]]9R.GJA2[I=:R-CJ0'C#<7;LU%R:?]Z,8 MGH)@0AT,C8("D:A1BRS?1D?'4LAIEO7X2/><)EM3D/4YS;FF-*#0/&L*$CRG MZ=84Y#FLCE&V\&<;]0>U'5;'/$4%A]4Q"@HYK(Y14,]A=8R"J@VKHY3Y,J>> M->(/*-2Z:DHQ7^C!-:4!IHY1B,8,_0PT/9KL!A1ZQ6ALVA1@GECO8O&&< M&&4+J[>O6+V$MI@_V`?EM`?0%F`[E--60%.P*X(%<4J:T[F#EL'I"V1BE`X4 M.H70,CAEP2S$*,5\#JMC^=:`0CO[B+9LA54=FSF<-^*>'&`S/L7"=@D)OUK3,%A9L7[$@R^G5L);! M:W2,$Z/@U3FLCE'P!AVQCE'P(CVGU\9ZG")#W3$;>^4/ZDZ44F3(:WQGH;4U MH-!'&9J"CR4@$ZNP#2CT88.6Z5,\Y_`AK:;@\]:W_!0```/__`P!02P,$%``&``@` M```A`"MW=#?9%@``7&D``!D```!X;"]W;W)K&UL ME)W94EQ)DH;OQVS>`>.^@5Q!QR2U59Z5?[AQSU6C\AS0A__^:^''UM_W3T]WZ\>/VV/=O:VM^X>;U=?[A^_ M?=K^GV7WCX/MK>>7F\?MO]]][S]S\___5\?_UX]_?'\_>[N90L6 M'I\_;7]_>?E9[>X^WWZ_>[AYWEG]O'N$Y.OJZ>'F!?_Y]&WW^>?3W-VM%`]_8J-U=>O][=WS>KVSX>[QY=HY.GNQ\T+_'_^?O_S M6:T]W/Z*N8>;IS_^_/F/V]7#3YCX_?['_Y/1>+:]]?O=\TMW'\IN;]W^^?RR>OB_ MJ#024]'(6(S@KQ@9'^P/Y6"^*N/WQD?S$:S M>8CAC8*0KH/'7RDXVQE-]]XK-I=B^*O/>_,Q^Z*/O_J8-_4Q"-=NX:_H[Z2.A_VD8=HCL^@_[U>3(=?=S]"Z/@ M5G06K%-HU*H11D(PVY2@+4%7@KX$0PD.2W!4@N,2G)3@M`1G)3@OP44)+DMP M58+K$BPSL(N6VC07&O<_:JZ@'YI+*WJA(+7?V+9>K1I:I"E!6X*N!'T)AA(< MEN"H!,@HL27);@J@37)5AFP+0-9DQJF^EL,W*"&/-Z-G+& MDYFM^X7H?-BT5TVD(=(2Z8CT1`8BAT2.B!P3.2%R2N2,R#F1"R*71*Z(7!-9 MYL2T#Q:FO'UT1@OXT_84VU5<#KMM(:7D0R2C-< M3:0ATA+IB/1$AIP8;Y&">-X&;+V-9#1-XYM(0Z0ETA'IB0PY,=YB\?:\#=AZ M&PGR&:WM.A(,`R4-D99*=9%,\2<;/%,[>/J-DIH>=A.2-Q?OM_?_K%8H>Y& MF\4DJ-M8(\EC%1T\,JOV?>MBLU%2%ULRU&UT/F._.B4@8'4]"Z'7(>S^V8"V'Q5!\7(T%8AE.+S8KFJ$5KAK`SK6*;T(A6 M-M^TC+I?LM4G+75U,+9LO"&)\.*-R86)5U!J@'H4$8+31S6"3"11*T,=%^P9 M#<:6=3NLIY[;<9TU;D=D!]:L2'MJK%3K;FF&WZP8#XUH%;:*";X5K7&JJ"Z9 M#QO)@YU1,;#[I*`U.1@S-OJP/GO1QW7;1"]+>>K\==B$ARDUH490-@);028( M*MBSK<$4M&Z'A=IS.R[@QFU!Z#G9J"F6KWH4M=X;6U$KZWZM%,Q0]TNV^J25 MFBDW;^,-Z[K&B\4IGCB\NM(AM:.945#J2;5HS<;9D(M:LZ35BI8)4+12P9YM M#8K6MFPT845/T6SF"Z:]P:!H;BN:Y>IGGG^MU6VJ(@B+J`Z"6M#L8(,: M1BT7[%BK9S089*/)TXR#3=:(Q*$<2X)"Q6132I'0U**%/V&B'D\_<*]4E=0% M6T:=(/,X3K!$"W-Q>!P2K&*4#,:RC3S/5-"YWYE=,,ZH1B*"BZD=(\I[I12< M9;U24-XK52OKE8JR7JG(Z94A1WACC)6],J846#)28T[*8XH%'`PQ8TY+`1)J M6*MEU#'J&0T&V>;*,Y:LHW+",I:$)6W24EN#03:VL$:GV-Z=TN*2;AHO(A.S:.%/BGE>IAKC MC9;ZV0K*;'5)*[=5;.;ZI*6V!H-LS&$Y3S%O1EA&UY"!8<5+'H_,! M*8@.$MIK?\K-I1II]FD9=8*P%UJW^WAG4G;+I*%5-A@[-DR;76P:A[.(B:!4 M[;4@Q*1/:A3E0<2"V:S:B59VGM`S&HPMZW58W74P(6GBQ9Z M4=:TLV*R:D3+],AH/D/=+]GJDU9JIMR6C3,O$`<['XHY8%!_U@\SH2,V$_I[ M+;G6MTNXHFP@"L(LI\W6*$I[WU90'J]J9>=O@N8IB1E4:VW+AI,G'I@_*)QB MBSR5]"/UKX6@.:;V396/R]]TZJ25(HRV4%!1RUH=HY[1P.B0T1&C8T8GC$X9 MG3$Z9W3!Z)+1%:-K1DN#;"OF>56V"DPYL1*4GUXP:ABUC#I&/:/!(.MV2'.< M:60:TQ_T6NT8"T'X]4)1S:AAU#+J&/6,!H.LVR&)\=R.R8UQ.Z)LMU=/(\H& M<<.H%905[`05V_XR>TA:6E:2D%=XD4BBE#=`1)E#-5[."N$BD7#F(X8D0E:M)`+I*#G%/1&2QUM MQ7QFJ],G6EM%^M4G+;4U&&2##CE*%K3F&-.8NYC@(K(I(IUA2$$YPYC..<50 MC33)M(K26MTI>OL(0[0V1QCENXJ#FED_S$8>P9#<:6=?N5'`&_^9+;$=GQ1*<84O#U4PQ52-&WC#I]?ORQRCO%2!H:^6#L MV#!?R2GP.S:%&5'6X6O1R@>/HCR*6##?4:GY-%)Z1H.Q9=U^):?`;V;DMB`X MDG1HMEHAD; M?5C7G1D//P]2]()2<]2B!5_T48T63%JM(!-$M)45[-G68`I:MU]).F:<=`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`1[JT#<'.<[KWE$XJ)>\G3OF% MMU-528\[4Y0>=Z[H5;M/M:]5ZW>VEJJP?9[M,."7PNDP\ M/3!=)J+\U&4>47:>T@C*M%I!V0\`'1?L&0V*TIG,C@5E3IRH5K)U MJBC9.F-TKB@5O%"4"EXRNA*4.7&M6LG64M':EFV:XGQELV_E#+9KDXX,R#X^T5#KL.A84 M?EO?S%WD](D6C(\;[<_X).U4=9+Q,T;GBL32AWUR_$)5DJ%+1E>"WG;\6@O* MX^;./+14G?7S3*_9QV21#^CW$H6UOMW/*4K=NQ:4-4S#6JV@["B\XX(]HT$0 M=J.ZRAVJK>3$$1<\%H0:U8(GJI7RD%-%J77.&)T+RIRX$(1?7-3\)1>\$I0Y M<:U:R8FE(J?)7CF@VN<#*D'9A%LS:ABUC#I&/:-!45Q=QLZWD(>JDA:S(T6I MXHX9G3`Z973&Z%R1..5\"G>A*LFI2T7)J2M&UXR6!MG15AQ@O3O:^&!K/R+3 MI(0:UFH9=8QZ1H,@_+BFO?I041HA1USPF-$)HU-&9XS.!65.7"A*3EQRP2M& MUXR6!MDF*PZVJ,GDG!]U$^\4C%>U/=P]?;NK[W[\>-ZZ7?WYB(5GC&_3/G_< M<+G-<+Y7_8:'HW0AP4\!53BE9@DZ9A4B90GZ)RY']"2X-?$WCR]08)U=E$\? M5TM7?U(MU^.AT/]M"OMN@6FU7'>4Y@YJM#UN`PF MD"KT0)9@'JE"%V,))HHJ]#268+ZH0H=C"::)*O0[1S+_`(G;7)"$98#+8(&O MPFK`$BSJ55@46(*E'$WL21;P;>'ZACF_JET)IOXJS`+\',SM59@,6((IO@IS M`DN0?*$5/-^0@U5A\>4RR+NJL`:S!-D66LZ3(.E"RWD2Y%YH.4^";4\5\FE^ M#G8[&&B>9`%K"]<:5A"1)BM((G05Z,5O`D2(_1 M"I[D$)*0#O%SL!VMPBZ&)=B55F$SPQ)L3JNPIV$)-J55V-JP!'O3*NQP6((M M:A4V.BS!=KX*>SJ68%=?A:T=2[";K\(.CR78U%=AH\<2[.VKL-]C"?;S5=CV ML:29SZMP.,42'$;!`T^"HR74M2?!J1#JS9/@C`<]T9,LX-O"]:V&I'8E.'JI MPO::O<9Q2Q5VV2S!.0LB]20XX8?$F\EQ.(\Z\"0X?4<=>!(&!)\$I,#SP)#C`A0>>!,>Q\,"3X.6&:O#7K#G6+/QN MR36*W['@M;=DXB.U)\!L3O/8D^,4(7GL2_"0$#SS)`EXO7*_Q[D@57J!P MO(:D<24M)*TKZ2#I7$D/27BY@I^SF,WAV_JWGZ)-:TAJ5])`$E[686MX(PF^ M>1*\F`0//`G>/$*;>I+%;`K?O'Z`]]S@FR?!NVWPS9.TD(37P=CK#I+P"AA+ M!DC"FV`L6_#:D[0HT[H2O'P+K[TR`R3A=55^#E['KQJ\ M#<\2O%R/>#Q)/<4,BY_PO#)8LUS)`K6S<&NGAJ1V)0TDX7UJ?@Y>%:_":]4L MP1OC57B[FB4]).$E:Y;@"S1X[64.BRE:&]_4]*%A.L MSOAPD:WA$]&J=B7X++0*'TYRF1:2\/TD2_"1:!6^F63)`$GX=)(EB\D,OKF] M%Y+P,2Z7P7?&\,V3X-MB^.9).DC"Y[AL;8`D?)7+DL5D`M_<'@))[4H:2!I7 M@J_5X9MG#1^MPS=/@B_3X9LG64RPFXHO!Q:S6`U)N!>`XVD@"=<#L`37',`W M3X+;#N";)\&5!O#-D]1CS`?Q9?["-USK484;.MB#Q1CC)[[;6I3!/1N(QQL+ M#23A+@JVAELV$(\GP64;5;B9@LOTD(0+*EB"FS40J2?!O4>(QUMEZC'Z:#Q? M+N+!G3LHX\TAN/T&9;R>B.MM4,:3U&.,4]SSPE[CVAB4\22X@*T*UY9Q&=PN M!FM>I+@^#-8\R6*,GNB>K>"*KZIV)0TDC2O!!5]5ZTIPSU?5N9(>DMZ5X%(O M>.WUT07J8.'7`23ASCBN'=R25X6KXUC20A)ND&,)[LRK.E?20Q+ND^,RBQ&R MSOC29M%W<`\C?//:M(&D<26X@A&^>65P$R,\\"0#).&"0L^W*7QS>^\(6:\,TK@PL\X9LGP3V>\,V3X+9.^.9+T$?CFQY%O>$&67CMCE-(PN6J'"EN MBH77G@07QL)K3X)[8^&U)\'%L/#-DRQ&R#I=KW$',7SSLD%A))R.,U)G9O9'28 MB-=\=]/`^"=O?MY\NSN]>?IV__B\]>/N*\ZR]]97?S[%?QTG_L=+O&QQZ_?5 M"_ZQFW#OXM9W_"M&=_B70O9V\*+9U]7J1?\#G6%W\^\B??Y_`0```/__`P!0 M2P,$%``&``@````A`,0@^TD;&P``NHD``!D```!X;"]W;W)K&ULE)U;4QRYDL??-V*_`\'[`9J^X0[;)Z;KVO?K[CXS&-O$&'`` M'SZ==LXN M3D]N'VX>O]P]?/MT^C_[^A]7IR?/+]7EY^C\_/GF^^W]]?/9X\_;!TB^/C[=7[_@GT_? MSI]_/MU>?SD4NO]Q?GEQ,3B_O[Y[./461D_OL?'X]>O=S6WY>//G_>W#BS?R M=/OC^@7^/W^_^_DLUNYOWF/N_OKICS]__N/F\?XG3/Q^]^/NY3\'HZC MR;>'QZ?KWW^@WO_N]*YOQ/;A'V3^_N[FZ?'Y\>O+&T>YSA_./YS#TN>/ M7^Y0`W?;3YYNOWXZ_:TSVG^X.#W__/%P@_[W[O;7<_+_)\_?'W\U3W=?YG4ZT>GWR@'JX?:XF\HUX&)-PH,0@'\_5L7&H9R^/N^"Z'C'3S#WU#@?7?B M0RC7<4W$Q^;R??>B5"*`QG@L^JZ0=R04G7A/WUM3 MN;F=>'??>8_D]EZ^]_:>^_YUZ)?E] M&1K?L8]BJ+AQZK\Y_4^GJ"MZWS/HOSY?=GL?S_^%3G\3=,:LT]$:A6BXCN_, MECFH#-#UDNXQU'VH."I)\$HB%9&:2$.D)3(A,B4R M(S(GLB"R)+(BLB:R(;(ELB.R3XD*#/*O-#"'K,UEG;)HX+S-E=`Q\V2`+IC$ M["J+V5'I&#,B%9&:2$.D)3(A,B4R(S(GLB"R)+(BLB:R(;(ELB.R3XF*&9)\ MBEGWZBPN*3EHKH@.FB=9T#YD03LJ'8-&I")2$VF(M$0F1*9$9D3F1!9$ED16 M1-9$-D2V1'9$]BE10<-"BX+V=D=S)73,/-$QZUUD,3LJ'6-&I")2$VF(M$0F M1*9$9D3F1!9$ED161-9$-D2V1'9$]BE1,7-[#FG0)-$[M M&"U"58=0S:AAU#*:,)HRFC&:,UHP6C):,5HSVC#:,MHQVBNDH^56Q5:TPFHY M'20]PMZSQ*%PF]_H@0DJ&56,:D8-HU8A[;9;1EIN^^6E:F0>P59TFU#I]N)= M3:)6Q:AFU#!J%=)NNT66Y;9??"FW/<*`&=WV"-U%4.F>",#M!%4!)07K@'I8 M+B2C8K:3WD0M,=\JI&OBEAY63?R21-7$H\2APCV_<",W_B0.91N49=02AZJ` M$EMUU$IM97MJ3=026ZU"NG(N14\J%QY4G`W12%Z^W]W\,7Z$VYWC;JM[IN*J MDW86CQ)'"]&")*ETMG%11BUQM`HHL55'K=16MJ!NHI;8:A72E78Y;E+IX[CM M'`5ADHP1ZV?A*()6'^43K2P-+H-6.N8PJM]EJXE: M7*@-2-?$%$U1SP891JVQIMUUF8G2L M2Y^QI!TK(-=2DP#DZ:L4U%I9?RAM6]F@7P4M_)&[4D?S[HGKU5DGZ]A-5)`R MK3*C:_]*@G')"49`JF\%K=@?2M:J`E*5H(*-7#'::E5![;;+!ZR@^3Q!!2T@ MW;>RR:Q`BW*-]*_ZEM=*FE\5"B:H?I>M)FK%,*7F=7U=(I'4]Z^FO$N?>*C[ M$%!L2D70ZE\>6UEM)P48*1ENMH(,M71V78"35.0X5(?%(9NI+ MC[(^E^4/1=!"+S_\#&&`WW)EHVI2L4 MR2RK[G(:$U#:,`-*&Z:@I&$&E#9,T4H:IJ"D80KBAMG-LA&J3M8P#_I9A$.6 M$CM5(5H1E8PJ1C6CAE'+:,)HRFC&:,YHP6C):,5HS6C#:,MHQVBOD&Z!:29V MA1;L?V;6Y40L("P19>XL&)6,*D8UHX91JY#V.LV@$J\Y@>IZE&QB%(Q*1A6C MFE'#J%5(>^U2#1FW$Z]]!I(.SUV/DE&V""C)"$I&%1>L`\HV%K*DMXE:$MU6 M(5V1-#-**L()4-.I/H93>\"%HAQ>UTD4A07;TA+)O$OTI*Q>2B%O1VBANT0HK; M/^ME*Z96S!PNIFJ.N%ECRP'K&3:@-&$("`F3U*$4%.M0,:K95A-0NEVC"FJO MT_PGQJO':8X@O:+,@E$$+:3.+A4;]CADD3->2.MBAED24)IVNIG6E704DW1^Q7Z$P:VK$P3KQ]#YLMX,[KR;C[G/*H7IOFT M.P44@U$$K:17E%(P:E4!J3IX6TG!AFVUJJ#VVLXU7/J0/2@)*.M.62LOI"#F MGS@5][-QJ@Q:R2JO8E2_RU83M6*0O/=6"W63=`S27Z4?O3"GI\'S2/4WC_JQ MVY2A(-;8XE054%+G.J"D8,.H5;9T\-PL+[7!XP=9)V$4HN@%I#M$-+P6#./5+,,6I@RC\V`]RC"Y0;^2=#5V8=L`&C%'U[4(QM1 M5?^K2![T=9Q/0(*8OK6@=;*E(NB$N MC215)]NC..AGU?'I"9(Q\;T(6@DJ&56,:D8-HY;1A-&4T8S1G-&"T9+1BM&: MT8;1EM&.T5XA';(T?4HZ'[;"\\X7D/ZQ9_[8LXA:$L"24<6H9M0P:AE-&$T9 MS1C-&2T8+1FM&*T9;1AM&>T8[172T4K3QC1:G#?V/4JWE!B5C"I&-:.&4:N0 M=MLE:<8(CUU4:F0>I7M*02M!):.*4N` MLIIDTW43M6)-@E^\J]1/,[VT)ISJ'52SF`0M=6MI6RD4A-OB4,6VZJB5A*F? M[7(T44MLM0KI,*5Y'2I'\V?VR`+/DZC_A,0NSM>%:$$2V],@WTN+6N)H%5#2 M%.JHE=K*$N,F:HFM5B%=:9=D68.#3[ZPP2%&QD@Q#[T,?V)-:&,I:(6-I=Z` MLS_1B`E2)2BF4;6@M_>5@A:2(I=L]L^ZV5JB%3.\KX2,T:SY@>NT**`T7P\H M71\+BI6H&-5LJPD(B:KOT.Z"@%7:6ND;` M1"-)UQG5`2'9>6UG*6K$>GJO_>"FZ_E*:C3@U$A0O/%%0.G6DJ"T%MY6,K36 M00NU$!\;1JVRI=U^)4=P;QMDB^&`LL5POK<4M%[?6Q*%6/N*41T0VM@A.L;> M4M20FK?*CJ[F*SF%2T_S:H:<(K;N(FBISN.UDI5M)5JQ8K68C[8:1JTJJ-U^ M):<8<$XA2'4>VET*6B[#CV/B()N&2M,6[2X%+=4:O5^A3_7/+C++3;Q^#)HO M8W4I-Z\;8_T@S/?)6"\HWOLBH*1GE*Q5!:0JX4A`:L+R6I@/ MQ84R:*4;3`&I&E+!)F@EMEIE2U?'I0U6J_/IA)JP`M)]+LM8BX'7"AM,`V.[ M7332H=X74NTRV$G[+N\O!5N8D-W`^0&G+NDW5EIU,57S899A_%5">=#7F8>@ MI!\&E.XO"4KVEP)*ZRM:R?Y20)B8I5&THL7[2T,W5R>!I.ID^TL'_:PZ?KI/ M-I.*H)6@DE'%J&;4,&H931A-&]/8+X$/.(0-R&4_,/X;YP^.H)=V\9%0QJADUC%I&$T931C-&/\4K`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`M:R:.S M,J!$JQ);\3%I2FC64")$W/1BK86@J*M):.5H%AP+2@6 MW##:!I0XL1.M:&LOZ&!+A^:5#:`KW@`2A($ZZ7^AQ,.IE(K/-6@OUQGV^:'I M0G2B\26CE:!@Z<.0'%^+2C2T8;0-Z&W'=U(P7&Y@C$-[T3E<3[>:;&^*GEAF MO^B[XCTK0;%Y%P$E@2E9JPHH^=5#S04;1FU`^(F1S'(3L16=F'+!64"XHU)P M+EHQ#UD(BM%9,EH%E#BQ#@B_,Q;S&RZX#2AQ8B=:T8F]("-DKVQ07?$&54#) M@%LP*AE5C&I&#:-6D)]=+HUS82:B$B>SJ:!XXV:,YHP6C):,5H*"4\:9(&M1 MB4YM!$6GMHQVC/8*Z=Z6;6#]96_CC:TKCU1("96L53&J&36,VH#P,W1IU1-! ML8=,N>",T9S1@M&2T2J@Q(FUH.C$A@MN&>T8[152(<,7V53&0R'+?M)QT-<; M7@%A-$RGVWRY';7D-I>,*D8UHX91RVC":,IHQFC.:,%HR6C%:,UHPVC+:,?( M?3W//8;TTXZ/HO\:GO_JUOWMT[?;XO;'C^>3F\<_'Y#Z7")A_?SQR/UW^,;# MP<@]S4$82#*$Y+!5E4L^7,C'^W))ISMRY\T:UKJ7(WUQ\+AQA0Z\\IL# MN:T.O,*IR5P&`^_(]6268/R%8Y8$WT[\S;(U=I2&5;X")L>1&UU9@CERY(9/EF`2'+E1 ME"68"T=N,&4)IL"1&U,MR0`2JZ$@:T6H+`F2UY'+=-@:$M:12WA8@C05X;4D M8_@V-GU#/C,J3`G2FI&;X?@ZR%M&;J)C"=*7D9OO6(*%!:)@^8;UQ<@EEEP& M:XJ1RR]9@I4$(F=)L*!`Y"P)UA6(G"7!DAYWU&IM6,GCCEJ2,:R-36M8]^&. M6M?!\F_D\GBN3P6)2^=9@L4>HF!)L.9#%"P)EGZ(@B690.)2?;X.MEIP1ZV: M8L<%=]228.,%=]228,,%+=Z28-\%+=Z28/L%+=Z28*L*-;4DV+%"32T)=JI0 M4TN"#2NT1$N"?2NT1$N"O2JT1$M27G41'VO(PT8K/+`DV#;%O;8DV/'$?;,D MV+]$2[0D8_@V-GTK("E,";85T1*M^F`K$2W1DF`/$36U)'AZ!8DU3>#!$^Z! M)<&3)=P#2X*'0K@'E@1/?7`/+`D>K,`#:T+",Q%X8$GPA`,>6!(\G(`'E@2/ M&N"!)<%OM$?NA\W6Y+Q$*T*OSMDW\9#C'SXV9LEP=2,WU$9$MR#L7D/\(/Z46%*2DA*4U)! M4IF2&I+:E#20-*9D/!B.QGB#@+W&NQJCPI24D+@W&+A,!4EE2O"VQLB]O,!E M6DC<.PPL&0_Z\,W*:@I(W%LQ7`8O_,`W2U)!XMZ1X3(U).Z]&):TD+C78U@R M'G3AF]4."DC<:U9FF`/QH,. MO+;Z:0&)>W6/RY20E*:D@J0R)7@C$5Y;UEI(W#M\?)VBCU:%5X19@C>.1^[E M89;@%5^4L=H.7MA%&4N"EVEQ#ZR[4T!2F)(2DM*4X/U9W`/+&EZC';E73MGK M!A+WYBE+<&(*O+8DXSZB[3<`LQ4!WK?'/;#&';Q0CS*6I.@CX\+KY^P!7EU' M&4LRAF]CTS><.S-R9Z^PM1(2=P0+2RI(W$DL+*DAJ4U)`XD[EX7+C'L8Q7#0 M#DMPHM&H,"4XQ6CD#OKA,CC,:.3.^V$)SC0:N3-^6-)"XH[Z8";)<$A:O#-DHQ[&*MPD)SE&\8J4U*BC#O(CLM4D%2F M!.?RP3>K#`[?@V^6I.ABW,$ADGP='$`Y:DW)N(O^XQ]DYCT8DL*4E)"X4Q/Y M.C@/$O6Q)#@6ILC4#CVI3TD#2F!*<`XY[ M8/DVQCT8OW(/,"::$IRMC[MCW;<*$G?L/-\#G+0_JDU)`XD[A)[+C"\Q)N*K M`BS!]QO@FR4I(7%?->`R^'0#?+,D^((#/+`D+23NNP9L;7R),=&?O)KW4T@* M4X*/@,`W:Q3#AS_@FR7!]S_@FR7!5S[@FRGIN#9J]M-+C)8X^8/K@Z_-P&M+ M@B_,P&M+4D%2F1)\;P9>6V7P01GX9DG&\'IL>EU`XK[KPU[CDT7PS9)4D+BO M_'`9?,`(+=&2X*-%\-J2C#O8*?&_YLZCW<%8A0]S6=?!6&5*\,$ME+%&)'P^ M"V4L";Y7A3)6+\'7IU#F(#D_.O?\^>//ZV^WB^NG;W&PO=V]R:W-H965TOWJ^8UP^/,L>';FQ M0JL*9TF*$5=,UT*U%?[U<.`4'9 M"G?.#4M"+.NXI#;1`U?PIM%&4@='TQ([&$[K<$GV)$_3&9%4*!P)2_,>AFX: MP?BC9@?)E8L0PWOJ('_;B<&>:9*]!R>IV1^&.Z;E`(B=Z(5["5",)%L^M4H; MNNNA[N=L0MF9'0XW>"F8T58W+@$UKP@"P*D55D+J,"W'1G>5'B=+3=3 M3%9EZ,]OP4_VXAG93I\^&U%_%8I#LV%,?@`[K??>^E1["2Z3F]O;,(#O!M6\ MH8?>_="G+URTG8-IAWA,]Q`)?I$4?@6@%ED^Q6C' MK=L*?Q*2.KDJC3PCF"FX[4+\EV3*'VID7UUZM\!PC MX%E0CZLBGY7D"&6P?YY-],#OZ,E&!P'Z&`+R?2.$5WT(:$V(N8G")2]_FU=< M\9#O5Y&.J?NW(%RD5>3S$11#1<\D-.8RT\D5^=P,KU9X`H,=*RWR^U?(:,K^ M9[IJ"$SKHB&Q@")/8(KGD-X10H[=B4IV7==B3"+RXX[%^4IN6OZ)][U%3!\4 MI.['.ZKC:J]SWX;7^F2Y#BM(QA>PB0-M^3=J6J$LZGD#R#290V(F+FT\.#V$ MK=II!SL8'COXMG!8JS0!U:GB& M7[C!-[O/G[8GI1]-Q;E%0&A,ABMKVPTAAE5<4A.HEC>P4R@MJ86E+HEI-:=Y M=TC6)`[#)9%4--@3-OHC#%44@O$[Q8Z2-]9#-*^IA?A-)5ISIDGV$9RD^O'8 M7C$E6T`<1"WL2P?%2++-0]DH30\UY/T MDS4!TFZ;"\C`E1UI7F1X'VUNHPB3W;8KT%_!3V;PCDRE3E^UR+^+AD.UH4^N M`P>E'IWI0^XD.$S>G+[O.O!3HYP7]%C;7^KTC8NRLM#NA3O"5`V>X(FD<'<` M4J?/&8[!@\AME>%D&2Q681+%"XP.W-A[XW'L<\9(1#[EZ)6$?NML%81!6DEQ`WI6W2;NV M#"--1^1S,9R:X10:VV>:)$D?FT=ZH^@]HU$"T*V9@CBU<]-7Q"L1%&;@..T= MCYC+$;,K2K1:!W`SSFDXBS'?*]&X5HMY/MR%04>SL7O+,9\KTSXJWG^>H:_OEQXMSV&>V4"OYZ'N[8/HC]7O)/'U%-.PPG?#R,_""37)?_"Z]H@IHX-1.7*TJO] M$-S'[GN9ZNEF[X&ULE%E-;]M& M$+T7Z'\@>(\EDI(E$98"BV3:`"U0%&E[IB7*(BR)`DG'R;_OF_T@=W8WMI-# M;+^=G7DSL_NX7-Y]_'8^!5^KMJN;RSJ,;J9A4%UVS;Z^/*[#?[Y\^K`,@ZXO M+_ORU%RJ=?B]ZL*/FU]_N7MIVJ?N6%5]``^7;AT>^_Z:3B;=[EB=R^ZFN587 MC!R:]ESV^+-]G'37MBKW8M+Y-(FGT]O)N:POH?20MN_QT1P.]:[*F]WSN;KT MTDE;G_+MC?>VTM_/N/>[.9?OT?/VP:\Y7N'BH3W7_73@-@_,N_?QX:=KR MX82\OT6SN7CKC]Z`[-B^_M?7^C_I2H=KH$W7@H6F>R/3SGB!,GCBS M/XD._-4&^^I0/I_ZOYN7WZOZ\=BCW7.:LFM.B(3_@W--:P"IE]_$SY=ZWQ_7 M87)[,U],DRB>A\%#U?6?:IH;!KOGKF_._TDC07UP$BLG^*F=)*].P*B(BI]Z MPKNC3F0&(O.\[,O-7=N\!%A.X-A=2UJ<40KN*F7%>R@">K$CZWLR7X>+,$!Z M'="OFR29WDV^HJH[9;-U;2)ND6D+JBRYS6V@,(`)F`YT4:R?H4OF1%<'VFI@ MY!];W+2%GI+;0&$`C!OZ8G.;S8?*T2C6B5&Y:#'CL;?*9C7PS1PD=Y#"1!BA M&2.D6TCH.IQA=PP]C!9+BXDR0AL,HSDWR@:CH58.4I@((X?%9E=KN;JA_2/W MC+OV:(8@KL-M)4)S#):W%LO!2$_+':0P$<;RUF4Y1U%^1)',.46)6!07%L7! M:*#H((6),(K8C$8A=9<)Y4P4PEMJ]3T;C`8F#E*8"&-"S\%12S030CD3A6`? M&6U;6349C`8F#E*8"&.R8DR$JMTF-PNT^4>=HQFXTE0S' MLU)5LZD2`F==B@RK2W1PA'(%Q6.5"PTE-)$')\7T!%=":@:7$&N>A(Q=FZ.1 MQ,>`"@;QX"2$GN!*'\W@$HK1#J-;UFDIHV92<%J$7S>W"[PM6?*+I5N=T4:G46A(*#/K7NR780%;U9'*#(+:;::LXN4`Y2Y4:,@3W"_#L2O# M"K*6CJ4RF;:22V<^IRW,=W`^FN@L"@UYND?*.B[MM\0RED)L"I2"V)*25K&Q MV;75"!4*2L3VX1WC"CXL*5>IZ0G.MW&FH`3KSUAEMA1JJ^05*=0VGJZ2W/Y$ MU:0ZLZHIP1X/$AEU'KDDL;'4%#0^'0MM)78PKQI)["NDOC17\[E'VQ#A&"D) MF81-">T<:V$H*.'*;;_X:"OT8ZS*:I0GSL*OREC]3G`)L>1,B+LU M]1:_BVNA>'%C7&>XTIM(Z*WTE!5/;WQIX#Q,735JZ^IG(B&6G@EQMZ8RZO3F MAG]7(A,)O96:2N>W'AHE"SDS;B\ M'SY7[6.55:=3%^R:YPM*@A";NP&65_+;>)62]N*,9(]@P(M'TY2N)3PS(MSO MRQ<.VU<48T0\K.R1>('XXJ3IC"PQ(@ZY>W3SN M9^D]ZNT.;&?X?N'#YREN(#WVMRFN_3PX^Q#'-[*-(WCS-3C#"+VGN`SPG@1OOI%MA+KA2L>=@\L/C'C['-VF M6WEQ9"W5#"/TTN]ZPRU$2N_^[@CN'A!'C$P&=_AZ=2T?JS_+]K&^=,&I.F!# M3\5M3BL_=,D_>GFZ#1Z:'M^MZ*`;'/%!LL)'FBF>_L&A:7K]!T)/AD^&PO8V%L8T-H M86EN+GAM;#R.00H",1`$[X)_"'-W9]>#B"194/`%^H"0'4T@F2R9(/I[X\5+ M0]%0W7I^YZ1>5"46-C`-(RAB7Y;(3P/WVW5W!"7-\>)283+P(8'9;C?:N^0O MP456WX1!+6!70FA2Z)-K=C/DK@@#ISF M=UJM%F!R-H6E;3(T-`):]LC[NHFE:4B]YY8H=T./K18OA)8T,-$Y71;8'$\G MB!DWBI`BN].(;`ZF=LFIXGC->\J<_2YK2=Z#7>N$E%D1XE[^-SVF(BO(=-%K M.)4H=-VUDF`_T`788/Y4@6S!EW3NCJC3K4,7]D,Y.O:6R\P-Y+"NW$`.*\7M M2848Z$?5(YE_/LZ.-@+YJ+)6.$NWBUN8[)$49.2G7&)Z"Y/2Z7)8TN[K MX[#/T)VGYQRT37.Z=!2R/0T'>7$ZM+5GP)PY>@Z2@\J]%^S=FW4GU0L^%0L] MI=M]\RCO+X:-`A)ZKC;[NX7PAMYCD]5!)FNN5I!L;#YNU%^(Y_:?%)V-3@?# M`?T..FMAL/L117\!``#__P,`4$L#!!0`!@`(````(0![H';J,@$``$`"```1 M``@!9&]C4')O<',O8V]R92YX;6P@H@0!**```0`````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M``````````````````"YMF\Q^AS4!E3PX$)XIO,;G; M@DT:I$GX2\A'/N+^>>5+.M;;(/"&A:5Q-6E"0#IUIMW+HFC\MY M?D4RC-)IV;0.:K(#)#-Q>E(ISU4;X#ZT'D(T@%DB.>3*UV03H^>4HMJ`E5@D MATOBJ@U6QG0-:^JE>I-KH).RO*`6HM0R2KH'YGXDD@&IU8CT[Z'I`5I1:,"" MBTA9P>BW-T*P^.=`KQPYK8D[GW8:XAZSM?H21_<6S6CLNJ[HIGV,E)_1Y\7= M0[]J;MR^*P5$[/MI),9%JG)E0%_OQ/8U-!GBIJ*_M4JK/AU7`60$G:7W^%>Z M@_(TO;E=SHF8E.P\+].Y7$Y*SAB?GKU4].`:YL4(M$.`?Q,/`-'G_OGGXA,` M`/__`P!02P$"+0`4``8`"````"$`5&:').H!``"Q%@``$P`````````````` M````````6T-O;G1E;G1?5'EP97-=+GAM;%!+`0(M`!0`!@`(````(0"U53`C M]0```$P"```+`````````````````",$``!?&PO=V]R:W-H M965T&UL4$L!`BT`%``&``@````A`#M;9-5A`@``5`4``!D` M````````````````MQ,``'AL+W=O&PO M=V]R:W-H965T&UL4$L!`BT`%``&``@````A`(9)9#0L!```'@\``!D````````````````` M.Q\``'AL+W=O(P``>&PO=V]R:W-H965T&UL4$L!`BT`%``& M``@````A`"Y4`7N!!0``714``!D`````````````````&RL``'AL+W=O&PO=V]R:W-H965T&UL4$L!`BT`%``&``@````A`#:*YXF[ M`@``G`<``!D`````````````````$SX``'AL+W=O&PO=V]R:W-H965T&UL4$L!`BT`%``&``@````A M`#V.N=ZH`P``9PP``!@`````````````````14@``'AL+W=O&PO=V]R:W-H965T&PO=V]R:W-H965T&UL4$L!`BT`%``&``@` M```A`/01-Q4(`@``/@0``!D`````````````````[L0``'AL+W=O&PO=V]R:W-H965T&UL M4$L!`BT`%``&``@````A`#*)A5?B!@``EQL``!@`````````````````'M0` M`'AL+W=O&PO=V]R:W-H965T&UL4$L!`BT`%``&``@````A M`$1Z$W`_`P``3PD``!D`````````````````&^$``'AL+W=O&PO=V]R:W-H965T&UL4$L!`BT`%``&``@````A`'U1Z:0=!0```1$` M`!D`````````````````Z?@``'AL+W=OS?)`0``#O2@``&0`````````````````]_@`` M>&PO=V]R:W-H965T&UL4$L!`BT`%``&``@````A`,0@^TD;&P``NHD``!D````````````` M````%"8!`'AL+W=O&PO=V]R:W-H965T M&UL4$L!`BT` M%``&``@````A`$^2C59N!P``)QT``!D`````````````````Y$8!`'AL+W=O M&PO8V%L8T-H86EN+GAM;%!+`0(M`!0` M!@`(````(0#KD'QDT0(``%<)```0`````````````````$U/`0!D;V-0&UL4$L!`BT`%``&``@````A`'N@=NHR`0``0`(``!$````````` M````````5%,!`&1O8U!R;W!S+V-O&UL4$L%!@`````L`"P`W0L``+U5 $`0`````` ` end XML 14 R33.htm IDEA: XBRL DOCUMENT v2.4.1.9
Business Development (Schedule of Assets Acquired) (Details) (Skilled Nursing Center, Barren County Health Care Center Inc, Glasgow, Kentucky, USD $)
In Thousands, unless otherwise specified
0 Months Ended
Feb. 01, 2015
Feb. 01, 2015
Skilled Nursing Center | Barren County Health Care Center Inc | Glasgow, Kentucky
   
Business Acquisition [Line Items]    
Purchase Price $ 7,000us-gaap_BusinessCombinationConsiderationTransferred1
/ us-gaap_BusinessAcquisitionAxis
= avca_SkilledNursingCenterMember
/ us-gaap_CounterpartyNameAxis
= avca_BarrenCountyHealthCareCenterIncMember
/ us-gaap_StatementGeographicalAxis
= avca_GlasgowKentuckyMember
 
Land 672us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLand
/ us-gaap_BusinessAcquisitionAxis
= avca_SkilledNursingCenterMember
/ us-gaap_CounterpartyNameAxis
= avca_BarrenCountyHealthCareCenterIncMember
/ us-gaap_StatementGeographicalAxis
= avca_GlasgowKentuckyMember
672us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLand
/ us-gaap_BusinessAcquisitionAxis
= avca_SkilledNursingCenterMember
/ us-gaap_CounterpartyNameAxis
= avca_BarrenCountyHealthCareCenterIncMember
/ us-gaap_StatementGeographicalAxis
= avca_GlasgowKentuckyMember
Buildings 5,778us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedBuildings
/ us-gaap_BusinessAcquisitionAxis
= avca_SkilledNursingCenterMember
/ us-gaap_CounterpartyNameAxis
= avca_BarrenCountyHealthCareCenterIncMember
/ us-gaap_StatementGeographicalAxis
= avca_GlasgowKentuckyMember
5,778us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedBuildings
/ us-gaap_BusinessAcquisitionAxis
= avca_SkilledNursingCenterMember
/ us-gaap_CounterpartyNameAxis
= avca_BarrenCountyHealthCareCenterIncMember
/ us-gaap_StatementGeographicalAxis
= avca_GlasgowKentuckyMember
Furniture, Fixtures, and Equipment 550us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedEquipment
/ us-gaap_BusinessAcquisitionAxis
= avca_SkilledNursingCenterMember
/ us-gaap_CounterpartyNameAxis
= avca_BarrenCountyHealthCareCenterIncMember
/ us-gaap_StatementGeographicalAxis
= avca_GlasgowKentuckyMember
550us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedEquipment
/ us-gaap_BusinessAcquisitionAxis
= avca_SkilledNursingCenterMember
/ us-gaap_CounterpartyNameAxis
= avca_BarrenCountyHealthCareCenterIncMember
/ us-gaap_StatementGeographicalAxis
= avca_GlasgowKentuckyMember
Total purchase price $ 7,000us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet
/ us-gaap_BusinessAcquisitionAxis
= avca_SkilledNursingCenterMember
/ us-gaap_CounterpartyNameAxis
= avca_BarrenCountyHealthCareCenterIncMember
/ us-gaap_StatementGeographicalAxis
= avca_GlasgowKentuckyMember
$ 7,000us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet
/ us-gaap_BusinessAcquisitionAxis
= avca_SkilledNursingCenterMember
/ us-gaap_CounterpartyNameAxis
= avca_BarrenCountyHealthCareCenterIncMember
/ us-gaap_StatementGeographicalAxis
= avca_GlasgowKentuckyMember
XML 15 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; word-wrap: break-word; } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 16 R25.htm IDEA: XBRL DOCUMENT v2.4.1.9
Stock-Based Compensation (Details) (USD $)
In Thousands, except Share data, unless otherwise specified
3 Months Ended
Mar. 31, 2015
Mar. 31, 2014
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]    
Stock-based compensation $ 155us-gaap_ShareBasedCompensation $ 141us-gaap_ShareBasedCompensation
Restricted Stock    
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]    
Grant of restricted common stock (shares) 74,000us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
/ us-gaap_AwardTypeAxis
= us-gaap_RestrictedStockMember
68,000us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
/ us-gaap_AwardTypeAxis
= us-gaap_RestrictedStockMember
Vest of restricted stock on each year (percentage) 33.00%avca_ShareBasedCompensationArrangementByShareBasedPaymentAwardVestingPercentage
/ us-gaap_AwardTypeAxis
= us-gaap_RestrictedStockMember
 
2005 Long Term Incentive Plan    
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]    
Number of shares reserved for future issuance 700,000us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
/ us-gaap_PlanNameAxis
= avca_TwoThousandAndFiveLongTermIncentivePlanMember
 
Expiration period 10 years  
2008 Stock Purchase Plan    
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]    
Number of shares reserved for future issuance 150,000us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
/ us-gaap_PlanNameAxis
= avca_TwoThousandAndEightStockPurchasePlanMember
 
Percentage of quoted market price offering rate 85.00%avca_ShareBasedCompensationArrangementByShareBasedPaymentAwardMarketPriceOfferingDate
/ us-gaap_PlanNameAxis
= avca_TwoThousandAndEightStockPurchasePlanMember
 
Restriction period 2 years  
2010 Long Term Incentive Plan | Stock Only Stock Appreciation Rights (SOSARS)    
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]    
Number of shares reserved for future issuance 380,000us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
/ us-gaap_AwardTypeAxis
= us-gaap_StockAppreciationRightsSARSMember
/ us-gaap_PlanNameAxis
= avca_TwoThousandAndTenLongTermIncentivePlanMember
 
ZIP 17 0000919956-15-000014-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0000919956-15-000014-xbrl.zip M4$L#!!0````(`)N`IT9X9VTE]J8``'Y>"``1`!P`879C82TR,#$U,#,S,2YX M;6Q55`D``V7%2U5EQ4M5=7@+``$$)0X```0Y`0``[%U;4W7^@\?/ MXYBFFYLK.U-<$\^V(V_;V9G]E$+0LID@T`$DV^?7SVH$$B#0Q99DH9"'5**^ MKONWNIONC_]\'OHG$QK%7AC\=HH^<*?CO]=G>FWNF7EZ?__/2_ M__/Q[V=G_]9NKTZ,T!D/:9"/'G)X\EWE\8_3P91.#SY'D8_O8G] MCY-!&`UIY+^<@QTD"#P:2"*Q';LO#3#/*U#/E?&@CZ>]/?C8B1,YS2.`P1J=9?2<HSN'SK$;>`.3YOGE!:Q*:'RE((P",;#^C'<)#I/7D;T'"J=02T:>I&Y081'312(IY# M:5XQ]IQZ$J"@AH`X&44-]:&DIL$X/GNP[=&LS<".^^E$LH(:84-)%/HTKFV3 MEM0W8GRH;Y26U#5*(OK0R"?E',KSJJS`K2CYC)_3PE+5I+:J,*V:%*MZRQ0T MB!,[<&8J][R@HD\XK8T413E/2V=58[>N(G2+SO]]?77G/-*A/:_LK:Y\-IL- M^*B_?62#7<1IR2T=G*2#7SRFBL?]D0Z5UP$7[24OZ2_Y3Y[+?AQX-#I)IT)+9.2Z MJ5_^?OJ)@S\*\$D0/YY7&T]'.5\8)AME!*85NJ6!@1-18D"T^,3FRM2*0WD' M\[)B"QJXA?H8U'`^H#NKG?\V'S+_)>-0`\\NIRR[>[0C&O?&"9,4BWD'R\"I M,B49.\@9YF:]9B5O88>5\:,EY!>U86ODDS](&\@G9XC?-OE&2GY['`C9T(&0 M[3N03&5:83%D1Q:#VV$Q>`<6DSF,'QDL^W%K!P]4??;BV2_7]K,W'`^OZ;!/ MHWVR:68Q](%E:=/?IC^Z,/CSR/<<+YG.Z\3UH,XT]\LF?C$CY?13_E.)EH_G MM5UE8Y\O#GY(GFX-N7G!\7T'>4+D:D,F1` M^H<>4==+U(>(4E;0/D$N$G;ZB5%V44O9;L5:"KOXC!,V";N5^EL)N_-X2[!'IEY'VFX4-DCQX]Q_;G^O#9M^.'\.EWJ#!V?KZT3Q\: MZA,Z=X*T7_RS)_!(ZB&BQF9<['7T[E/X]YV"FG4>/"F4)YYMGL:#:]".YA2.6MUY06T-ZAQ#&G;^T=Z MDW*8:G;PL]HT#!Z`L4,V\/W+J)P*L*'B&_O%[ONTC7K5@!YJF;E4DS88M4D6 MV=AUPMC:T#6RG!O0HC#W"YCX#0$3OVWD7$U]FVRM(<#D#DA-K'`D%C@ MLVYHY+#F_7!"K[Q^&&UB8$<3L!MM;2O,W(^!'`:PV-6B3Q%8+(&0[7;YRW#C MOOW?;L%#76;0K0,<7P[0!.K`E;EAD+K1/@")WF``_M1EX+A]XFT$2ZN(;+,! MUV1['1SIX,BAP9$=A2[R![JV(\QUJUH')>WI1OE.3M9TDCXH2?\B$>V*)E"6 MK\>T3Y&.(9#5R:#->EZW\]:MVW;KMD>R;KO;'.39?B]2H[Z71'8" M7&%'Q]VQ3^^!38/('M*"/:RNW!YEGRK5>N3G*K@N_6UVKHMPD7U]1*.1'24O M7TOZ\"VP!P.P4_8)ELEF[M&XXB5S!O4&U[8_BFPG\1RVRSB.V'<)J:T%[CW( M\G(FU9(CO8G"`8V9Q&R_T,.59_?;BDQKV)GI5S,_M^7H7BF.N2]<3QZMUO^: M\UVOU>+42FXB.A@'+G4-Z`-:0A2Y"8$K+=3=5ZM/JMXK&/%KG1[+U>R/@IHU M>]J[+SH[D*';400\C2\#I_.SK_>S3=SLO&P+#.:OM0RF@R8=-.F,9A',=TI_ ME'JWYY10?;(CMV;S,DXBSP$/<9>$SL]O@9?$MW??VJ<2)?**^P9+Z&NU?&M" M:R?B/8OX($-'\;1FIQ'O9_2[^N3^-49_K*+]98V\&-EO?#LH9U+W3^']8SB. M[<`%(,3V,MEN"=L"@KR9$3VAK%'[M*)(:K[`OPFMK8[XZR&ZU"[4T2BBCI?N M=]QZ#X])?*?>WE62Z55ZRDE7;RI-7JNUR5K=::VM"UBK%,YD8 M4N'C@<`>NG!TS3ZX'5%'&3_>/MRZV&HB6":[U' M/3*+`@#=650;+6HFN".VJ/Q7",(9`A^K1M=X[3I[Y.Y'[TN;K**!#9DVU?%A M:S;0?+L[X^-%[\L>`1@G;_GB`V-VZQ7ZX5+OAYE.27NY2M_E+.K:EW&0Q!// M]ZGJVWU[:+?'M0)A%W6$9=K30-E^=_OQQKO]V[V'./,]_QK[+^N\W)"ZD.M> M&Z2_KB%?]_9IR-(.WF2H7O_3_"6H9K-'<-/RER_4]I-''6*Z3EGUFN^HC_P! MCR6?>*[%J#V$FN-\2,2H`3Q'!5O>&SQ4HXR\8921MQQEBH]+K((;B?,(.A8& MOT,V85?![;7]GS"ZB4*80/*B@UW$Y:O&I@>UM+'GL^=CJ^?RLW9WX_Y_J)/< MA[U(G=B>S^ZRLL*H!X7L4?*'*PJI3_5+WTK+4MWVN+Z5D*B.^]OR<_7"*]PM M5B>];0V^L?!+'S6OEOY^4];W?K[BLLL?WB=_J%Z/NXO`3'I.LDJLGR-*@Y3X M]N&_%7)M(FVO(1MQFX7L4OUMA>PN,=PG2),V!&G2;I8".E3>SB6]J?CX?XT# MNO8;G%\]YS$$(-921[YN`KV$S'U*7-Q)M.XD?D@2KSIU<4.G+N[$J7>([AT0 M7?D(#;<#XW_+DLH1B/45JQ5'EXC7/=NZ=._X[B>S`_?K.(K9>PWIBG9EG:S; M/]C&YG0SH[>UI-7M7[3&3"\[;_T>WGJWVU@;G]M1)^DI*8?^ND=V*BSH3NML MZCVZ('](ZMP%^:,]I%`Z&;4\9NMCWP]![;[3./G3BQZ\P+,K9@+R"(=TQD3- M]MF-RG>/E"9JX*JNFVJ6[1M>[/AA/(YHK+W`?T9A;/N?HW`\8E?S^V.V,3>]A$>BK9K5N:VO!;4?6V#0;T+MJ[DL?[6ME6;W^MH%5[+K7IP?NBCPF3 MZK;+X<2I^0E(X2.:!279KW\X MC%/,O#I:]F5*EQEVF>'AXE$6-;>.1X4.CW9X]-CPZ`%=/&F%?'F MT(RH-JGKC.3@H\[!Z/`[)1[CP)LJ\#AV2THRA'`,K/WDQ2'AD73Q[<[(>\F+ M"AVS;NIZ3:58VV]VF1X4OZ+;*_LI'GM)<\=9A5=T;=E.^LY[<]]YC5=T/KTW ML+GK:?DK.@[&"U:>M\YT`?[YBGZGQM`\X6GY*SH&=;NA47HA8ZEWUYN`.RDI M/6OS=3QDQAN6(N*Z2OJWTFPJ714&,6@0#KV@>9C,---;)%>.4^TM+YM3N(I' M&JTWR>G12>J^QG!H`O+ZT1O\T"/J+K6@2LU7##9EU!*E;.3DJIXO`ZC)HL*/ MFQ#\\A)CK=9<9[#I,6]V6A8H3].2Q]!W+YFFTSCY2I.O8>",V1,Q9)B7T MA,TA[2MUQY),"$3;C^<;S.CM%$`JT$B!(LF8-Q`OFT0%!*#+G"1F%(B&J$D+ M%$A$?CT%Y057/?1]"!>1[7]-O5UOT'L*JJGB2G(NOUI%B2!B8`G+NJ$C722B M)."<'J3K%E^@)W>%"&?4O&)V3:2QMSO#`?M-?8AH"GO*A-2L?S3M&$S-==9/ MAO_F).N:QILBTSW)(HHJ2*;,9R3SAHK$TT\WPE^U)-;,LD!0'=+Z;'O!51C' MO2#'9[U!;450@-[@WG[.8\(B]=/=R*(D^:(<10L;&J<1S%F<:BF(YW!&E""* MLEC6RWGDX3[,E'.[!.R/,<)RQJBJC`21<%CG)4D29873<\98BJR](V/R%P&F M!_]GCOK:?O:&XV&V`7##/@1(0^;8]M4@@+_]EPV-7-)5218-$^N&@7E%Y[%J MYFY7%H4%MXLD8>ZS7C_+.:73C(:QRXK"H3[E$7B%0D:2))'7'R>LL_OPQF9^ M,&47\Y(+;JW>'DJ.6I,T648FQTF";,H8*2HA&6^SU)YA5,% M7M60J.F:@47-F`4%4R!+.,&10^6$X?GCA+J;:H6%"`0`F2>*+/&*!;JASGA! M9%W8BU9D<]\'-Y9K!@8(I"H*SRL&,C!&6+6XG!LFQLML9'N:L80;`^C1!*R< MO%S3Y#$$G#P!E,P`%VL?#IA?2IT0&^3&]M92AY*+Y#55U31#YXFH6C)2."3F M,5'G9,-\V#(7@B'BY"U3 M.\VFX]Y@BLXOXWBA/X%\89RP?5*V:+DIO%$L@/-#G[&UV&4/-@/ ME!6OHS]E%B-+D0P%*R8V(7)@20C/ M\\J;B`[&H!>N`7U`2P9[TR65/,-L8AZG6;)N$DX`$[0DWN(9),V!=\U?F]]]T6^]^*=N1Q$P+*[YP/R5;"_< MW3R@<9QN>A1ZN/+L?DKP*@'(!A$`"A$)&1HQ$`)OGVNOSLMX8=$&K2F`!29N MC_-_K<7Y;X$]&``+P)3<='O5HPOG,=Z9][Q!>`'XK4N;M)-HLWS2P-;BHB08(*K4R5"-(+G M#ARI-2%57D[7JBENF\`5F$%!ND5,\%06;UBRH>@$D$*^,LAIN$J@3%;(;1/Z MTK6%?!TQ72V]I0%]LOUIU7)&_/:73Q!KCB>".VE#);(LX/A`+AC_Y+^K37 M6CA#Y359E@BGBIQ@&3*1U%Q-58.H@#/X&=!XY33F=``*G*)%P/<:T#KPZI?7 M"VNXD3[G0 MJAENJ:*JJY:(-)&`[8%N(PXX(8D69ZF0A"Y(GO`'P8K>V][D6V+L%I)%%>FR MK&@RIT+PT!D_%-E4#%X1JOS8*3N.[S*<1KYKB&BJ)(H&"XV*PHM$D2Q=TU4D MFH;$J56^*]S.^;[^+?R-5!F8ES7=D$6.5T4DR*HLR4R;+,%234-6JE1AK.R. MK#?=2MSL0#01&1@@BPXA,EV;)`QUB3H'/UJ6N!`==V8P;[KPL9$^B`:0B6). M,G3+4G13EK`&]*E8!Q?)6UR5/GEGD?&@WIUK5GFB$R3P@BRQ30P-88`3EBZ; M&'&ZJ%MHP9!WAI6J_-HNG8B3-!7+$B>:R!`0-A49L(-J:KR))4DWMD-GR8=F M:T8>W13!(L1AE?!$EBR1,TT-$\FU/9^(-?(:`L9HB5CCA`BB!96=8$S6<06 M34TVB,;5,+KJ^G?`Z$W?4VDDCZ@JSTDFTGA!L$S"`QYD<4TBHD009Z!W(N^8 M;P]IE(5`!,[B!1&L6E2)J(C@[T#5#%[3L4!*^W_S$]$'((TVFC5251;"3!&; M@J!A0<``?(#7`.M4'JO2._-Z"Z"<*)#$FKK)FYJI(QU2#!Z!94,TUT05]*J6 MPNH"P%LIG'Y`N&$<%T1B@5!DQ0('BP5)L;`\VQHFLE[CDT@U3UHZG[6GGQX7 MW73KU]`L"6*R!6K$JP(B.I>?ZL`&@*BZXZMKHI!T.HN3+^Z'S#9!LJ\M-L50 MEFCPQ))T03`LB[R##U+-!99.:!OSG]K^?>39?B]2H[Z7 M3!U#OK-T[PWI("HE"VM47N4S`&$12>(Q$B59D`#F`QK(#UH+$L*UO'D;:]AF M6-S0:K:+D6[Y-L'EX]BR(T@R1)TMUQ%.TTQ9U\1<+8G$2444MO@=0A7X;L34 MJDS"078Z(\Q.9VQJ8(33#=D`,^-DB^<44T3YYJ,I*Z53T8L?ALR.?37,I6:R M6?JE`J$QR/?*FS1N#U0^DRC/6S<$D969-,7>46%D"( M(E;GVCB5YFD7LD8(_B6W6#O_F<+=VL%#^9Z;_[+WI#U.)%G^%<3GA8D7=[1V MD>)LH=UN:*!GM!]-51985-G(=M$POWY>I)WI(R^?Q=$@=1=E;.<[(MY]K))? M@SF"&)SESEB&ZC,YQI`Q&4]#T#866Y=\&UOT_ M>&>+-EW M$P2&H[661*R+LF.RME&"PSFG>\/WJK@NBKNR#V%6W*"#4ER_7DRO/KPFG"@*IK)Z42J0^WDU$K?RTK"/ST[B.*M:5P0?\2I6OIS'Y9 MO^7EZ$O9YO77:'9=_F\>/Q>SJ_$\/_EYKCN=S,=7Y9/Z3;/RP_5@MF4!6X9W M>5?G*(_*7^W'CS.D60G2J_&[]XOYZU%SV$TK!N6K#^=C?^]*B;=>,9+ M=-'1"5_!OQ0&:XW2@*CYOA>3%AFVTVBI)1<\^(C7BS$+H2XO]4+I9L7;9I_E MI?CRD_,G<_[-7],!SH-S7'(OC6#1$BLE^OLE)2Y!XW\5F1KH1BPKC;<.Y(-2 M?K-YA1";T(Q@P)#,*FGI:GTLE/2=O:[RJ91GIWT?A<[-D6+^?-)?S?D@!Y^# M",R1:*34B@#SMK8UI711MQS\LQ_[-2G.1F3T*6Z*\2)'R)$\\?/'\2H`_DT0 M'5R,SI0V<^":0"[JK.*T46_EP"NBGXGB@W1Y.`[L+XXNSYU-B>2"AIS:TTE" MT!Y"BKR62(31;BOZ7-?B)-*=C8&_XOL6]2-_G4WGG;W+#W)I`MH\EM(H@2LG M)4$=76L*+;:2&V>^-"V4.!N5-_K1_F;F[[#CHZQUR0>6K``!P6L@=5MG4%9> MTO'IY,M/SC^`X\-T5@.^3]5V.SV:$^I)258`4 M^$*&6A>\E%Z9E("S&&TER#TQ";K. MAG@JOKNCL1S*LFZAG9<)TS?O1Y,5_;I!*1W5/#DYC<:S#E^B6_56KU9#XDJ> M#=Q9ZH$&%6,$IV50(1JZMFQHIS@73^L&T6^#3C\"WUX5^.CQU6*5L_T3*3]_ M]?K/`1.)&J:2]R90:K6R/@^&615=YKK%;@[RGQP\C(/=0ON(FQ<39RS/W>51 MYJD<*OAZ#@UCG'7QS3P5)YNV/_EVCIOGK5(2[6$E>5+,2`JVDIU!A^XXLWYJ MV(_&P=]&LP_%HM2@+VYNBCQ')#]B,-Z<+8_MDEPT)=Z\G][/E]5H,8.^K&"I MJK7P$X,M#L`]>B,!+Q2Q3G-JZQ%#E!FUV96[GD&F3Q:''40X`WG_B>=S.9KE M"E]")AX8R.\XYX-EWTDR`5PG$WD,T@"IVQ&8AJV(_9J.[.3#W<#V``K.#TQ8 M?JM)+!^(YJC72?`ASP-/J-TK/SM$DKJ%"YA]Z7].6IV/1=O)FF^5/T%I154P M*G)'-.2Q[55E#_7.=$YS/23)>#9"G8,Y2YJMH5@-)'P^R?<= M7]B4\>L@;*[TY`+_"\HICA>#5BXDS5-C'S][">3_3Z9M.YY#%-S+PV[ZS55? MQD8)RY*W7R_6+2,#(R4(KQ0#[@*K1W6[W'1]7"'5N>GSP_'C:T=PAI.Y7)CH MO)$N+0$)1OU@!V/#W?K:`CPIB)*2P'VT0:L4K*X"0AY-%G-I>EF&$:P[K\IV8EK?#,U^,%X>%3U6G&HAM7%6"TJ- M)%I4MP[O8S#?-5W(4,7U(_VR+SF-YU>CV[R>(RZW M$>_Q=.U%%";/X.$F,+R?AE>VLTQ2B\?/GCP!6B[K[GM2#4J87I7W:_F.)=,3 MOM:S1&S-,@W2&Z&YD<)H]+D]K2NMA)3F\;,_5F!T/J4#C@SIOE`(5#&&4.5" M8H$FFF<\5@?'R1QURY]J@Z-^2@.*)83[I*D_7"'!E">+RU M1;WS20TXLB#?X_$\RD03!,%CY)[2Q->#@8C)AP+(DS^V'YR_NGY>+"_MYYY-VX2@G*I=";&FC M=>WZ6OC%`$;;I-"PQ9^`AD\R(&J-*WES=R\%L=H).8!*B>X*J%_LU55^ M;;Y:E/!F-KHN_#'+DGD`(610*`R028E16M]%QIGTN^!JH$L%N@:5+O\;PW($9+X"2(UR;![\7B*"(3H1,P3B0"R6,0@H1: M_9+(&OU"'*BBK3"WP7("T+U+J),(#A`2*1QJ*&FM4;4AGUQCV`MGY1+J(X&> M%:OT5!X\=/">'-3F25DN(L\!V""U@BJ'%C5>K\:>/2IW(=T"X$#H!I;<"$Z] M,43EB>JY)5"@@5&EGIR!QAT[`+#[N_N\#_LZ%.M(#?[]MOQ,'LUYEZ7]OY<9 MO]7`HNPHY+&=V0?Z>'>XQ$AXF"T36=LPY#E-IG+P$#?2H#6>=N"[U#X+W`]$ MC+Y+8FDD7`L3%#"GC%;K*0%<&MM<`R-1KCXH,4H/..OZ6?$>3U"IZW:W9!YV M`)A13%CF8D(UAS9<0*NMPIG2W+O)VPMJD/.\049983#!UQH4A*RO$Z.(P>86QH-W1&U(YV M&X3H9`3ZSBI"22Q#J:.-!>1&%K%U]!1L8]TZ?IWB)R%P>SO]*\_13--9F-Z_ M7=SZ1,W==E(P=BZLT%VZSHN/\6*]+J[R$M=Q,8^?\PCNXGJY M<_WNX_VB5"DO;N)H-D&7<%Y%8]M\IWVL,.*YQUM%&4>-'WD.-ZXKF5+;R!:J M=T3$.0!_"%(,F'S*:Q\$=6A$.Z,!?7)3F7R4@Q7=.&2&#)CHRKGS@JG(] MF371[>*@6`L"QX!Y,6S[..:=EHGE<;V4.R)X@E3W$*(F;)QLIBZ!;;6T#J7* MV_%D^;8I6F;7J\^\F8TF\^7D3>B%8-J&9 M8I6`A%R1`CV$7CMU`_)1.L`HE11H$FF"`U4&I:\`962L=XT%)I0 M2@\Q\71>7(S;[6&-OPVW`^>&9ZN!4>,@"".]6W';2:H:)K@0@S?V=%9+?YU.K_]"=K0^Y/?B M;WJC4=6FI//8'$EM$*"XS&MN@83(92"-`5S[*.%S<&.+XWXT?X]OS#\V"HWL M`JDT^X+D[NCG97W>1C1&:A$)GN>@$Z+%JK0B(UHT)!E3>CM/MQ=,Y\""]YBZ M5%%`?Q(")!8#X\'7)7\5&[HZI':_X`;'HYH6W7#E'&=H2,F^XYZX>9\\Y M#0WW)/>4?ATL^MP.23@)@AB%C&"*>QV@"E%$1*R)1?[`);!8%K.@W)CE;1:A M6/X\./I$-5%YNXG6H(0U-C%6171I@J9D>$+-'NBT`W=&K(9RA\@BD%H&+[FA M>;5T'65@A-%&E.$)A7VXM"=:+V?37"]Y[;[\.4?I.$DH,2=7N7;Y:C'^5(K` M]G5^!W,OZXE$1^*%+I@'%7H M?'A&G!`I#Q[/B$L/"4PCCO]@*#\ORU$NP6O$D4DAB2`!'")*@55:0+H4FDG3 MYHD^&MA+HCW`Z;Q=5FOIB`DQ]RXQ%^LU@K'16CW(Z?.A7*\3.CNG?8@,S1/M M'/IAAA+A4UWUREDS&,DD&63UWM!>$N\!5B<:(#@PR5K$$JBUO!JAPHP/S50I M"-741F?"?'IW-UZ4U?!9#Y3O?E=,VM<+EF;/&@TTM6/6^I0)SPP@Y!4:/H2T MTZ'Q^-'G^?B7R?CV?QXO9O?%XT?_.!Z.TG#9(*?S$94ZC83H/*)>NSJQY)S8 M-1N'X5CE-ZMN@#IK@HKP%G^TE.NWUO!_*!.!2!Z*,+F11/J`3ST:J*AF10;;EALNN[]X!S/-B]9.?.AY1- MZA30F;!HD=%Z.`"Z?^&R8#^?S^_WH/1V+46RH"PJW*08'OZ\X[/.DQHGVK81 M2+:3A>\`Y#A@>Q?V66H-24ZZF[8BNJ40/+I3P=V*[>@$'R"HJ" MGJ#)KE$R6II+3:O4I##H0;=!#&(`XMU&@./`[B,T.#RY5`J22_(]#R+46>%( M*7-M8%/&3P;[B.A*]#SWY>3VP9BW+.C5;67T4)+52EM2ME3@:ZSYB]S MP>UT8A>+V?CM_:)L$YCFU:"(U&QZ>[O4HI``[I-$`Z$;X!ZS$K#N`H,\K@)`4Q!)7$ELGS747YF.%--ZG7"%XJW MBW4=-SZQK2RQ+06X_<%&SBT/I_N_:=4VOMZ8/9X4+U;[Y_%A.=?U9:,/_7T> M:_$)'0AT\@XOSEU^<&.>0'Y4U74U-*(S$IF;4#DU6@V_KL)>C?NHB:,>DAUI^3^WEQ[::SV?2O7.TP^HAH(5)[ MM`CW7.M7Q:?I[:?\?5OO&=H@YJD'XDF@3"3NO$!_IXYE4MH0;`!E^J/SAO?B MUJ0)^L:YHZ!4-XWSP_Z@OXV^#)^?)<+VW:PHZSH&ZR8-FC$L(_N/S=V/:>$!=ULP)-R]V[T`G0:\`-&8`0/@21T M4YA4UO*@ZBD1W`31=+L!VFE_"/#XKF6ATK&]Z98&-+6H]]I;SOY#WK4UMW'D MZO^R[Z[J^^5EJ_J:9(^]\B:;I/9IBY8HFW5DTD5*V?C?'X#4-,GI(6JGO, M$G8#]6O:J3MP5^D)CQ1/=U@V1E//,^0::3J=;&FT;:T259-651 MTWHW'DYT,R!<<,YN[K=_V/0X?CT>'5UCS)B)+&2,42J3C?4JQ-B8-]B$KD1@ M;#M:&,;9OCBZWM%_F,SF.)",PW;-=,UZSJ;^IWYZOUA.B^/N.JP"X=WNIK-_ M;[!L_->WB]M):3('?W`APN9DGNG(]59&.4]1.HR0VH4 MK0G!@ANH;@[9&C2[L-#[%;J=,7_^]OJ?Q"=<;_(>`?5NGIYQML87XBG8)P'? MZ3"+H=9(V=2T(=-O8R%B.$,'2.A,+EY`3#U.C\0($3>D?=Y(]-99)56&3$,] MI?&&*?X*Q(0!VKJD$J%C%"%KI?C'T47D- M/GOT'3S$QXHIZR2%"-_HF)M&N,`$K:JYD*1\8SZKLW/,#?V_GA*SVLN$WU MX^GA87$WG?\.,FF&RUP)PNUXNK17Z':E&9!!P:Y@$[HKT27J%:DF6@,%VE M.Y=42-,[NWPNI73@10VIB'BLMQNXQ+,4B1C&8Q-?1L-9U6+3+@UWDS&.U+XZ MB":,:9)P.4!0BF)GS'9_`N<8#1;Q^]XNVJZ1RT1 MYU`;$<1H6$O]WB)"&W$!;11P+>=(L/>C20IE%NUFF<'2?:9F',7'):R!6J9( MR$PXB^]'V,'8`!Z3-H[+8`EW4OR\9>/GZ1I-;V1S^&L1[4@O/->,L0'*= M_`X"33V#1H42^X6*7H+.)?_H)*NG)D)^[$GD!A./Y)JCDAQC'4L`6"LY.9'\ M]9:)=]/'3SA"B5-8>&?=_&<^7:X^S;[T=(P<.CX0?P=O*.7P7[142AY*W=/N MKZS?=AK(72:&DC6`F1-APJB"(Z$0.S-P%XSA<%>666+CJ[M1M`HX!X@81^BQ MH\(B7'Y42Q;@&G>")\@$RFN7R=4`NM3T=$+_Q,FFI]GJTUK^]_A\W=%J$'5B+ZS-D]`@SC\\%8Q&I!;.07&=I$J MYSAX78U]#W\"NGMN+7W^F_5PY&KDK'E.B8N<)2,\$!EH*!W8CG4\>6O=:I`_ MF^9K2Z!'P=A?SV2(V5,$IY#*EU!%Y62J:IZ5C,DK2F"_^+>9#7T"LSUC]#A: MI30N&$^&,DC77"A!0>#`=HU2W4)?[:?I;!;ZS%!3:B"NR=8'\'Y&BK+<*!CN M*]\GKTM_Z[EMNGHWFR^6ZWU;FP=>,/?];QET90_0I3$:O(X.QG$//M4)P=T"<-1[9@C*)YRS1BE>8-"#:+?_[DVNGW0.+L;T.2KFFB>' MF_T"%9%D\*IESE:BE[BDBJ_)Y7&5.BVD=,$[+A%\#L+GG5A,O(>BW".5VUP7P6:WN/HC,N3XH[N?#[2!: M9>$CEE%]YD$%:C1J)2`2ON+5,S(8"'D-:NF+5730D3N&FVLDS6:]^:S!JXJA M#NO:G6@ORM9W9?>$*B&T$0HROARYS#YO[!YN&\CJZU$0^XH.V'=K]Y1CPWE4 MWB;K`E7*0$@/6G$Y9L=MG8E3_0(&LI\"E)6G&],X.1B`V(9GSF+RU#B/DTFT MC.T'3FM(@G."@:.D?RN!]&$%4)/A0J;".$J5-AZ2EV:@3W5L`#S+2UY'(!?* MZ!"=.",(3,@Y.<(<*6]V4;-X$/4-'ZGI.'FA*MR?5SKX!9M MAJ.N#2.&9?@?T^1),LGV.\)%M7XVU^?8O8&\,`8<0.0T:J]4=$U[DB"LC6![ M*6U?ZI2?9>O!@I5[PY'D.C<>*AOAZ?J.;R$+`R?3U MX7YQ(VQD-,7`=?8RQ3*&+H+KZ/,XH.]>`K>+,T]K<=(L>)8L7/"""+%^D2WH MW5G6`/52VD,4;DD80^31!<9:*]PF1RQ<2@BHYVTIS&:CJLAM[QP"X@81L:72QP27#]@O_+;AU',NJ_9S)JO#.8+,JW#:Y\PH45+S]=6E M0M0QI;)HPGK$.W6"YT120%B55%6$BMM5+U;4_`^\SJ%\-7CB;J">P[]OTP?[G^:KYZ66'&%3TZ7?YS>Q@G'WEHM&(*6X_",PE3@ M60^@AYUSBCT5F MT0*9-O((4B=9)$E,::G5SE<'R;3]YVFT;]I<1CH(U:VSW$_;6.3+.Q0 M%P9R5N:MDM$YGIN>4X9_6GD+WLX1]G[^:;3U@2YDXN'6Q@&9Z."?4U5B$F6I MJN),(]LME(=I>SN%`&2*[T^XG&:Y1`C+=7&@;*Q9OTU!3C&?_F?RT(E=":)] M-UGVS=[_B('M'_C"Y1XF'R:?)Q609"8N1FHQ2J:$)H]SWCF`$V=@?]31O_SU MO?S7EJT1I%^!=?:WI_F4#GB?6POA[[/;3XN'R48.[;V9.XAC/H.CB9!&9XZ0 M=)%&$(3!W-\BL-MK%$1K'*;GH?+=S=[^/Q\EM\XK@MC4.5&#BC>*(9"H$2_$ M+W[PYAZ[F]!37^W8"^V9L])H03F#4Z\8(G-8SVR,@7B-^*ED!/O[Y%]'`MY3'F.'P+>7#W]'&P#=S\N!OD::8@NM:< MFN@#ER&"@P]6^Y!E%,:^YE-PANF#JS/!0F*J(;1E<,-YA6P;L(A(7'"O6=GB MYO:QS_Q_6$ZG\^/G/3O%$M$Y>L:]9('@H!9HGF2#:P;6^,GB58J@`:WN\X"/ MMY]F\]5B_C^3^6JRJ@3`DG86X0*9C,;!L5<.5X`KB`>84M9;U`& MP#/=39>KS5O):>E-YFE=ZS:$*&X\.'178)(](37P,+/$[,>/?02=2?VQ_`:\ M+;C;X%D(/&'-19>104DLZP!YEK95(QI+_:B1]Q@AC^`T44&]AKS!0M30Y&,Y M^2H=%A!3L$/D=@V)GSO4#MY:!IW!AVF:%(>+G#2/=U$343W8"&O$P=/00^!8 M4%OL_#2E_&C&[BB"(EK+9V77`@!^7[S2B@I"?7^>*JOSOC7O%CFI\>GY?3]XF%V M^_7Y`?=$8`*-&R6L3!I.*!=@/F%'I<)5A6I*9;=.#Y'3HGV[XJ&"P6MO`;C$ M"H3]I1IX3\C,--[+DAA/6-GU%7VNU^/6*Q5W&1C.V2;9XN2*K(%!)F:L`4_G M0U0J0EQ29LMIKA^Y=!M6;Q!KA9S)G[@HI%K_T*O4T:L=]ME%I%\(.`-+)DJ1 M4X2@NZS$(S5@OZKV])S"U;XX%O./_WQ&F.ATG_V@&MTJ+O.ICWGQM'R_F,T? M\W9KCONP0!#I#XN3$"]&GB9(58W0ACO!*1B)XT879!MNZF*GJ`[3CI!.D-X^ MQO>+2^_M]!'^KCDE/8,#(D5&*?=:R$24@=R_]$!P"1E25>BD1'V',AN^G687 M%318EZBBGJG`=4R4^()8S;@T=06[,NK+H6I"9R!#N=8=EY M7!U]PS.XTPKQ%FHREOLQO*\;J9S%.V!6XV@)Y^>D$`FE.=K=F&5GQYDRNINS?OHNS=JE]U&TQ",<]0DB M.>PQ]3EP7I`(&X$P"^Y\-D_K\W]_?PA7?X?7WJSR$9+H628.(9 MHET((9H'9YKXWB;*JPAHYY&_=`&X^?QI\A`@+EC"-[V=?3[0MOR/G5'$@$V! MT^67R?+QZ]\GGZ=;V?SR8T`C"9/EU[P]M/T[ND!XO0N8M:AQ_SN MG_#9G^Z`M]D]_&[/XMXO%_?3U6H]Z;CS#25E[0V#G2<4+I0(.05G'O*K4/`I M533]RT`'RK!7[L^)2?,A4"8("]%FOVOQ&`\JH7V$7PHQHERK"G&=G^9WT[L(WP&?!.>Y*77U[G+E,H(/-X2Y##>Z MD,&4BSQK4=5FKG..<9YF`W;R<3J__;KNS9X\_#J_P\(C'L^[XS?D@,"^XT7WV MW%)IN8/<"W="-$W"TE05`T84'.ERPL^ M7K%"I3R7%=R>.%E]6D,[@E7ZK[^N,)[-LSD<2'QI-MS-5AD[35[3>'RW)04G`6O4X4SIU09,V2\T+E&EI( M@A*K/( MZX9W[+J#4TOUMD-5U].C9VAX+.N;^QRA#M,Q!VF^;#G,!L5<5(+R1[2[YJ_-T$>.4&A&=$5+5 MXS0CF&HL.;_+MAZO54J-9/.")_0BQFFHM>"7*!-.@>?UUFQ7'01&:UBA,U0\ MEO?2@72&=68%UDD99@PN2I&,*&4=(7G]'$78RG/MWI9!E31`AC MHW&1LU(EY\+J6G>4\6_,TT7,DTA%@N'4)9R#M]RG2$J>TN6&A&5C^;S@&;V, M?4*\:HFAT03!(I.1IX(6&X*JA^G%H$ME).=;!(339VAB,()#1!>LIH$[9@OX M@E0^=FR#7S\6[+.R_?FG4-8G8HF3$`('CK5CQGHO"JPX[5AD]08N]C&$705X MF8'CSMYP\-8(J!I%5"6X"BK4MM'"K3^9PDOSUZ,79.V/R>QA\]&P^/QY,=_MQAR\+&O_0D*/S11DVCH&Y964TI5W M!ETO77A#V^_R)U)X6>YZU":UAJLV@64'3WR0G)7($.T)U8Q( MDQW-I.E7\":U\9:1X/9],8S@]I_= M,F3]#!R9(4P0[X1U*9=BKMQ#15__T+_\=6>IV0!R]LB_V>=PU'T6LZ&<0[@, MYLN%="#NQC$E2V,]/[Q_OCM(.)W$OM(*I&^$ZP0^TT#&XBRA);:W'0/SIE4L M&DQCF0QKIDC?S>98!<8_`;+ZAUO^"_!7]?^Q=ZW/;1M)_E]!>6]SNU6Q=MX/ MN^ZJYIG+51+[;&7W,RU!%F\ED@N2<71__?6`Q)`B0$*D(,6.\\&)+9'`KZ=[ M^C4]W1#-VP`>J/8&0B4J@O=I\!*X#83YMB'"&NU9S9[5>N`2GW(?-QJ*0?M& M;I70C-$@=NH8Y,]$^`>M+)G MZ<+CJ<`W#41.O0;@N7!1B)QB;WS M,AW?"VKKYC--2$RUB>U.XI+OA(\/A`DV>U:5U[#:=2%*HTLVQ2GS_UF.;L97 M=RD>F?]7>?FQ7$]+.:57O8Q,>ZP=8@J\=Q^X(4V]8P`_LB4K]9RQ7:(>!?G) M5Z"O`9NG&B4W"\(:H4BZ[Y;KEQQJ'WI@J3[+%3B%^QX\'PB,TR1?38)!F/CF M3--K%EK!',9Z&-J?ENJ^YC*&">6!=LR5],2)('/3+.[;63Q,!I+Y8Z@^>?H$ M4308@YEFZ;:^\4'E\T@P6J;=JP\_F+C.UMJG$='7;X(KKX0/2!D'ZHE0PANC MD%J%MX>7/7Q/[B?BL;<"M2#,1N<="T9X%(+'>3>!!]%JDB$H[]A./1?O'HST M\'U+",>T%=@([3D-@>3F4)28T`HX&?SXT4A/=1`X`9,?-8O>*:\1428W=Z1@ MN=HFBM*=`X?]2$X&?&AUL<<,6!X4K&U$\`\OFV#'(:MM6[]H=GAY#P%.OQO- MKQ\7NJ?"((9,5.GFT:I&3XQ"[MSLFB@Z5V(7D5+Q]/?*$5Y$(,%H1@9%F MVN8D-R6X':Q1W*'E>O&^'=W5E[KCM'I;32_*\K+N95M_>8A#4$G!\56<1R4M ML\HCRW)7'F;*X$\NYULIL./=(R0)94B#TB%4!^RL:Z2,IVD.+2FCN).4;CB/0MZ7402W M/B)*(5+BU@H=(FM8P"QK5Q%0R@=$GFKLZDZ3]:?-Y'+U@S)E*4YBA`X>]CEG M,4T(ER%2D:_J>!],^^Z$Z*.F#^+P)/9P##$K"%@ZH\#5L3JPS3`()KEN6;DG M(2\7B9Q6"B<"TD;$U,?:.H@FK30YE,>$M[+TBNYATWT<)X+M6W`A4I(7MG6P M#!'I6:Y`8=KACO[F[#%HZV7_?CY?IES=:SX$UX`$]:4] MTH9$$4+@P,'`88KR>&B.1)LMK;N:PY$%9GY65HN[MS>C2 M8\(`<2)XKP&LA.9<.Q\R4;Z=S9([5^P>#FTPBGK8A",$/`I",@E,22<4$%\V MN\=0UB[;9[C;!SF9I&;P'R1-+;&:D*8DZ#`(()GV9,2QK=#8R!C MG[1UX7D4]+ZR/K!AL$=L5`Y;+2AHLN9P%CQA,_1C0]PSVVU'UIJH/>"[_ M/KI9ELTDE-[`>;H&9"8^O=SLUQ<`T/_K^NZQ4&66$ZQYD:`'03W MW#FD?6YY82C>=I'F]9N:_B7[2-C%\RCH!]=1YK*VW-/BG MAYYL_]$K[KP45N,@%%5&@=!HFH-LB(10!^P>Q"L8)Z,]N,B(86\P1YI3[067 M7JC&A<91!O)D:-\L%_/%:)+.A(]<8,$<&"8.`H&U@F`_^GQP'@3FX7C(6U@> MA_O@4GOL@Y281(8,2[..J,]!)0WWQH\-BKO6-,>E0`483?#2#',LIBZD$`UG M+X`XU7+6]N*LWWT\MD/9SI#J^".+/EVN54XZE^TC9XBW/)3CL*6Y%9WS*D[* MT%,9([$LJ5P326KYF.MF&`^BW5^)[O38?@"BQU-PN(N$(CR=B$@L+:96,9(; M\6O>[I1(6B[NT11LNT9E^UJO#BIB-!RC5-C6`]Z+L4OTHD\7UTAWHKN7V*T4]BT>?F#,?6M MNQ",:JL@M$7!2`3&.0 MTNV]A0"($,ZB#6GO06B$!FBK<$=2^61X`^M-BPRA*P><(20\UP\2QM,,41^=-=N1<=.UV$A`3TM-@ M;XT<2_>;3FL93&@4RGGDHA$!_/W<%=%)*5M@E;AOE3LAG`+R8,]KGBZ(I*++ M(*,A5)$\/X<9HULI^I3*.!;D+!]&]'E9QSL^'BL!HFRL!!/'+"/YRE=P5K9; M=I/=-7XXN`&IZK\QZT!RB7".U-%*P/DFOQ4=]:44X:'(6HS&D_(RC*H)."1S MV!O+V^5-RO7Y\FI\L=OTJF\/(&M3WQPL@0+!$-/`J(82HD3[=@LG.V.X^A$] MFH##UA0AX9B2%H6(9"!&Y1,?[=I]DU]RM3-3[T@"ND:\G:1^%%(Z@O,OL"!@ M5:6@F[,JJ]NS/S%6]/[>/@#E=,B'%IN`=&"BHP3M'IGD0N1.SAR\U?99+4%2 M#@;YU%([ZH5%EBD>C20>(UCOW*O+8MRN!V9$J%[4>ZK7C@5^<+FE\UZF257* M&D0I8=E3!'UCVX?Y*^5_(O#.^.=XA0_&RDALO;:PS$@(FN^7<`7_ZSX3VT+< M">,DI'W5N%:`O1=<&6FE=-S+3:D$T^W:E-VV0"SSJ]'DW7T">[153E>I'O<;\MJ/-U[5)[O5]7/;;5$#K>SF^E= MN:J?Z>LBC;6V$`4@01$#EP0D,WEJXCM?R,:_&%\6`SPK7FPL^PB/-W M[W_NX091BENL`@W: M1^.JXRQ@J,U"MFV.P093XKD)7!$KO-WL%4GHCNK>/M;M5S'/O5J_'P8^>*=M ML](3!EX#9P%1<'Z3/<[%*LRCW2G!?[`2(-4OGN]7B^P$9O6HPYB2)%XR9+46 MGCGP/7*M/P^QRSCM.GG/M!R?"0\&=P^PQP$>2PW!@J,`1BGZ?,9!C.G@P,YT M]C\X\-A=$#BQ#E&<8F&FG"`^Y*$)$.AWE85(]@GL+,47PX#3C-2CCO*4?2ICV10','>R0Z# MU_>NU#6LP+LYQJ^-%]N=YQ^_&1`A!-14&C"61G,&R7-[U0UV9@SQ5$_C:\6-FI[R<756J:Y,O5_Y\C MFN1(&*P]HHP(;1UAJ#EBY5'H+N_YN79%]YI\B0PY;9L@HQSU$G'*L*5@NH7. MM2F4WKM`_E6QYN_U]GS&C(ME4=;WD:6&2-,[[/,0(JY$Z#H"V"FO>*[%^)(X M<-JFB(@3(BFI:_$15BJ@?.X9'>O*O'#Y]?#B,XCV(:9GT8$]<5%K9CG66Q8E MTKW1/C]#^OFY]+F$AL_#QI."?0:1BI=$P-;36%IKD,@353G>K4;99BACOUN& MYCZX.]<03_&B5VTV9K,*EK]^_[M$POR]>?=^9PY<*HZ]/SSN_-/T_'JZG(\F MEVGV5CEIRMQRS7WZ3N_H^!@L,R+-&D$!:UP/CV^*O,'MZ#I34`.%I_M6\K?D M4]\ZA\2@U27@975Q#2]]R"J3J*C%R#*ON$9>,4)RXS1L5=?)S>Y0J:]JE=,@ M\I/$F1HP0_.;-V%J2_)A%_+ZF(, M`@=ZO'R7T/PP_516J[_MG<:ZWS2LYH!N7;A)=W3V**11U1I,>3HA]JY-2C>B M]N?>3#IFY]ZK"T%."Y;N:D=A"0N"Y2YBS""^UV9A=,9ZI6`8/OTA$`,*!"B. M'J]40>R&=?#".4P]DMSE1AS:Q+T"0?9[&N3AUX%@2U1)!57FFB= M,$S)W"HAI\9(WI[$A+'D.U43+01' M`SQXHS`-3V!($(R"Q;!/29ZVY#!J-W'&F&AQ#,#S\G8VK4;5W>IW:09ZW6[[ M-EV"NS_#Z.WH^-L046-BD<2IA:^(//4=S@N,-&FU,]P"?C2RH>DZQ!>*%,B" MLCPB%=/`DX@:NBR)^%`ONT'IZ@\U#O:=40`YM1X"*@B2P5+XTX0("O[;E4>\ M)UT]1$A)&V*R4U]H9%99A#T6L?8QY:Z)D\ M13SV(D^G5MH> M-UI/5-P+L)W>?0B^0\:.>UB]0+TEQJ3Z*1QHHVKK";>/Q;>3K&YR1WY\LTPY M^L-;ZB%=D9#6U-`@N5(&!<(YS7=?"6-=I_M2^0D![V`4!Z6Y1$6774/#V7J4=1. MJW]"Y+`=QS5#->[65ZGAFZ?>.=8R2.0MBIIR"VX<9S@WON/6MJ8W,':_-7,$C7UZ-;LCR>OZ=W/P M0E]A-%N\?O'-Q\7KG:_?C"?ER^N:OZ\P07_>^YWT\ZYWCB?70/-B]WN)S)?` MK>EJC.&K90K2T\M63_SAS4_?O3P/[WXL?+#GA?G)%]__!/\.[\^+=^8\%.__ M8=ZFU_XM/;?!\#<`_A`:9J/+)(\O%]/9*S'[=2B:ZN^=7Y=%DI/1Y*ZX'LV+ MT<>JK(\PYL6G\>*Z&!7S.]@-%Z-%64ROB@^CR3_GQ=6T@E_<3JO%1]@_Q0($ MIKB9CB;%7UZ\J<8?QY/13?%C\]L?X!I^??WG1R%&76`]%`T'#TI"%;@/_WAY:B6KJW3X?K[LWI#$,H_E\ MFA*U\/%:!21QZR0_B_GNTXM/9>K!O6JB4RVHT>,9_DKG=UBG66I?=EE>'A#0C(?RN/!5=;:7G^A,GH[6J1>6V"\KJOI\N-U86;5^*:@J+:*8!N' MT;0/Y@Z1W_(AN=/2D=UTGM7&OUMJ:_\L;^8OCL]%XC-LVUI.@>C)Q7@&6R_Q M=9P&?X-W5LQ&=RG'#Q[79'%]@-*--@.W&\P8-/-4PO+%&_=/1OK%M?C:@&QW3"[;?II`O`GL.?J M$+=,7`,CTO"KS/.O5O[!S1B"RNDZVF@ZZ%:Y_^I:2:7+6JLG';*W>\.;%"-< MI"[/+V%-$HYJ%>:L'M:5X6@]HK;EN\H#P'W)UF!ERN_)7!<+FD\M/_POV(.T MXVY2!X"]N(!%^P`KM74NL,P10]6L;C:NF^1( M^E%1K:\XI#*@L_8"?P[Q3VBL9%&KP&*M^=A.BJN6F]IQ6BFL]\!96-=:SNKM ML*/([N6_MA(#N]^K$P/GG0]3P]?[$5X]GBS+]'L(O"$ZG\_SJ]-S+ZY3C5IZ:M+DU?QZ/$L?O(#/ M@:1MI/V_ES=-.K=/UL_!P)P@ZCM?RY*^^[C;T3_72=89*)3Q=#D'9(WT;V1_ M][5_2/]G)/T@XL4,`N71I#Y\6\G@FF$="?//9C]\EB;I]^;Y;\Z[+@?:FG+8 MG9DE='[0T=DZ,%N+82JC!=JJE7P.=+(RK%G:)F@TBS_6P19.1:PG._[?W MI;^-W$C?G_V]G%\[$M418SK6ZE#WO\ M_O5O%]3E*R^NCXI$A5X(Z_@H M."\A/F1;C4Q!TPOX1(ONLE252VL:"7# MG9MKASBB$;O8(FEC']%)W=9>EK#VH\T=$6E`S$JMO1<()(-!&)70M"]=K[1; M.O,FB@N4[U08C#1O5\7L1NP^S.9#H6EO@\I\!-T.3J$U!J_)'7(`UJ$'$&XG M>])3#P-Z<:CI48BZ3"22S@/J_2EWA00.[6`";YIY`QXST)414CP/-" M^)")EV"ZHB66+,BK(^!<[@KCS^%"""3P.XX51/#>9(#$25E.JC?TL9+\B)=_ M$EDO0_FD9,OO!A?^%G>'[GS;#6P1A#12'L#=`QC.D"$0OX@RM,:0PG+WLA M^OFIC$W8Z($E2I&ILZ>$&'DB<*`&(JZK@+\OO[%_,!!5'L3F/<:3-PX7B:6?GZ]8]:8RX=0RQZ`1,PON*Z=&YWHOY!+;07V=ZZF$P@5S"L>PV4Z?NQ$!A/&0CG2 MC,.>C=8M4_`.'D1](,NDSQMNMYMZ<[25W27!-17LN1R>17Y*3;A);(RA-6?= M`S"/N<:\]&:SIS'U:A"\S,,+,@,*TPI]>Q2G3DYM_SM,G/V0<5^)PAD!Y$$6 MBR.1:6-G$#63A3GB@33`1SE?U7:>05>AO/`@^9A?)W2??7![T-+)I7:_:$;B MH1[U[=(1E1>$ZRA1V`" M0P?TN"S]`?CYPAY!L33B<6<(..'@FH,H/N,X1#3/'Z5N.%Y\.;@]M1XB+K\. M8#7&G@^_P>6#VS.KUZA5WLQ[*UQ0;&YIR?KFKZ+@6%#6(#=M!E-(7I%AG66N8J9N!QCR'-2/'\@=(_BH)ES159O4 MU[.-=G(/DA1\YXZ3R>E+HM,PU63<_P(6C8;?GU^**>A23WHW;Q,>$]BECA!_ M7B@VC%DR*9[$:D-<7,2E:U%VRTZ%%X5E*B.9CB%#CM+%FJGFHLF.%;@;Z!N) M!RP\W>*Y?,,3SP4'0_P@3&^5CJB%`O6>'EX1-0!I78BTSP;10P1X+<6C$U>% M8$A6J(8\H.=]RDH295*Q5YD2J,G=CO-Z]676`^\PZYL'P^N+G8QQY`N3D[OP M:2IUE,\>;'\4;RW-84*88818R%Y&[/CO7SYN7@V>JX\_12,"G-US%@Q]+OJ8 MP0.PHCZX&E_#"L&M8@:;%)/W.LW+P6EST+YHG)Y?G/?;IXV+I"W3Z5G]0(K) MSZZ^W5Y]^7P^N/M\]4W4DI\.;C_?6E>7UO7-Q>W%MSOY"WR^_/QM\.WL\^"+ M=0M?7GR%WVZ-5&V)L37O;Z6;*")A3X:&E,\GT]-F3)(ID+(>[Y3.Z;Q_,-L) M)^+/6[EA(J_'2$L0W0=\Q`$C,&Z+FR)/$\]QGD]$;CG8U[A-PA]<,/2&MJBT MAH$.XT!._$(1)DY#]P%@YB.6BC(7]W$!4V3@V`S2B4CTOKA"IW8-4^2&NFQ!24WK#P_(9SVB^O:9V$A0"28?A`H:QMX# M(IKT-$2$3#8!G+)PXHWB#/&1`(][254$PM33[9FW`;0%GR,-1*7K!&P#6?.& M2\*]$6ZSH/MV$($$7,ZB)J(MXZN21I[@(L;=C+S/?":3[.Z?L^:I-#"\"+S6 M2*1J9"O%1-Y!Y"A8`KV-822!(TI3*TN1JRLNE+..#Y]R\$(12\Z8+[:@LR8` M7CSVO-!%2P'=<\=#'P^C`'")([/UDQ#:4CY,YK/$>542BX*J:C9Q#@_,Q:(7 MD88VQ`3SI,0?CXV`3[?X=#&WP11H/+0SY,/"`N8*T\RWO"D/\88LK<2>]5)B M80VE4@M@Q$DS![2Y+=NNQZ1,UB.N`A(?<0KKRV:&>7/HM(F<7V';B."`\[PR;I.^4NS\BW4\C+!A)=E/E?G4@@[$IICM/3S?7''Y9#1":F($F(ET?]XUB:T:6>8H]=)7"F/'&P0**EU6$ M#Z?V,U;ELA\SF0XE&\2-(["=L`V&@*I@$\\H`#/:P2YA\!X[]JI=-A\#7U_: M84W00!9;43X3F6NI4;S*2E/U#S<,6UQ@'/$2D-2JUT[^E?#O&`QN6\ZR8![> M-:2L&2C)X[+U3C;M_)&[NF>86>RA3.5-FI%6:L-+BZ:EQ?]UOGY MY?E%K=9IIP=LM9MG!Q(]O+V[.OO7R>G@]N+<.KOZ>GWQ[5:$"[=6$.)]ML,? MW$_H\_#QLU85@??=^];0`0GZ]1VR][N/R1#-&J_\N+"Y>/6(`4=@#20BJHSF"P*OC=+ M@\,R)4?T_4T]&;D)9.,I-4'52MO+)2]Y^\:[(&97YR:B[%T\%\_XFTA-!B], M33V-J""\^H]*\2)UA/TO$H"9.CE&U!O)**NDA?6`IU_*9?.90!$L^0.5+7X( MLD5],UP+T.Y<0TV?W"/41"?14BPMM!^)Z@KX0TU!]*&TT[,T5+QND8C1VRTBO)7%9=:HLF\%9](*:4+N>5?[-FZ9GZ`YI63 M$]`E=RR*ZK+'J@:,J9$O5@.-1B"Y+\Y^$J&R^*:UF!UN&*6(@\(^'O,A4Q_T M,&6[>`D.7A3@!*R6D#GNT[)D`11JXN8+QR9[*MV:.:K?3A1R[%>$S9W!8)?Y M39DN;F)?/+`=VW^NQ+GI$DH]-PHJ&+6-ET+D/R;*(KNH655WFI M(Y5]$),-M_V5TQPW*E(N\LO,@-ME:4Q>RS3#)V]W&)V9LJQTBT1875;)B<1_ MR3-/'/21T',BHIQ@AZR3Q?T.1!IW!%PY\9X86&*5./:<9S1`BE#L[X;Q4]'9 MOWD=.T47&]/!DL"66KT0Q!&.1=X&Z.L(T.;AO+?8P1#V:>V-,8Q[,) MERXD+/$W+U90JIW5U!Z](NV6/<8*5=DLM-&.FX5JC/OL7F^IP=?J-2V&9KVV MKJ$)5\YKKPH@+:*D:E.&'1D>L0_P\YS09KA!E%@JW5NO*?A-'KZ&J6IGCD!4 MO%S9SHK-F;%J`)K,V&:OG&;L]A8<.;BO.+CJA,;?)&0A2_XG3I+6X^OJSC8Z ME_A;8!#VF$/'VX*YP%P0=J4*18\2L;>./_P0*?P:;)EUR='56=59X#)V]%6: M9.`Z8S_->V%#E8/"IC/'>V8J1T-6;@>KUQNS)]#;D`V@E]6`+7H,J`$SA2FJ M`'R%W8T_R5CHLSPM3`Y;/2G,V9Z)4UK-F]OIJ\/G&1B+:$QCYEYQC8R:NGP4 M5VU/^$%8P8ZLV,Q3FK/8[1`,69$\*7(BIR8OWBC2A82Y6TEM=$S%\7&MW:4V.K#(/>9.B;1!+I.10$>HVM^4 M-W,,*8P#]<9*MJ=L;B08D`BRR5891ED81G4%2^#`T,8,G8RS@/7)CY[<$9/> M"6XLQZ6!*0<"17,CQ;2B;#=:2[;ZFB(B&MJ9]C::8ELSC*-A"NRCJJ7-I&_F M@@$8,PS0+U4I46AI,S"1/^F;7<82DAU\UMF7B1_BL''XJ18_A6-*FOR?6MT6C.=>E(C(=M2S@'V*_\B2")^5&;B?_(48C\-U?WW7?6?YX,6( MO^O)M1_#4?JGO_0)8C"_OFNT@#JY9Z3/7OJ\]-9ZK;?MK:UM;^P7?^/6=VXX MR54+I5CQ$>,AH.`4;]Q[8>A-?\[)!@8%LHR?_2ROSWTE.1._>768&6G$ID:8 M:_9IPD<@@7H]KV1G_.6][!RUD^$VWA5.JS+0A_AG3?YI&L$_ZZO(;6(%3U)+ MWH-%*!\4'ZVZ+L$(I0X"I0KFLBL9+?U(L$6PI86AU$G0A%J&H)9R9Q0EZK,? MELCOM.(`RD$RX>W5[>#FY8`Z8=I.,.THV>TBWE&[Q@CJ3J'OWAY^?_"]R!V= MJ$#H<,C8>+P')IV/A^ADTJNT&W:6I!.TUTJ[1G=YHSS= M1#*%5_"^C7>%]\4E!Z87M.M-X[GMKX6Q51FPIE/M=`EH#LO7V24)?Y,91OM$ M&&-D)ZF/:VA#7%.6>=F:Q"#[-==TC9VPK4IE\/T#M_W M"W$.%_ED=T32SDH?C&2A8U5@NY/#HF6O5ZWWR5LB;VE]E383QY)B<2#6;V"O M9VW\LX-`O3%*;@8QGVDEM7J;R''7Q=$[V"CL-+3Z@EN3>!?D,@X`2B3KQFG'A;Z'X>@98Z4T6GKW];:FHBFL1NZ:H7JU6'?- M%'8LAT=F#)R!T]79/\5,81Z-?M5'T65CZ?5K=@[9^\2HK0FU-:&V)M369.^> ML)D1EKW3A_BG5)$4:FMRV%Q&*$4H12A%74R,9C(S0*I@)KM)^J(2;A%N:6$I M45]KG=LA09_Q)`UJOJ0['9N:+VU$NWIS M^9D_5.5G`)<VY^HT,@M/M7RT'7#TM85\#M0[)-^0 M?$.SU-3A=%>J-ZL]\H?('UJ;A/\1QW*2.P3WO6]W=:JFQ37?'3',[?Y':NB` MO:5VM:5M*\04SB=G:7>T/2NZ@=]A>E![Z$!V\*9@B22TO`KN5O9K))]M7[8:D^\%$VJZJU>L>T?CJ$=E7GR:9SZ.PQY-#A/95T2EA[!>M5^ MD^"K\*X/A0WLI:X-&2K^$04A'S_OGY!['.]M-)W:/GPWLNQAR!]Y^&QY8RN< M,"LM&;)$BKWUN\O#P!I[OOCY-O2&WZWK"*PK&X^C=6S7XH%EXQ4.Z(W@DXXY M'VTGC4Z_VFUTVIU&^R=C^FFT:S]MURVBT=SRQOJV+RSZ?<6\L"2NG7&FHV&U MG\;1A_AG3?XYRD)/:J-!*&4"?8A_"*6HC88I3&8&2%$;C0-BJ:/$+6JC81QT M'65?@TR,C["M>&P[2IZC7AHZ&91Z:6Q/NU:'RJ7B>9K&)`>F$K2K3..YC5II MY+/YFU0Z=F"^#K72*$9VFEK5M"DKO&MM3$KW@(O#J)4&N8D;T99::6PL8N0; MDF]HEIHZG!(O:J5!_M!&)*16&FDKC4:#6FE0*PWREC8(OM7ZY"R1L[0N;:F5 MAK%U_-1*HS026EX%MS]Q)1$MOXB2MT:M.'8ILQV]D4DJ93=2/(W3GH^XG)(1\X=(,YFU&7A'-2\Z\Z8RY@7@+?ICR,&0L[GQRZMG^"#^< MS7Q0QB/K`5.R`KQ"=D&Y<`KF%#+I]\@PL26.]C MWZI1^_GVZG9P$R1?U'_^8(%U'#]GAK?!VT(QCJGM?V>A-?/Y,!D;CMQVG_\6 M`$9-I_".0-P)?^"O8F#6R`Y9U;+NL$N+>)UX1?SP1Q:$A:U;L_F3EF6+)SCF M?A!6K`#>!5/":843[N-?+@>U$-@^9T%,JY0:%7$I^S&#!7WSW.6VY:+9O=6\ MGD'B`VOL>].U%_")P20>L6I"4L!'PH_@`Y&7HA;8CYO'@REY$\(C(S7PQS`JLSQQY MJY`\)TNPQ%KPV=0&&?8R<5A;6$A:1B%"NFD0 M:65L=YMG2VR1W00%-HB>?$'T`85PC51*CO7R$ MH$Z*;^FDV.M5&[VZSCZ*]?X;&RG6^P7W)]SZOJ(;-VY]7ZLL`SWX"99FH&;+ M1$GVCLNU.47T.?)N2YOVLB2&6I^AS.@(9QQ]B']*!4C&T8?XA_"'^(?P9R_T M(2^$A.X(A,[L7M7$3V0$$!X1'NT,CSZ[H<_=@`^)HPB1")&,H`\ATD:(5!)' MI>CS*FSW`3.M2"Y)+K4PU(5*JB2&.E1#81_'G]")$X1/>MA)'"9Q0DQ%&$48 M50)V(HS:I7NSAS.%S')_8FO5NL;"'I+@/4CP49YK1>QF:K^N@V2W3(\EXCF" M..*Y\O,(YPSE.>HG_(+/=+JM6JKAET,_EJO5]O:>G$;1#[C M!%P[`!K?MY4.G,RU*JI7EW0KHA-6"&F*;0QZD)WMVUI/8"'I(NDB/4YZ?+D> M;[4(:PAK]H\UI,E)NDBZ2).3)B=-3N?H%"1`C6JS*^*FG6I#VWGOA,7ZZ6,, MQ^@F0AF0M5UM:X-54Q9RUY8:@8`Q(*!?(!KUFDY3@V2"9((48PD58[W2;6L] M+="4U20D.!HDV(%4]+LD$R03)98)THYZM&-';TC.E-7<2^2-0O^T9[+'-.4" MB5@&PAE#K+)QW,N$>_6T89V4+<=ISHV.WBWTK4E\%"<]DVB3,C$,$XGC2)EH M4R:M/BD34B8E$&U2)ML0+A-9^"C.B%QV?6&BD"'3PB&:V<6H(Z%U$NX63RL] MD66+>Z"2<*K\41EYC+? M=L25]FC*71Z$>`;M(TL>Z/F6-Q,'9;L/R9=R`-%,'0<]=.P@X&-@83$6>+!X M?VZ`XMQE=1QU?"([F\X<[YFQ('\N=')"O3SH/7AMSAH.91VN>1[O7^OM]E(] ML\UB%GJ2\%_KK>4;>EN-G,N%+VKPX<1GBP756XU\"E].U"'I@<5BRUSP(\_!T@QWE^^0SV^.]?/D;!R8-MSSZ=\V#H>$'DLZOQ6089;B2^ MG'E!&-Q.;)^=(GA38@E8OTNV'C7]]=GN,R_[O^?W?G[RP^@B_L87C2J)_VF^?M M5N>BWV[7+P;ULPOXI]FX[/:;[5J_]>[OIM!?U%0=W8HJ/G<; M%`NN+@^?$:<1--B?$7[*:P?'=@-45C/@!R8.)[]G:'PLLO0V>AAG1X=;3SZU MNJW4HQN^]6#K[AO/M6ZT@#I;'HY;ZVU[:VO;&_O%W[CUG1M.LB09\V:Y).8U MNC6./L0_FF(!Q?"/X:!PCH18UM]3/ MA+=7MX,;ZAF]CVV98V2W?&O\G4*?07N'N]R"S71$KECG;,BF]\RW5$AX,;AJ MPD:L.9O]7:VU20??$*%$(F><7M"N-XWG-FJ^DKVO4^UT"6@.R]?9)0G%04WK MQ[0,J@W3+SL2<'N->D,;XIJRS+M6R:1Y=QNVW,"_(KDP78,89+_NDK:Q$ZY- MN1RF=_A>;R;X:S1*^61W1-+.2A^,9*%C56"[D\.B9:]7K>_^D!93A(B\)0TJ M;<9]-L(L\Z'M8B:<1NVV@T"],4IN!R;D:_0RA6?(]3)(<^U:QDBN2B-7Y+JM MN=LGRD"LE=4?5!5,+29*"0`EDG7C-.[;^$[K/F0I>%7?)N6;8;/T*-FI=AK[ M)V(SKZGHSO56"YNT+O;WHQBA:$5]MP5=F9+6;2RMR]%[=H\-" MW\-P](RQ4HSI\&0*JY&[9JA>+=9=,X4=R^&1&0-GX'1U]D\Q4YA'HU^UNCW8 MNIU#]C^Q%SO=:.A.,]_Y9N8%MO,;,,@L^"RZA8'4X"MA?-R-V.A*=@#SW"`= MR":M;EK=VGFM?MYHUKKMRWZOU6N=GZI6-^W+LWYGYZUN-"WI?$K;[8MKO8]6/PBM M_W!L'<-M2[(%QWF^>0(*F7ISJFZN+8]^8WP\EJVEK,',YX[5E,55%=&&*.XV M)ZKGV,CB;NA9MFO90U M8GWY(0K+L">? MYX[$R1ANW%;F!$XLNO=@!$L[XP M?/G[=]F/[SY(0EU-V8,MGLC\*8PY9.+9CKC%9EJ_X47+G#9-DL>/GE: MGF-Y,%I_U4IQAC3,KU#%$L2Q0)P`DP$@!H^U4]?2T MZA4F//^,8+7JRV0'>W@Y##D"OPU!`P78[`5;4L7%]/A\.3 M>YC4%G)JC3T?I@+JE&$S,^`%'>TII8%=[U3:M>7G,V[SO'S33=L)O#P6XI)> M\G'(&'9,',RC1`X#CE7D4<0!5X>1[P-IG$5MXB66DQ2/,;QA3J4`98%/X-I_ M,-N!SV=@N@%U75M:)T@ M[>?'YY&-D;0Y72@X-]5;+(8J!YO'CJ*A`B3;=2-0EK@TUDQU?[1&$;.$W;;( MQ??/NB2UTM/4_NS_AR]X_(S8"[;/SKB>>HX01BK;(*0G;]G6#'8`?S M.^,K]9"YAR36U]1VZOGA`T@=D`XE-TW9L52?XYP^BY4!D*<4^OQN3D,#6D2. M$CK;>K#A?VJ:H]3RQ_7*S?IIPH<30"/DKI0/Y+,"O#H#>*@*X5>X>U'D*_EF MG_@D%/Z,SVFE3F<\L)QA>HO,*D4:7IM>K-`!GAW:/W+SRMDG8"?K8<)NI=U8 MGF6TI:R+A8*AQ^VMP=;WAMR.R22F(J:E;PZ-2K??U"=(N/""4?)8('J\HEJ< MS0"H77!@TL[B`"2!!=#E/\/-&*L`]O&]*4BA;XT8:$U4JD@5X?F(QX";@P(: MS4X0^@+T99[9K1TR./X:D1(;QS[*`#(?U!893'YSEX_@R#GFS-(R-> M>@(7+A(8F.IZI?+2F((;\)%PHJ3Q@)B*3X&7#K&C^[SQH:;Z-VL M(%V0/:8BU32`_R(<\S1A0!(F?=68!'Q-S4QS&`%;R<%4Y<-\PC-<\']-9(3AY5T<&4'X@]C$7 M/=#XR;%89`#RS\CVT>T$`XZ'ZCB4(!X1^P'?)<;/P/^.MDJ6SY1MY0U%V$&( M]BV;A;*#&$!0,W:0X\;[RKI.'C7S.3;G%]YR[M4@.@\@FL'BP++>$%PUAHND M2#KT#F&%V`G8;$APGTUM*8+V M<.A%:-'[;,CX(V[DR;FLL'00"`7\Z5/5]6[32%W]OE/7:420MC;I%),W[;_F M-G,O;!\E*;AFOM@#WF27]ORL/SCKG5]VFA>MWFF[?CIH7JA=VD:GWAH#FV^=OO]U:[[];H/D_ELSO&TT72 M\%LFV`MF#A\*L1AQ)X^+P#<8-IS"70&RPY(C5F3PSXL">`"H-/9C"+I$W"CN M^+0U.=)I]+>;?7K;>BE:+PV&3G^9?.JVJ\U^K=-H_Z3M")C^&X^`Z71^VO(` MF&WO:Q7]0II@"0M@5CLAO>VPK+B:78]?1"OJ.SP+T/H*OTT"ZP)M M5GSTLAR[)/U^`TH;QH=F)3Z71'A7595-2WRXV>;]$4(Z8P/^L+QL'L MJ=Q7L$.Y=R!",:&7RYF3Z9?BSUOF/_(A9BE]=H?57`1M`HX(W/)R6&Q;^2]P M<8QG;RI/+4+C$,<1Q^U'$^6)5BN":G,/;.T\VR";329V]-6.GL@I7B^;PLRS M0LRM'B]3#;@V)\N455P5B263W]PHF"F\]W$?2''L$+'+J$`A M1MHNN>P+"X)/<>KT?"P`U)7(+?0<1R2$JC3E3N`PB% M"(7F4:A>J=>*.W*6<(AP*&>+ZCR7EQK*"N:CAK+I$ZBA['%.D)K='5P72FHH M>X3F`0GOYL)K1C]!]19AGRR\@MI8'H:D$MM1CTOC%000Q:1MH4(V..9/>*'& ME'N/K9K#@<81CCB..,YH]9&GV/SYE*53$]?SYW\EQ7+UG^6Y8;L07I)1LN2( M?XA_RN`)]%IEQ_@T@]NX[L+&UTGK2Q5XC=G*D"*PBTIZTSD`[Z-*^0-1>,9S M&^%-+B6I5M77@(C2Y0F']A`C*,9^G'M@02=7O%062'Z?N6KPD,23^(?XQ\2X M0;U6^N#PE01ST>L^T_@E*?C>7:7WX=2#@@6K;;.?+%BR8-^J(H]*].IU$CT2 MO7)9%X=F1/QF<]?R7'039UY@.P58#_M-22]'V/T5&IG"/;N.OA\[/I%D1B4);5*U/5/*I#AA;2>CW'`LAH2>A-]^@ M.C"[:65!UYM2]C<0=$U-H$HAST9UB-H%Q4IE5^KJ'E4*UJ/64@4E/A"Z$;IM M9$#W"=T(W4Q!MYTU/BC]AN.+):TC[D2A;.!$%>E4D6XDX8CCB..,UB0'%EDQ MN#[6%!)I\QAV-^=2I`>8LIYX'VW_[T\9$1:4#`NT5J)2SC!A1-E3A.8>>*`% MI^1AD8=%/CUQ7-DXCLI.YFM7=Y]?^F:;?A\V+9VD3C;MGE(SRR@O^I(H25Y( M7G;G`QZ``C>O;O1P2N/W4/AF?.>]78?$R5?8J`L46KN\U1 M+G5$8EW249(MN6>&2NJ^A;&XFE$*AY"\E7U+?#_5GR=;Y+1O(*JZZJ)6K5,I M%&IQ!5-O:=M?FDJJ`NM$J1+$/\0_98CEM$N/_*?;'JN]60AZ&UNN-,'I3J76:N_?!C:%I?`^VADO MU0[108MGN]+ODGB2>.Y;/-^8N%)^6^-\^WY';X:STJ%6L4:%*2RR:W`Z=@PZ M;IDJUA(@F3H.F[[&0BHKF?ZHW:3[F%J2/1=1+N M;L(L,//8,`PP"W5AD!L^4]F.2I:$?(S8T)/)KI^0&$JF&Q6XX*UO$X^R;'=4 MV+@;O9Z^@=]>W0YN`C%^;R:R@2TO#=-;3\R'M?DQ=*(1&\F^%2&LUM";SJ)0 M#`Q73*7N6,!M+MRU)+V'N\61IU9?1&KS%[567TPGV6;4%+ZBWP!CX<_X&P6'XFL">YE[[##;'OVZ4*M[S7SQ5[?'0SQU/&&W__^O__S MEU^2J_Z,>/C\E843;_39?61!.&5N&&!5`JQOE+E-M#"$#S=L_.N[RW-7G<'@\N*LV;CL]B_.^H/>N[_/ MZ;3LW._X%%CO&WNR;KRIO=H,>$DEZC:TWK)H\RP1N6!@XHCEXR_^_?OGN_^S MOE[<_>/JW/K\[3\7MW=?+[[=:3$'L$1WET8H@@Y/N`5!('*!/43.A2V`:#SF M#D>4\-G8`>3#XA978`@'+O*YZ(B97G]O.[8[!,"9,$`VGSGP;8"H8ULS8-ZI M/7RV_O#@5NL17@AL: